

not relevant for CoG 10 - Hest.

Case 20918

Bei Leichter

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 December 2002 (12.12.2002)

PCT

(10) International Publication Number
WO 02/099095 A2(51) International Patent Classification?: C12N 9/02,
9/12, 9/88, 15/53, 15/54, 15/60, 15/61, 1/20, 1/21, C12P
7/02, 17/06(74) Agent: HEIROTH, Ulrike; 124 Grenzacherstrasse,
CH-4070 Basle (CH).

(21) International Application Number: PCT/EP02/06171

(22) International Filing Date: 5 June 2002 (05.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/296,299 6 June 2001 (06.06.2001) US(71) Applicant (for all designated States except US): ROCHE
VITAMINS AG [CH/CH]; 124 Grenzacherstrasse,
CH-4070 Basle (CH).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERRY, Alan
[US/CH]; 99 Mattweg, CH-4144 Arlesheim (CH).
BRETZEL, Werner [DE/DE]; 93B Tuellinger Strasse,
79539 Loerrach (DE). HUEMBELIN, Markus
[CH/CH]; 2 Wollbacherstrasse, CH-4058 Basle (CH).
LOPEZ-ULIBARRI, Rual [MX/CH]; 3 Wasser-
weg, CH-4334 Sisseln (CH). MAYER, Anne Fran-
coise [LU/CH]; 100 Rennweg, CH-4052 Basle (CH).
YELISEEV, Alexei [RU/US]; 1076 Carol Lane, # 118,
Lafayette, CA 94549 (US).

Published:

- without international search report and to be republished upon receipt of that report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

any of the seq. (42, 44, 46, 48, 50, 52) represent
the mevalonate operonmvaA gene
idi
hcs gene
mvaK
mvaL gene
pmkSEQ ID No. 42
44
SEQ ID No. 46
48
SEQ ID No. 52
50Seq. listing
13
22
30
39
56
48

WO 02/099095 A2

(54) Title: IMPROVED ISOPRENOID PRODUCTION

(57) Abstract: Isolated polynucleotides encoding polypeptides having the activity of enzymes in the mevalonate pathway, e.g. hydroxymethylglutaryl-CoA reductase, isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase, mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase; are provided, useful for recombinantly producing isoprenoid compounds such as carotenoids like phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinenone and adonirubin. Expression vectors, cultured cells, and methods of making isoprenoid compounds are also provided.

BEST AVAILABLE COPY

Improved Isoprenoid Production

The present invention relates to novel polynucleotides and polypeptide sequences useful in the isoprenoid biosynthetic pathway. More particularly, the present invention provides recombinantly produced cells that exhibit improved production of zeaxanthin. Methods of making and using such cell lines are also provided.

Carotenoids are commercially important C-40 isoprenoid compounds used as nutritional supplements, pharmaceuticals and food colorants for humans and as pigments for animal feed. Currently industrially important carotenoids are produced mainly by chemical synthesis (β -carotene, canthaxanthin and astaxanthin) or extraction from natural sources (lutein from marigold, capsanthin from paprika). Production of carotenoids, however, using microorganisms has been achieved in some cases. For example, β -carotene is produced by fermentation with the fungus *Blakeslea trispora* (US 5,328,845) or by pond culture using the halotolerant alga *Dunaliella salina* [Borowitzka, J. Biotechnol. 70:313-321 (1999)]. Lycopene production has also been reported in *B. trispora* (WO 00/77234).

Astaxanthin is produced by fermentation using yeast (*Phaffia rhodozyma*, (recently renamed *Xanthophyllomyces dendrorous*)) (US 6,015,684) or in photobioreactors or open ponds using the alga *Haematococcus pluvialis* [Lorenz and Cysewski, Trends Biotechnol. 18:160-167 (1999); Olaizola, J. Appl. Phycol. 12:499-506 (2000)]. Such microbial production systems, however, do not produce carotenoids in amounts sufficient for economical industrial scale production.

In the mid-1960's, scientists at Hoffmann-La Roche isolated several marine bacteria that produced the yellow carotenoid zeaxanthin, which has application in poultry pigmentation and in the prevention of age-related macular degeneration in humans. One bacterium, which showed promising levels of zeaxanthin production, was given the strain designation R-1512, and it was deposited at the American Type Culture Collection (ATCC, Manassas, VA, USA) as strain ATCC 21588 (US 3,891,504). Using the accepted taxonomic standards of that time (classification performed by the Eidgenössische Technische Hochschule (Zürich) and the National Collection of Industrial Bacteria, Torrey Research Station (Aberdeen, Scotland)), the zeaxanthin-producing organism was classified as a member of the genus *Flavobacterium*, but no species designation was assigned.


- 2 -

An extensive mutagenesis and screening program was subsequently conducted to isolate mutants of R-1512 with higher zeaxanthin productivities. With respect to the presently described work, two such mutants are significant. These mutants, listed in order of their zeaxanthin productivities, are R1534 and R114. A variety of other mutants have been used
 5 over the years for biochemical studies of carotenoid biosynthesis [Goodwin, Biochem. Soc. Symp. 35:233-244 (1972); McDermott et al., Biochem. J. 134:1115-1117 (1973); Britton et al., Arch. Microbiol. 113:33-37 (1977); Mohanty et al., Helvetica Chimica Acta 83:2036-2053 (2000)].


The early attempts to develop a commercially viable fermentation process for the produc-
 10 tion of zeaxanthin using classically derived mutants of strain R-1512 were not successful. However, with the advent of molecular biology, the possibility arose that higher zeaxanthin-producing strains could be developed. The first step in this direction was taken with the cloning and sequencing of the carotenoid gene cluster from strain R1534 (US 6,087,152), which is hereby incorporated by reference as if recited in full herein).
 15 US 6,087,152 discloses that the carotenoid genes were functionally expressed in *Escherichia coli* and *Bacillus subtilis* resulting in zeaxanthin production in these hosts. US 6,087,152 also disclosed that by modifying the carotenoid gene cluster or by adding a gene from an astaxanthin producing bacterium, it was possible to produce carotenoids other than zeaxanthin (EP 872,554). Moreover, EP 872,554 disclosed that carotenoid production was
 20 increased in strain R1534 by introducing cloned carotenoid gene clusters on a multi-copy plasmid.

Despite the enormous structural diversity in isoprenoid compounds, all are biosynthesized from a common C-5 precursor, isopentenyl pyrophosphate (IPP). Up until the early
 25 1990's it was generally accepted that IPP was synthesized in all organisms via the mevalonate pathway, even though some experimental results were not consistent with this biogenic scheme [Eisenreich et al., Chemistry and Biology 5:R221-R233 (1998)].

Mevalonate pathway:




- 3 -




- 5 The discrepancies have since been reconciled by the discovery of an alternate pathway of IPP biosynthesis, the deoxyxylulose (DXP) pathway (Note: The alternate pathway of IPP biosynthesis has been referred to by various names in the scientific literature (DXP pathway, DOXP pathway, MEP pathway, GAP/pyruvate pathway and the non-mevalonate pathway). We use the name DXP pathway here only for the sake of simplicity). The first
- 10 five reactions of the DXP pathway have been identified [Herz et al., Proc. Nat. Acad. Sci. 97:2486-2490 (2000)], but the subsequent steps leading to formation of IPP have not yet been elucidated.

DXP pathway:



- 4 -



- McDermott et al. (*supra*) and Britton et al. [J. Chem. Soc. Chem. Comm. p. 27 (1979)]
- 5 showed that crude extracts of zeaxanthin producing mutant strains derived from the original Roche isolates incorporated labeled mevalonate into zeaxanthin. While there was no reason to question this evidence for IPP biosynthesis via the mevalonate pathway, the work was done prior to the discovery of the DXF pathway, and it has been reported that some bacteria (*Streptomyces* species) possess both pathways for IPP synthesis and that expression
- 10 of these pathways is temporally regulated [Seto et al., Tetrahedron Lett. 37:7979-7982 (1996); Dairi et al., Mol. Gen. Genet. 262:957-964 (2000)]. In addition, at present, only a small number of eubacteria have been shown to possess the mevalonate pathway for IPP synthesis. The genes encoding the enzymes of the mevalonate pathway have been cloned and sequenced from some of these bacteria [Wilding et al., J. Bacteriol. 182:4319-4327
- 15 (2000); Takagi et al., J. Bacteriol. 182:4153-4157 (2000)].

Several examples exist where the application of metabolic engineering has succeeded in altering or improving carotenoid production in microorganisms [Lagarde et al., Appl. Env. Microbiol. 66:64-72 (2000); Wang et al., Biotechnol. Bioeng. 62:235-241 (1999); Wang et al., Biotechnol. Prog. 16:922-926 (2000) (and references therein); Sandmann et al., Trends

20 Biotechnol. 17:233-237 (2000); Misawa and Shimada, J. Biotechnol. 59:169-181 (1998); Matthews and Wurtzel, Appl. Microbiol. Biotechnol. 53:396-400 (2000); Albrecht et al., Nature Biotechnol. 18:843-846 (2000); Schmidt-Dannert et al., Nature Biotechnol. 18:750-753 (2000)]. For example, *E. coli*, a non-carotenogenic bacterium, can be engineered to produce carotenoids by introducing the cloned carotenoid (*crt*) genes from the bacteria

Agrobacterium aurantiacum, *Erwinia herbicola* or *Erwinia uredovora* (Misawa and Shimada, supra). Harker and Bramley [FEBS Lett. 448:115-119 (1999)] and Matthews and Wurtzel (supra) disclosed that carotenoid production in such engineered *E. coli* strains could be increased by over-expressing the gene coding for 1-deoxy-D-xylulose 5-phosphate
5 synthase (DXPS), the first enzyme in the DXP pathway (*E. coli* possesses only the DXP pathway for isoprenoid biosynthesis and does not use the mevalonate pathway [Lange et al., Proc. Nat. Acad. Sci. 97:13172-13177 (2000)]). Harker and Bramley (supra) also disclosed an increase in the isoprenoid compound ubiquinone-8, in the cells overproducing DXPS. These results supported the hypothesis that limited availability of IPP, resulting
10 from insufficient *in vivo* activity of DXPS, was limiting the production of carotenoids and other isoprenoid compounds in the engineered strains. Using a similar *E. coli* system, Kim and Keasling [Biotechnol. Bioeng. 72:408-415 (2001)] disclosed that the combined over-expression of the genes encoding DXPS and the second enzyme of the DXP pathway, DXPS reductoisomerase (1-deoxy-D-xylulose-5-phosphate reductoisomerase) gave higher carotenoid
15 production than over-expression of just the gene encoding DXPS.

All of these studies were done in *E. coli* engineered to produce carotenoids. Accordingly, one disadvantage to these studies was that the amount of carotenoids produced by these recombinant *E. coli* strains were very low compared to the amounts produced by even non-recombinant microorganisms used for industrial production of carotenoids. Further-
20 more, improved carotenoid production in bacteria by genetic engineering of the IPP biosynthetic pathway has only been shown in organisms that utilize the DXP pathway for IPP formation. No similar studies have been reported for bacteria that produce IPP via the mevalonate pathway.

Metabolic engineering of the mevalonate pathway to improve production of isoprenoid
25 compounds has been reported in yeast. For example, WO 00/01649 disclosed that production of isoprenoid compounds is increased in *Saccharomyces cerevisiae* when the gene coding for 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) is over-expressed. However, it has not been shown that this strategy improves isoprenoid production in bacteria, and in particular, it has not been shown that carotenoid
30 production in bacteria can be improved by amplifying expression of mevalonate pathway genes. While it has been shown that some mevalonate pathway genes from eukaryotes [Campos et al., Biochem. J. 353:59-67 (2001)] and from the bacterium *Streptomyces* sp. strain CL190 (Takagi et al., supra) can be expressed in *E. coli*, no increase in isoprenoid production was reported in the strains.

In addition to the reactions that form IPP (via the DXP or mevalonate pathways) and the reactions that convert farnesyl pyrophosphate (FPP) to various other isoprenoids (*e.g.*, carotenoids, quinones) two other reactions are known to be involved in isoprenoid biosynthesis. IPP isomerase interconverts IPP and its isomer, dimethylallyl pyrophosphate (DMAPP). Two forms of IPP isomerase exist, the type 1 enzyme is well known in eukaryotes and some bacteria, and the newly identified type 2 enzyme that is FMN- and NADP(H)-dependent [Kaneda et al., Proc. Nat. Acad. Sci. 98:932-937 (2001)].

Several reports disclose that in *E. coli* engineered to produce carotenoids, amplification of native or heterologous type 1 IPP isomerase (*idi*) genes stimulates carotenoid production [Kajiwara et al., Biochem. J. 324:421-426 (1997); Verdoes and van Ooyen, Acta Bot. Gallica 146:43-53 (1999); Wang et al., supra]. In one report (Wang et al, supra), it was further disclosed that over-expression of the *ispA* gene, encoding FPP synthase (Farnesyl diphosphate synthase) increased carotenoid production in an engineered carotenogenic strain of *E. coli* when combined with over-expression of the *idi* and *crtE* (GGPP synthase/Geranylgeranyl diphosphate synthase) genes. As is the case for the pathway of IPP biosynthesis, however, it has not been shown that over-expression of genes coding for IPP isomerase or FPP synthase improves carotenoid production in a naturally carotenogenic microorganism. Also, the levels of carotenoids produced in the *E. coli* strains described above are very low, and it has not been shown that these strategies work in an industrial microorganism where carotenoid production was already high.

In sum, there is no prior evidence that increased expression of gene(s) coding for enzymes of the mevalonate pathway can improve production of carotenoids in naturally carotenogenic bacteria or in naturally non-carotenogenic bacteria engineered to be carotenogenic.

One embodiment of the present invention is an isolated polypeptide that includes an amino acid sequence selected from the following group: (a) an amino acid sequence shown as residues 1 to 340 of SEQ ID NO:43; (b) an amino acid sequence shown as residues 1 to 349 of SEQ ID NO:45; (c) an amino acid sequence shown as residues 1 to 388 of SEQ ID NO:47; (d) an amino acid sequence shown as residues 1 to 378 of SEQ ID NO:49; (e) an amino acid sequence shown as residues 1 to 305 of SEQ ID NO:51; (f) an amino acid sequence shown as residues 1 to 332 of SEQ ID NO:53; (g) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, wherein said fragment has at least 30 contiguous amino acid residues; (h) an amino acid sequence of a fragment of a polypeptide selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, the fragment having the activity of HMG-CoA reductase, isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase (HMG-CoA

✓ The essential finding of the present invention is

- 7 -

synthase), mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase; (i) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides of SEQ ID NO:42 or a complement of SEQ ID NO:42, wherein the

5 polypeptide has the activity of HMG-CoA reductase, isopentenyl diphosphate isomerase, HMG-CoA synthase, isopentenyl diphosphate isomerase, mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase; and (j) a conservatively modified variant of SEQ ID NOs:43, 45, 47, 49, 51 or 53.

As noted above, the present invention includes SEQ ID Nos: 43, 45, 47, 49, 51, and 53,

10 which are polypeptide sequences that correspond to the following enzymes of the mevalonate pathway: hydroxymethyl glutaryl CoA (HMG-CoA) reductase, isopentenyl diphosphate (IPP) isomerase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase, respectively. The present invention also includes at least 30 contiguous amino acids of each identified sequence or a sufficient

15 number of contiguous amino acids to define a biologically active molecule.

The present invention also includes fragments of a polypeptide selected from SEQ ID NOs: 43, 45, 47, 49, 51, and 53. The fragment should be at least about 30 amino acids in length but must have the activity of the identified polypeptide, *e.g.*, in the case of SEQ ID NO:43, a fragment thereof that falls within the scope of the present invention has the activity of

20 HMG-CoA reductase. As used herein, a measure of activity of the respective fragments is set forth in Example 1. A fragment having an activity above background in the assays set forth in Example 1 is considered to be biologically active and within the scope of the present invention.

The present invention also includes an amino acid sequence of a polypeptide encoded by a

25 polynucleotide that hybridizes under stringent conditions, as defined above, to a hybridization probe that contains at least 30 contiguous nucleotides of SEQ ID NO:42 (*i.e.*, the mevalonate operon) or a complement of SEQ ID NO:42. The polynucleotide must encode at least one of the enzymes in the mevalonate pathway. For purposes of the present invention, a "hybridization probe" is a polynucleotide sequence containing from about 10-

30 9066 nucleotides of SEQ ID NO:42.

In this embodiment, the isolated polypeptide may have the amino acid sequence of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51 or SEQ ID NO:53. Alternatively, the isolated polypeptide may contain about 30 contiguous amino acids selected from an area of the respective amino acids sequences that have the least

- 8 -

identity when compared to an enzyme with the same function from different species.

Thus, for example, a polypeptide of the present invention may include amino acids 68-97 of SEQ ID NO:43, 1-30 of SEQ ID NO:45, 269-298 of SEQ ID NO:47, 109-138 of SEQ ID NO:49, 198-227 of SEQ ID NO:51 or 81-110 of SEQ ID NO:53.

- 5 Another embodiment of the invention is an isolated polypeptide having an amino acid sequence selected from: (a) an amino acid sequence shown as residues 1 to 287 of SEQ ID NO:159; (b) at least 30 contiguous amino acid residues of SEQ ID NO:159; (c) an amino acid sequence of a fragment of SEQ ID NO:159, the fragment having the activity of farnesyl-diphosphate synthase (FPP synthase); (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe containing at least 30 consecutive nucleotides of the *ispA* gene (i.e., nucleotides 295-1158 of SEQ ID NO:157) or a complement thereof, wherein the polypeptide has the activity of FPP synthase; and (e) conservatively modified variants of SEQ ID NO:159.

- 15 Thus, in this embodiment the amino acid may be encoded by the entire open reading frame that encodes FPP synthase, i.e., residues 1-287 of SEQ ID NO:159, at least 30 contiguous residues thereof, or a fragment of SEQ ID NO:159 that has FPP synthase activity as measured by the assay set forth in Example 1. Furthermore, this embodiment of the invention also includes amino acid sequence(s) encoded by polynucleotide(s) that hybridize under stringent conditions, as defined above, to a hybridization probe that includes at least 20 30 consecutive nucleotides of the *ispA* gene (i.e., nucleotides 295-1158 of SEQ ID NO:157) or a complement thereof, wherein the polypeptide has FPP synthase activity as defined above.

In a preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO:159.

- 25 Another embodiment of the invention is an isolated polypeptide having an amino acid sequence selected from the following group: (a) an amino acid sequence shown as residues 1 to 142 of SEQ ID NO:160; (b) at least 30 contiguous amino acid residues of SEQ ID NO:160; (c) an amino acid sequence of a fragment of SEQ ID NO: 160, the fragment having the activity of 1-deoxyxylulose-5-phosphate synthase (DXPS); (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe containing at least 30 consecutive nucleotides spanning positions 1185-1610 of SEQ ID NO:157 or a complement thereof, wherein the polypeptide has the activity of DXPS; and (e) conservatively modified variants of SEQ ID NO:160.

- 9 -

Thus, in this embodiment the amino acid may be encoded by the entire open reading frame that encodes DXPS, *i.e.*, residues 1-142 of SEQ ID NO:160, at least 30 contiguous residues thereof, or a fragment of SEQ ID NO:160 that has DXPS activity as measured by as measured by the assay set forth in Example 1. Furthermore, this embodiment of the invention also includes amino acid sequence(s) encoded by polynucleotide(s) that hybridize under stringent conditions, as defined above, to a hybridization probe that includes at least 30 consecutive nucleotides of the DXPS gene (*i.e.*, nucleotides 1185-1610 of SEQ ID NO:157) or a complement thereof, wherein the polypeptide has DXPS activity as defined above.

- 10 In a preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO:160.

Another embodiment of the invention is an isolated polypeptide having an amino acid sequence selected from: (a) an amino acid sequence shown as residues 1 to 390 of SEQ ID NO:178; (b) at least 30 contiguous amino acid residues of SEQ ID NO:178; (c) an amino acid sequence of a fragment of SEQ ID NO:178, the fragment having the activity of acetyl-CoA acetyltransferase; (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe containing at least 30 consecutive nucleotides of the *phaA* gene (*i.e.*, nucleotides 1-1179 of SEQ ID NO:177) or a complement thereof, wherein the polypeptide has the activity of acetyl-CoA acetyltransferase, and (e) conservatively modified variants of SEQ ID NO:178.

Thus, in this embodiment the amino acid may be encoded by the entire open reading frame that encodes acetyl-CoA acetyltransferase, *i.e.*, residues 1-143 of SEQ ID NO:178, at least 30 contiguous residues thereof, or a fragment of SEQ ID NO:178 that has acetyl-CoA acetyltransferase activity as measured by the assay set forth in Example 1. Furthermore, this embodiment of the invention also includes amino acid sequence(s) encoded by polynucleotide(s) that hybridize under stringent conditions, as defined above, to a hybridization probe that includes at least 30 consecutive nucleotides of the *phaA* gene (*i.e.*, nucleotides 1-1170 of SEQ ID NO:177), or a complement thereof, wherein the polypeptide has the acetyl-CoA acetyltransferase activity as defined above.

- 30 In a preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO:178.

Another embodiment of the invention is an isolated polypeptide having an amino acid sequence selected from: (a) an amino acid sequence shown as residues 1 to 240 of SEQ ID

- 10 -

NO:179; (b) at least 30 contiguous amino acid residues of SEQ ID NO:179; (c) an amino acid sequence of a fragment of a polypeptide of SEQ ID NO:179, the fragment having the activity of acetoacetyl-CoA reductase; (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe containing at least 30 consecutive nucleotides of the *phaB* gene (i.e., nucleotides 1258-1980 of SEQ ID NO:177) or a complement thereof, wherein the polypeptide has the activity of acetoacetyl-CoA reductase; and (e) conservatively modified variants of SEQ ID NO:179.

Thus, in this embodiment the amino acid may be encoded by the entire open reading frame that encodes acetoacetyl-CoA reductase, i.e., residues 1-240 of SEQ ID NO:179, at least 30 contiguous residues thereof, or a fragment of SEQ ID NO:179 that has acetoacetyl-CoA reductase activity as measured by the assay set forth in Example 1. Furthermore, this embodiment of the invention also includes amino acid sequence(s) encoded by polynucleotide(s) that hybridize under stringent conditions, as defined above, to a hybridization probe that includes at least 30 consecutive nucleotides of the *phaB* gene (i.e., nucleotides 1258-1980 of SEQ ID NO:177) or a complement thereof, wherein the polypeptide has acetoacetyl-CoA reductase activity as defined above.

In a preferred embodiment, the polypeptide has the amino acid sequence of SEQ ID NO:179.

The terms "polypeptide," "polypeptide sequence," "amino acid," and "amino acid sequence" are used interchangeably herein, and mean an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, as well as naturally occurring or synthetic molecules. In this context, "fragments," "immunogenic fragments," or "antigenic fragments" refer to fragments of any of the polypeptides defined herein which are at least about 30 amino acids in length and which retain some biological activity or immunological activity of the polypeptide in question. Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

With respect to polypeptides, the term "isolated" means a protein or a polypeptide that has been separated from components that accompany it in its natural state. A monomeric protein is isolated when at least about 60 to 75% of a sample exhibits a single polypeptide sequence. An isolated protein will typically comprise about 60 to 90% W/W of a protein sample, more usually about 95%, and preferably will be over about 99% pure. Protein

purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes, using HPLC or other means well known in the art may provide higher resolution for purification.

- 5 As used herein, the term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic polypeptide, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.
- 10 Another embodiment of the invention is an isolated polynucleotide sequence having the nucleotide sequence of the mevalonate operon (SEQ ID NO:42), variants of SEQ ID NO:42 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (*see* Table 14) or fragments of SEQ ID NO:42. The variants and fragments of SEQ ID NO:42 must encode a polypeptide having an activity selected from:
 - 15 HMG-CoA reductase, isopentenyl diphosphate isomerase activity, hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase), mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase. This embodiment also includes polynucleotide sequences that hybridize under stringent conditions, as defined above, to a hybridization probe, the nucleotide sequence of which consists of from about 10 to about 9066 nucleotides of SEQ ID NO:42, preferably at least 30 contiguous nucleotides of SEQ ID NO:42, or
 - 20 a complement of such sequences, which polynucleotide encodes a polypeptide having an activity selected from: HMG-CoA reductase, isopentenyl diphosphate isomerase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase.
- 25 This embodiment also includes isolated polynucleotide sequences spanning the following residues of SEQ ID NO:42: 2622 to 3644, 3641 to 4690, 4687 to 5853, 5834 to 6970, 6970 to 7887, 7880 to 8878. Fragments of these sequences are also within the scope of the invention, so long as they encode a polypeptide having HMG-CoA reductase activity, isopentenyl diphosphate isomerase activity, HMG-CoA synthase activity, mevalonate
- 30 kinase activity, phosphomevalonate kinase activity, and diphosphomevalonate decarboxylase activity, respectively.

This embodiment also includes polynucleotide sequences that hybridize under stringent conditions, as defined above, to a hybridization probe selected from a nucleotide sequence which consists of at least 30 contiguous nucleotides of the following residues of SEQ ID

- 12 -

NO:42: 2622 to 3644, 3641 to 4690, 4687 to 5853, 5834 to 6970, 6970 to 7887, 7880 to 8878 or a complement thereof, wherein the polynucleotide encodes a polypeptide having HMG-CoA reductase activity, isopentenyl diphosphate isomerase activity, HMG-CoA synthase activity, mevalonate kinase activity, phosphomevalonate kinase activity, or diphosphomevalonate decarboxylase activity, respectively.

Preferably, the isolated polynucleotide consists of nucleotides 2622 to 3644, 3641 to 4690, 4687 to 5853, 5834 to 6970, 6970 to 7887 or 7880 to 8878 of SEQ ID NO:42.

Another embodiment of the invention is an isolated polynucleotide sequence having the nucleotide sequence of SEQ ID NO:157, variants of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (see Table 14) or fragments of SEQ ID NO:157 that encode a polypeptide having FPP synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity or the activity of XseB. This embodiment also includes polynucleotide sequences that hybridize under stringent conditions, as defined above, to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:157, or the complement of SEQ ID NO:157, wherein the polynucleotide encodes a polypeptide having FPP synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity or the activity of XseB.

Preferably, the isolated polynucleotide consists of nucleotides 59-292, 295-1158 or 1185-1610 of SEQ ID NO:157.

An isolated polynucleotide sequence is also provided that has a nucleotide sequence selected from the following group: nucleotides spanning positions 59-292 of SEQ ID NO:157; variants of the nucleotide sequence spanning positions of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of the nucleotide sequence spanning positions 59-292 of SEQ ID NO:157 that encode a polypeptide having a function of XseB, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 59-292 of SEQ ID NO:157, or the complement of such a sequence, wherein the polynucleotide encodes a polypeptide having a function of XseB.

Preferably, the isolated polynucleotide consists of nucleotides 59 to 292 of SEQ ID NO:157.

An isolated polynucleotide sequence is also provided that has a nucleotide sequence selected from the following group: nucleotides spanning positions 295-1158 of SEQ ID

NO:157, variants of the nucleotide sequence spanning positions 295-1158 of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of the nucleotide sequence spanning positions 295-1158 of SEQ ID NO:157 that encode a FPP synthase activity, and polynucleotide
5 sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 295-1158 of SEQ ID NO:157, or the complement of such a sequence, wherein the polynucleotide encodes a polypeptide having FPP synthase activity.

Preferably, the isolated nucleotide sequence consists of nucleotides 295-1158 of SEQ ID
10 NO:157.

Another embodiment of the invention is an isolated polynucleotide sequence having the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157, variants of the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (*see* Table
15 14) or fragments of the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157 that encode a polypeptide having 1-deoxyxylulose-5-phosphate synthase activity. This embodiment also includes polynucleotide sequences that hybridize under stringent conditions, as defined above, to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 1185-1610 of SEQ ID
20 NO:157, or a complement thereof, wherein the polynucleotide encodes a polypeptide having 1-deoxyxylulose-5-phosphate synthase activity.

Preferably, the isolated polynucleotide consists of nucleotides 1185 to 1610 of SEQ ID NO:157.

Another embodiment of the invention is an isolated polynucleotide sequence having the
25 nucleotide sequence of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (*see* Table 14) or fragments of SEQ ID NO:177 that encode a polypeptide having an activity selected from acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase. This embodiment also includes polynucleotide sequences that hybridize under stringent conditions, as defined
30 above, to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:177, or a complement thereof, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase.

In this embodiment the isolated polynucleotide sequence may include nucleotides 1 to 1170 of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (see Table 14) or fragments of SEQ ID NO:177 that encode a polypeptide having acetyl-CoA acetyltransferase activity.

5 This embodiment also includes polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of nucleotides 1 to 1170 of SEQ ID NO:177, or a complement thereof, wherein the polynucleotide encodes a polypeptide having acetyl-CoA acetyltransferase activity.

10 Preferably, the isolated polynucleotide sequence consists of nucleotides 1-1170 of SEQ ID NO:177.

In this embodiment, the isolated polynucleotide sequence may alternatively be nucleotides 1258-1980 of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain 1534 codon usage table (see Table 14) or

15 fragments of SEQ ID NO:177 that encode a polypeptide having acetoacetyl-CoA reductase activity. This embodiment also includes polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of nucleotides 1258-1980 of SEQ ID NO:177, or a complement thereof, wherein the polynucleotide encodes a polypeptide having acetoacetyl-CoA reductase activity.

20 Preferably, the isolated polynucleotide consists of nucleotides 1258-1980 of SEQ ID NO:177.

In another embodiment of the invention, the isolated polynucleotide sequence has a nucleotide sequence selected from SEQ ID NO:42, SEQ ID NO:157, SEQ ID NO:177, and combinations thereof. As used herein, the phrase "and combinations thereof" when used
25 in reference to nucleotide sequences means that any combination of the recited sequences may be combined to form the isolated polynucleotide sequence. Moreover, in the present invention, multiple copies of the same sequence, i.e., concatamers may be used. Likewise, and as set forth in more detail below, multiple copies of plasmids containing the same
30 polynucleotide sequence may be transferred into suitable host cells.

As used herein, an "isolated" polynucleotide (e.g., an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components which naturally accompany a native sequence or polypeptide, e.g., ribosomes, polymerases, many other

genome sequences and proteins. The term embraces a polynucleotide that has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems.

- 5 The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes chromosomal DNA, self-replicating plasmids, infectious polymers of DNA or RNA and DNA or RNA that performs a primarily structural role.

- 10 An "expression control sequence" is defined as an array of nucleic acid control sequences that direct transcription of an operably linked nucleic acid. An example of such an expression control sequence is a "promoter." Promoters include necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is
- 15 active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the
- 20 nucleic acid corresponding to the second sequence.

- A polynucleotide sequence is "heterologous to" an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the
- 25 promoter was derived, or, if from the same species, a coding sequence which is different from any naturally occurring allelic variants.

- In the case of both expression of transgenes and inhibition of endogenous genes (*e.g.*, by antisense, or sense suppression) one of skill will recognize that the inserted polynucleotide sequence need not be identical, but may be only "substantially identical" to a sequence of
- 30 the gene from which it was derived.

In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional polypeptide, one of skill will recognize that because of codon degeneracy a number of polynucleotide sequences will encode the same polypeptide. These vari-

ants are specifically within the scope of the present invention. In addition, the present invention specifically includes those sequences that are substantially identical (determined as described below) to each other and that encode polypeptides that are either mutants of wild type polypeptides or retain the function of the polypeptide (e.g., resulting from conservative substitutions of amino acids in the polypeptide). In addition, variants can be those that encode dominant negative mutants as described below.

Two nucleic acid sequences or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of Meyers & Miller, Computer Applic. Biol. Sci. 4:11-17 (1988), e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif., USA).

The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to sequences or subsequences that have at least 60%, preferably 80%, most preferably 90-95%, nucleotide or amino acid residue identity when aligned for maximum correspondence over a comparison window as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This

definition also refers to a sequence of which the complement of that sequence hybridizes to the test sequence.

- For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and
- 5 reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- 10 A "comparison window," as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be
- 15 conducted, *e.g.*, by the local homology algorithm of Smith and Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software
- 20 Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection.

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show

25 relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, *J. Mol. Evol.* 35:351-360 (1987). The method used is similar to the method described by Higgins and Sharp, *CABIOS* 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000

30 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and

35

their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm [Altschul et al., J. Mol. Biol. 215:403-410 (1990)]. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences [see, e.g., Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)]. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences,

or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acid codons encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein that encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid that encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, or substitutions to a peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids (*i.e.* less than 20%, such as 15%, 10%, 5%, 4%, 3%, 2% or 1%) in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

- Alanine (A), Serine (S), Threonine (T);
- Aspartic acid (D), Glutamic acid (E);
- Asparagine (N), Glutamine (Q);
- Arginine (R), Lysine (K);
- Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- Phenylalanine (F), Tyrosine (Y), Tryptophan (W). (see, *e.g.*, Creighton, *Proteins* (1984)).

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two

molecules or their complements hybridize to each other under stringent conditions, as described below.

The phrase "specifically hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization
5 conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target sequence, typically in a complex mixture of nucleic acid sequences, but to no other sequences. Stringent conditions are sequence-dependent and will be
10 different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of Principles of Hybridization and the Strategy of Nucleic Acid Assays" (1993). Generally, highly stringent conditions are selected to be about 5-10°C lower than the
15 thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Low stringency conditions are generally selected to be about 15-30°C below the T_m . The T_m is the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m , 50% of the probes are
20 occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0M sodium ion, typically about 0.01 to 1.0M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition
25 of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization.

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides that they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon
30 degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.

In the present invention, genomic DNA or cDNA containing nucleic acids of the invention can be identified in standard Southern blots under stringent conditions using the nucleic

- 21 -

acid sequences disclosed here. For the purposes of this disclosure, suitable stringent conditions for such hybridizations are those which include hybridization in a buffer of 40% formamide, 1M NaCl, 1% sodium dodecyl sulfate (SDS) at 37°C, and at least one wash in 0.2X SSC at a temperature of at least about 50°C, usually about 55°C to about 60°C, for 20 minutes, or equivalent conditions. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.

A further indication that two polynucleotides are substantially identical is if the reference sequence, amplified by a pair of oligonucleotide primers, can then be used as a probe under stringent hybridization conditions to isolate the test sequence from a cDNA or genomic library, or to identify the test sequence in, e.g., a northern or Southern blot.

The present invention also includes expression vectors as defined above. The expression vectors include one or more copies of each of the polynucleotide sequences set forth above. The expression vectors of the present invention may contain any of the polynucleotide sequences defined herein, such as for example SEQ ID NO:42, or the following residues of SEQ ID NO:42: 2622 to 3644, 3641 to 4690, 4687 to 5853, 5834 to 6970, 6970 to 7887, 7880 to 8878, as well as residues 59-292, 295-1158 or 1185-1610 of SEQ ID NO:157 and residues 1-1170 or 1258-1980 of SEQ ID NO:177. The expression vectors may contain combinations of the polynucleotide sequences identified herein, such as for example, SEQ ID NO:42, SEQ ID NO:157, and SEQ ID NO:177.

The polynucleotide sequences in the expression vectors may optionally be operably linked to an expression control sequence as defined above and exemplified in the Examples.

The present invention also includes for example, the following expression vectors: pBBR-K-mev-op16-1, pBBR-K-mev-op16-2, pDS-*mvaA*, pDS-*idi*, pDS-*hcs*, pDS-*mvk*, pDS-*pmk*, pDS-*mvd*, pDS-His-*mvaA*, pDS-His-*idi*, pDS-His-*hcs*, pDS-His-*mvk*, pDS-His-*pmk*, pDS-His-*mvd*, pBBR-K-Zea4, pBBR-K-Zea4-up, pBBR-K-Zea4-down, pBBR-K-*PctE-crtE-3*, pBBR-tK-*PctE-mvaA*, pBBR-tK-*PctE-idi*, pBBR-tK-*PctE-hcs*, pBBR-tK-*PctE-mvk*, pBBR-tK-*PctE-pmk*, pBBR-tK-*PctE-mvd*, pBBR-K-*PctE-mvaA-crtE-3*, pDS-His-*phaA*, pBBR-K-*PctE-crtW*, pBBR-K-*PctE-crtWZ*, pBBR-K-*PctE-crtZW*, and combinations thereof. These expression vectors are defined in more detail in the examples below. Moreover, the present invention also includes any expression vector that contains one of the sequences defined herein, which expression vector is used to express an isoprenoid compound, such as a carotenoid, preferably zeaxanthin, in a suitable host cell.

As used herein, the phrase "expression vector" is a replicatable vehicle that carries, and is capable of mediating the expression of, a DNA sequence encoding the polynucleotide sequences set forth herein.

In the present context, the term "replicatable" means that the vector is able to replicate in a given type of host cell into which it has been introduced. Immediately upstream of the polynucleotide sequence(s) of interest, there may be provided a sequence coding for a signal peptide, the presence of which ensures secretion of the encoded polypeptide expressed by host cells harboring the vector. The signal sequence may be the one naturally associated with the selected polynucleotide sequence or of another origin.

The vector may be any vector that may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication; examples of such a vector are a plasmid, phage, cosmid or mini-chromosome. Alternatively, the vector may be one which, when introduced in a host cell, is integrated in the host cell genome and is replicated together with the chromosome(s) into which it has been integrated. Examples of suitable vectors are shown in the examples. The expression vector of the invention may carry any of the DNA sequences of the invention as defined below and be used for the expression of any of the polypeptides of the invention defined below.

The present invention also includes cultured cells containing one or more of the polynucleotide sequences and/or one or more of the expression vectors disclosed herein. As used herein, a "cultured cell" includes any cell capable of growing under defined conditions and expressing one or more of polypeptides encoded by a polynucleotide of the present invention. Preferably, the cultured cell is a yeast, fungus, bacterium, or alga. More preferably, the cultured cell is a *Paracoccus*, *Flavobacterium*, *Agrobacterium*, *Alcaligenes*, *Erwinia*, *E. coli* or *B. subtilis*. Even more preferably, the cell is a *Paracoccus*, such as for example, R-1506, R-1512, R1534 or R114. The present invention also includes the progeny of any of the cells identified herein that express a polypeptide disclosed herein. In the present invention, a cell is a progeny of another cell if its AFLP DNA fingerprint is indistinguishable using the conditions set forth in Example 2 from the fingerprint of the putative parental cell.

Thus, the cultured cells according to the present invention may contain, for example, SEQ-ID NO:42, or the following residues of SEQ ID NO:42: 2622 to 3644, 3641 to 4690, 4687

to 5853, 5834 to 6970, 6970 to 7887, 7880 to 8878, as well as residues 59-292, 295-1158 or 1185-1610 of SEQ ID NO:157 and residues 1-1170 or 1258-1980 of SEQ ID NO:177.

These sequences may be transferred to the cells alone or as part of an expression vector.

These sequences also may optionally be operatively linked to expression control

- 5 sequence(s). The cultured cells may also contain combinations of the polynucleotide sequences identified herein, such as for example, SEQ ID NO:42, SEQ ID NO:157, and SEQ ID NO:177.

- The cultured cells according to the present invention may further contain polynucleotides that encode one or more enzymes in the carotenoid biosynthetic pathway. For example,
- 10 the cultured cells according to the present invention may contain one or more copies of SEQ ID NOs:180, 182, and 184 alone or in combination with any of the polynucleotide sequences identified herein. Thus, the polynucleotide sequences disclosed herein may be transferred into a cultured cell alone or in combination with another polynucleotide sequence that would provide enhanced production of the target isoprenoid compound,
- 15 such as, for example, carotenoids like zeaxanthin or astaxanthin. In this regard, the present invention includes the use of any polynucleotide encoding, for example, a polypeptide involved in carotenoid biosynthesis, such as GGPP synthase, β -carotene- β 4-oxygenase (ketolase), and/or β -carotene hydroxylase. In addition, combinations of polynucleotides encoding polypeptides involved in carotenoid biosynthesis may be used in combination
- 20 with one or more of the polynucleotides identified herein on the same or different expression vectors. Such constructs may be transferred to a cultured cell according to the present invention to provide a cell that expresses an isoprenoid of interest.

- For example, a cultured cell according to the present invention may contain one or more of the following expression vectors: pBBR-K-mev-op16-1, pBBR-K-mev-op16-2, pDS-
- 25 *mvaA*, pDS-*idi*, pDS-*hcs*, pDS-*mvk*, pDS-*pmk*, pDS-*mvd*, pDS-His-*mvaA*, pDS-His-*idi*, pDS-His-*hcs*, pDS-His-*mvk*, pDS-His-*pmk*, pDS-His-*mvd*, pBBR-K-Zea4, pBBR-K-Zea4-up, pBBR-K-Zea4-down, pBBR-K-*PctE-crtE-3*, pBBR-tK-*PctE-mvaA*, pBBR-tK-*PctE-idi*, pBBR-tK-*PctE-hcs*, pBBR-tK-*PctE-mvk*, pBBR-tK-*PctE-pmk*, pBBR-tK-*PctE-mvd*, pBBR-K-*PctE-mvaA-crtE-3*, pDS-His-*phaA*, pBBR-K-*PctE-crtW*, pBBR-K-*PctE-crtWZ*,
- 30 pBBR-K-*PctE-crtZW*, and combinations thereof.

Another embodiment of the invention is a method of producing a carotenoid. In this method, a cultured cell as defined above is cultured under conditions permitting expression of a polypeptide encoded by the polynucleotide sequence as defined above. Culture conditions that permit expression of a polypeptide are provided in the Examples

below, but may be modified, if required, to suit the particular intended use. The carotenoid is then isolated from the cell or, if secreted, from the medium of the cell.

In the present invention, a "carotenoid" includes the following compounds: phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinenone, adonirubin, and combinations thereof. Preferably, the carotenoid is zeaxanthin.

Another embodiment of the invention is a method of making a carotenoid-producing cell. This method includes (a) introducing into a cell a polynucleotide sequence encoding an enzyme in the mevalonate pathway, which enzyme is expressed in the cell; and (b) selecting a cell containing the polynucleotide sequence of step (a) that produces a carotenoid at a level that is about 1.1-1,000 times the level of the carotenoid produced by the cell before introduction of the polynucleotide sequence.

As used herein, the phrase "an enzyme in the mevalonate pathway" means the enzymes involved in the mevalonate pathway for IPP biosynthesis and encoded by the *atoB* or *phaA*, *hcs*, *mvaA*, *mvk*, *pmk*, and *mvd* genes. For purposes of the present invention, an enzyme is "expressed in the cell" if it is detected using any one of the activity assays set forth in Example 1. Assays for detecting the production of a carotenoid are well known in the art. Examples 1, 11, and 12 provide typical assay procedures for identifying the presence of zeaxanthin, lycopene, and astaxanthin, respectively. In a similar manner, assays for the other carotenoids may be used to detect the presence in the cell or medium of *e.g.* phytoene, canthaxanthin, adonixanthin, cryptoxanthin, echinenone, and adonirubin.

Thus, this method may be used to make the following exemplary carotenoids: phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinenone, adonirubin, and combinations thereof. In this method, zeaxanthin is the preferred carotenoid.

This method includes producing cells capable of producing a carotenoid at a level that is about 1.1-1,000 times, preferably about 1.5-500 times, such as about 100 times or at least 10 times, the level of the carotenoid produced by the cell before introduction of the polynucleotide sequence.

In this method, the cell produces from about 1 mg/L to about 10 g/L of a carotenoid. It is preferred that the cell produces from about 100 mg/L to about 9 g/L, such as, for example, from about 500mg/L to about 8 g/L, or from about 1 g/L to about 5 g/L, of a carotenoid.

In this method, the cell may be selected from a yeast, fungus, bacterium, and alga. Preferably, the cell is a bacterium selected from *Paracoccus*, *Flavobacterium*, *Agrobacterium*, *Alcaligenes*, *Erwinia*, *E. coli*, and *B. subtilis*. More preferably, the bacterium is a *Paracoccus*.

In this method, the cell may be a mutant cell. As used herein, a "mutant cell" is any cell
 5 that contains a non-native polynucleotide sequence or a polynucleotide sequence that has been altered from its native form (e.g., by rearrangement or deletion or substitution of from 1-100, preferably 20-50, more preferably less than 10 nucleotides). Such a non-native sequence may be obtained by random mutagenesis, chemical mutagenesis, UV-irradiation, and the like. Preferably, the mutation results in the increased expression of one
 10 or more genes in the mevalonate pathway that results in an increase in the production of a carotenoid, such as zeaxanthin. Methods for generating, screening for, and identifying such mutant cells are well known in the art and are exemplified in the Examples below. Examples of such mutants are R114 or R1534. Preferably, the mutant cell is R114.

In this method, the polynucleotide sequence is SEQ ID NO:42, or the following residues of
 15 SEQ ID NO:42: 2622 to 3644, 3641 to 4690, 4687 to 5853, 5834 to 6970, 6970 to 7887, 7880 to 8878, as well as residues 59-292, 295-1158 or 1185-1610 of SEQ ID NO:157 and residues 1-1170 or 1258-1980 of SEQ ID NO:177. These sequences may be used in this method alone or as part of an expression vector. These sequences also may optionally be operatively linked to expression control sequence(s). In this method, combinations of the
 20 polynucleotide sequences identified herein may be used, such as for example, SEQ ID NO:42, SEQ ID NO:157, and SEQ ID NO:177.

Examples of expression vector that may be selected for use in this method include pBBR-K-mev-op16-1, pBBR-K-mev-op16-2, pDS-*mvaA*, pDS-*idi*, pDS-*hcs*, pDS-*mvk*, pDS-*pmk*, pDS-*mvd*, pDS-His-*mvaA*, pDS-His-*idi*, pDS-His-*hcs*, pDS-His-*mvk*, pDS-His-*pmk*,
 25 pDS-His-*mvd*, pBBR-K-Zea4, pBBR-K-Zea4-up, pBBR-K-Zea4-down, pBBR-K-*PctE-crtE-3*, pBBR-tK-*PctE-mvaA*, pBBR-tK-*PctE-idi*, pBBR-tK-*PctE-hcs*, pBBR-tK-*PctE-mvk*, pBBR-tK-*PctE-pmk*, pBBR-tK-*PctE-mvd*, pBBR-K-*PctE-mvaA-crtE-3*, pDS-His-*phaA*, pBBR-K-*PctE-crtW*, pBBR-K-*PctE-crtWZ*, pBBR-K-*PctE-crtZW*, and combinations thereof.

30 In this method, the polynucleotide sequence is introduced into the cell using any conventional means. Examples of suitable methods for introducing a polynucleotide sequence into a cell include transformation, transduction, transfection, lipofection, electroporation [see e.g., Shigekawa and Dower, *Biotechniques* 6:742-751 (1988)], conjugation [see e.g., Koehler and Thorne, *Journal of Bacteriology* 169:5771-5278 (1987)], and biolistics.

The use of conjugation to transfer a polynucleotide sequence, such as in the form of an expression vector, into recipient bacteria is generally effective, and is a well-known procedure. (e.g. US 5,985,623). Depending on the strain of bacteria, it may be more common to use transformation of competent cells with purified DNA.

- 5 Known electroporation techniques (both *in vitro* and *in vivo*) function by applying a brief high voltage pulse to electrodes positioned around the treatment region. (e.g. US 6,208,893). The electric field generated between the electrodes causes the cell membranes to temporarily become porous, whereupon molecules of the implant agent enter the cells. In known electroporation applications, this electric field comprises a single
10 square wave pulse on the order of 1000 V/cm of about 100 μ s duration. Such a pulse may be generated, for example, in known applications of the Electro Square Porator T820, made by the BTX Division of Genetronics, Inc.

- Biolistics is a system for delivering polynucleotides into a target cell using microprojectile bombardment techniques. An illustrative embodiment of a method for delivering poly-
15 nucleotides into target cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA or cells through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with cultured target cells. The screen disperses the particles so that they are not delivered to the target cells in large aggregates. It is believed that a screen intervening between the projectile apparatus and the cells to be
20 bombarded reduces the size of projectiles aggregate and may contribute to a higher frequency of transformation by reducing damage inflicted on the recipient cells by projectiles that are too large.

- For the bombardment, cells in suspension are preferably concentrated on filters or solid culture medium. Alternatively, other target cells may be arranged on solid culture
25 medium. The cells to be bombarded are positioned at an appropriate distance below the microprojectile stopping plate. If desired, one or more screens are also positioned between the acceleration device and the cells to be bombarded. Through the use of these well-known techniques one may obtain up to 1000 or more foci of cells transiently expressing a marker gene. The number of cells in a focus which express the exogenous gene product 48
30 hours post-bombardment often range from 1 to 10 and average 1 to 3.

In bombardment transformation, one may optimize the prebombardment culturing conditions and the bombardment parameters to yield the maximum numbers of stable transformants. Both the physical and biological parameters for bombardment are important in this technology. Physical factors are those that involve manipulating the polynucleotide/-


microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells before and immediately after bombardment, the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment, and also the nature of the transforming
5 DNA, such as linearized DNA or intact supercoiled plasmids.

Accordingly, it is contemplated that one may wish to adjust various of the bombardment parameters in small-scale studies to fully optimize the conditions. One may particularly wish to adjust physical parameters such as gap distance, flight distance, tissue distance, and helium pressure. One may also minimize the trauma reduction factors (TRFs) by modify-
10 ing conditions which influence the physiological state of the recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation. The execution of other routine adjustments will be known to those of skill in the art in light of the present disclosure.

15 The methods of particle-mediated transformation is well known to those of skill in the art. E.g. US 5,015,580 (specifically incorporated herein by reference) describes the transformation of soybeans using such a technique.

Another embodiment of the invention is a method for engineering a bacterium to produce an isoprenoid compound. Such a bacterium is made by (a) culturing a parent bacterium
20 in a medium under conditions permitting expression of an isoprenoid, and selecting a mutant bacterium from the culture medium that produces about 1.1-1,000 times more of an isoprenoid than the parent bacteria; (b) introducing into the mutant bacterium an expression vector containing a polynucleotide sequence represented by SEQ ID NO:42 operably linked to an expression control sequence; and (c) selecting a bacterium that con-
25 tains the expression vector and produces at least about 1.1 times more of an isoprenoid than the mutant in step (a).

In this embodiment, an isoprenoid compound means a compound structurally based on isopentenyl diphosphate (IPP) units of the formula:



30 Such compounds include the hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, triterpenes (e.g., phytosterols, phytoestrogens, phytoecdysones, estrogens, phytoestrogens),

- 28 -

tetraterpenes (carotenoids), and polyterpenes. Preferably, the isoprenoid is a carotenoid, such as for example, one of the carotenoids identified above, in particular zeaxanthin.

The bacterium may be any bacterium that is capable of producing an isoprenoid compound using the processes disclosed herein. Preferably, the bacterium is a *Paracoccus*,
5 *Flavobacterium*, *Agrobacterium*, *Alcaligenes*, *Erwinia*, *E. coli*, or *B. subtilis*. Even more preferably, the bacterium is a *Paracoccus*. Preferably, the parent bacterium is R-1506 or R 1512, and the mutant bacterium is R1534 or R114, preferably R114.

The bacterium is cultured in a media and under conditions that are optimized for the production of the isoprenoid. The selection of media and culture conditions are well within
10 the skill of the art. The assays set forth in Examples 1, 11, and 12 provide exemplary methods for measuring the presence of certain carotenoids in a culture media. By optimizing the culture conditions and measuring for the production of the target isoprenoid, the culturing and selection of a mutant that meets the specific production parameters recited herein may be met. In this way, a mutant bacterium producing from
15 about 1.1-1,000 times more of an isoprenoid than the parent bacterium may be selected. Preferably, the mutant bacterium produces from about 1.5-500 times more of an isoprenoid than the parent bacterium, such as for example, at least about 100 times or at least about 10 times more of an isoprenoid than the parent bacterium. That bacterium is then cultured and used in subsequent steps.

20 After selecting the mutant bacterium that produces the desired level of an isoprenoid, an expression vector is introduced into the bacterium using any of the methods set forth above or described in the examples. Any of the expression vectors defined herein may be introduced into the mutant cell. Preferably, the expression vector contains SEQ ID NO:42.

Once the expression vector is introduced into the mutant bacteria, a stable transformant is
25 selected that produces at least about 1.1 times, such as about 5 to about 20 times, more of an isoprenoid than the untransformed-mutant. The selected transformant is then cultured under conditions suitable for isoprenoid production, and then the isoprenoid is isolated from the cell or the culture medium.

A further step in this method is introducing a mutation into the mutant bacterium that
30 results in the increased production of an isoprenoid compound by the bacterium. The mutation may be selected from at least one of the following: inactivating the polyhydroxyalkanoate (PHA) pathway, increasing expression of acetyl-CoA acetyltransferase, increasing expression of FPP synthase, increasing expression of an enzyme in a carotenoid

biosynthetic pathway, and increasing the expression of an enzyme for converting isopentenyl diphosphate (IPP) to dimethylallyl diphosphate (DMAPP).

The inactivating of the PHA pathway may be achieved by selecting for a mutant bacterium that does not express a polypeptide encoded by *phaB* (nucleotide positions 1258-1980 of SEQ ID NO:177) or by disrupting expression of the wild type *phaB* gene by homologous recombination using SEQ ID NO:177 or fragments thereof.

In this method, increasing expression of acetyl-CoA acetyltransferase may be achieved by introducing into the mutant bacterium a vector containing a polynucleotide sequence represented by SEQ ID NO:175 or nucleotide positions 1-1170 of SEQ ID NO:177 operably linked to an expression control sequence. In this method, increasing expression of FPP synthase may be achieved by introducing into the mutant bacterium a vector containing a polynucleotide sequence represented by nucleotides 295-1158 of SEQ ID NO:157 operably linked to an expression control sequence. In this method, increasing expression of a carotenoid gene may be achieved by introducing into the mutant bacterium a vector comprising a polynucleotide sequence that encodes one or more enzymes in the carotenoid biosynthetic pathway, such as for example a polynucleotide sequence selected from the group consisting of SEQ ID NOs:180, 182, and 184 operably linked to an expression control sequence.

In this method, it is preferred that the isoprenoid compound is isopentenyl diphosphate (IPP). It is also preferred that the isoprenoid compound is a carotenoid, such as for example, phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinenone, adonirubin, and combinations thereof.

Another embodiment of the invention is a microorganism of the genus *Paracoccus*, which microorganism has the following characteristics: (a) a sequence similarity to SEQ ID NO:12 of >97% using a similarity matrix obtained from a homology calculation using GeneCompar v. 2.0 software with a gap penalty of 0%; (b) a homology to R-1512, R1534, R114 or R-1506 of >70% using DNA:DNA hybridization at 81.5°C; (c) a G+C content of its genomic DNA that varies less than 1% from the G+C content of the genomic DNA of R114, R-1512, R1534, and R-1506; and (d) an average DNA fingerprint that clusters at about 58% similarity to strains R-1512, R1534, R114 and R-1506 using the AFLP procedure of Example 2, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966).

- 30 -

Methods for determining each of these characteristics are fully set forth in Example 2, and it is contemplated when these methods are used that microorganisms meeting the above criteria will be readily identifiable. It is preferred that a microorganism of the present invention have each characteristic set forth above (i.e., a-d). However, any combination of the characteristics a-d, which provides sufficient information to taxonomically validly describe a microorganism belonging to the same species as R114, R-1512, R1534, and R-1506, with the exception of *Paracoccus* sp. (MBIC3966) is also within the scope of the invention.

Another embodiment of the invention is a microorganism of the genus *Paracoccus*, which microorganism has the following characteristics: (a) 18:1w7c comprising at least about 75% of the total fatty acids of the cell membranes; (b) an inability to use adonitol, i-erythritol, gentiobiose, β -methylglucoside, D-sorbitol, xylitol and quinic acid as carbon sources for growth; and (c) an ability to use L-asparagine and L-aspartic acid as carbon sources for growth, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966).

Methods for determining each of these characteristics are also fully set forth in Example 2, and it is contemplated when these methods are used that microorganisms meeting the above criteria will be readily identifiable. It is preferred that a microorganism of the present invention have each characteristic set forth above (i.e., a-c). However, any combination of the characteristics a-c, which provides sufficient information to taxonomically validly describe a microorganism belonging to the same species as R114, R-1512, R1534, and R-1506, with the exception of *Paracoccus* sp. (MBIC3966) is also within the scope of the invention.

Another embodiment of the invention is a microorganism of the genus *Paracoccus*, which microorganism has the following characteristics: (a) an ability to grow at 40°C; (b) an ability to grow in a medium having 8% NaCl; (c) an ability to grow in a medium having a pH of 9.1; and (d) a yellow-orange colony pigmentation, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966).

Methods for determining each of these characteristics are also fully set forth in Example 2, and it is contemplated when these methods are used that microorganisms meeting the above criteria will be readily identifiable. It is preferred that a microorganism of the present invention have each characteristic set forth above (i.e., a-d). However, any combination of the characteristics a-d, which provides sufficient information to taxonomically validly describe a microorganism belonging to the same species as R114, R-1512, R1534,

- 31 -

and R-1506, with the exception of *Paracoccus* sp. (MBIC3966) is also within the scope of the invention.

A microorganism of the present invention may also be identified using any combination of the 11 characteristics set forth above, which provide sufficient information to taxonomically validly describe a microorganism belonging to the same species as R114, R-1512, R1534, and R-1506, with the exception of *Paracoccus* sp. (MBIC3966).

In accordance with the foregoing the present invention provides

(1) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- 10 (a) an amino acid sequence shown as residues 1 to 340 of SEQ ID NO:43, in particular an amino acid sequence corresponding to positions 68-97 of SEQ ID NO:43;
- (b) an amino acid sequence shown as residues 1 to 349 of SEQ ID NO:45, in particular an amino acid sequence corresponding to positions 1-30 of SEQ ID NO:45;
- 15 (c) an amino acid sequence shown as residues 1 to 388 of SEQ ID NO:47, in particular an amino acid sequence corresponding to positions 269-298 of SEQ ID NO:47;
- (d) an amino acid sequence shown as residues 1 to 378 of SEQ ID NO:49, in particular an amino acid sequence corresponding to positions 109-138 of SEQ ID NO:49;
- (e) an amino acid sequence shown as residues 1 to 305 of SEQ ID NO:51, in particular an amino acid sequence corresponding to positions 198-227 of SEQ ID NO:51;
- 20 (f) an amino acid sequence shown as residues 1 to 332 of SEQ ID NO:53, in particular an amino acid sequence corresponding to positions 81-110 of SEQ ID NO:53;
- (g) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, wherein said fragment has at least 30 contiguous amino acid residues;
- 25 (h) an amino acid sequence of a fragment of a polypeptide selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, the fragment having the activity of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase), mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase;
- 30 (i) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides of SEQ ID NO:42 or a complement of SEQ ID NO:42, wherein the polypeptide has the activity of HMG-CoA reductase, isopentenyl diphosphate

isomerase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase; and

(j) a conservatively modified variant of SEQ ID NO:43, 45, 47, 49, 51 or 53.

- 5 (2) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 287 of SEQ ID NO:159;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:159;
 - (c) an amino acid sequence of a fragment of SEQ ID NO: 159, the fragment having the activity of farnesyl diphosphate synthase (FPP synthase);
 - 10 (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 295-1158 of SEQ ID NO:157 or a complement thereof, wherein the polypeptide has the activity of FPP synthase; and
 - (e) a conservatively modified variant of SEQ ID NO:159.
- 15 (3) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 142 of SEQ ID NO:160;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:160;
 - (c) an amino acid sequence of a fragment of SEQ ID NO: 160, the fragment having the activity of 1-deoxyxylulose-5-phosphate synthase (DXPS);
 - 20 (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 1185-1610 of SEQ ID NO:157 or a complement thereof, wherein the polypeptide has the activity of DXPS;
 - 25 (e) a conservatively modified variant of SEQ ID NO:160.
- (4) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 390 of SEQ ID NO:178;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:178;
 - 30 (c) an amino acid sequence of a fragment of a polypeptide of SEQ ID NO: 178, the fragment having the activity of acetyl-CoA acetyltransferase;
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 1-1170 of SEQ ID NO:177 or a complement thereof, wherein the polypeptide has the activity of acetyl-CoA acetyltransferase; and
 - 35 (e) a conservatively modified variant of SEQ ID NO:178.

- (5) an isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 240 of SEQ ID NO:179;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:179;
 - 5 (c) an amino acid sequence of a fragment of a polypeptide of SEQ ID NO: 179, the fragment having the activity of acetoacetyl-CoA reductase;
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 1258-1980 of SEQ ID NO:177 or a complement thereof, wherein the polypeptide has the activity of acetoacetyl-CoA reductase;
 - 10 (e) and
 - (e) a conservatively modified variant of SEQ ID NO:179.
- (6) an isolated polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:42, variants of SEQ ID NO:42 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having an activity selected from the group consisting of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase), mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:42, or the complement of SEQ ID NO:42, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of HMG-CoA reductase, isopentenyl diphosphate isomerase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase; in particular
- (a) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 2622 to 3644 of SEQ ID NO:42, fragments thereof that encode a polypeptide having HMG-CoA reductase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 2622 to 3644 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a polypeptide having HMG-CoA reductase activity, more particularly a polynucleotide sequence consisting of nucleotides 2622 to 3644 of SEQ ID NO:42;
 - 30 (b) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 3641 to 4690 of SEQ ID NO:42,
- 35

- variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having isopentenyl diphosphate isomerase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 3641 to 4690 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a polypeptide having isopentenyl diphosphate isomerase activity, more particularly a polynucleotide sequence consisting of nucleotides 3641 to 4690 of SEQ ID NO:42.
- (c) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 4687 to 5853 of SEQ ID NO:42, variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having HMG-CoA synthase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 4687 to 5853 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a polypeptide having HMG-CoA synthase activity, more particularly a polynucleotide sequence consisting of nucleotides 3641 to 4690 of SEQ ID NO:42;
- (d) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 5834 to 6970 of SEQ ID NO:42, variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having mevalonate kinase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 5834 to 6970 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a polypeptide having mevalonate kinase activity, more particularly a polynucleotide sequence consisting of nucleotides 3641 to 4690 of SEQ ID NO:42;
- (e) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 6970 to 7887 of SEQ ID NO:42, variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having phosphomevalonate kinase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 6970 to 7887 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a

- polypeptide having phosphomevalonate kinase activity, more particularly a polynucleotide sequence consisting of nucleotides 3641 to 4690 of SEQ ID NO:42; or
- (f) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 7880 to 8878 of SEQ ID NO:42, variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:42 that encode a polypeptide having diphosphomevalonate decarboxylase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 7880 to 8878 of SEQ ID NO:42, or a complement thereof, wherein the polynucleotide encodes a polypeptide having diphosphomevalonate decarboxylase activity, more particularly an isolated polynucleotide consisting of nucleotides 7880 to 8878 of SEQ ID NO:42, more particularly a polynucleotide sequence consisting of nucleotides 3641 to 4690 of SEQ ID NO:42;
- (7) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:157, variants of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:157 that encode a polypeptide having farnesyl diphosphate (FPP) synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity or a polypeptide having the activity of XseB, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:157, or the complement of SEQ ID NO:157, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of FPP synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity, and the activity of XseB, in particular
- (a) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of a nucleotide sequence spanning positions 59-292 of SEQ ID NO:157, variants thereof containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of the nucleotide sequence spanning positions 59-292 of SEQ ID NO:157 that encode a polypeptide having the function of XseB, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 59-292 of SEQ ID NO:157, or the complement of such a sequence, wherein the polynucleotide encodes a polypeptide having the function of XseB, more particularly an isolated polynucleotide consisting of nucleotides 59 to 292 of SEQ ID NO:157;

- (b) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence spanning positions 295-1158 of SEQ ID NO:157, variants of the nucleotide sequence spanning positions 295-1158 of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of the nucleotide sequence spanning positions 295-1158 of SEQ ID NO:157 that encode a FPP synthase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 295-1158 of SEQ ID NO:157, or the complement of such a sequence, wherein the polynucleotide encodes a polypeptide having FPP synthase activity, more particularly an isolated polynucleotide consisting of nucleotides 295 to 1158 of SEQ ID NO:157;
- (c) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157, variants of the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of the nucleotide sequence spanning positions 1185-1610 of SEQ ID NO:157 that encode a polypeptide having 1-deoxyxylulose-5-phosphate synthase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning positions 1185-1610 of SEQ ID NO:157, or the complement of such a sequence, wherein the polynucleotide encodes a polypeptide having 1-deoxyxylulose-5-phosphate synthase activity, more particularly an isolated polynucleotide consisting of nucleotides 1185 to 1610 of SEQ ID NO:157;
- (8) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:177 that encode a polypeptide having an activity selected from the group consisting of acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:177, or the complement of SEQ ID NO:177, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase, in particular

- (a) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 1 to 1170 of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:177 that encode a polypeptide having acetyl-CoA acetyltransferase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 1 to 1170 of SEQ ID NO:177, or a complement thereof, wherein the polynucleotide encodes a polypeptide having acetyl-CoA acetyltransferase activity, more particularly an isolated polynucleotide sequence consisting of nucleotides 1-1170 of SEQ ID NO:177;
- (b) an isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of nucleotides 1258-1980 of SEQ ID NO:177, variants of SEQ ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table (Table 14), fragments of SEQ ID NO:177 that encode a polypeptide having acetoacetyl-CoA reductase activity, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides spanning residues 1258-1980 of SEQ ID NO:177, or a complement thereof, wherein the polynucleotide encodes a polypeptide having acetoacetyl-CoA reductase activity, more particularly an isolated polynucleotide sequence consisting of nucleotides 1258-1980 of SEQ ID NO:177;
- (9) an isolated polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:42, SEQ ID NO:157, SEQ ID NO:177, and combinations thereof;
- (10) an expression vector comprising the polynucleotide sequence of any one of (6) (a) to (6) (f), (7) (a) to (7) (c), (8) (a), (8) (b) or (9), in particular an expression vector wherein the polynucleotide sequence is operably linked to an expression control sequence, e.g. an expression vector further comprising a polynucleotide sequence that encodes an enzyme in the carotenoid biosynthetic pathway, more particularly an expression vector wherein the polynucleotide sequence is selected from the group consisting of SEQ ID NO:180, SEQ ID NO:182, SEQ ID NO:184, and combinations thereof which are operably linked to an expression control sequence;
- (11) an expression vector selected from the group consisting of pBBR-K-mev-op16-1, pBBR-K-mev-op16-2, pDS-*mvaA*, pDS-*idi*, pDS-*hcs*, pDS-*mvk*, pDS-*pmk*, pDS-*mvd*, pDS-His-*mvaA*, pDS-His-*idi*, pDS-His-*hcs*, pDS-His-*mvk*, pDS-His-*pmk*, pDS-His-*mvd*, pBBR-K-Zea4, pBBR-K-Zea4-up, pBBR-K-Zea4-down, pBBR-K-*PrtE-crtE-3*,

pBBR-tK-*PcrE-mvaA*, pBBR-tK-*PcrE-idi*, pBBR-tK-*PcrE-hcs*, pBBR-tK-*PcrE-mvk*, pBBR-tK-*PcrE-pmk*, pBBR-tK-*PcrE-mvd*, pBBR-K-*PcrE-mvaA-crtE-3*, pDS-His-*phaA*, pBBR-K-*PcrE-crtW*, pBBR-K-*PcrE-crtWZ*, pBBR-K-*PcrE-crtZW*, and combinations thereof, in particular

- 5 (a) an expression vector selected from the group consisting of pBBR-K-mev-op16-1 and pBBR-K-mev-op16-2,
- (b) an expression vector selected from the group consisting of pBBR-K-Zea4, pBBR-K-Zea4-up, and pBBR-K-Zea4-down;
- (c) an expression vector selected from the group consisting of pBBR-K-*PcrE-crtE-3*,
- 10 pBBR-tK-*PcrE-mvaA*, pBBR-tK-*PcrE-idi*, pBBR-tK-*PcrE-hcs*, pBBR-tK-*PcrE-mvk*, pBBR-tK-*PcrE-pmk*, pBBR-tK-*PcrE-mvd*, and combinations thereof;
- (d) an expression vector which is pBBR-K-*PcrE-mvaA-crtE-3*;
- (e) an expression vector which is pDS-His-*phaA*; or
- (f) an expression vector selected from the group consisting of pBBR-K-*PcrE-crtW*,
- 15 pBBR-K-*PcrE-crtWZ*, and pBBR-K-*PcrE-crtZW*;
- (12) a cultured cell comprising the polynucleotide sequence of any one of (6) (a) to (f), (7) (a) to (c), (8) (a), (8) (b) or (9), or an expression vector of (10) or (11), or a progeny of the cell, wherein the cell expresses a polypeptide encoded by the polynucleotide sequence, in particular a cell which is further characterized by a feature selected from
- 20 (a) further comprising a polynucleotide sequence that encodes an enzyme in the carotenoid biosynthetic pathway, more particularly a cultured cell wherein the polynucleotide sequence that encodes an enzyme in the carotenoid biosynthetic pathway is selected from the group consisting of SEQ ID NOs:180, 182, and 184, or a progeny of the cell, wherein the cell expresses polypeptides encoded by the polynucleotide sequences, and
- 25 (b) from being a member of a group selected from yeast, fungus, bacterium and alga, in particular a bacterium selected from the group consisting of *Paracoccus*, *Flavobacterium*, *Agrobacterium*, *Alcaligenes*, *Erwinia*, *E. coli*, and *B. subtilis*, more particularly *Paracoccus*, more particularly *Paracoccus* selected from the group consisting of R-1506, R-1512, R1534, and R114;
- 30 (13) a method of producing a carotenoid comprising culturing a cell of (12) under conditions permitting expression of a polypeptide encoded by the polynucleotide sequence, and isolating the carotenoid from the cell or the medium of the cell;
- (14) a method of making a carotenoid-producing cell comprising:
- 35 (a) introducing into a cell a polynucleotide sequence encoding an enzyme in the mevalonate pathway, which enzyme is expressed in the cell; and

- 39 -

- (b) selecting a cell containing the polynucleotide sequence of step (a) that produces a carotenoid at a level that is about 1.1-1,000 times the level of the carotenoid produced by the cell before introduction of the polynucleotide sequence, in particular a method selected from a method characterized by a feature selected from
- 5 (i) the selecting step comprising selecting a cell containing the polynucleotide sequence of step (a) that produces a carotenoid at a level that is about 1.5-500 times, particularly about 100 times, or at least about 10 times, the level of the carotenoid produced by the cell before introduction of the polynucleotide sequence;
- 10 (ii) the cell producing from about 1 mg/L to about 10 g/L of a carotenoid.
- (iii) the cell being selected from the group consisting of a yeast, fungus, bacterium, and alga, in particular selected from the group consisting of *Paracoccus*, *Flavobacterium*, *Agrobacterium*, *Alcaligenes*, *Erwinia*, *E. coli*, and *B. subtilis*, more particularly from *Paracoccus*;
- 15 (iv) the cell in step (a) being a mutant cell, in particular being selected from the group consisting of R114 and R1534, in particular the mutant cell producing about 1.1-1,000 times, in particular about 1.5-500 times, more particularly at least about 100 times more or at least about 10 times more, the level of a carotenoid compared to its non-mutant parent;
- 20 (v) the polynucleotide sequence being selected from polynucleotide sequences of (6) (a) to (f), (7) (a) to (c), (8) (a), (8) (b) and (9), in particular wherein the polynucleotide sequence is operably linked to an expression control sequence;
- (vi) the polynucleotide sequence being an expression vector of (10) or (11);
- (vii) the introducing step being selected from the group consisting of transformation, transduction, transfection, lipofection, electroporation, conjugation, and biolistics.
- 25 (viii) the carotenoid being selected from the group consisting of phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinenone, adonirubin, and combinations thereof, in particular the carotenoid being zeaxanthin;
- 30 (15) a method for engineering a bacterium to produce an isoprenoid compound comprising:
- (a) culturing a parent bacterium in a medium under conditions permitting expression of an isoprenoid compound, and selecting a mutant bacterium from the culture medium that produces about 1.1-1,000 times more of an isoprenoid compound than
- 35 the parent bacterium;

(b) introducing into the mutant bacterium an expression vector comprising a polynucleotide sequence represented by SEQ ID NO:42 operably linked to an expression control sequence; and

(c) selecting a bacterium that contains the expression vector and produces at least
5 about 1.1 times more of an isoprenoid compound than the mutant in step (a), in particular

(i) a method further comprising introducing a mutation into the mutant bacterium, more particularly a method wherein the mutation causes an effect selected from at least one of the following: inactivating the polyhydroxyalkanoate (PHA) pathway, in-
10 creasing expression of acetyl-CoA acetyltransferase, increasing expression of farnesyl diphosphate (FPP) synthase, increasing expression of an enzyme in a carotenoid pathway, increasing the expression of an enzyme for converting isopentenyl diphosphate (IPP) to dimethylallyl diphosphate (DMAPP),

most particularly a method wherein inactivating of the PHA pathway comprises
15 selecting for a mutant bacterium that does not express a polypeptide encoded by *phaB* (nucleotide positions 1258-1980 of SEQ ID NO: 177) or by disrupting expression of the wild type *phaB* gene by homologous recombination using SEQ ID NO:177 or a fragment thereof, or

a method wherein increasing expression of acetyl-CoA acetyltransferase comprises
20 introducing into the mutant bacterium a vector comprising a polynucleotide sequence represented by SEQ ID NO:175 or nucleotide positions 1-1170 of SEQ ID NO:177 operably linked to an expression control sequence, or

a method wherein increasing expression of FPP synthase comprises introducing into the mutant bacterium a vector comprising a polynucleotide sequence represented by
25 nucleotides 295-1158 of SEQ ID NO:157 operably linked to an expression control sequence, or

a method wherein increasing expression of an enzyme in a carotenoid pathway comprises introducing into the mutant bacterium a vector comprising a polynucleotide sequence selected from the group consisting SEQ ID NOs:180, 182,
30 and 184 operably linked to an expression control sequence;

(b) a method wherein the isoprenoid is isopentenyl diphosphate (IPP).

(c) a method wherein the isoprenoid is a carotenoid, in particular a method wherein the carotenoid is selected from the group consisting of phytoene, lycopene, β -carotene, zeaxanthin, canthaxanthin, astaxanthin, adonixanthin, cryptoxanthin, echinen-
35 one, adonirubin, and combinations thereof;

- 41 -

- (d) a method wherein the parent bacterium is a *Paracoccus*, in particular R-1512 or R-1506, or R1534 or R114, in particular wherein the mutant is R114;
- (16) a microorganism of the genus *Paracoccus*, which microorganism has the following characteristics:
- 5 (i) a sequence similarity to SEQ ID NO:12 of >97% using a similarity matrix obtained from a homology calculation using GeneCompar v. 2.0 software with a gap penalty of 0%;
- a homology to strain R-1512, R1534, R114 or R-1506 of >70% using DNA:DNA hybridization at 81.5°C;
- 10 a G+C content of its genomic DNA that varies less than 1% from the G+C content of the genomic DNA of R114, R-1512, R1534, and R-1506; and
- an average DNA fingerprint that clusters at about 58% similarity to strains R-1512, R1534, R114 and R-1506 using the AFLP procedure of Example 2, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966);
- 15 (ii) 18:1w7c comprising at least about 75% of the total fatty acids of the cell membranes;
- an inability to use adonitol, i-erythritol, gentiobiose, β -methylglucoside, D-sorbitol, xylitol and quinic acid as carbon sources for growth; and
- an ability to use L-asparagine and L-aspartic acid as carbon sources for growth, with
- 20 the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966); or
- (iii) an ability to grow at 40°C;
- an ability to grow in a medium having 8% NaCl;
- an ability to grow in a medium having a pH of 9.1; and
- a yellow-orange colony pigmentation, with the proviso that the microorganism is not
- 25 *Paracoccus* sp. (MBIC3966).

The following examples are provided to further illustrate certain aspects of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

Example 1: Analytical and Biochemical Methods

30 (a) Analysis of Carotenoids

Sample preparation. A solvent mixture of 1:1 dimethylsulfoxide (DMSO) and tetrahydrofuran (THF) was first prepared. This solvent mixture was stabilized by the addition of butylated hydroxytoluene (BHT, 0.5 g/l solvent mixture). Four milliliters of the stabilized DMSO/THF mixture was added to 0.4 ml of bacterial culture in a disposable 15-ml poly-

propylene centrifuge tube (gives a final dilution factor of 1/11). The tubes were capped and mixed using a Vortex mixer for 10 seconds each. The samples were then put on a Brinkmann Vibramix shaker for 20 minutes. The tubes were centrifuged at room temperature for 4 minutes at 4000 rpm and aliquots of the clear yellow/orange supernatant were transferred into brown glass vials for analysis by High Performance Liquid Chromatography (HPLC).

HPLC. A reversed phase HPLC method was developed for the simultaneous determination of astaxanthin, zeaxanthin, canthaxanthin, β -carotene, and lycopene. The method was also able to separate the main *cis*-isomers of zeaxanthin. Chromatography was performed using an Agilent 1100 HPLC system equipped with a thermostatted autosampler and a diode array detector. The method parameters were as follows:

Column: YMC Carotenoid C30 column, particle size 5 micron
250* 4.6mm I.D., steel
(YMC, Part No. CT99S052546WT)

Guard column: Pelliguard LC-18 cartridge, 20 mm
(SUPELCO, Part No. 59654)

Mobile phase: Methanol (MeOH)/Methyl tert-butyl ether (TBME) gradient

| | % MeOH | % TBME |
|--------|--------|--------|
| Start | 80 | 20 |
| 10 min | 65 | 35 |
| 20 min | 10 | 90 |

Run time: 28 min; Typical column pressure: 90 bar at start; Flow rate: 1.0 ml/min.;

Detection: UV at 450 nm; Injection volume: 10 μ l; Column temperature: 15°C

Reagents. Methanol and TBME were HPLC grade and were obtained from EM Science and J.T. Baker, respectively. DMSO (Omnisolve) was purchased from EM Science. THF (HPLC solvent) was from Burdick and Jackson.

Calculations. Quantitative analyses were performed with a two level calibration using external standards (provided by Hoffmann-La Roche, Basel, Switzerland). Calculations were based on peak areas.

Selectivity. The selectivity of the method were verified by injecting standard solutions of the relevant carotenoid reference compounds. The target compounds (all-*trans*-carotenoids) were completely separated and showed no interference. Some minor *cis* isomers may coelute, although these potentially interfering isomers are rare and need not be considered in routine analyses. The retention times of the compounds are listed in Table 1.

Table 1. HPLC retention times for carotenoids.

| Carotenoid | Retention time (min.) | Carotenoid | Retention time (min.) |
|-------------------------------|-----------------------|-------------------|-----------------------|
| Astaxanthin | 6.99 | Canthaxanthin | 9.95 |
| Adonixanthin | 7.50 | Cryptoxanthin | 13.45 |
| 15- <i>cis</i> -Zeaxanthin | 7.80 | β -Carotene | 17.40 |
| 13- <i>cis</i> -Zeaxanthin | 8.23 | Lycopene | 21.75 |
| all- <i>trans</i> -Zeaxanthin | 9.11 | | |

Linearity. 25 Milligrams of all-*trans*-zeaxanthin were dissolved in 50 ml of DMSO/THF mixture (giving a final zeaxanthin concentration 500 $\mu\text{g/ml}$). A dilution series was prepared (final zeaxanthin concentrations of 250, 100, 50, 10, 5, 1, and 0.1 $\mu\text{g/ml}$) and analyzed by the HPLC method described above. A linear range was found from 0.1 $\mu\text{g/ml}$ to 250 $\mu\text{g/ml}$. The correlation coefficient was 0.9998.

Limit of detection. The lower limit of detection for zeaxanthin by this method was determined to be 60 $\mu\text{g/l}$. A higher injection volume and optimization of the integration parameters made it possible to lower the detection limit to approximately 5 $\mu\text{g/l}$.

Reproducibility. The retention time for all-*trans*-zeaxanthin was very stable (relative standard deviation (RSD), 0.2 %). The peak area reproducibility, based on ten repetitive analyses of the same culture sample, was determined to be 0.17 % RSD for all *trans*-zeaxanthin and 1.0 % for cryptoxanthin.

15 (b) Preparation of crude extracts and enzyme assay methods.

Preparation of crude extracts. Crude extracts of *Paracoccus* and *E. coli* were prepared by resuspending washed cell pellets in 1 ml of extraction buffer (buffer used depended on the enzyme being assayed – compositions are specified along with each enzyme assay procedure described below). Cell suspensions were placed in a 2-ml plastic vial and disrupted by agitation with glass beads using a Mini Bead Beater 8 (Biospec Products, Bartlesville, OK, USA). Disruption was performed at 4°C using a medium agitation setting. The disrupted preparations were centrifuged at 21,000 x g for 20 minutes at 4°C to sediment the cell debris, and the supernatants were used directly for enzyme assays.

Protein determinations. Protein concentrations in crude extracts were determined by the method of Bradford [Anal. Biochem. 72:248-254 (1976)] using the Bio-Rad Protein Assay

Reagent (Bio-Rad, Hercules, CA, USA). Bovine serum albumin was used as the reference protein for construction of standard curves.

Acetyl-CoA acetyltransferase assays. Crude extracts were prepared in 150 mM EPPS (N-[2-hydroxyethyl] piperazine-N'-[3-propanesulfonic acid]) buffer, pH 8.0. Assays were performed in the thiolysis direction according to the method described by Slater et al. [J. Bacteriol. 180:1979-1987 (1998)]. This assay measures the disappearance of acetoacetyl-CoA spectrophotometrically at 304 nm. Reaction mixtures contained 150 mM EPPS buffer (pH 8.0), 50 mM MgCl₂, 100 µM CoA, 40 µM acetoacetyl-CoA and crude extract. Reactions were carried out at 30°C and were initiated by addition of crude extract. The disappearance of acetoacetyl-CoA at 304 nm was monitored using a SpectraMAX Plus plate reader (Molecular Devices Corp., Sunnyvale, CA, USA) and a quartz microtiter plate (any standard spectrophotometer can also be used). Activity (expressed as U/mg protein) was calculated using a standard curve constructed with acetoacetyl-CoA (1 unit of activity = 1 µmol acetoacetyl-CoA consumed/min.). The lower limit of detection of Acetyl-CoA acetyltransferase activity was 0.006 U/mg.

HMG-CoA synthase assays. HMG-CoA synthase was assayed according to the method of Honda et al. [Hepatology 27:154-159 (1998)]. In this assay, the formation of HMG-CoA from acetyl-CoA and acetoacetyl-CoA is measured directly by separating the reaction product and substrates by HPLC. Crude extracts were prepared in 50 mM Tris-HCl buffer (pH 8.0). Reaction mixtures (0.1 ml) contained 50 mM Tris-HCl buffer (pH 8.0), 0.1 mM EDTA, 20 mM MgCl₂, 0.1 mM acetoacetyl-CoA, 0.8 mM acetyl-CoA and crude extract. Reactions were pre-incubated for 2 minutes at 30°C before adding the crude extract. After 5 minutes of reaction at 30°C, the reactions were stopped by adding 0.2 ml of 200 mM tetra-butyl ammonium phosphate (TBAP, dissolved in methanol-water (3:2, final pH was 5.5) and containing 0.2 mM propionyl-CoA as an internal recovery standard). The mixture was then centrifuged for 3 minutes at 21,000 x g at 4°C and subsequently kept on ice until analyzed by reversed phase ion-pair HPLC. HMG-CoA and propionyl-CoA were separated from acetyl-CoA and acetoacetyl-CoA using a Nova-Pak C18 column (3.9 x 150 mm, Waters Corporation, Milford, MA, USA). The injection volume was 20 µl, the mobile phase was 50 mM TBAP dissolved in methanol-water (1:1, final pH was 5.5), and the flow rate was 1.0 ml/min. HMG-CoA and propionyl-CoA were detected by absorbance at 254 nm. HMG-CoA produced in the reaction was quantified by comparison with a standard curve created using authentic HMG-CoA. Activity is defined as U/mg protein. One unit of activity = 1 nmol HMG-CoA produced/min. The lower limit of detection of HMG-CoA synthase was about 1 U/mg.

- HMG-CoA reductase assays. Crude extracts were prepared in 25 mM potassium phosphate buffer (pH 7.2) containing 50 mM KCl, 1 mM EDTA and a protease inhibitor cocktail (Sigma Chemical Co., St. Louis, MO, USA, catalog #P-2714). Assays were performed according to the method of Takahashi et al. [J. Bacteriol. 181:1256-1263 (1999)]. This
- 5 assay measures the HMG-CoA dependent oxidation of NADPH spectrophotometrically at 340nm. Reaction mixtures contained 25 mM potassium phosphate buffer (pH 7.2), 50 mM KCl, 1 mM EDTA, 5 mM dithiothreitol, 0.3 mM NADPH, 0.3 mM R,S-HMG-CoA and crude extract. Reactions were performed at 30°C and were initiated by the addition of HMG-CoA. HMG-CoA-dependent oxidation of NADPH was monitored at 340 nm using
- 10 a SpectraMAX Plus plate reader (Molecular Devices Corp., Sunnyvale, CA, USA) and a quartz microtiter plate (any standard spectrophotometer may be used). Activity (expressed as U/mg protein) was calculated using a standard curve constructed with NADPH (1 unit of activity = 1 μ mol NADPH oxidized/min.). The lower limit of detection of HMG-CoA reductase activity was 0.03 U/mg.
- 15 Mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate decarboxylase assays. The preparation of substrates and the assay procedures for mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate decarboxylase have been described in detail by Popják [Methods Enzymol. 15:393-425 (1969)]. For all assays, one
- 20 unit of enzyme activity is defined as 1 μ mol of product formed/minute. In addition to these spectrophotometric and radiochromatographic assays, alternate methods, for example using HPLC separation of reaction substrates and products, can be used. The lower limit of detection of mevalonate kinase, phosphomevalonate kinase and mevalonate diphosphate decarboxylase is typically about 0.001 U/mg protein.
- IPP isomerase assays. Crude extracts were prepared in 50 mM Tris-HCl buffer (pH 7.5).
- 25 Assays were performed using the method of Spurgeon et al. [Arch. Biochem. Biophys. 230:445-454 (1984)]. This assay is based on the difference in acid-lability of IPP and DMAPP. Reaction mixtures (0.1 ml final volume) contained 50 mM Tris-HCl buffer (pH 7.5), 2 mM dithiothreitol, 5 mM $MgCl_2$, 20 μ M [1- ^{14}C]-IPP and crude extract. Reactions
- 30 were carried out at 30°C for 15 minutes and terminated by the addition of 0.3 ml of a mixture of concentrated HCl:methanol (4:1) and an additional incubation at 37°C for 20 min. Hexane (0.9 ml) was added and the tubes were mixed (4 times for 10 seconds using a vortex mixer). After centrifugation (21,000 x g, 5 minutes), 0.6 ml of the hexane layer was transferred to a scintillation vial, scintillation fluid was added, and the radioactivity
- counted. Activity is expressed as U/mg protein. One unit of activity = 1 pmol [1- ^{14}C]-IPP incorporated into acid labile products/min. The lower limit of detection of IPP isomerase
- 35 activity was 1 U/mg.

FPP synthase assays. Crude extracts were prepared in 50 mM Tris-HCl buffer (pH 8.0). The FPP synthase assay procedure was similar to the IPP isomerase assay described above, being based on the difference in acid lability of IPP and FPP (Spurgeon et al., supra). Reaction mixtures (0.1 ml final volume) contained 50 mM Tris-HCl buffer (pH 8.0),
5 2 mM dithiothreitol, 5 mM MgCl₂, 20 μM [1-¹⁴C]-IPP, 25 μM GPP (geranyl pyrophosphate) and crude extract. Reactions were carried out at 30°C for 15 minutes and terminated by the addition of 0.3 ml of a mixture of concentrated HCl:methanol (4:1) and an additional incubation at 37°C for 20 minutes. Hexane (0.9 ml) was added and the tubes were mixed (4x, 10 seconds using a vortex mixer). After centrifugation (21,000 x g, 5
10 minutes), 0.6 ml of the hexane layer was transferred to a scintillation vial, scintillation fluid was added, and the radioactivity counted. Units of enzyme activity, and the lower limit of detection, were the same as defined above for IPP isomerase. In cases where high IPP isomerase activity interferes with measurement of FPP synthase activity, crude extract may be preincubated for 5 minutes in the presence of 5mM iodoacetamide to inhibit IPP
15 isomerase activity.

GGPP synthase assays. Crude extracts were prepared in 50 mM Tris-HCl buffer (pH 8.0) containing 2 mM dithiothreitol. GGPP synthase was assayed according to the procedure of Kuzuguchi et al. [J. Biol. Chem. 274:5888-5894 (1999)]. This assay is based on the same principle as described above for FPP synthase. Reaction mixtures (0.1 ml final volume)
20 contained 50 mM Tris-HCl buffer (pH 8.0), 2 mM dithiothreitol, 5 mM MgCl₂, 20 μM [1-¹⁴C]-IPP, 25 μM FPP and crude extract. All reaction conditions and subsequent treatment of samples for scintillation counting were identical to those described above for FPP synthase. Treatment of extract with iodoacetamide to inhibit IPP isomerase activity may also be used as above. Units of enzyme activity, and the lower limit of detection, were the same
25 as defined above for IPP isomerase.

Acetoacetyl-CoA reductase assays. Crude extracts are prepared in 50 mM Tris-HCl buffer (pH 7.5) containing 50 mM KCl and 5 mM dithiothreitol. Acetoacetyl-CoA reductase was assayed according to the procedure of Chohan and Copeland [Appl. Environ. Microbiol. 64:2859-2863 (1998)]. This assay measures the acetoacetyl-CoA-dependent oxidation of
30 NADPH spectrophotometrically at 340 nm. Reaction mixtures (1 ml) contain 50 mM Tris-HCl buffer (pH 8.5), 15 mM MgCl₂, 250 μM NADPH, and 100 μM acetoacetyl-CoA. Reactions are performed in a quartz cuvette at 30°C and are initiated by the addition of acetoacetyl-CoA. Activity (expressed as U/mg protein) was calculated using a standard curve constructed with NADPH (1 unit of activity = 1 μmol NADPH oxidized/min). The
35 lower limit of detection of acetoacetyl-CoA reductase activity is about 0.01 U/mg.

Example 2: Taxonomic Reclassification of *Flavobacterium* sp. as *Paracoccus*

This Example describes the taxonomic re-classification of the zeaxanthin-producing bacterium formerly designated *Flavobacterium* sp. strain R-1512 (ATCC 21588) as *Paracoccus* sp. strain R-1512 (ATCC 21588). A comprehensive genomic and
 5 biochemical/physiological analysis was performed by the Belgian Coordinated Collections of Microorganisms/Laboratorium voor Microbiologie, Universiteit Gent (BCCM™/LMG), using state-of-the-art methods currently accepted as the scientific standards for bacterial classification. Besides *Paracoccus* sp. strain R-1512, several other bacteria belonging to the genus *Paracoccus* were included in the study (summarized in Table 2).

10 Table 2. Bacteria used in taxonomic study.

| Bacterium | Strain designation | Source or reference |
|---------------------------|------------------------|---|
| <i>Paracoccus</i> sp. | R-1512 (ATCC 21588) | ATCC (environmental isolate) US 3,891,504 |
| <i>Paracoccus</i> sp. | R1534 | mutant derived from R-1512; US 6,087,152 |
| <i>Paracoccus</i> sp. | R114 | mutant derived from R-1512; This work |
| <i>Paracoccus</i> sp. | R-1506 | environmental isolate; This work |
| <i>Paracoccus</i> sp. | MBIC3024 | H. Kasai, Kamaishi Institute, Japan |
| <i>Paracoccus</i> sp. | MBIC3966 | H. Kasai, Kamaishi Institute, Japan |
| <i>Paracoccus</i> sp. | MBIC4017 | H. Kasai, Kamaishi Institute, Japan |
| <i>Paracoccus</i> sp. | MBIC4020 | H. Kasai, Kamaishi Institute, Japan |
| <i>P. marcusii</i> | DSM 11574 ^T | Harker et al., infra |
| <i>P. carotinifaciens</i> | E-396 ^T | Tsubokura et al., infra |
| <i>P. solventivorans</i> | DSM 6637 ^T | Siller et. al., Int. J. Syst. Bacteriol. 46:1125-1130 (1996) |

Strains R1534 and R114 are mutants derived from strain R-1512 by classical mutagenesis and screening for improved zeaxanthin production. The primary screening was accomplished by selecting the highest color intensity producing colonies. A secondary screening

ATCC deposit

24.4.01 PTA- 3336

24.4.01 PTA- 3335

5.6.01 PTA- 3431

was accomplished in liquid culture media by the HPLC methods according to Example 1. Strain R-1506 is an independent isolate obtained from the same initial screening of environmental microorganisms that provided strain R-1512. Strains MBIC3024, MBIC3966, MBIC4017 and MBIC4020 were identified as members of the genus *Paracoccus* by the
5 nucleotide sequences of their 16S rDNA genes (DNA sequences were deposited in the public EMBL database, see Table 5). *Paracoccus marcusii* DSM 11574^T and *Paracoccus carotinifaciens* E-396^T are recently described type strains of carotenoid-producing bacteria [Harker et al., Int. J. Syst. Bacteriol. 48:543-548 (1998); Tsubokura et al., Int. J. Syst. Bacteriol. 49:277-282 (1999)]. *Paracoccus solventivorans* DSM 6637^T was included as a
10 "control" strain, being a member of the genus *Paracoccus* but distantly related to the other bacteria used.

Preliminary experiments resulted in the following conclusions. Each of the methods set forth herein has a well-recognized ability to define taxonomic relatedness or relative degree of similarity between organisms. The methods and their use for delineating bacterial taxa
15 were described and compared in detail by Van Damme et al., Microbiological Reviews 60:407-438 (1996) and Janssen et al., Microbiology 142:1881-1893 (1996).

- (1) Fatty acid analysis of the cell membranes of strains R1534 and R114 showed that the two strains were highly similar and indicated a taxonomic relatedness of these strains to *Paracoccus denitrificans* and *Rhodobacter capsulatus*.
- 20 (2) One-dimensional gel electrophoresis of cellular proteins showed a high similarity (i.e., a relatedness at the intra-species level) between R1534 and R114, but the profiles did not justify allocation of these strains to either *R. capsulatus* or *P. denitrificans*.
- (3) DNA:DNA hybridization between strain R1534 and *R. capsulatus* LMG2962^T and *P. denitrificans* LMG4218^T confirmed that strain R1534 is neither *R. capsulatus* nor *P. denitri-*
25 *ficans*.
- (4) Sequencing of 16S rDNA genes from strains R1534 and R114 showed that these organisms belong to the genus *Paracoccus*, but that they represent a new species. The highest degree of sequence similarity was observed with the 16S rDNA gene of *Paracoccus* sp. strains MBIC3966, MBIC4020 and MBIC3024.
- 30 (5) DNA fingerprinting of strains R1534 and R-1512 using Amplified Fragment Length Polymorphism (AFLPTM) showed high overall similarity of the genomic DNA from the two strains, indicating an infraspecific relatedness (i.e. AFLPTM can differentiate between two members of the same species).

In the following sections, the results and conclusions of the present comprehensive taxonomic study of *Paracoccus* sp. strain R-1512 (and its mutant derivatives R1534 and R114) are set forth.

16S rDNA sequencing and phylogenetic study. The bacteria set forth in Table 2 were grown in LMG medium 185 ((TSA) BBL 11768 supplemented where necessary with 1.5% Difco Bacto agar). Genomic DNA was prepared according to the protocol of Niemann et al. [J. Appl. Microbiol. 82:477-484 (1997)]. Genes coding for 16S rDNA were amplified from genomic DNA from strains R-1512, R1534, R114 and R-1506 by polymerase chain reaction (PCR) using the primers shown in Table 3.

Table 3. Primers used for PCR amplification of DNA coding for 16S rDNA in *Paracoccus* sp. strains R-1512, R1534, R114, and R-1506.

| Primer name ^a | Sequence (5'→3') | SEQ ID NO | Position ^b |
|--------------------------|------------------------------|-------------|-----------------------|
| 16F27 | AGA GTT TGA TCC TGG CTC AG | SEQ ID NO:1 | 8-27 |
| 16F38 | CTG GCT CAG GAC/T GAA CGC TG | SEQ ID NO:2 | 19-38 |
| 16R1522 | AAG GAG GTG ATC CAG CCG CA | SEQ ID NO:3 | 1541-1522 |

^aF, forward primer; R, reverse primer. Forward primer 16F27 (Synonym: PA) was used for strains R1534 and R-1506, while forward primer 16F38 (Synonym: ARI C/T) was used for strains R-1512 and R114. The reverse primer 16R1522 (Synonym: PH) was used for all strains.

^bHybridization position referring to *E. coli* 16S rDNA gene sequence numbering.

The PCR-amplified DNAs were purified using the Qiaquick PCR Purification Kit (Qiagen GmbH, Hilden, Germany). Complete sequencing was performed using an Applied Biosystems, Inc. 377 DNA Sequencer and the protocols of the manufacturer (Perkin-Elmer, Applied Biosystems Division, Foster City, CA, USA) using the "ABI PRISM™ Big Dye™ Terminator Cycle Sequencing Ready Reaction Kit (with AmpliTaq® DNA Polymerase, Fs)". The primers used for DNA sequencing are shown in Table 4.

Table 4. Primers used for sequencing PCR-amplified segments of genes coding for 16S rDNA in *Paracoccus* sp. strains R-1512, R1534, R114 and R-1506.

| Primer name ^a / Synonym | Sequence (5'→3') | SEQ ID NO | Position ^b |
|---------------------------------------|------------------|-----------|-----------------------|
|---------------------------------------|------------------|-----------|-----------------------|

| | | | |
|---------------|----------------------------|--------------|-----------|
| 16F358/*Gamma | CTC CTA CGG GAG GCA GCA GT | SEQ ID NO:4 | 339-358 |
| 16F536/*PD | CAG CAG CCG CGG TAA TAC | SEQ ID NO:5 | 519-536 |
| 16F926/*O | AAC TCA AAG GAA TTG ACG G | SEQ ID NO:6 | 908-926 |
| 16F1112/*3 | AGT CCC GCA ACG AGC GCA AC | SEQ ID NO:7 | 1093-1112 |
| 16F1241/*R | GCT ACA CAC GTG CTA CAA TG | SEQ ID NO:8 | 1222-1241 |
| 16R339/Gamma | ACT GCT GCC TCC CGT AGG AG | SEQ ID NO:9 | 358-339 |
| 16R519/PD | GTA TTA CCG CGG CTG CTG | SEQ ID NO:10 | 536-519 |
| 16R1093/3 | GTT GCG CTC GTT GCG GGA CT | SEQ ID NO:11 | 1112-1093 |

^aF, forward primer; R, reverse primer.

^bHybridization position referring to *E. coli* 16S rDNA gene sequence numbering.

Five forward and three reverse primers were used to obtain a partial overlap of sequences, ensuring highly reliable assembled sequence data. Sequence assembly was performed using the program AutoAssembler (Perkin-Elmer, Applied Biosystems Division, Foster City, CA, USA). Phylogenetic analysis was performed using the software package Gene-Compar™ (v. 2.0, Applied Maths B.V.B.A., Kortrijk, Belgium) after including the consensus sequences (from strains R-1512, R1534, R114 and R-1506) in an alignment of small ribosomal subunit sequences collected from the international nucleotide sequence library EMBL. This alignment was pairwise calculated using an open gap penalty of 100% and a unit gap penalty of 0%. A similarity matrix was created by homology calculation with a gap penalty of 0% and after discarding unknown bases. A resulting tree was constructed using the neighbor-joining method.

The nucleotide sequence of the 16S rDNA gene from *Paracoccus* sp. strain R-1512 is illustrated as SEQ ID NO:12. The distance matrix, presented as the percentage of 16S rDNA sequence similarity, between strain R-1512 and its closest relatives, is shown in Table 5. The sequences from strains R-1512 and its mutant derivatives R1534 and R114 were identical. The sequence from R-1506 differed by only one nucleotide from the sequence from latter strains. This demonstrated strains R-1512 and R-1506 are phylogenetically highly related and likely belong to the same species (confirmed by DNA:DNA hybridization, see below). Comparison of the R-1512 and R-1506 sequences with those publicly available at the EMBL library located R-1512 and R-1506 in the genus *Paracoccus*. However, the sequence similarities observed with all currently taxonomically validly described *Paracoccus* species was <97%, the value generally accepted as the limit for a possible relatedness at the species level [Stackebrandt and Goebel, Int. J. Syst. Bacteriol.

44:846-849 (1994)]. This demonstrated that strains R-1512 (and its mutant derivatives) and R-1506 belong to one or two new *Paracoccus* species. Sequence similarities of >97% (significant for a possible relationship at the species level), were observed between four unnamed *Paracoccus* strains and strains R-1512, R1534, R114 and R-1506, suggesting that one or more of the unnamed (MBIC) strains may relate at the species level to strains R-1512 and R-1506. Based on cluster analysis (phylogenetic tree depicting the phylogenetic relatedness between *Paracoccus* sp. strains R-1512, R1534, R114, R-1506, MBIC3966, and other members of the genus *Paracoccus*), strains R-1512, R1534, R114, R-1506 and four unnamed *Paracoccus* strains (MBIC3024, MBIC3966, MBIC4017 and MBIC4020) were selected for DNA:DNA hybridization experiments to analyze species relatedness.

Table 5. Distance matrix, presented as the percentage of 16S rDNA sequence similarity, between *Paracoccus* sp. strain R-1512 and its closest relatives.

| Strain ^a | EMBL Accession number | % Similarity |
|--|-----------------------|--------------|
| R-1512 | - | 100 |
| R1534 | - | 100 |
| R114 | - | 100 |
| R-1506 | - | 99.9 |
| <i>Paracoccus</i> sp. MBIC3966 | AB018688 | 100 |
| <i>Paracoccus</i> sp. MBIC3024 | AB008115 | 98.2 |
| <i>Paracoccus</i> sp. MBIC4020 | AB025191 | 98.1 |
| <i>Paracoccus</i> sp. MBIC4036 | AB025192 | 97.0 |
| <i>Paracoccus</i> sp. MBIC4017 | AB025188 | 96.9 |
| <i>Paracoccus</i> sp. MBIC4019 | AB025190 | 96.8 |
| <i>Paracoccus</i> sp. MBIC4018 | AB025189 | 96.4 |
| <i>Paracoccus marcusii</i> DSM 11574 ^T | Y12703 | 96.2 |
| <i>Paracoccus carotinifaciens</i> E-396 ^T | AB006899 | 96.1 |
| <i>Paracoccus solventivorans</i> DSM 6637 ^T | Y07705 | 95.4 |
| <i>Paracoccus thiocyanaticus</i> THIO11 ^T | D32242 | 95.3 |
| <i>Paracoccus aminophilus</i> -JCM 7686 ^T | D32239 | 95.1 |
| <i>Paracoccus alcaliphilus</i> JCM 7364 ^T | D32238 | 95.0 |

| | | |
|--|--------|------|
| <i>Paracoccus pantotrophicus</i> ATCC 35512 ^T | Y16933 | 95.0 |
| <i>Paracoccus denitrificans</i> ATCC 17741 ^T | Y16927 | 94.8 |
| <i>Paracoccus versutus</i> IAM 12814 ^T | D32243 | 94.7 |
| <i>Paracoccus kocurii</i> JCM 7684 ^T | D32241 | 94.6 |
| <i>Paracoccus aminovorans</i> JCM 7685 ^T | D32240 | 94.4 |
| <i>Paracoccus alkenifer</i> A901/1 ^T | Y13827 | 94.3 |
| <i>Rhodobacter capsulatus</i> ATCC 11166 ^T | D16428 | 92.9 |

^aType strains are followed by a ^T

- DNA:DNA hybridization and determination of G+C content. The bacteria set forth in Table 5 were grown in LMG medium 185. Genomic DNA was prepared according to the protocol of Wilson [In Ausabel et al. (eds.), Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York, 2.4.1-2.4.5 (1987)]. The G+C content of the DNA's was determined by HPLC according to Mesbach et al. [Int. J. Syst. Bacteriol. 39:159-167 (1989)] as modified by Logan et al. [Int. J. Syst. Evol. Microbiol. 50:1741-1753 (2000)]. Reported values are the mean of these measurements on the same DNA sample. DNA:DNA hybridizations were performed using the initial renaturation rate method as described by De Ley et al. [Eur. J. Biochem. 12:133-142 (1970)]. The hybridization temperature was 81.5°C. For this method, an average deviation of +/-5.8% has been reported by Vauterin et al. [Int. J. Syst. Bacteriol. 45:472-489 (1995)]. The G+C content of the bacterial DNA's and the results of the DNA hybridization experiments are summarized in Table 6.
- 15 Table 6. G+C content (mol %) of DNA from *Paracoccus* spp. strains and per cent DNA homology between the strains.

| Strain | %G+C | % DNA Homology | | | | | | | |
|----------|------|----------------|-----------------|-----|-----|-----|-----|-----|--|
| R-1512 | 67.6 | 100 | | | | | | | |
| R1534 | 67.7 | 96 | 100 | | | | | | |
| R114 | 67.5 | 100 | 97 | 100 | | | | | |
| R-1506 | 67.5 | 94 | 90 | 88 | 100 | | | | |
| MBIC3024 | 65.4 | 31 | nd ^a | nd | 31 | 100 | | | |
| MBIC3966 | 66.9 | 93 | nd | nd | 88 | 32 | 100 | | |
| MBIC4017 | 67.2 | 32 | nd | nd | 31 | 24 | 24 | 100 | |

| | | | | | | | | | |
|----------|------|----|----|----|----|----|----|----|-----|
| MBIC4020 | 68.4 | 27 | nd | nd | 25 | 25 | 23 | 34 | 100 |
|----------|------|----|----|----|----|----|----|----|-----|

^anot determined

- Strains R-1512, R1534, R114, R-1506 and MBIC3966 showed a DNA homology of >70% (the generally accepted limit for species delineation [Wayne et al., Int. J. Syst. Bacteriol. 37:463-464 (1987)]), and therefore belong to the same species within the genus *Paracoccus*.
- 5 The G+C content of these five strains varied from 66.9%-67.7%, thus remaining within 1%, characteristic for a well defined species. On the other hand, the low DNA homology between strains MBIC3024, MBIC4017 and MBIC4020 and strains R-1512, R1534, R114, R-1506 and MBIC3966 showed that MBIC3024, MBIC4017 and MBIC4020 each belong to a different genomic species within the genus *Paracoccus*.
- 10 DNA fingerprinting using AFLP™. AFLP™ is a PCR-based technique for whole genome DNA fingerprinting via the selective amplification and selective visualization of restriction fragments [Vos et al., Nucleic Acids Research 23:4407-4414 (1995); Janssen et al., supra]. In this analysis, *Paracoccus* sp. strains R-1512, R1534, R114, R-1506, MBIC3966, and *Paracoccus marcusii* DSM 11574^T were compared to evaluate infraspecies relatedness. These
- 15 bacteria were grown in LMG medium 185. Genomic DNA from each of these bacteria was prepared according to the protocol of Wilson (supra). Purified DNA was digested by two restriction enzymes, a 4-base cutter and a 6-base cutter. In this way, a limited number of fragments with two different ends and of suitable size for efficient PCR were obtained. Adaptors (small double-stranded DNA molecules of 15-20 bp) containing one compatible
- 20 end were ligated to the appropriate "sticky" end of the restriction fragments. Both adaptors are restriction halfsite-specific, and have different sequences. These adaptors serve as binding sites for PCR primers. Here, the restriction enzymes used were *ApaI* (a hexacutter, recognition sequence GGGCC/C) and *TaqI* (a tetracutter, recognition sequence T/GCA). The sequences of the adaptors ligated to the sticky ends generated by
- 25 cleavage with the restriction enzymes are shown in Table 7 (SEQ ID Nos:13-22). PCR was used for selective amplification of the restriction fragments. The PCR primers specifically annealed with the adaptor ends of the restriction fragments. Because the primers contain, at their 3' end, one so-called "selective base" that extends beyond the restriction site into the fragment, only those restriction fragments that have the appropriate complementary
- 30 sequence adjacent to the restriction site were amplified. The sequences of the six PCR primer combinations used are also shown in Table 7.

Table 7. Adaptors and PCR primers used for AFLP™ analysis.

| | Sequence | SEQ ID NO |
|--|----------------------------|--------------|
| Adaptors corresponding to restriction enzyme <i>Apal</i> | | |
| Adaptor 93A03 | 5'-TCGTAGACTGCGTACAGGCC-3' | SEQ ID NO:13 |
| Adaptor 93A04 | 3'-CATCTGACGCATGT-5' | SEQ ID NO:14 |
| Adaptors corresponding to restriction enzyme <i>TaqI</i> | | |
| Adaptor 94A01 | 5'-GACGATGAGTCCTGAC-3' | SEQ ID NO:15 |
| Adaptor 94A02 | 3'-TACTCAGGACTGGC-5' | SEQ ID NO:16 |
| | Sequence | SEQ ID NO |
| Primer combination 1 (PC A) | | |
| A01 | 5'GACTGCGTACAGGCCCA3' | SEQ ID NO:17 |
| T01 | 5'CGATGAGTCCTGACCGAA3' | SEQ ID NO:18 |
| Primer combination 2 (PC B) | | |
| A01 | 5'GACTGCGTACAGGCCCA3' | SEQ ID NO:17 |
| T02 | 5'CGATGAGTCCTGACCGAC3' | SEQ ID NO:19 |
| Primer combination 3 (PC D) | | |
| A02 | 5'GACTGCGTACAGGCCCC3' | SEQ ID NO:20 |
| T01 | 5'CGATGAGTCCTGACCGAA3' | SEQ ID NO:18 |
| Primer combination 4 (PC I) | | |
| A03 | 5'GACTGCGTACAGGCCCG3' | SEQ ID NO:21 |
| T03 | 5'CGATGAGTCCTGACCGAG3' | SEQ ID NO:22 |
| Primer combination 5 (PC G) | | |
| A03 | 5'GACTGCGTACAGGCCCG3' | SEQ ID NO:21 |
| T01 | 5'CGATGAGTCCTGACCGAA3' | SEQ ID NO:18 |
| Primer combination 6 (PC H) | | |
| A03 | 5'GACTGCGTACAGGCCCG3' | SEQ ID NO:21 |
| T02 | 5'CGATGAGTCCTGACCGAC3' | SEQ ID NO:19 |

Following amplification, the PCR products were separated according to their length on a high resolution polyacrylamide gel using a DNA sequencer (ABI-377). Fragments that contained an adaptor specific for the restriction halfsite created by the 6-bp cutter were

visualized by autoradiography due to the 5'-end labeling of the corresponding primer with ³²P. The electrophoretic patterns were scanned and numerically analyzed with Gel-Compar™ 4.2 software (Applied Maths, B.V.B.A., Kortrijk, Belgium) and clustered using the Pearson curve matching coefficient and unweighted pair group averages linking [clustering methods were reviewed by Sneath and Sokal, In: Numerical Taxonomy. Freeman & Son, San Francisco (1973)].

In all six primer combinations (PC A-H, Table 7), the DNA fingerprints of *Paracoccus* sp. strains R-1512, R1534 and R114 were highly similar if not identical. In cases where minor differences were observed, reproducibility was not evaluated. The high similarity or identity among the three strains was expected as strains R1534 and R114 were derived from strain R-1512. With all primer combinations, strains R-1512, R1534 and R114 were clearly discriminated from strains R-1506 and MBIC3966, the latter two strains equally belonging to the new *Paracoccus* species. However, the fingerprints provide no clear indication that strains R-1512, R1534 and R114 are more related to either R-1506 or MBIC3966. Under the conditions used, the five strains of the new species cluster at an average level of about 58% similarity (this value is the mean of the six values of the branching points of the new species in the six AFLP™ experiments (six primer combinations)), and the cluster can clearly be discriminated from the profile of *Paracoccus marcusii* DSM 11574^T, the type strain of a phylogenetically related carotenoid-producing *Paracoccus* species. The mean similarity value of the six branching points for *Paracoccus marcusii* DSM 11574^T and the new species was about 11%.

Fatty acid analysis. The fatty acid composition of the cell membranes of *Paracoccus* sp. strains R-1512, R1534, R114, R-1506, MBIC3966 were compared to the type strains *P. marcusii* DSM 11574^T, *P. carotinifaciens* E-396^T and *P. solventivorans* DSM 6637^T. The bacteria were grown for 24 hours at 28°C in LMG medium 185. The fatty acid compositions were determined by gas chromatography using the commercial system MIDI (Microbial Identification System, Inc., DE, USA). Extraction and analysis of fatty acids was performed according to the recommendations of the MIDI system. Table 8 summarizes the results for all strains tested. For the five strains of the new *Paracoccus* species (R-1512, R1534, R114, R-1506, MBIC3966), the mean profile was calculated. All eight organisms showed a comparable fatty acid composition of their cell membranes, with 18:1 w7c as the major compound. Only minor differences in fatty acid composition were observed between the new *Paracoccus* species and the three type strains.

Utilization of carbon sources for growth. For testing the aerobic utilization of carbon sources, BIOLOG-SF-N Microplate microtiter plates (Biolog Inc., Hayward, CA, USA) containing 95 substrates were used with the exception that the substrate in well E6 was D,L-lactic acid methyl ester instead of the usual sodium salt of D,L-lactic acid. Cells from each of the strains identified in Table 9 were grown for 24 hours at 28°C in LMG medium 12 (Marine Agar, Difco 0979). A cell suspension with a density equivalent to 0.5 McFarland units was prepared in sterile distilled water. From this suspension, 18 drops were transferred into 21 ml of AUX medium (API 20NE, bioMérieux, France) and mixed gently. 0.1 Milliliters of the suspension was transferred to each well of the BIOLOG MicroPlates, and the plates were incubated at 30°C. Wells were visually checked for growth after 48 hours and after 6 days. Also, at 6 days the visual scoring was confirmed by reading the microtiter plates using the BIOLOG plate reader.

The results of the BIOLOG analysis are shown in Table 9. Growth (positive reaction) was determined as increased turbidity compared to the reference well without substrate. A distinction was made between good growth (+), weak growth (\pm) and no growth (-). Results in parentheses are those obtained after 6 days if different from the results obtained after 48 hours. A question mark indicates an unclear result at 6 days. Of the 95 carbon sources tested, 12 could be used, and 47 could not be used, for growth by all five strains comprising the new *Paracoccus* species (R-1512, R1534, R114, R-1506 and MBIC3966). These five strains gave variable growth responses to the remaining 36 substrates. The new *Paracoccus* species could be distinguished from the two other carotenoid-producing bacteria (*P. marcusii* DSM 11574^T and *P. carotinifaciens* E-396^T) by their inability to use seven carbon sources (adonitol, i-erythritol, gentiobiose, β -methylglucoside, D-sorbitol, xylitol and quinic acid). Two carbon sources that were utilized by all five members of the new *Paracoccus* species (L-asparagine and L-aspartic acid) were not used for growth by *P. marcusii* DSM 11574^T.

Table 8. Fatty acid composition of cell membranes of *Paracoccus* sp. strains R-1512, R1534, R114, R-1506, MBIC3966 and three type strains of other *Paracoccus* species, i.e. *P. marcusii* DSM 11574^T, *P. carotinifaciens* E-396^T and *P. solventivorans* DSM 6637^T

| | Mean % for: | % for: | | |
|----------|--|------------------------|--------------------|-----------------------|
| Name | R-1512, R1534, R114, R-1506 and MBIC3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| 10:0 3OH | 4.9 \pm 1.1 | 6.2 | 3.4 | 3.6 |

| | | | | |
|------------------|---|------------------------|--------------------|-----------------------|
| Unnamed 11.799 | 3.6 ± 0.5 | 4.9 | 2.8 | 3.0 |
| Unnamed 15.275 | 1.5 ± 0.3 | 2.9 | 1.1 | ND ^a |
| 16:0 | 0.3 ± 0.2 | ND | 0.3 | 0.7 |
| 17:1 w8c | ND | ND | 0.6 | 0.8 |
| 17:0 | 0.1 ± 0.1 | ND | 0.3 | 1.3 |
| 18:1 w7c | 80.5 ± 1.8 | 80.3 | 84.0 | 79.0 |
| | Mean % for: | % for: | | |
| Name | R-1512, R1534, R114, R-1506 and MBIC3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| 18:0 | 3.6 ± 0.4 | 2.6 | 5.2 | 6.6 |
| 18:0 3OH | 0.6 ± 0.4 | ND | ND | ND |
| 19:0 | ND | ND | ND | 0.7 |
| 20:1 w7c | 0.8 ± 0.2 | ND | 0.2 | 2.0 |
| Summed feature 2 | 2.7 ± 0.4 | 3.0 | 2.1 | 2.6 |
| Summed feature 3 | 0.7 ± 0.5 | ND | 0.2 | ND |
| TOTAL | 99.3 | 99.9 | 100.2 | 100.3 |

^aND, not detected

Biochemical tests. Selected biochemical features were tested using the API 20NE strip (bioMérieux, France). Cells from each of the bacterial strains identified in Table 10 were grown for 24 hours at 28°C on LMG medium 12. Cell suspensions were prepared and strips inoculated according to the instructions of the manufacturer. Strips were incubated at 28°C and results determined after 24 and 48 hours. The results are summarized in Table 10. Of the nine features tested, only one (urease activity) gave a variable response among the five strains of the new *Paracoccus* species. These nine tests did not differentiate between the new *Paracoccus* species and *Paracoccus marcusii* DSM 11574^T and *P. carotini-faciens* E-396^T.

Table 9. Utilization of carbon sources for growth by *Paracoccus* spp. strains.

| | R1512 | R1534 | R114 | R1506 | MBIC 3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
|--|-------|-------|------|-------|--------------|---------------------------|--------------------|--------------------------|
| | | | | | | | | |

| | | | | | | | | |
|------------------------|------------|-----------|------|------------|--------------|---------------------------|--------------------|--------------------------|
| α -Cyclodextrin | - | - | - | - | - | - | - | - |
| Dextrin | - | - | - | - | - | - | - | -(\pm) |
| Glycogen | - | - | - | - | - | - | - | - |
| Tween 40 | - | - | - | - | - | - | -(?) | - |
| Tween 80 | - | - | - | - | - | - | - | - |
| GalNAc | - | - | - | - | - | - | - | - |
| | R1512 | R1534 | R114 | R1506 | MBIC 3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| GlucNAc | - | - | - | - | - | - | - | -(?) |
| Adonitol | - | - | - | - | - | + | + | - |
| L-Arabinose | - | - | - | - | - | + | - | + |
| D-Arabitol | + | + | + | + | \pm (+) | + | + | - |
| Cellobiose | \pm (+) | \pm (+) | -(?) | -(+) | -(\pm) | + | + | -(+) |
| i-Erythritol | - | - | - | - | - | + | + | - |
| D-Fructose | + | + | + | + | - | + | + | + |
| L-Fucose | - | - | - | - | - | - | + | - |
| D-Galactose | + | + | + | \pm (+) | \pm (+) | + | + | -(\pm) |
| Gentiobiose | - | - | - | - | - | + | + | -(\pm) |
| α -D-Glucose | + | + | + | \pm (+) | -(+) | + | \pm (+) | + |
| m-Inositol | + | + | + | -(+) | -(+) | + | -(\pm) | - |
| α -Lactose | + | \pm (+) | -(+) | -(+) | -(+) | + | + | \pm (+) |
| Lactulose | -(\pm) | -(+) | -(+) | -(\pm) | - | + | + | -(+) |
| Maltose | + | + | -(+) | -(+) | -(\pm) | + | + | -(+) |
| D-Mannitol | + | + | + | + | -(+) | + | + | -(\pm) |
| D-Mannose | + | + | + | + | -(\pm) | + | + | -(+) |
| D-Melibiose | + | + | + | -(+) | -(+) | + | + | -(?) |
| β -Methylgluc | - | - | - | - | - | + | + | + |

| | | | | | | | | |
|----------------------|-------|-------|------|-------|--------------|---------------------------|--------------------|--------------------------|
| D-Psicose | -(+) | ±(+) | ±(+) | - | -(+) | - | ± | - |
| D-Raffinose | - | - | - | - | - | -(+) | + | - |
| L-Rhamnose | - | - | - | - | - | - | - | -(?) |
| D-Sorbitol | - | - | - | - | - | + | + | - |
| Sucrose | + | + | ±(+) | -(+) | - | + | + | + |
| D-Trehalose | + | + | -(+) | -(+) | -(+) | + | + | + |
| | R1512 | R1534 | R114 | R1506 | MBIC 3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| Turanose | -(+) | -(+) | - | - | - | + | + | + |
| Xylitol | - | - | - | - | - | + | + | - |
| Methylpyruvate | ± | - | ± | -(?) | ± | - | + | -(±) |
| MMSucc | ±(+) | ± | -(±) | -(+) | -(±) | -(+) | + | - |
| Acetic acid | - | - | ± | - | - | - | - | + |
| Cis-aconitic acid | - | ± | ± | - | - | ± | - | - |
| Citric acid | - | ± | ± | - | - | ± | - | - |
| Formic acid | - | - | - | - | - | - | - | - |
| GalAlactone | -(±) | -(±) | -(±) | - | - | - | -(±) | -(?) |
| GalacturonicA | - | - | - | - | - | -(+) | -(±) | - |
| D-Gluconic acid | + | + | + | -(±) | -(±) | + | + | + |
| GlucosaminicA | - | - | - | - | - | - | - | - |
| GlucuronicA | ± | + | + | -(±) | - | ±(+) | - | - |
| AHBA | -(±) | - | -(±) | - | -(+) | - | - | - |
| BHBA | + | + | + | -(±) | ± | -(+) | + | + |
| GHBA | - | - | - | - | - | - | - | - |
| PHPAA | - | - | - | - | - | - | - | -(+) |
| Itaconic acid | - | - | - | - | - | - | - | - |

| | | | | | | | | |
|------------------|-------|-------|------|-------|--------------|---------------------------|--------------------|--------------------------|
| AKBA | - | - | - | - | - | - | - | -(±) |
| AKGA | - | - | - | -(±) | -(?) | -(±) | -(+) | -(±) |
| AKVA | - | - | - | - | - | - | - | - |
| LAME | - | - | - | - | - | - | - | - |
| Malonic acid | - | - | - | - | - | - | - | - |
| Propionic acid | - | ± | ± | - | - | ± | + | + |
| | R1512 | R1534 | R114 | R1506 | MBIC 3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| Quinic acid | - | - | - | - | - | + | + | - |
| SaccA | -(+) | ± | - | -(±) | - | - | - | - |
| Sebacic acid | -(+) | -(+) | -(+) | -(+) | -(±) | - | -(+) | - |
| Succinic acid | - | - | - | - | - | -(+) | ± | -(?) |
| BromosuccA | - | - | - | - | - | ± | - | - |
| Succinamic acid | - | - | - | - | - | -(+) | -(+) | - |
| Glucuronamide | - | - | - | - | -(±) | - | - | - |
| Alaninamide | - | - | - | - | - | -(+) | + | - |
| D-Alanine | - | - | -(+) | - | - | - | - | - |
| L-Alanine | + | + | + | + | - | -(+) | + | + |
| L-Alanyl-glycine | -(+) | - | -(+) | - | - | - | -(+) | -(?) |
| L-Asparagine | + | + | ±(+) | + | ±(+) | - | + | - |
| L-Aspartic acid | + | + | ±(+) | -(+) | -(+) | - | + | - |
| L-Glutamic acid | + | + | + | + | ±(+) | -(+) | + | -(+) |
| GAA | - | - | - | -(±) | - | - | - | - |
| GGA | -(?) | - | - | -(?) | - | - | -(±) | - |
| L-Histidine | - | - | - | - | - | -(?) | - | + |
| HydPro | - | - | - | - | - | - | - | + |
| L-Leucine | -(±) | -(+) | -(+) | -(+) | - | -(+) | -(?) | -(+) |

| | | | | | | | | |
|-----------------|-------|-------|------|-------|--------------|---------------------------|--------------------|--------------------------|
| L-Ornithine | - | -(+) | ±(+) | -(±) | - | - | -(+) | - |
| L-Phenylalanine | - | - | - | - | - | - | - | - |
| L-Proline | + | + | + | + | - | -(+) | + | + |
| PyroGluA | + | + | + | + | ±(+) | -(+) | + | - |
| D-Serine | - | - | - | - | - | - | - | - |
| L-Serine | ± | ±(+) | -(+) | -(±) | -(+) | -(+) | -(+) | + |
| | R1512 | R1534 | R114 | R1506 | MBIC 3966 | DSM 11574 ^T | E-396 ^T | DSM 6637 ^T |
| L-Threonine | - | - | - | - | - | -(+) | - | - |
| D,L-Carnitine | - | - | - | - | - | - | - | - |
| GABA | - | - | - | - | -(+) | - | -(+) | -(+) |
| Urocanic acid | - | - | - | - | - | - | - | -(+) |
| Inosine | - | -(±) | - | - | - | -(±) | -(+) | -(+) |
| Uridine | - | - | - | - | - | -(±) | -(+) | - |
| Thymidine | - | - | - | - | - | -(±) | -(±) | - |
| PEA | - | - | - | - | - | - | - | - |
| Putresceine | - | - | - | - | - | - | - | - |
| 2-Aminoethanol | - | - | - | - | - | - | - | - |
| 2,3-Butanediol | - | - | - | - | - | - | - | - |
| Glycerol | + | + | + | -(+) | - | + | + | - |
| GlycP | - | - | - | - | -(±) | - | - | - |
| Gluc-1-P | - | - | - | - | - | - | -(±) | - |
| Gluc-6-P | - | - | - | - | - | - | - | - |

GalNAc: N-Acetyl-D-galactosamine; GlucNAc: N-Acetyl-D-glucosamine; β-Methylgluc:

β-Methylglucoside; MMSucc: Mono-methylsuccinate; GalAlactone: D-Galactonic acid

lactone; GalacturonicA: D-Galacturonic acid; GlucosaminicA: D-Glucosaminic acid;

GlucuronicA: D-Glucuronic acid; AHBA: α-Hydroxybutyric acid; BHBA: β-Hydroxy-

5 butyric acid; GHBA: γ-Hydroxybutyric acid; PHPAA: p-Hydroxyphenylacetic acid; AKBA:

- 62 -

- α -Ketobutyric acid; AKGA: α -Ketoglutaric acid; AKVA: α -Ketovaleric acid; LAME: D,L-Lactic acid methyl ester; SacCA: D-Saccharic acid; BromosuccA: Bromosuccinic acid; GAA: Glycyl-L-aspartic acid; GGA: Glycyl-L-glutamic acid; HydPro: Hydroxy-L-proline; PyroGluA: L-Pyroglutamic acid; GABA: γ -Aminobutyric acid; PEA: Phenylethylamine;
- 5 GlycP: D,L- α -Glycerolphosphate; Gluc-1-P: Glucose-1-phosphate; Gluc-6-P: Glucose-6-phosphate

Table 10. Biochemical features of *Paracoccus* spp. strains: 12 = R1512; 34 = R1534; 14 = R114, 06 = R1506; 66 = MBIC3966; 74 = DSM 11574^T, 96 = E-396^T, 37 = DSM 6637^T

| | 12 | 34 | 14 | 06 | 66 | 74 | 96 | 37 |
|----------------------------------|---------|---------|---------|---------|----|----|----|----|
| Reduction nitrate to nitrite | - | - | - | - | - | - | - | + |
| Reduction nitrate to nitrogen | - | - | - | - | - | - | - | + |
| Indole from tryptophan | - | - | - | - | - | - | - | - |
| Fermentation of glucose | - | - | - | - | - | - | - | - |
| Arginine hydrolase | - | - | - | - | - | - | - | - |
| Urease | S / + 5 | - | - | S / + 5 | + | - | - | - |
| Esculine hydrolysis ^a | weak | S / + 5 | S / + 5 | + | + | + | + | + |
| Gelatine hydrolysis ^b | - | - | - | - | - | - | - | - |
| β -Galactosidase | + | + | + | + | + | + | + | - |

^a: β -glucosidase; ^b: protease; S / + 5: Slow + 5 days

- 10 **Physiological tests.** Several physiological and morphological tests were performed on the five strains of the new *Paracoccus* species, along with *Paracoccus marcusii* DSM 11574^T, *Paracoccus carotinifaciens* E-396^T and *Paracoccus solventivorans* DSM 6637^T. The methods used for each test were as follows.

Temperature range for growth. Cells were grown for 24 hours at 28°C on LMG medium 12.

- 15 A cell suspension with a density of between 1-2 McFarland units was prepared in sterile distilled water. From this suspension, 3 drops were transferred onto the agar surface of LMG medium 12. One drop was diluted by streaking, the other 2 drops were left undisturbed. The plates were incubated under aerobic conditions at 10°C, 25°C, 30°C, 33°C, 37°C and 40°C, and checked for growth after 24 hours, 48 hours and 5 days. Growth was
- 20 determined as visual growth (confluent in the drops and as colonies in the streaks with

diluted inoculum) compared to the growth at 30°C (i.e., the "control"). Scoring was done (vs. the control plate) as follows; better growth (++), good (equivalent to the control) growth (+), weaker growth (\pm), poor growth (\pm), and no growth (-). Results in parentheses are those observed in the streaks if different from the confluent growth in the undisturbed drops.

Salt tolerance. Cells were grown for 24 hours at 28°C on LMG medium 12. A cell suspension with a density of between 1-2 McFarland units was prepared in sterile distilled water. From this suspension, 3 drops were transferred onto the agar surface of LMG medium 12 supplemented with NaCl to reach final concentrations of 3%, 6% and 8%. One drop was diluted by streaking, the other 2 drops were left undisturbed. The plates were incubated under aerobic conditions at 28°C and checked for growth after 24 hours, 48 hours and 5 days. Growth was determined as visual growth (confluent in the drops and as colonies in the streaks with diluted inoculum) compared to the growth without added NaCl (control). Scoring was done (vs. the control plate) as follows; better growth (++), good (equivalent to the control) growth (+), weaker growth (\pm), poor growth (\pm), and no growth (-). Results in parentheses are those observed in the streaks if different from the confluent growth in the undisturbed drops.

pH Range for growth. Cells were grown for 24 hours at 28°C in LMG medium 12. A cell suspension with a density of between 1-2 McFarland units was prepared in sterile distilled water. From this suspension, 3 drops were transferred into tubes containing 10 ml liquid LMG medium 12 with modified pH, giving final pH values after autoclaving of pH 6.1, pH 6.3, pH 7.0, pH 7.7, pH 8.1 and pH 9.1. The liquid cultures were incubated aerobically (with shaking) at 28°C. Growth was checked at 24 hours, 48 hours, 3 days and 6 days. Growth was determined as increased turbidity (measured as % transmission using the BIOLOG turbidimeter) compared to growth at pH 7.0 (control). Scoring was done (vs. the control) as follows; better growth (++), good (equivalent to the control) growth (+), weaker growth (\pm), poor growth (\pm), and no growth (-).

Starch hydrolysis. Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A loopful of cells was taken from the plate and transferred as one streak onto the agar surface of LMG medium 12 supplemented with 0.2% soluble starch. Plates were then incubated under aerobic conditions at 28°C. When the strains had developed good growth (after 48 hours), the plate was flooded with lugol solution (0.5% I₂ and 1% KI in distilled water). Hydrolysis was determined as a clear zone alongside the growth (in contrast to the blue color of the agar where starch was not hydrolyzed).

Denitrification. Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A loopful of cells was taken from the plate and stabbed into tubes containing semi-solid (0.1% agar) LMG medium 12 supplemented with 1% KNO₃. The plates were incubated at 28°C for 5 days. Denitrification (N₂ from nitrate) was determined as gas formation alongside the stab.

Growth under anaerobiosis without electron acceptor added. Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A loopful of cells was taken from the plate and streaked onto the agar surface of LMG medium 12. The agar plates were incubated under anaerobic conditions (ca. 10% CO₂ + ca. 90% N₂) at 30°C. Plates were checked for growth after 24 hours and after 5 days. Growth was determined visually and compared to the aerobic (control) condition. Scoring was done (vs. the control) as follows; better growth (++), good (equivalent to the control) growth (+), weaker growth (±), poor growth (±), and no growth (-).

Growth under anaerobic conditions with glucose added (fermentation). Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A loopful of cells was taken from the plate and stabbed into tubes containing the basal agar medium of Hugh and Leifson [J. Bacteriol. 66:24-26 (1953)]. Paraffin oil was added to the top of the medium, and the tubes were incubated at 30°C. Tubes were checked for growth and acid formation after 48 hours and after 5 days. Growth was determined visually. Scoring was done as follows; good growth (+), poor growth (±), and no growth (-).

Growth under anaerobic conditions with KNO₃ as electron acceptor. Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A loopful of cells was taken from the plate and streaked onto the agar surface of LMG medium 12 supplemented with 0.1% KNO₃. The plates were incubated under anaerobic conditions (ca. 10% CO₂ + ca. 90% N₂) at 30°C, and checked for growth after 3 days. Growth was determined as visual growth compared to the aerobic (control) condition. Scoring was done (vs. the control) as follows; better growth(++), good (equivalent to the control) growth (+), weaker growth (±), poor growth (±), and no growth (-).

Catalase and oxidase reactions. Cells were grown for 24 hours at 28°C on LMG medium 12 plates. A positive result for catalase activity was the production of gas bubbles after suspending a colony in one drop of 10% H₂O₂. A positive result for oxidase activity was the development of a purple-red color after rubbing a colony on filter paper soaked with 1% tetramethylparaphenylene.

- 65 -

Colony pigmentation. Cells were grown for 5 days at 28°C on LMG medium 12. Color of colonies was observed visually.

Cell morphology and motility. Cells were grown for 24 hours at 28°C on LMG medium 12. Cell suspensions were made in sterile saline. Cell morphology and motility were observed
5 microscopically using an Olympus light microscope equipped with phase contrast optics (magnification 1000x).

The results of the physiological and morphological tests are summarized in Table 11. The five strains of the new *Paracoccus* species responded essentially identically in all physiological and morphological tests performed. The tests that gave identical responses for all five
10 strains of the new *Paracoccus* species and that allowed discrimination of these organisms from *Paracoccus marcusii* DSM 11574^T and/or *Paracoccus carotinifaciens* E-396^T were: growth at 40°C, growth with 8% NaCl, growth at pH 9.1, and colony pigmentation.

Zeaxanthin production in strains R-1512, R1534, R114 and R-1506 strains. Strains R-1512, R1534, R114, and R-1506 were grown in ME medium, which contains (per liter
15 distilled water): 5 g glucose, 10 g yeast extract, 10 g tryptone, 30 g NaCl and 5 g MgSO₄·7H₂O. The pH of the medium was adjusted to 7.2 with 5N NaOH before sterilizing by autoclaving. All cultures (25-ml volume in 250-ml baffled Erlenmeyer flasks with plastic caps) were grown at 28°C with shaking at 200 rpm. Seed cultures were inoculated from frozen glycerolized stocks and grown overnight. Aliquots were
20 transferred to the experimental flasks to achieve an initial optical density at 660 nm (OD₆₆₀) of 0.16. Cultures were then grown at 28°C with shaking at 200 rpm. Growth was monitored throughout the cultivation and at 6, 10 (or 15 for strain R114), and 24 hours, an aliquot of the culture was removed for analysis of carotenoids by the method described in Example 1.

25 The doubling times of strains R-1512, R1534 and R-1506 under these conditions were 0.85 hours, 1.15 hours and 1.05 hours, respectively. Strain R114 reproducibly exhibited a bi-phasic growth profile; the doubling time of strain R114 in the initial phase was 1.4 hours while the doubling time in the second phase was 3.2 hours.

Table 12 shows the zeaxanthin production and Specific Formation (zeaxanthin production
30 normalized to OD₆₆₀) by the *Paracoccus* sp. strains in ME medium. The data are averages of four independent experiments, and within each experiment each strain was tested in duplicate flasks. The improved zeaxanthin production in the classically-derived mutant strains R1534 and R114 compared to the parental strain R-1512 is clearly shown. Zea-

- 66 -

xanthin production by strain R-1506 was approximately the same as strain R-1512. No other carotenoids were detected in any of the cultures.

Table 11. Physiological characteristics of *Paracoccus* spp. strains: 12 = R1512; 34 = R1534; 14 = R114, 06 = R1506; 66 = MBIC3966; 74 = DSM 11574^T, 96 = E-396^T, 37 = DSM 6637^T

| Time [days] | 12 | 34 | 14 | 06 | 66 | 74 | 96 | 37 |
|---------------------|------|------|------|------|------|------|------|------|
| Growth at 10°C | | | | | | | | |
| 1 | - | - | - | - | - | - | - | - |
| 5 | ±(±) | ±(±) | ±(-) | ±(±) | ±(-) | ±(±) | ±(±) | ±(±) |
| Growth at 25°C | | | | | | | | |
| 1 | + | + | + | + | +(±) | +(±) | +(±) | +(-) |
| 5 | + | + | + | + | + | + | + | + |
| Growth at 30°C | | | | | | | | |
| 1 | + | + | + | + | + | + | + | + |
| 5 | + | + | + | + | + | + | + | + |
| Growth at 33°C | | | | | | | | |
| 1 | + | + | + | + | + | + | + | + |
| 5 | + | + | + | + | + | + | + | + |
| Growth at 37°C | | | | | | | | |
| 1 | + | + | +(±) | + | + | ±(-) | ±(-) | + |
| 5 | + | + | + | + | + | ±(-) | ±(±) | + |
| Growth at 40°C | | | | | | | | |
| 1 | + | +(±) | +(-) | +(±) | ±(-) | - | - | +(*) |
| 5 | + | +(±) | +(-) | + | +(-) | - | - | +(*) |
| Growth with 3% NaCl | | | | | | | | |
| 1 | + | + | + | + | + | + | + | ± |
| 5 | + | + | + | + | + | + | + | + |
| Growth with 6% NaCl | | | | | | | | |
| 1 | +(±) | ±(±) | ±(±) | + | ±(±) | ±(-) | ±(-) | - |
| 5 | + | + | + | + | +(*) | +(±) | +(±) | - |

| Time [days] | 12 | 34 | 14 | 06 | 66 | 74 | 96 | 37 |
|-------------|--|------|------|------|------|------|------|----|
| | Growth with 8% NaCl | | | | | | | |
| 1 | +(±) | ±(±) | ±(-) | +(±) | ±(±) | - | - | - |
| 5 | + | + | + | + | +(*) | ±(-) | ±(-) | - |
| | Growth at pH 6.1 | | | | | | | |
| 1 | + | + | + | + | - | - | - | - |
| 6 | + | + | + | + | + | + | + | + |
| | Growth at pH 6.3 | | | | | | | |
| 1 | + | + | + | + | + | ± | + | ± |
| 6 | + | + | + | + | + | + | + | + |
| | Growth at pH 7.0 | | | | | | | |
| 1 | + | + | + | + | + | + | + | + |
| 6 | + | + | + | + | + | + | + | + |
| | Growth at pH 7.7 | | | | | | | |
| 1 | + | + | + | + | + | ± | ± | ± |
| 6 | + | + | + | + | + | + | + | + |
| | Growth at pH 8.1 | | | | | | | |
| 1 | + | + | + | + | + | - | - | ± |
| 6 | + | + | + | + | + | + | + | + |
| | Growth at pH 9.1 | | | | | | | |
| 1 | ± | + | - | - | + | - | - | - |
| 6 | + | + | + | + | + | - | + | + |
| | Starch hydrolysis | | | | | | | |
| | - | - | - | - | - | - | - | - |
| | Denitrification | | | | | | | |
| | - | - | - | - | - | - | - | + |
| | Growth in anaerobiosis without electron acceptor added | | | | | | | |
| | - | - | - | - | - | - | - | - |

| | | | | | | | | |
|--|--|--------------|--------------|--------------|------------------------|------------------------|------------------------|------------------------|
| | 12 | 34 | 14 | 06 | 66 | 74 | 96 | 37 |
| | Growth in anaerobiosis with glucose added (fermentation) | | | | | | | |
| | - | - | - | - | - | - | - | ± |
| | Growth in anaerobiosis with KNO ₃ added | | | | | | | |
| | - | - | - | - | - | - | - | - |
| | Catalase reaction | | | | | | | |
| | + | + | + | + | + | + | + | + |
| | Oxidase reaction | | | | | | | |
| | + | + | + | + | + | + | + | + |
| | Gram stain | | | | | | | |
| | - | - | - | - | - | - | - | - |
| | Motility | | | | | | | |
| | - | - | - | - | - | - | - | - |
| | Colony pigmentation | | | | | | | |
| | Y - O | Y - O | Y - O | Y - O | Y - O | O - P | O - P | P Y |
| | Cell morphology | | | | | | | |
| | S to C | S to C | S to C | C | S to C | S | S | S |
| | Cell dimensions (µm) | | | | | | | |
| | 0.8 x 1.2 | 0.8 x 1.2 | 0.8 x 1.2 | 0.9 x 1.1 | 0.8 x 1.2 to 1.5 | 0.8 x 1.5 to 2.0 | 0.9 x 2.0 to 2.5 | 0.8 x 1.5 to 2.0 |

Y - O: yellow-orange; O - P: orange-pink; P Y: pale yellow; S to C: short rod to coccoid; S: short rod; C: coccoid

Table 12. Zeaxanthin production by *Paracoccus* sp. strains R-1512, R1534, R114 and R-1506.

| Strain | Time (h) | Zeaxanthin (mg/l) | | Specific Formation (mg zeaxanthin/OD ₆₆₀) | |
|--------|----------|-------------------|--------------------|--|--------------------|
| | | Average | Standard Deviation | Average | Standard Deviation |
| R-1512 | 6 | 0.23 | 0.10 | 0.10 | 0.04 |
| | 10 | 2.05 | 0.70 | 0.25 | 0.08 |
| | 24 | 3.78 | 0.59 | 0.38 | 0.06 |
| R1534 | 6 | 0.75 | 0.10 | 0.26 | 0.02 |
| | 10 | 3.45 | 0.57 | 0.43 | 0.07 |
| | 24 | 9.13 | 0.97 | 0.95 | 0.06 |
| R114 | 6 | 0.65 | 0.17 | 0.86 | 0.24 |
| | 15 | 7.53 | 1.12 | 1.13 | 0.21 |
| | 24 | 19.7 | 1.82 | 2.68 | 0.20 |
| R-1506 | 6 | 0.13 | 0.06 | 0.07 | 0.01 |
| | 10 | 1.35 | 0.31 | 0.19 | 0.04 |
| | 24 | 3.55 | 0.68 | 0.38 | 0.07 |

Example 3: IPP Biosynthesis via the Mevalonate Pathway in the Zeaxanthin-Producing *Paracoccus* sp. strain R114.

In order to determine the biosynthetic origin (*i.e.*, the mevalonate or DXP pathway) of isoprenoid precursors in *Paracoccus* sp. strain R114, a "retrobiosynthesis" approach [Eisenreich and Bacher, In: Setlow (ed.), Genetic Engineering, Principles and Methods, Kluwer Academic/Plenum Publishers, New York 22:121-153 (2000)] was taken. This predictive approach for data analysis permits the unequivocal assessment of glucose catabolism from the analysis of a single down-stream natural product. In the present work, this involved growth of the bacterium in media containing various binary mixtures of unlabeled glucose and specific ¹³C-labeled glucoses, followed by purification of the zeaxanthin produced and analysis of the labeling patterns by NMR spectroscopy. Details of the methods used and the experimental results are given below.

Growth of *Paracoccus* sp. strain R114 for ¹³C labeling experiments. Unlabelled D-glucose monohydrate was purchased from Fluka (Milwaukee, WI, USA). [U-¹³C₆]-D-Glucose was purchased from Isotec (Miamisburg, OH, USA), while [1-¹³C₁] D-glucose, [2-¹³C₁] D-glucose and [6-¹³C₁] D-glucose were from Cambridge Isotope Laboratories (Andover, MA, USA). Yeast extract and peptone (from casein, pancreatically digested) were purchased

- 71 -

from EM Science (Gibbstown, NJ, USA). All other salts and solvents were analytical grade and were purchased from standard chemicals suppliers.

All cultures were initiated from frozen cell suspensions (cell density of 12 OD₆₆₀ units, 25% glycerol, stored at -70°C). One ml of thawed cell suspension was used to inoculate pre-cultures (500-ml baffled shake flasks) containing 100 ml of 362F/2 medium having the following composition: 30 g/l D-glucose, 10 g/l yeast extract, 10 g/l peptone, 5 g/l NaCl, 2.5 g/l MgSO₄·7H₂O, 0.75 g/l (NH₄)₂HPO₄, 0.625 g/l K₂HPO₄, 187.5 mg/l CaCl₂·2H₂O, 0.2 g/l (NH₄)₂Fe(SO₄)₂·6H₂O, 15 mg/l ZnSO₄·7H₂O, 12.5 mg/l FeCl₃·6H₂O, 5 mg/l MnSO₄·H₂O, 0.5 mg/l NiSO₄·6H₂O, 15 mg/l Na-EDTA and 9.375 µl/l HCl (37% stock solution). The initial pH of the medium was 7.2.


The pre-culture was incubated at 28°C with shaking at 200 rpm for 24 h, after which time the OD₆₆₀ was about 22 absorbance units. The main cultures were grown in Bioflo 3000 bioreactors (New Brunswick Scientific, Edison, NJ, USA) containing 362F/2 medium containing the following composition: 30 g/l total D-glucose (see below for ratios of ¹³C-labeled:unlabeled glucose), 20 g/l yeast extract, 10 g/l peptone, 10 g/l NaCl, 5 g/l MgSO₄·7H₂O, 1.5 g/l (NH₄)₂HPO₄, 1.25 g/l K₂HPO₄, 0.4 g/l (NH₄)₂Fe(SO₄)₂·6H₂O, 375 mg/l CaCl₂·2H₂O, 30 mg/l ZnSO₄·7H₂O, 25 mg/l FeCl₃·6H₂O, 10 mg/l MnSO₄·H₂O, 1 mg/l NiSO₄·6H₂O, 30 mg/l Na-EDTA and 18.75 µl/l HCl (37% stock solution). The amounts of each ¹³C-labeled glucose used (expressed as a percentage of the total 30 g/l glucose in the medium) in four separate experiments were: Condition 1, 4% [U-¹³C₆] D-glucose; Condition 2, 50% [1-¹³C₁] D-glucose; Condition 3, 25% [2-¹³C₁] D-glucose + 1% [U-¹³C₆] D-glucose; Condition 4, 25% [6-¹³C₁] D-glucose + 1% [U-¹³C₆] D-glucose. A control with only unlabeled glucose was also included. For Conditions 1 and 2 (and the unlabeled control), the culture volume was 2 l, while the culture volume for Conditions 3 and 4 was 1 l. The bioreactors were inoculated with pre-culture (20 ml/l initial volume) and cultivation proceeded for 22-24 hours, at which time no glucose was left in the medium. Cultivation conditions were: 28°C, pH 7.2 (controlled with 25% H₃PO₄ and 28% NH₄OH), dissolved oxygen controlled (in a cascade with agitation) at a minimum of 40%, agitation rate and aeration rate 300 rpm (minimum) and 1 vvm, respectively.

Purification of zeaxanthin. At the end of the cultivations, the cultures were cooled down to 15°C. Five hundred ml of absolute ethanol was added per liter of culture and stirring was continued at 100 rpm for 20 min. The treated culture was centrifuged for 20 min. at 5000 x g, and the supernatant was discarded. The wet pellet was then extracted with 5 volumes of THF for 20 min. with stirring. The extracted mixture was centrifuged, the

- 72 -

supernatant saved and the resulting pellet extracted a second time with 1 volume THF under the same conditions and again centrifuged. The supernatants (extracts) were combined and concentrated to 50 ml by rotary evaporation. Five milliliters of hexane were added to the concentrated THF solution. After mixing, the system formed an emulsion that could be separated by centrifugation. The aqueous phase was collected, diluted with an equal volume of saturated NaCl solution and re-extracted with dichloromethane. The dichloromethane phase was collected and combined with the THF/hexane phase. The mixture of organic extracts was concentrated again in a rotary evaporator to remove dichloromethane. The solution was then applied to a silica gel column and eluted with a mixture of n-hexane and ether (1:1). A small light yellow band eluted first and was discarded. The main zeaxanthin product eluted in a broad band that moved slowly in the column. About 2 liters of solvent was needed to elute the main band completely. The eluate was collected in a round-bottomed flask and the solvent was removed by rotary evaporation at 40°C. The residue was dissolved in a small amount of dichloroethane at 40°C and the solution was then allowed to cool slowly. Hexane was added to the mixture dropwise until a turbidity was observed. The crystallization was complete within 48 hours at 4°C. The crystals were collected on a paper filter, washed with cold methanol and dried under vacuum.

NMR studies. Zeaxanthin was analyzed by NMR spectroscopy. For reference, the chemical structure of zeaxanthin is illustrated in the following formula



¹H-NMR and ¹³C-NMR spectra were recorded at 500.13 MHz and 125.6 MHz, respectively, with a Bruker DRX 500 spectrometer. Acquisition and processing parameters for one-dimensional experiments and two-dimensional INADEQUATE experiments were according to standard Bruker software (XWINNMR). The solvent was deuterated chloroform. The chemical shifts were referenced to solvent signals.

¹³C NMR spectra of the isotope labeled zeaxanthin samples and of the zeaxanthin sample at natural ¹³C abundance were recorded under the same experimental conditions. Integrals were determined for every ¹³C NMR signal, and the signal integral for each respective carbon atom in the labeled compound was referenced to that of the natural abundance material, thus affording relative ¹³C abundances for each position in the labeled

molecular species. The relative abundances were then converted into absolute abundances from ^{13}C coupling satellites in the ^1H NMR signal of H-18 at 1.71 ppm. In the ^{13}C NMR spectrum of the multiply-labeled zeaxanthin sample each satellite was integrated separately. The integral of each respective satellite pair was then referenced to the total
5 signal integral of a given carbon atom. Zeaxanthin comprises a total of eight isoprenoid moieties (2 DMAPP units and 6 IPP units); only 20 ^{13}C NMR signals are observed due to chemical shift degeneracy.

In the experiment with the mixture of [$\text{U-}^{13}\text{C}_6$] glucose and unlabeled glucose (1:7.5; w/w), all carbon atoms of zeaxanthin were labeled and showed satellites due to $^{13}\text{C}^{13}\text{C}$ couplings
10 (Table 13). The signals of 4 carbon atoms have intense satellites due to $^{13}\text{C}^{13}\text{C}$ couplings ($61.2 \pm 0.6\%$ in the global NMR signal intensity of a given atom, Table 13). The signal accounting for the methyl atoms C-17/C-17' displayed only weak ^{13}C -coupled satellites at a relative intensity of 6%. The central signals represent material derived from unlabeled glucose. The signals showed no evidence of long-range coupling. Carbon connectivity
15 was easily gleaned from $^{13}\text{C}^{13}\text{C}$ coupling constants (Table 13) and from two-dimensional INADEQUATE experiments.

Three of the carbon atoms acquired label from [$6\text{-}^{13}\text{C}_1$] glucose. The other two carbons were labeled from [$2\text{-}^{13}\text{C}_1$] glucose. No significant amounts of label were contributed to zeaxanthin by [$1\text{-}^{13}\text{C}_1$] glucose.

20 The ^{13}C abundance for all non-isochronous carbon atoms was determined by comparison with spectra of unlabeled zeaxanthin and by evaluation of the $^1\text{H}^{13}\text{C}$ coupling satellites in ^1H NMR spectra (Table 13). The fraction of jointly transferred carbon atom pairs in the experiment with [$\text{U-}^{13}\text{C}_6$] glucose was determined by integration of the coupling satellites.

The labeling patterns of the IPP building block can be reconstructed accurately as shown
25 by the standard deviations found for the reconstructed IPP precursor. The reconstructed labeling patterns of DMAPP and IPP were identical within the experimental limits.

Table 13. NMR results for ^{13}C labeled zeaxanthin produced by *Paracoccus* sp. strain R114 supplied with ^{13}C labeled glucoses.

| Position | $\delta - ^{13}\text{C}$ ppm | J_{CC}, Hz | ^{13}C -labeled glucose precursor | | | | |
|----------|---------------------------------|----------------------------|--|-----------------------|-----------------------|--|--------------------------------|
| | | | $[1-^{13}\text{C}]$ - | $[2-^{13}\text{C}]$ - | $[6-^{13}\text{C}]$ - | $[\text{U-}^{13}\text{C}_6]\text{glucose}$ | |
| | 134.08 | 44.2 (18, 18') | % ^{13}C | % ^{13}C | % ^{13}C | % ^{13}C | % $^{13}\text{C}^{13}\text{C}$ |
| 1, 1' | 37.13 | 36.0 (16, 16') | 1.10 | 10.71 | 2.22 | 3.47 | 61.2 |
| 2, 2' | 48.46 | 35.8 (3, 3') | 1.20 | 2.58 | 10.27 | 3.65 | 61.1 |
| 3, 3' | 65.10 | 35.8 (2, 2') | 1.12 | 12.47 | 2.38 | 3.64 | 60.4 |
| 4, 4' | 42.57 | 37.1 | 1.27 | 2.59 | 10.63 | 3.89 | 8.4 |
| 5, 5' | 126.17 | 44.2 (18, 18') | 1.14 | 12.45 | 3.19 | 3.68 | 61.1 |
| 6, 6' | 137.77 | 56.4 (7, 7') | 1.30 | 2.15 | 9.98 | 3.60 | 60.4 |
| 7, 7' | 125.59 | 56.2 (6, 6') | 1.12 | 10.11 | 2.82 | 4.09 | 61.4 |
| 8, 8' | 138.50 | 71.6, 55.7 | 1.28 | 2.24 | 9.95 | 3.92 | 4.3, 5.0 |
| 9, 9' | 135.69 | 43.1 (19, 19') | 1.12 | 9.53 | 2.95 | 3.84 | 61.7 |
| 10, 10' | 131.31 | 59.7 (11, 11') | 1.21 | 3.18 | 9.61 | 3.80 | 61.1 |
| 11, 11' | 124.93 | 59.7 (10, 10') | 1.10 | 8.79 | 2.70 | 4.02 | 61.0 |
| 12, 12' | 137.57 | 70.5 | 1.20 | 2.01 | 8.80 | 3.59 | 5.1 |
| 13, 13' | 136.48 | 43.1 (20, 20') | 1.12 | 9.86 | 3.59 | 3.93 | 61.4 |
| 14, 14' | 132.60 | 60.4 (15, 15') | 1.21 | 2.83 | 10.51 | 3.77 | 59.5 |
| 15, 15' | 130.08 | 60.4 (14, 14') | 1.12 | 9.18 | 3.33 | 4.02 | 61.2 |
| 16, 16' | 30.26 | 36.3 (1, 1') | 1.27 | 3.19 | 12.31 | 3.91 | 62.0 |
| 17, 17' | 28.73 | 34.9 (1, 1') | 1.30 | 3.43 | 12.31 | 3.88 | 6.0 |
| 18, 18' | 21.62 | 44.2 (5, 5') | 1.27 | 3.01 | 11.66 | 3.70 | 62.0 |
| 19, 19' | 12.82 | 43.1 (9, 9') | 1.29 | 3.12 | 11.64 | 3.86 | 62.3 |
| 20, 20' | 12.75 | 42.9 (13, 13') | 1.33 | 3.21 | 11.99 | 3.75 | 62.1 |

The experimental labeling patterns determined above can be compared with various pre-
 5 dictions, taking into account not only the mevalonate pathway vs. the DXP pathway for
 isoprenoid biosynthesis, but also different pathways of glucose metabolism. Eubacteria
 typically utilize glucose primarily via the glycolytic pathway or via the Entner-Doudoroff
 pathway. Glycolysis generates two triose phosphate molecules from glucose. The C-1 and
 C-6 of glucose are both diverted to the 3-position of the triose phosphates produced
 10 during glycolysis. On the other hand, in the Entner-Doudoroff pathway, glucose is con-
 verted to a mixture of glyceraldehyde 3-phosphate and pyruvate. The C-1 of glucose is

exclusively diverted to C-1 of pyruvate, and the C-6 of glucose is exclusively diverted to C-3 of glyceraldehyde 3-phosphate.

- Intermediates and products of the glycolytic and Entner-Doudoroff pathways serve as starting material for both isoprenoid biosynthetic pathways. With regard to the mevalonate pathway, pyruvate as well as triose phosphate can be converted to the precursor acetyl-CoA. Glucose catabolism via the glycolytic pathway diverts label from C-1 as well as C-6 of glucose to the methyl group of acetyl-CoA. Glucose catabolism via the Entner-Doudoroff pathway results in loss of C-1 from glucose during the transformation of pyruvate to acetyl-CoA.
- 10 The experimentally observed enrichment and $^{13}\text{C}^{13}\text{C}$ coupling patterns of the zeaxanthin produced by *Paracoccus* sp. strain R114 were in perfect agreement with the labeling pattern required for zeaxanthin biosynthesis by the combination of the Entner-Doudoroff pathway and the mevalonate pathway. If both the glycolytic and Entner-Doudoroff pathways had been simultaneously operative under the experimental conditions used, at
- 15 least some label from $[1-^{13}\text{C}_1]$ glucose should have been contributed to the zeaxanthin. Furthermore, the mevalonate pathway can at best contribute blocks of two carbon atoms to terpenoids, while in the DXP pathway three carbon units can be delivered to isoprenoids via triose phosphate precursors. Although such three-carbon blocks become separated by the rearrangement involved in the DXP pathway, blocks of three labeled
- 20 carbon atoms can still be recognized via long-range coupling. Corresponding ^{13}C - ^{13}C long-range couplings have been observed in the biosynthesis of the carotenoid lutein from $[2,3,4,5-^{13}\text{C}_4]$ 1-deoxy-D-xylulose by cultured plant cells (*Cantharantus roseus*) [Arigoni et al., Proc. Nat. Acad. Sci. 94:10600-10605 (1997)]. No such long-range coupling was observed in the present experiments with zeaxanthin produced by *Paracoccus* sp. strain
- 25 R114.

It should be noted that while the results presented here confirm isoprenoid production in *Paracoccus* sp. strain R114 via the mevalonate pathway, and indicate that, under the growth conditions used, there was little or no glucose metabolism via glycolysis, they do not rule out the possibility of some metabolism of glucose via the pentose phosphate pathway in

30 addition to the Entner-Doudoroff pathway. Quantitative determination of glucose metabolism via the latter two pathways could be obtained by analysis of labeling patterns of pyruvate-derived amino acids (as was done for *Paracoccus denitrificans* [Dunstan et al., Biomedical and Environ. Mass Spectrometry 19:369-381 (1990)]).

Example 4: Cloning and Sequencing of the Genes Encoding IPP Isomerase and the Enzymes of the Mevalonate Pathway from *Paracoccus* sp. strain R114.

Culture conditions. *Paracoccus* sp. strain R114 was grown at 28°C in F-medium (10 g/l tryptone, 10 g/l yeast extract, 30 g/l NaCl, 10 g/l D-glucose, 5 g/l MgSO₄·7H₂O, pH 7.0) or
5 in the pre-culture medium described in Example 3 above. Liquid cultures were grown in a rotary shaker at 200 rpm.

Isolation of genomic DNA. A 600-ml culture of *Paracoccus* sp. strain R114 was centrifuged for 10 minutes at 10,000 x g at 4°C and the pellet was washed once with 200 ml lysis buffer (0.1M NaCl, 50mM EDTA, 10mM Tris-HCl, pH 7.5) and once with 100 ml lysis buffer.
10 The final pellet was resuspended in 20 ml lysis buffer containing 50 mg lysozyme and 1 mg RNase A (DNase free). After incubation for 15 minutes at 37°C, 1.5 ml of 20% sodium N-lauroyl-sarcosinate and 2.25 mg of proteinase K were added. After incubation at 50°C for 30-60 minutes, the lysate was extracted with one volume of buffer-saturated phenol, pH 7.5-7.8 (LifeTechnologies, Rockville, MD, USA) by gentle but thorough mixing. The
15 emulsion was centrifuged for 20 minutes at 30,000 x g and the aqueous phase was re-extracted with phenol. The phases were separated as before and the aqueous phase was extracted twice with one volume phenol:chloroform (1:1). At this step centrifugation for 20 minutes at 3,200 x g in a swinging bucket rotor was sufficient to obtain satisfactory phase separation. After a final extraction with one volume of chloroform, 0.1 volume 3M
20 sodium-acetate (pH 5.2) was added and the solution was overlaid with 2 volumes ice-cold ethanol. The precipitated DNA was spooled with a glass-rod, soaked in 70% ethanol for 5 minutes, rinsed with chloroform and then air dried for 5-10 minutes. The DNA was re-suspended overnight in 5 ml TE (10mM Tris-HCl, pH 7.5, 1mM EDTA). Since the solution was yellow due to traces of zeaxanthin, the organic extractions and the spooling were
25 repeated as above to obtain a clear preparation.

Isolation of λ-DNA: The Qiagen® Lambda Kit (Qiagen, Hilden, Germany) was used following the manufacturer's instructions.

Polymerase chain reaction (PCR): Oligonucleotides were purchased from LifeTechnologies (Rockville, MD, USA). PCR was performed in a GeneAmp® PCR system 9700 (PE
30 Applied Biosystems, Foster City, CA, USA) using the GC-rich PCR system (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturers instructions. Typically, the MgCl₂ concentration used was 1.5mM and the resolution solution was added to 1M final concentration.

DNA Labeling and detection: The PCR-DIG Probe Synthesis Kit and the DIG
35 Luminescent Detection Kit were used for DNA labeling and detection, respectively (both obtained from Roche Molecular Biochemicals, Mannheim, Germany)

- 77 -

DNA sequencing: Sequencing reactions were performed using the BigDye[®] DNA sequencing kit (PE Applied Biosystems, Foster City, CA, USA) according to the manufacturers instructions. Sequencing reactions were purified on DyeEx[™] spin columns (Qiagen, Hilden, Germany) and fragment separation and detection was done with an ABI Prism[™] 310 Genetic Analyzer (PE Applied Biosystems, Foster City, CA, USA).

λ-library: A custom made library with partially *Sau3AI* digested *Paracoccus* sp. strain R114 DNA in lambda FIX[®] II was purchased from Stratagene (La Jolla, CA, USA).

Cloning, sequencing and characterization of the mevalonate pathway gene cluster from *Paracoccus* sp. strain R114. One of the enzymes of the mevalonate pathway, mevalonate diphosphate decarboxylase, contains highly conserved regions spanning several amino acids. Three such regions were chosen from an alignment of all available eubacterial mevalonate diphosphate decarboxylases and oligonucleotides were designed using the preferred codon usage found in the carotenoid gene cluster of *Paracoccus* sp. strain R1534 (Table 14).

The oligonucleotides designed from two homology regions are shown in Table 15. To reduce the degree of degeneracy, sets of oligonucleotides were designed from each peptide. For instance, oligonucleotides mvd-103a-d differ only in the third nucleotide from the 3' end, each accounting for one possible codon for glycine (GGA, although rarely used, was included because of the close proximity to the 3' end). Alternate amino acids were accounted for by designing oligonucleotides to both residues, e.g. oligonucleotides mvd-101a and mvd-101b are specific for leucine or isoleucine, respectively, in the second position of peptide 1 (Table 15). PCR with oligonucleotides mvd-101 and mvd-104 or mvd-106, using *Paracoccus* sp. strain 114 DNA as template, gave a product of the expected size. The PCR product was cloned in the vector pCR[®]2.1-TOPO (Invitrogen, Carlsbad, CA, USA) and sequenced. The cloned fragment was used as a probe for a Southern analysis of *Paracoccus* sp. strain R114 DNA and was found to hybridize to a *Bam*HI-*Sal*I fragment of about 950 bp. *Paracoccus* sp. strain R114 DNA was cut with *Bam*HI and *Sal*I and the fragments were separated by agarose gel electrophoresis. The region around 950 bp was isolated and cloned in the vector pUC19. This partial library was then screened using the *mvd*-PCR fragment as a probe and the insert of a positive clone was sequenced. In parallel, a λ-library prepared from *Paracoccus* sp. strain R114 DNA was screened using the *mvd*-PCR fragment as a probe. DNA was isolated from two positive λ-clones and cut with *Bam*HI and *Sal*I or *Eco*RI and *Sal*I. A number of the restriction fragments were isolated and cloned in the vector pUC19. Several of the fragments contained sequences homologous to genes encoding proteins of the mevalonate pathway. The clones connecting these individual sequences were obtained by PCR with primers derived from the sequences of

- the cloned restriction fragments using the DNA of the λ -clones as template. The assembled sequence from all fragments (SEQ ID NO:42, 44, 46, 48, 50, and 52) and the sequences of the encoded proteins are shown in the Sequence Listing (SEQ ID Nos:43, 45, 47, 49, 51, and 53). Due to a limitation of the PatentIn Program, operons with overlapping
- 5 genes cannot be shown as a single sequence. Thus, for each gene in the mevalonate operon, the entire nucleotide sequence of the operon is repeated for each gene. Accordingly, SEQ ID Nos:42, 44, 46, 48, 50, and 52 are identical. For purposes of the present invention, we use SEQ ID NO:42 to refer to the nucleotide sequence of the mevalonate operon.
- 10 The arrangement of the mevalonate pathway genes in the *Paracoccus* sp. strain R114 is unique when compared to known mevalonate gene clusters of other bacteria. Besides *Paracoccus* sp. strain R114, only *Borrelia burgdorferi* and *Streptomyces* sp. strain CL190 (Takagi et al., supra) have all mevalonate genes in a single operon (Wilding et al., supra). In *Streptococcus pyogenes* all mevalonate genes are clustered in a single locus but they are
- 15 grouped in two operons. All other species have two loci with the two kinases and the mevalonate diphosphate decarboxylase grouped in one operon and the HMG-CoA synthase and the HMG-CoA reductase on a second locus, either forming an operon (in *Streptococcus pneumoniae*) or as separate transcription units. All species except the members of *Staphylococcus* have an additional gene linked with the mevalonate cluster,
- 20 which was recently identified as an IPP isomerase (*idi* gene in *Streptomyces* sp. strain CL190) (Kaneda et al., supra). The two *Enterococcus* species and *Staphylococcus haemolyticus* have an acetyl-CoA acetyltransferase gene linked with the HMG-CoA reductase gene. In the *Enterococcus* species the latter two genes are fused.

Table 14: Codon usage in *Paracoccus* sp. strain R1534 carotenoid (*crt*) genes

| Amino acid | Codon | Number used | % Used |
|------------|-------|-------------|--------|
| A – Ala | GCT | 3 | 1.4 |
| | GCC | 96 | 46.2 |
| | GCA | 15 | 7.2 |
| | GCG | 94 | 45.2 |
| C – Cys | TGT | 0 | 0.0 |
| | TGC | 15 | 100.0 |
| D – Asp | GAT | 46 | 38.0 |
| | GAC | 75 | 62.0 |
| E – Glu | GAA | 17 | 25.4 |
| | GAG | 50 | 74.6 |
| F – Phe | TTT | 3 | 5.6 |
| | TTC | 51 | 94.4 |
| G – Gly | GGT | 16 | 10.8 |
| | GGC | 87 | 58.8 |
| | GGA | 5 | 3.4 |
| | GGG | 40 | 27.0 |
| H – His | CAT | 30 | 56.6 |
| | CAC | 23 | 43.4 |
| I – Ile | ATT | 5 | 6.4 |
| | ATC | 72 | 92.3 |
| | ATA | 1 | 1.3 |
| K – Lys | AAA | 4 | 14.3 |
| | AAG | 24 | 85.7 |
| L – Leu | TTA | 0 | 0.0 |
| | TTG | 5 | 2.9 |
| | CTT | 15 | 8.7 |
| | CTC | 11 | 6.4 |
| | CTA | 1 | 0.6 |
| | CTG | 140 | 81.4 |
| M – Met | ATG | 49 | 100.0 |
| N – Asn | AAT | 4 | 20.0 |
| | AAC | 16 | 80.0 |

- 80 -

| Amino acid | Codon | Number used | % Used |
|------------|-------|-------------|--------|
| P – Pro | CCT | 2 | 2.3 |
| | CCC | 41 | 47.7 |
| | CCA | 3 | 3.5 |
| | CCG | 40 | 46.5 |
| Q – Gln | CAA | 6 | 11.3 |
| | CAG | 47 | 88.7 |
| R – Arg | CGT | 11 | 7.3 |
| | CGC | 103 | 68.2 |
| | CGA | 2 | 1.3 |
| | CGG | 26 | 17.2 |
| | AGA | 2 | 1.3 |
| | AGG | 7 | 4.6 |
| S – Ser | TCT | 1 | 1.1 |
| | TCC | 17 | 19.5 |
| | TCA | 0 | 0.0 |
| | TCG | 39 | 44.8 |
| | AGT | 2 | 2.3 |
| | AGC | 28 | 32.2 |
| T – Thr | ACT | 2 | 2.7 |
| | ACC | 36 | 48.9 |
| | ACA | 4 | 5.3 |
| | ACG | 33 | 44.0 |
| V – Val | GTT | 6 | 5.7 |
| | GTC | 61 | 57.5 |
| | GTA | 1 | 0.9 |
| | GTG | 38 | 35.8 |
| W – Trp | TGG | 27 | 100.0 |
| Y – Tyr | TAT | 28 | 62.2 |
| | TAC | 17 | 37.8 |

Table 15: Oligonucleotides designed from two conserved bacterial Mvd peptides.

| | | SEQ a |
|--|--|----------|
| Peptide 1 | AlaLeuIleLysTyrTrpGlyLys Ile ² | 23 |
| Nucleotide sequence ¹ | CCSCTGATCAARTAYTGGGGBAARATC | 24 |
| Oligonucleotide mvd-101a (5' - 3') | GCSCCTGATCAARTAYTGGGG | 25 |
| Oligonucleotide mvd-101b (5' - 3') | GCSATCATCAARTAYTGGGG | 26 |
| Oligonucleotide mvd-103a (5' - 3') | ATCAARTAYTGGGGTAA | 27 |
| Oligonucleotide mvd-103b (5' - 3') | ATCAARTAYTGGGGCAA | 28 |
| Oligonucleotide mvd-103c (5' - 3') | ATCAARTAYTGGGGGAA | 29 |
| Oligonucleotide mvd-103d (5' - 3') | ATCAARTAYTGGGGAAA | 30 |
| Peptide 2 | ThrMetAspAlaGlyProAsnVal Gln ² | 31 |
| Nucleotide sequence ¹ (5'-3') | ACSATGGAYGCSGGBCCSAAYGTS CAR | 32 |
| Complement (3'-5') | TGSTACCTRCGSCCVGGSTTRCAS GTY | 33 |
| Oligonucleotide mvd-104a (3' - 5') | TGGTACCTACGSCCVGG | 34 |
| Oligonucleotide mvd-104b (3' - 5') | TGGTACCTGCGSCCVGG | 35 |
| Oligonucleotide mvd-104c (3' - 5') | TGCTACCTACGSCCVGG | 36 |
| Oligonucleotide mvd-104d (3' - 5') | TGCTACCTGCGSCCVGG | 37 |
| Oligonucleotide mvd-106a (3' - 5') | TACCTACGSCCVGGSTTRCA | 38 |
| Oligonucleotide mvd-106b (3' - 5') | TACCTGCGSCCVGGSTTRCA | 39 |
| Oligonucleotide mvd-106c (3' - 5') | TACCTACGSCCVGGSGTYCA | 40 |
| Oligonucleotide mvd-106d (3' - 5') | TACCTGCGSCCVGGSGTYCA | 41 |

^a: SEQ ID NO:¹ using the preferred codons of *Paracoccus* sp. strain R1534, see table 1² alternate amino acid present in some enzyme

5 S = C or G; R = A or G; Y = C or T; B = C or G or T; V = A or C or G

The genes of the mevalonate operon from *Paracoccus* sp. strain R114 were identified by homology of the gene products to proteins in general databases. An amino acid alignment of the HMG-CoA reductase from *Paracoccus* sp. strain R114 (SEQ ID NO:43) was performed with bacterial class I HMG-CoA reductases of *Streptomyces* sp. Strain CL190 (SEQ

- ID NO:54), *S. griseolosporeus* (SEQ ID NO:55), and *Streptomyces* sp. strain KO-3899 (SEQ ID NO:56). EMBL/GenBank/DDBJ database accession numbers are q9z9n4 for *Streptomyces* sp. strain CL190, q9znh1 for *S. griseolosporeus* and q9znh0 for *Streptomyces* sp. strain KO-3899. There are two classes of HMG-CoA reductases [Bochar et al., Mol. Genet. Metab. 66:122-127 (1999); Boucher et al., Mol. Microbiol. 37:703-716 (2000)]. Eubacterial HMG-CoA reductases are generally of class II, whereas class I enzymes are found in eukaryotes and archaea. The *Streptomyces* and the *Paracoccus* HMG-CoA reductases together with the enzyme from *Vibrio cholerae* are the only eubacterial HMG-CoA reductases of class I known so far.
- 10 An amino acid alignment of isopentenyl diphosphate isomerase (IPP isomerase) (*idi*) from *Paracoccus* sp. strain R114 (SEQ ID NO:45) was performed with close homologs found in the EMBL database, i.e. *Erwinia herbicola* (Q01335) (SEQ ID NO:57), *Borrelia burgdorferi* (O51627) (SEQ ID NO:58), *Synechocystis* sp. PCC 6803 (P74287) (SEQ ID NO:59), *Streptomyces* sp. CL190 (Q9KWG2) (SEQ ID NO:60), *Streptomyces griseolosporeus* (Q9KWF6) (SEQ ID NO:61), *Sulfolobus solfataricus* (P95997) (SEQ ID NO:62), *Rickettsia prowazekii* (Q9ZD90) (SEQ ID NO:63), *Deinococcus radiodurans* (Q9RVE2) (SEQ ID NO:64), *Aeropyrum pernix* (Q9YB30) (SEQ ID NO:65), *Halobacterium* sp. NRC-1 (O54623) (SEQ ID NO:66), *Archaeoglobus fulgidus* (O27997) (SEQ ID NO:67), *Pyrococcus abyssi* (Q9UZS9) (SEQ ID NO:68), *Pyrococcus horikoshii* (O58893) (SEQ ID NO:69),
- 20 *Methanobacterium thermoautotrophicum* (O26154) (SEQ ID NO:70), *Methanococcus jannaschii* (Q58272) (SEQ ID NO:71), *Thermoplasma acidophilum* (CAC11250) (SEQ ID NO:72) and *Leishmania major* (Q9NDJ5) (SEQ ID NO:73). EMBL/GenBank/DDBJ database accession numbers are given after the organism's name in parentheses. The first nine sequences are from eubacteria and the next eight sequences are from archaea. Interestingly,
- 25 ly, one eukaryotic species, the protozoan parasite *Leishmania major* (SEQ ID NO:73), also has a protein that is highly homologous. This is unexpected because other eukaryotes have a different *idi*, designated type 1 (Kaneda et al., supra). A conserved hypothetical protein from *Bacillus subtilis*, YpgA, also has substantial homology but is considerably smaller than the type 2 *idi*'s.
- 30 An amino acid alignment of bacterial HMG-CoA synthase from *Paracoccus* sp. strain R114 (SEQ ID NO:47) was performed with close homologs found in the EMBL database, i.e. *Streptococcus pneumoniae* (AAG02453) (SEQ ID NO:74), *Streptococcus pyrogenes* (AAG02448) (SEQ ID NO:75), *Enterococcus faecalis* (AAG02438) (SEQ ID NO:76), *Enterococcus faecium* (AAG02443) (SEQ ID NO:77), *Staphylococcus haemolyticus* (AAG02427) (SEQ ID NO:78), *Staphylococcus epidermis* (AAG02433) (SEQ ID NO:79),
- 35

Staphylococcus aureus (AAG02422) (SEQ ID NO:80), *Staphylococcus carnosus* (Q9ZB67) (SEQ ID NO:81), *Streptomyces* sp. CL190 (Q9KWG1) (SEQ ID NO:82), *Streptomyces griseolosporeus* (Q9KWF5) (SEQ ID NO:83) and *Borrelia burgdorferi* (051626) (SEQ ID NO:84). EMBL/GenBank/DDBJ database accession numbers are given after each
 5 organism's name in parentheses. The first 43 amino acids of the sequence from *Streptomyces griseolosporeus* are missing in the database version.

An amino acid alignment of bacterial mevalonate diphosphate decarboxylase from *Paracoccus* sp. strain R114 (SEQ ID NO:53) was performed with the orthologous proteins from other bacteria, i.e. *Streptococcus pneumoniae* (AAG02456) (SEQ ID NO:85), *Streptococcus*
 10 *pyrogenes* (AAG02451) (SEQ ID NO:86), *Enterococcus faecalis* (AAG02441) (SEQ ID NO:87), *Enterococcus faecium* (AAG02446) (SEQ ID NO:88), *Staphylococcus haemolyticus* (AAG02431) (SEQ ID NO:89), *Staphylococcus epidermis* (AAG02436) (SEQ ID NO:90), *Staphylococcus aureus* (AAG02425) (SEQ ID NO:91), *Streptomyces* sp. CL190 (Q9KWG4) (SEQ ID NO:92), *Streptomyces griseolosporeus* (Q9KWF8) (SEQ ID NO:93) and *Borrelia*
 15 *burgdorferi* (051629) (SEQ ID NO:94). EMBL/GenBank/DDBJ database accession numbers are given after each organism's name in parentheses.

Two proteins from *Myxococcus xanthus*, Tac and Taf (database accession numbers q9xb06 and q9xb03, respectively) and a protein from *B. subtilis*, PksG, a putative polyketide biosynthesis protein (database accession number p40830), have substantial homology to the
 20 *Paracoccus* sp. strain R114 HMG-CoA synthase. The homology between the *Paracoccus* sp. strain R114 HMG-CoA synthase and the Tac and Taf proteins of the *M. xanthus* is greater than the homology between the HMG-CoA synthases from *Paracoccus* sp. strain R114 and eukaryotes. The bacterial HMG-CoA synthases and the bacterial mevalonate diphosphate decarboxylases share substantial homology with their eukaryotic orthologs. Archaeal
 25 HMG-CoA synthases form a more distantly related group of enzymes (Wilding et al., supra) and no mevalonate diphosphate decarboxylase orthologs are found in archaea [Smit and Mushegian, Genome Res. 10:1468-1484 (2000)].

Alignments of the mevalonate kinase (Mvk) (SEQ ID NO:49) and the phosphomevalonate kinase (Pmk) (SEQ ID NO:51) from *Paracoccus* sp. strain R114 were performed to the
 30 orthologous proteins from other bacteria, i.e. *Streptococcus pneumoniae* (AAG02455) (SEQ ID NO:95), *Streptococcus pyrogenes* (AAG02450) (SEQ ID NO:96), *Enterococcus faecalis* (AAG02440) (SEQ ID NO:97), *Enterococcus faecium* (AAG02445) (SEQ ID NO:98), *Staphylococcus haemolyticus* (AAG02430) (SEQ ID NO:99), *Staphylococcus epidermis* (AAG02435) (SEQ ID NO:100), *Staphylococcus aureus* (AAG02424) (SEQ ID NO:101),
 35 *Streptomyces* sp. CL190 (Q9KWG5) (SEQ ID NO:102), *Streptomyces griseolosporeus*

- (Q9KWF9) (SEQ ID NO:103) and *Borrelia burgdorferi* (051631) (SEQ ID NO:104)(Mvk); and *Streptococcus pneumoniae* (AAG02457) (SEQ ID NO:105), *Streptococcus pyrogenes* (AAG02452) (SEQ ID NO:106), *Enterococcus faecalis* (AAG02442) (SEQ ID NO:107), *Enterococcus faecium* (AAG02447) (SEQ ID NO:108), *Staphylococcus haemolyticus* (AAG02432) (SEQ ID NO:109), *Staphylococcus epidermis* (AAG02437) (SEQ ID NO:110), *Staphylococcus aureus* (AAG02426) (SEQ ID NO:111), *Streptomyces* sp. CL190 (Q9KWF3) (SEQ ID NO:112), *Streptomyces griseolosporeus* (Q9KWF7) (SEQ ID NO:113) and *Borrelia burgdorferi* (051630) (SEQ ID NO:114) (Pmk). EMBL/GenBank/DDBJ database accession numbers are given after each organism's name in parentheses.
- 10 There is much less homology among the bacterial kinases than among the bacterial orthologs of the other enzymes of the mevalonate pathway. The mevalonate kinase from *Paracoccus* sp. strain R114 (SEQ ID NO:49) has a 37 amino acid insert in the amino-terminal region, which is lacking in other mevalonate kinases. Together with the bacterial Mvk's some archaeal enzymes, e.g. from *Archaeoglobus fulgidus*, *Methanobacterium thermoautotrophicum* and *Pyrococcus abyssi*, are among the best homologues to the Mvk from *Paracoccus* sp. strain R114. The homology among bacterial phosphomevalonate kinases is even weaker than the homology among the bacterial mevalonate kinases. The proteins with the best homologies to the Pmk from *Paracoccus* sp. strain R114 (SEQ ID NO:51) are Mvk's from archaea, e.g. *Aeropyrum pernix*, *Pyrococcus horikoshii*, *M. thermoautotrophicum*, *P. abyssi* and *A. fulgidus*. Since no Pmk's are found in archaea (Smit and Mushegian, supra), this suggests that the same kinase might perform both phosphorylations.

Example 5: Over-expression of the Mevalonate Pathway Genes and the *idi* Gene from *Paracoccus* sp. strain R114 in *E. coli*

- Cloning and expression of the mevalonate operon in *E. coli*. A λ clone, designated clone 16, from the *Paracoccus* sp. strain R114 λ library (see Example 4) was used as a template for PCR amplification of the entire mevalonate operon. Primers Mevop-2020 and Mevop-9027 (Table 16) were used for PCR.

Table 16. Primers used for amplification of mevalonate operon from *Paracoccus* sp. strain R114.

| Primer | Sequence (5'→3') |
|------------|--|
| Mevop-2020 | GGGCAAGCTTGTCCACGGCACGACCAAGCA (SEQ ID NO:115) |
| Mevop-9027 | CGTAATCCGCGGCCGCGTTTCCAGCGCGTC (SEQ ID NO:116) |

- The resulting PCR product was cloned in TOPO-XL (Invitrogen, Carlsbad, CA, USA), resulting in plasmid TOPO-XL-mev-op16. The insert carrying the mevalonate operon was excised with *Hind*III and *Sac*I and cloned in the *Hind*III-*Sac*I cut vector pBBR1MCS2 [Kovach et al., Gene 166:175-176 (1995)], resulting in plasmid pBBR-K-mev-op16.
- 5 Plasmid pBBR-K-mev-op16 was used to transform electroporation-competent *E. coli* strain TG1 [Stratagene, La Jolla, CA; Sambrook et al., In: Nolan, C. (ed.), Molecular Cloning: A Laboratory Manual (Second Edition), p. A.12 (1989)]. Two representative positive transformants (*E. coli* TG1/ pBBR-K-mev-op16-1 and *E. coli* TG1/ pBBR-K-mev-op16-2) were grown in Luria Broth (LB, GibcoBRL, Life Technologies) containing 50 mg/l
- 10 kanamycin and tested for HMG-CoA reductase activity (encoded by the *Paracoccus* sp. strain R114 *mvaA* gene) using the methods described in Example 1. *E. coli* does not possess a gene coding for the enzyme HMG-CoA reductase, hence the lack of detectable activity. The crude extracts of both representative transformants of *E. coli* TG1/ pBBR-K-mev-op16 had easily measurable HMG-CoA reductase activity, demonstrating the
- 15 heterologous expression of the cloned *mvaA* gene.

Table 17. HMG-CoA reductase activity in crude extracts of *E. coli* TG1 cells carrying the cloned mevalonate gene cluster from *Paracoccus* sp. strain R114.

| Strain | HMG-CoA reductase activity (U/mg) |
|---------------------------------------|-----------------------------------|
| <i>E. coli</i> TG1 | Not detected ^a |
| <i>E. coli</i> TG1/ pBBR-K-mev-op16-1 | 0.25 |
| <i>E. coli</i> TG1/ pBBR-K-mev-op16-2 | 0.78 |

^aLess than 0.03 U/mg

- Cloning and expression of the *idi* gene and the individual mevalonate pathway genes from
- 20 *Paracoccus* sp. strain R114 in *E. coli*. The coding regions of the mevalonate operon genes from *Paracoccus* sp. strain R114 were amplified by PCR using the primers shown in Table 18. The primers were designed such that the ATG start codons constituted the second half of an *Nde*I site (cleavage recognition site CATATG), and *Bam*HI sites (GGATCC) were introduced immediately after the stop codons. All PCR products were cloned in the
- 25 pCR[®]2.1-TOPO vector. The names of the resulting vectors are listed in Table 19. Except for the mevalonate kinase gene, all genes contained restriction sites for *Bam*HI, *Nde*I or *Eco*RI, which had to be eliminated in order to facilitate later cloning steps. The sites were eliminated by introducing silent mutations using the QuikChange[™] site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) and the oligonucleotides shown in Table 20.
- 30 The mutagenized coding regions were excised from the TOPO-plasmids with *Bam*HI and *Nde*I and ligated with the *Bam*HI-*Nde*I cleaved expression vectors pDS-His and pDS.

These expression vectors were derived from pDSNdeHis, which is described in Example 2 of EP 821,063. The plasmid pDS-His was constructed from pDSNdeHis by deleting a 857 bp *NheI* and *XbaI* fragment carrying a silent chloramphenicol acetyltransferase gene. The plasmid pDS was constructed from pDS-His by replacing a small *EcoRI*-*Bam*HI fragment with the annealed primers S/D-1 (5' AATTAAAGGAGGGTTTCATATGAATTCG) (SEQ ID NO:117) and S/D-2 (5' GATCCGAATTCATATGAAACCCTCCTTT) (SEQ ID NO:118).

Table 18: Oligonucleotides for the cloning of the mevalonate operon genes.

| Gene | Forward primer | | Reverse primer | |
|-------------|----------------------|---|----------------------|--|
| | Name | Sequence (5'-3') | Name | Sequence (5'-3') |
| <i>mvaA</i> | MvaA-Nde | AAGGCCTCATATGATTC CCATACCCCGGT (SEQ ID NO:119) | MvaA-Bam | CGGGATCCTCATCGCTCCAT CTCCATGT (SEQ ID NO:120) |
| <i>idi</i> | Idi-Nde | AAGGCCTCATATGACCGA CAGCAAGGATCA (SEQ ID NO:121) | Idi-Bam | CGGGATCCTCATTGACGGAT AAGCGAGG (SEQ ID NO:122) |
| <i>hsc</i> | Hcs-Nde | AAGGCCTCATATGAAAGT GCCTAAGATGA (SEQ ID NO:123) | Hcs-Bam | CGGGATCCTCAGGCCTGCCG GTCGACAT (SEQ ID NO:124) |
| <i>mvk</i> | Mvk-Nde ¹ | AAGGCCTCATATGAGCAC CGGCAGGCCTGAAGCA (SEQ ID NO:125) | Mvk-Bam ² | CGGGATCCTCATCCCTGCCC CGGCAGCGGTT (SEQ ID NO:126) |
| <i>pmk</i> | Pmk-Nde | AAGGCCTCATATGGATCA GGTCATCCGCGC (SEQ ID NO:127) | Pmk-Bam | CGGGATCCTCAGTCATCGAA AACAAGTC (SEQ ID NO:128) |
| <i>mvd</i> | Mvd-Nde | AAGGCCTCATATGACTGA TGCCGTCCGCGA (SEQ ID NO:129) | Mvd-Bam | CGGGATCCTCAACGCCCTC GAACGGCG (SEQ ID NO:130) |

¹The second codon TCA was changed to AGC (silent mutation - both codons encode serine).

²The last codon GGC was changed to GGA (silent mutation - both codons encode glycine).

Table 19: Names of expression plasmids and construction intermediates.

| Gene | PCR fragments in pCR [®] 2.1-TOPO | After first mutagenesis | After 2 nd mutagenesis | Genes in pDS | Genes in pDS-His |
|-------------|--|-------------------------|-----------------------------------|------------------|-----------------------|
| <i>mvaA</i> | TOPO- <i>mvaA</i> -BB | TOPO- <i>mvaA</i> -B | TOPO- <i>mvaA</i> | pDS- <i>mvaA</i> | pDS-His - <i>mvaA</i> |
| <i>idi</i> | TOPO-ORFX-B | TOPO- <i>idi</i> | n/a | pDS- <i>idi</i> | pDS-His - <i>idi</i> |
| <i>hsc</i> | TOPO- <i>hcs</i> -EN | TOPO- <i>hcs</i> -N | TOPO- <i>hcs</i> | pDS- <i>hcs</i> | pDS-His- <i>hcs</i> |
| <i>mvk</i> | TOPO- <i>mvk</i> | n/a | n/a | pDS- <i>mvk</i> | pDS-His - <i>mvk</i> |
| <i>pmk</i> | TOPO- <i>pmk</i> -B | TOPO- <i>pmk</i> | n/a | Nd | pDS-His - <i>pmk</i> |
| <i>mvd</i> | TOPO- <i>mvd</i> -B | TOPO- <i>mvd</i> | n/a | pDS- <i>mvd</i> | pDS-His - <i>mvd</i> |

n/a: not applicable; nd: not done

Table 20: Oligonucleotides for site-directed mutagenesis.

| Gene/ Site | Forward primer | | Reverse primer | |
|----------------------------------|----------------|---|-----------------|--|
| | Name | Sequence (5'-3') | Name | Sequence (5'-3') |
| <i>mvaA</i> / <i>Bam</i> HI-1 | Mva-B1up | CCGGCATTCTGGGCGGC ATCCAGGTCTCGCTG (SEQ ID NO:131) | Mva-B1down | CAGCGAGACCTGGATG CCGCCGAATGCCGG (SEQ ID NO:132) |
| <i>mvaA</i> / <i>Bam</i> HI-2 | Mva-B2up | CGTGCAGGGCTGGATT CTGTCCGAATACCCG (SEQ ID NO:133) | Mva-B2down | CGGGTATTCCGACAGA ATCCAGCCCTGCACG (SEQ ID NO:134) |
| <i>idi</i> / <i>Bam</i> HI | Idi-Bup2 | GGGCTGCGCGCCGGCA TCCGGCATTTCGACG (SEQ ID NO:135) | Idi-Bdown2 | CGTCGAAATGCCGGAT GCCGGCGCGCAGCCC (SEQ ID NO:136) |
| <i>hcs</i> / <i>Eco</i> RI | Hcs-Eup | GGGTGCGACGGGCGAG TTCTTCGATGCGCGG (SEQ ID NO:137) | Hcs-Edown | CCGCGCATCGAAGAAC TCGCCGTCGCACCC (SEQ ID NO:138) |
| <i>hcs</i> / <i>Nde</i> I | Hcs-Nup-c | CACGCCCCGTACATAC GACGAATACGTTGCC (SEQ ID NO:139) | Hcs-Ndown- c | GGCAACGTATTCGTCG TATGTGACGGGCGTG (SEQ ID NO:140) |
| <i>pmk</i> / <i>Bam</i> HI | Pmk-Bup | GAGGCTCGGGCTTGGC TCCTCGGCGGCGGTG (SEQ ID NO:141) | Pmk-Bdown | CACCGCCGCCGAGGAG CCAAGCCGAGCCTC (SEQ ID NO:142) |
| <i>mvd</i> / <i>Bam</i> HI | Mvd-Bup | CGGCACGCTGCTGGAC CCGGGCGACGCCCTC (SEQ ID NO:143) | Mvd-Bdown | GAAGGCGTCGCCCGGG TCCAGCAGCGTGCCG (SEQ ID NO:144) |

- 5 *E. coli* strain M15 [Villarejo and Zabin, J. Bacteriol. 120:466-474 (1974)] carrying the *lacI* (lac repressor)-containing plasmid pREP4 (EMBL/GenBank accession number A25856) was transformed with the ligation mixtures and recombinant cells were selected for by

growth on LB-Agar plates supplemented with 100 mg/L ampicillin and 25 mg/L kanamycin. Positive clones containing the correct mevalonate operon gene insert were verified by PCR.

- For expression of the inserted genes, each of the *E. coli* strains were grown overnight at 37°C in LB medium containing 25 mg/L kanamycin and 100 mg/L ampicillin. The next day, 25 ml of fresh medium was inoculated with 0.5 ml of the overnight cultures and the new cultures were grown at 37°C. When the OD₆₀₀ of the cultures reached 0.4, expression of the cloned genes was induced by addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM, and the incubation of the cultures (with shaking) was continued for four hours, after which the cells were collected by centrifugation.

Crude extract preparation, HMG-CoA reductase assays, and IPP isomerase assays were performed as described in Example 1. Tables 21 and 22 show the HMG-CoA reductase and IPP isomerase activities, respectively, in the recombinant *E. coli* strains. Upon IPTG induction, strains M15/pDS-*mvaA* and M15/pDS-*idi* contained high levels of the HMG-CoA reductase and IPP isomerase activity, respectively. This illustrates the ability to over-express the mevalonate pathway genes (and overproduce their cognate gene products in an active form) from *Paracoccus* sp. strain R114 in *E. coli*.

Table 21. Induction of HMG-CoA reductase activity in *E. coli* strains over-expressing the cloned *mvaA* gene from *Paracoccus* sp. strain R114.

| Strain/plasmid | IPTG Induction | HMG-CoA reductase activity (U/mg) |
|----------------------------------|----------------|-----------------------------------|
| M15/pDS- <i>mvaA</i> | - | 8.34 |
| M15/pDS- <i>mvaA</i> | + | 90.0 |
| M15/pDS-His- <i>mvaA</i> | - | 1.74 |
| M15/pDS-His- <i>mvaA</i> | + | 2.95 |
| M15/pDS- <i>mvd</i> ^a | - | 0.05 |

^aM15/pDS-*mvd* was included as a negative control

Table 22. Induction of IPP isomerase activity in *E. coli* strains over-expressing the cloned *idi* gene from *Paracoccus* sp. strain R114.

| Strain/plasmid | IPTG Induction | IPP isomerase activity (U/mg) |
|----------------------------------|----------------|-------------------------------|
| M15/pDS- <i>idi</i> | - | Not detected ^b |
| M15/pDS- <i>idi</i> | + | 22.0 |
| M15/pDS-His- <i>idi</i> | - | Not detected |
| M15/pDS-His- <i>idi</i> | + | Not detected |
| M15/pDS- <i>mvd</i> ^a | - | Not detected |

^aM15/pDS-*mvd* was included as a negative control

^b<1 U/mg

- 5 The crude extracts used for the enzyme assays were analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). For strains *E. coli* M15/pDS-*mvaA* and *E. coli* M15/pDS-His-*mvaA*, the presence or absence of a highly expressed protein of the expected molecular mass (36.3 kD) correlated with the HMG-CoA reductase activity measured in the extracts (Table 21). The absence of the His-tagged protein could be
- 10 explained by reduced expression at the level of transcription or translation by instability of the mRNA or the protein. The crude extracts of *E. coli* M15/pDS-*idi* and *E. coli* M15/pDS-His-*idi* both showed highly expressed proteins of the expected molecular masses of 37.3 kD and 39.0 kD, respectively. However, only the extract from *E. coli* M15/pDS-*idi* had increased IPP isomerase activity (Table 22), indicating that the histidine-tagged form of
- 15 the enzyme was not functional under these conditions.

By SDS-PAGE analysis of crude extracts of *E. coli* strains over-expressing the other four genes of the *Paracoccus* sp. strain R114 mevalonate operon (*hcs*, *pmk*, *mvk*, and *mvd*, refer to Table 19) high expression of the native form of the enzyme was not detected upon IPTG induction, although some expression cannot be ruled out. On the other hand, high

20 expression was observed with the His-tagged form of all four proteins.

Example 6: Improved Zeaxanthin Production in *Paracoccus* sp. strain R114 by Over-Expression of the *crtE* Gene

- Construction of pBBR-K-Zea4, pBBR-K-Zea4-up and pBBR-K-Zea4-down and effects of these plasmids on zeaxanthin production in *Paracoccus* sp. strain R114. The carotenoid
- 25 (*crt*) gene cluster of *Paracoccus* sp. strain R1534 was excised from plasmid pZea-4 [Pasa-montes et al., Gene 185:35-41 (1997)] as an 8.3 kb *Bam*HI - *Eco*RI-fragment. This fragment containing the *crt* gene cluster was ligated into the *Bam*HI and *Eco*RI-cut vector pBBR1MCS-2 (GenBank accession #U23751) resulting in pBBR-K-Zea4. Plasmid pBBR-

K-Zea4 was introduced into *Paracoccus* sp. strain R114 by conjugation to test for improved zeaxanthin production. The control strain R114 and two independent isolates of strain R114/pBBR-K-Zea4 were tested for zeaxanthin production in shake flask cultures (using medium 362F/2, see Example 11). The data in Table 23 show that both recombinant strains carrying plasmid pBBR-K-Zea4 produced significantly higher levels of zeaxanthin than R114, and had higher specific rates of production (mg zeaxanthin/OD₆₆₀). This suggested that one or more of the genes within the cloned insert in pBBR-K-Zea4 encoded an enzyme(s) that was limiting for zeaxanthin production in *Paracoccus* sp. strain R114.

Table 23. Zeaxanthin production by strains R114 and R114/pBBR-K-Zea4.

| Strain | 24 Hours | | 48 Hours | | 72 Hours | |
|-------------------------------|----------------------------|-----------------------------|---------------|----------------|---------------|----------------|
| | ZXN ^a (mg/l) | Spec. Form. ^b | ZXN (mg/l) | Spec. Form. | ZXN (mg/l) | Spec. Form. |
| R114 | 54.5 | 2.2 | 81.7 | 4.1 | 78.1 | 4.5 |
| R114/pBBR-K-Zea4 (clone 4) | 41.0 | 3.0 | 100.7 | 5.2 | 97.6 | 6.2 |
| R114/pBBR-K-Zea4 (clone 5) | 41.1 | 3.1 | 110.5 | 5.7 | 102.1 | 6.5 |

^aZeaxanthin

^bSpecific Formation (mg ZXN/l/OD₆₆₀)

To localize the positive effect, two plasmid derivatives were created that contained sub-cloned regions of the cloned insert present in pBBR-K-Zea4. The "upstream" region of the pBBR-K-Zea4 insert, comprising ORF 5 and the genes *atoB* and *crtE*, (Pasamontes et al., supra) is flanked by unique sites for the restriction enzymes *Xba*I and *Avr*II. Plasmid pBBR-K-Zea4-down was constructed by digesting pBBR-K-Zea4 with these two enzymes and deleting the "upstream" region. Analogously, plasmid pBBR-K-Zea4-up was constructed by deletion of the "downstream" region within the cloned insert in pBBR-K-Zea4, using the restriction enzymes *Eco*RV and *Stu*I. The two new plasmids were transferred to *Paracoccus* sp. strain R114 by conjugation. Zeaxanthin production was compared (shake flask cultures, same conditions as described above) in strains R114 (host control), R114/pBBR-K (empty vector control), R114/pBBR-K-Zea4-down and R114/pBBR-K-Zea4-up (Table 24). The data clearly showed that the positive effect on zeaxanthin production was a result of the presence in multiple copies of the cloned segment containing ORF5, *atoB* and *crtE*, i.e., the insert present in plasmid-pBBR-K-Zea4-up. A series of deletion plasmids was constructed from pBBR-K-Zea4-up. By introducing each of these plasmids into strain R114 and testing for zeaxanthin production, it was determined that it

was over-expression of the *crtE* gene that was providing the improved zeaxanthin production in strains R114/pBBR-K-Zea4 and pBBR-K-Zea4-up. This result is consistent with the activity of GGPP synthase (encoded by *crtE*) being limiting for zeaxanthin production in *Paracoccus* sp. strain R114. Using the methods described in Example 1, crude extract of strain R114/pBBR-K-Zea4-up was found to have 2.6-fold higher GGPP synthase activity than R114. To prove this directly, a new plasmid allowing over-expression of only the *crtE* gene was constructed as described in the following two sections.

Table 24. Zeaxanthin production by strains carrying deletion derivatives of plasmid pBBR-K-Zea4.

| Strain | 24 Hours | | 48 Hours | | 72 Hours | |
|-----------------------|----------------------------|-----------------------------|---------------|----------------|---------------|----------------|
| | ZXN ^a (mg/l) | Spec. Form. ^b | ZXN (mg/l) | Spec. Form. | ZXN (mg/l) | Spec. Form. |
| R114 | 35.0 | 1.2 | 75.7 | 4.1 | 73.9 | 4.4 |
| R114/pBBR-K | 32.0 | 1.5 | 59.3 | 3.1 | 63.3 | 3.9 |
| R114/pBBR-K-Zea4-up | 51.5 | 2.2 | 98.8 | 5.5 | 85.5 | 5.7 |
| R114/pBBR-K-Zea4-down | 41.6 | 1.8 | 63.4 | 3.3 | 66.4 | 3.9 |

^aZeaxanthin

^bSpecific Formation (mg ZXN/l/OD₆₆₀)

Construction of the expression vectors pBBR-K-*PcrtE* and pBBR-tK-*PcrtE*. The vector pBBR1MCS-2 was cut with *Bst*XI and *Bsu*36I and the larger fragment was ligated with the annealed oligonucleotides MCS-2 up (5' TCAGAATTCGGTACCATATGAAGCTTGGATCCGGGG 3') (SEQ ID NO:145) and MCS-2 down (5' GGATCCAAGCTTCATATGGTACCGAATTC 3') (SEQ ID NO:146), resulting in vector pBBR-K-Nde. The 270 bp region upstream of the *crtE* gene in the carotenoid gene cluster from *Paracoccus* sp. strain R114, which contains the putative *crtE* promoter (*PcrtE*) including the ribosome binding site and the *crtE* start codon (Pasamontes et al., supra) was amplified from *Paracoccus* sp. strain R114 DNA by PCR with primers *crtE*-up (5' GGAATTCGCTGCTGAACGCGATGGCG 3') (SEQ ID NO:147) and *crtE*-down (5' GGGGTACCATATGTGCCTTCGTTGCGTCAGTC 3') (SEQ ID NO:148). The PCR product was cut with *Eco*RI and *Nde*I and inserted into the *Eco*RI-*Nde*I cut backbone of pBBR-K-Nde, yielding plasmid pBBR-K-*PcrtE*. An *Nde*I site, which contains the ATG start codon of *crtE*, was included in primer *crtE*-down. Hence, any introduced coding region with the start codon embedded in a *Nde*I site should be expressed using the ribosomal binding site of *crtE*. The plasmid pBBR-K-*PcrtE* was cut with *Bam*HI and the annealed oligonucleotides pha-t-up

(5' GATCCGGCGTGTGCGCAATTTAATTGCGCACACGCCCCCTGCGTTTAAAC 3')
(SEQ ID NO:149) and pha-t-down

(5' GATCGTTTAAACGCAGGGGGCGTGTGCGCAATTAAATTGCGCACACGCGG 3')
(SEQ ID NO:150) were inserted. The insertion was verified by sequencing, and the version

- 5 of the plasmid having the oligos inserted in the orientation that reconstitutes the *Bam*HI site closer to the *PcrE* promoter was named pBBR-tK-*PcrE*. The inserted sequence carries the putative transcriptional terminator found between the *Paracoccus* sp. strain R114 *phaA* and *phaB* genes (see Example 10) and should, therefore, ensure proper termination of the transcripts initiated from the *PcrE* promoter.

- 10 Construction of plasmid pBBR-K-*PcrE*-*crtE*-3. To construct a multi-copy plasmid for increased expression of the *crtE* gene in the *Paracoccus* sp. strain R114 host, the *crtE* gene was amplified from plasmid p59-2 (Pasamontes et al., supra) by PCR using the primers *crtE*-Nde (5' AAGGCCTCATATGACGCCCAAGCAGCAATT 3') (SEQ ID NO:151) and *crtE*-Bam (5' CGGGATCCTAGGCGCTGCGGCGGATG 3') (SEQ ID NO:152). The
- 15 amplified fragment was cloned in the pCR[®]2.1-TOPO vector, resulting in plasmid TOPO-*crtE*. The *Nde*I-*Bam*HI fragment from TOPO-*crtE* was subcloned in *Nde*I-*Bam*HI-digested plasmid pBBR-K-*PcrE*, yielding pBBR-K-*PcrE*-*crtE*. Finally, pBBR-K-*PcrE*-*crtE*-3 was constructed by replacing the smaller *Bgl*II fragment from pBBR-K-*PcrE*-*crtE* with the smaller *Bgl*II fragment from pBBR-K-Zea4-up. Plasmid pBBR-K-*PcrE*-*crtE*-3
- 20 was transferred to *Paracoccus* sp. strain R114 by electroporation. Using the methods described in Example 1, GGPP synthase activity in crude extracts was found to be 2.9-fold higher in strain R114/pBBR-K-*PcrE*-*crtE*-3 than in strain R114. This degree of elevated activity was similar to that observed in R114/pBBR-K-Zea4-up. Table 25 shows the zeaxanthin production by strain R114/pBBR-K-*PcrE*-*crtE*-3 was essentially identical to
- 25 strain R114/pBBR-K-Zea4-up.

Table 25. Comparison of zeaxanthin production by strains R114/pBBR-K-*PcrtE-crtE-3* and R114/pBBR-K-Zea4-up.

| Strain | 24 Hours | | 48 Hours | | 72 Hours | |
|----------------------------------|----------------------------|-----------------------------|---------------|----------------|---------------|----------------|
| | ZXN ^a (mg/l) | Spec. Form. ^b | ZXN (mg/l) | Spec. Form. | ZXN (mg/l) | Spec. Form. |
| R114 | 49.0 | 1.6 | 83.9 | 3.3 | 97.8 | 4.3 |
| R114/pBBR-K | 42.6 | 1.8 | 73.7 | 3.8 | 88.8 | 4.9 |
| R114/pBBR-K- <i>PcrtE-crtE-3</i> | 64.6 | 2.9 | 127.0 | 5.8 | 165.6 | 8.5 |
| R114/pBBR-K-Zea4-up | 64.7 | 2.9 | 118.0 | 5.9 | 158.0 | 10.1 |

^aZeaxanthin

^bSpecific Formation (mg ZXN/l/OD₆₆₀)

- 5 Example 7: Expression of Individual Genes of the *Paracoccus* sp. strain R114 Mevalonate Operon in the Native Host, *Paracoccus* sp. strain R114
- Expression of individual cloned genes of the *Paracoccus* sp. strain R114 mevalonate operon in the *Paracoccus* sp. strain R114 host. The mutagenized coding regions of the mevalonate operon genes in TOPO-plasmids (see Example 5) were excised with *Bam*HI and *Nde*I and
- 10 ligated with the *Bam*HI-*Nde*I cleaved vector pBBR-tK-*PcrtE* (see Example 6). The resulting plasmids pBBR-tK-*PcrtE-mvaA*, pBBR-tK-*PcrtE-idi*, pBBR-tK-*PcrtE-hcs*, pBBR-tK-*PcrtE-mvk*, pBBR-tK-*PcrtE-pmk* and pBBR-tK-*PcrtE-mvd* were introduced into *Paracoccus* sp. strain R114 by electroporation. Transformants were selected on agar medium containing 50 mg/l kanamycin and verified by PCR.
- 15 To illustrate that the plasmid-borne mevalonate pathway genes can be expressed in the native host *Paracoccus* sp. strain R114, HMG-CoA reductase activity was compared in crude extracts of strains R114/pBBR-K (control) and R114/pBBR-tK-*PcrtE-mvaA* (methods used are set forth in Example 1). The specific activities of HMG-CoA reductase in strains R114/pBBR-K and R114/pBBR-tK-*PcrtE-mvaA* were 2.37 U/mg and 6.0 U/mg,
- 20 respectively. Thus the presence of the *mvaA* gene on a multicopy plasmid (and expressed from the *PcrtE* promoter) resulted in a 2.5-fold increase in HMG-CoA reductase activity relative to the basal (i.e., chromosomally encoded) activity of R114 carrying the empty vector pBBR-K.

Example 8: Construction of "Mini-Operons" for Simultaneous Over-Expression the Cloned Genes of the Mevalonate Pathway with the *Paracoccus* sp. strain R114 *crtE* Gene

- Plasmid constructions. As was shown in Example 6, introduction of plasmid pBBR-K-*PcrtE-crtE*-3 into *Paracoccus* sp. strain R114 resulted in increased production of zeaxanthin, indicating that GGPP synthase activity was rate limiting for zeaxanthin biosynthesis in strain R114. Example 7 further showed that genes coding for the enzymes of the mevalonate pathway could be over-expressed in the native host *Paracoccus* sp. strain R114, and resulted in increased activity of the encoded enzyme. However, none of the recombinant strains of *Paracoccus* sp. strain R114 that carried plasmids containing each individual gene of the mevalonate operon showed increased zeaxanthin production compared to strain R114. It is possible that the benefit of over-expression of the genes of the mevalonate operon in *Paracoccus* sp. strain R114 could be masked by the downstream "bottleneck" in the zeaxanthin pathway (GGPP synthase). Creation of plasmids that allow simultaneous over-expression of each mevalonate pathway gene (or perhaps combinations of these genes) together with *crtE* could relieve all rate limitations in the overall zeaxanthin biosynthetic pathway, thereby improving zeaxanthin production. The next section describes the construction of "mini-operons" designed to allow co-over-expression of *crtE* and each of the genes coding for the five enzymes of the mevalonate pathway.
- The *crtE*, *mvaA*, *idi* and *mvk* genes were excised from the respective TOPO-plasmids (described in Examples 5 and 6) with *Bam*HI and *Nde*I and ligated with *Bam*HI-*Nde*I-cleaved vector pOCV-1 (described in Example 12). The *crtE* gene does not have an adenine as the last nucleotide of the coding region, and in addition, has a TAG rather than a TGA stop codon and an unsuitable distance between the stop codon and the *Bam*HI site. Therefore, the end of *crtE* does not meet the requirements of the operon construction vectors (refer to Example 12) and *crtE* must be the last gene in any operon constructed with pOCV-1-*crtE*. To meet the requirement for an adenine as the first nucleotide of the second codon and the last nucleotide of the last codon, mutations had to be introduced in three genes of the mevalonate operon. The second codon of *pmk*, GAT, encoding Asp, was changed into AAT, encoding Asn. The last codon of *mvd* ends with a T and the last codons of *pmk* and *hcs* end with C. Changing these nucleotides to A results in silent mutations except for *pmk* where the last amino acid is changed from Asp to Glu. Oligonucleotides were designed to introduce the necessary changes by PCR. The sequences of the oligonucleotides and the templates used for those PCR reactions are shown in Table 26. All PCR products were cloned in the pCR[®]2.1-TOPO vector, resulting in plasmids TOPO-*mva*^{OCV}, TOPO-*pmk*^{OCV} and TOPO-*hcs*^{OCV}. The inserts were excised

with *Nde*I and *Bam*HI and ligated with the *Nde*I-*Bam*HI cut backbone of pOCV-2 (see Example 12). The final cloning steps to assemble each of the "mini-operons" were analogous, and are illustrated by the representative scheme for construction of pBBR-K-*PcrE-mvaA-crtE*-3.

5 Table 26: Oligonucleotides and templates used for PCR in the construction of plasmids TOPO-*mvd*^{OCV}, TOPO-*pmk*^{OCV} and TOPO-*hcs*^{OCV}.

| Gene | Forward primer | | Reverse primer | | Template |
|------------|----------------|---|----------------|---|--------------------------|
| | Name | Sequence (5'-3') | Name | Sequence (5'-3') | |
| <i>Hcs</i> | Hcs-Nde | AAGGCCTCATATGAAA GTGCCTAAGATGA (SEQ ID NO:123) | Hcs-mut3 | CCGGATCCTCATGCC TGCCGGTCGACATAG (SEQ ID NO:153) | pBBR-tK- <i>PcrE-hcs</i> |
| <i>Pmk</i> | Pmk-mut5 | GAAGGCACATATGAAT CAGGTCATCCGCGC (SEQ ID NO:154) | Pmk-mut3 | GCCGGATCCTCATTC ATCGAAAACAAGTCC (SEQ ID NO:155) | pBBR-tK- <i>PcrE-pmk</i> |
| <i>Mvd</i> | Mvd-Nde | AAGGCCTCATATGACT GATGCCGTCCGCGA (SEQ ID NO:129) | Mvd-mut3 | ACGCCGGATCCTCAT CGCCCTCGAACGGC (SEQ ID NO:156) | pBBR-tK- <i>PcrE-mvd</i> |

Example 9: Cloning and Sequencing of the *ispA* Gene Encoding FPP Synthase from *Paracoccus* sp. strain R114

- 10 Because FPP synthase lies in the central pathway for zeaxanthin biosynthesis in *Paracoccus* sp. strain R114, increasing the activity of this enzyme by increasing the dosage of the *ispA* gene has the potential to improve zeaxanthin production. For this reason, the *ispA* gene from *Paracoccus* sp. strain R114 was cloned and sequenced as follows. The amino acid sequences of six bacterial FPP synthases were obtained from public databases. These
- 15 sequences have several highly conserved regions. Two such regions, and the oligonucleotides used for PCR, are shown in Table 27. PCR with oligonucleotides GTT-1 and GTT-2, using *Paracoccus* sp. strain R114 DNA as template, gave a product of the expected size. The PCR product was cloned in the vector pCR[®]2.1-TOPO and sequenced. The cloned fragment was used as a probe for a Southern analysis of *Paracoccus* sp. strain R114 DNA
- 20 and was found to hybridize to a *Bam*HI-*Nco*I fragment of about 1.9 kb. *Paracoccus* sp. strain R114 DNA was cut with *Bam*HI and *Nco*I and the fragments were separated by agarose gel electrophoresis. The region between 1.5 and 2.1 kb was isolated and cloned in the *Bam*HI and *Nco*I sites of a cloning vector. This partial library was then screened using the *ispA*-PCR fragment as a probe, and two positive clones were isolated. Sequencing con-
- 25 firmed that the plasmids of both clones contained the *ispA* gene. Upstream of *ispA* (SEQ ID NO:159) is the gene for the small subunit of exonuclease VII, XseB (SEQ ID NO:158),

- 96 -

and downstream is the *dxs* gene (SEQ ID NO:160) encoding the 1-deoxyxylulose-5-phosphate synthase. This is the same gene arrangement as found in *E. coli*. The sequence of the *NcoI*-*Bam*HI fragment is illustrated in SEQ ID NO:157, the amino acid sequences of XseB, IspA and Dxs are illustrated in SEQ ID NO:158, SEQ ID NO:159, and SEQ ID NO:160, respectively. The start codon of *ispA* may be GTG or ATG resulting in two or one methionine residues, respectively, at the amino-terminus of the native IspA.

Using the same general cloning strategy described in Examples 5-7, a new plasmid, pBBR-tK-*PcrtE-ispA-2* was constructed to allow for over-expression of the *ispA* gene in the native host *Paracoccus* sp. strain R114. The plasmid was introduced into strain R114 by electroporation, and transformants were confirmed by PCR. Three representative transformants and a control strain (R114/pBBR-K) were grown in 362F/2 medium (Example 11), crude extracts were prepared and assayed for activity of the *ispA* gene product, FPP synthase according to the methods described in Example 1. The basal (chromosomally-encoded) FPP synthase specific activity in R114/pBBR-K was 62.6 U/mg. The FPP synthase activity in the three transformants was 108.3 U/mg (73% increase), 98.5 U/mg (57% increase) and 83.8 U/mg (34% increase), demonstrating the over-expression of the *ispA* gene and over-production of its product, FPP synthase, in an active form in *Paracoccus* sp. strain R114.

Table 27: Oligonucleotides designed from two conserved bacterial IspA peptides.

| | |
|------------------------------------|---|
| Peptide 1 | |
| <i>Bradyrhizobium japonicum</i> | Val His Asp Asp Leu Pro (SEQ ID NO:161) |
| <i>Rhizobium</i> sp. strain NGR234 | Val His Asp Asp Leu Pro (SEQ ID NO:162) |
| <i>Bacillus stearothermophilus</i> | Ile His Asp Asp Leu Pro (SEQ ID NO:163) |
| <i>Bacillus subtilis</i> | Ile His Asp Asp Leu Pro (SEQ ID NO:164) |
| <i>Escherichia coli</i> | Ile His Asp Asp Leu Pro (SEQ ID NO:165) |
| <i>Haemophilus influenzae</i> | Ile His Asp Asp Leu Pro (SEQ ID NO:166) |
| Oligonucleotide GTT-1 (5'-3') | tc cay gay gay ctg cc (SEQ ID NO:167) |
| Peptide 2 | |
| <i>Bradyrhizobium japonicum</i> | Asp Asp Ile Leu Asp (SEQ ID NO:168) |
| <i>Rhizobium</i> sp. strain NGR234 | Asp Asp Ile Leu Asp (SEQ ID NO:169) |
| <i>Bacillus stearothermophilus</i> | Asp Asp Ile Leu Asp (SEQ ID NO:170) |
| <i>Bacillus subtilis</i> | Asp Asp Ile Leu Asp (SEQ ID NO:171) |
| <i>Escherichia coli</i> | Asp Asp Ile Leu Asp (SEQ ID NO:172) |
| <i>Haemophilus influenzae</i> | Asp Asp Ile Leu Asp (SEQ ID NO:173) |
| Reverse complement of | |
| Oligonucleotide GTT-2 (5'-3') | gay gay atc ctg gay (SEQ ID NO:174) |

Y = C or T

Example 10: Cloning and Sequencing of the Genes Coding for Acetyl-CoA

Acetyltransferase from *Paracoccus* sp. strain R114

The first committed step in IPP biosynthesis is the condensation of acetyl-CoA and aceto-
5 acetyl-CoA to hydroxymethylglutaryl-CoA (HMG-CoA) by HMG-CoA synthase. The sub-
strate acetoacetyl-CoA is formed by the enzyme acetyl-CoA acetyltransferase (also known
as acetoacetyl-CoA thiolase or β -ketothiolase) by condensation of two molecules of acetyl-
CoA. Because this reaction links central metabolism (at acetyl-CoA) to isoprenoid biosyn-
thesis via the mevalonate pathway, increasing the activity of acetyl-CoA acetyltransferase
10 by gene amplification has the potential to increase carbon flow to carotenoids and other
isoprenoids *in vivo*. In *Paracoccus* sp. strain R114, there are at least two genes, *atoB* and
phaA, that encode acetyl-CoA acetyltransferases. The end of the *atoB* gene is 165 nucleo-
tides upstream of the start of *crtE* in *Paracoccus* sp. strains R1534 (US 6,087,152) and R114
(this work). The nucleotide sequence of the *atoB* gene and the corresponding amino acid
15 sequence of the encoded acetyl-CoA acetyltransferase from *Paracoccus* sp. strain R1534 are
illustrated in SEQ ID NO:175 and SEQ ID NO:176, respectively.

Using the same general strategy as described in Example 5, the *atoB* gene was cloned in
plasmids pDS and pDS-His. The new plasmids, pDS-*atoB* and pDS-His-*atoB* were intro-
duced into *E. coli* strain M15. The resulting strains M15/pDS-*atoB* and M15/pDS-His-
20 *atoB* were grown with and without IPTG induction (as described in Example 5), and crude
extracts were prepared for acetyl-CoA acetyltransferase assays (methods used were
described in Example 1) and SDS-PAGE analysis. The acetyl-CoA acetyltransferase
specific activities in extracts of M15/pDS-*atoB* and M15/pDS-His-*atoB* (with IPTG
induction) were 0.2 U/mg and 13.52 U/mg, respectively. The basal activity measured in *E.*
25 *coli* without the plasmids was 0.006 U/mg. Upon IPTG induction the *atoB* gene product,
acetyl-CoA acetyltransferase, is overproduced in *E. coli* M15. Both the native (M15/pDS-
atoB) and His-tagged (M15/pDS/his-*atoB*) forms were overproduced. The degree of
overproduction was much higher in M15/pDS-His-*atoB*, consistent with the measured
acetyl-CoA acetyltransferase activity in the (induced) extracts of the two strains.

30 Acetoacetyl-CoA is also the substrate for the first committed step in poly-
hydroxyalkanoate (PHA) biosynthesis. In many bacteria the genes involved in PHA
biosynthesis are grouped in operons [Madison and Huisman, Microbiol. Mol. Biol. Rev.,
63:21-53 (1999)]. In *Paracoccus denitrificans* the *phaA* and *phaB* genes, encoding the
acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase, respectively, are clustered in

an operon [Yabutani et al., FEMS Microbiol. Lett. 133:85-90 (1995)] whereas *phaC*, the gene encoding the last enzyme in the pathway, poly(3-hydroxyalkanoate) synthase, is not part of this operon [Ueda et al., J. Bacteriol. 178:774-779 (1995)]. PCR fragments containing parts of *phaA* from *Paracoccus* sp. strain R1534 and *phaC* from *Paracoccus* sp. strain R114 were obtained using primers based on the *P. denitrificans* *phaA* and *phaC* gene sequences. The PCR fragments were then used as probes to screen a *Paracoccus* sp. strain R114 λ -library (see Example 4). Several λ -clones hybridizing with the *phaA* or the *phaC* probes were isolated, and the presence of the *phaA* or *phaC* genes in the inserts was verified by sequence analysis. Three *phaA* λ -clones were further analyzed by subcloning and sequencing, whereby the *phaB* was found downstream of *phaA*. Therefore, as is the case in *P. denitrificans*, the *phaA* and *phaB* genes are clustered whereas the *phaC* gene is located elsewhere in the genome. The nucleotide sequence of the *phaAB* cluster from *Paracoccus* sp. strain R114 and the deduced amino acid sequences of the acetyl-CoA acetyltransferase (PhaA) are illustrated in SEQ ID NO:177, and SEQ ID NOs:178 and 179, respectively. The clustering of genes involved in PHA biosynthesis in operons suggests that at least *phaA* and *phaB* are expressed together when the cell produces poly(3-hydroxyalkanoates). On the other hand, a putative transcriptional stop signal is found between the *phaA* and *phaB* genes from *Paracoccus* sp. strain R114 which is absent in the *P. denitrificans* *phaAB* operon (Yabutani et al., supra). Thus, the expression of the two genes might not be coupled in *Paracoccus* sp. strain R114.

Using the same general strategy as described in Example 5, the *phaA* gene was cloned in plasmid pDS-His. The new plasmid, pDS-His-*phaA*, was introduced into *E. coli* strain M15. The resulting strain M15/pDS-His-*phaA* was grown with and without IPTG induction (as described in Example 5) and crude extracts were prepared for SDS-PAGE analysis. The cloned His-tagged *Paracoccus* sp. strain R114 PhaA (acetyl-CoA acetyltransferase) is overproduced upon IPTG induction in the *E. coli* M15 host.

The potential benefit of amplifying the *atoB* or *phaA* genes, encoding acetyl-Co acetyltransferase, on zeaxanthin production is mentioned above. In addition, it may be beneficial for zeaxanthin production to decrease or eliminate the activity of acetoacetyl-CoA reductase (the *phaB* gene product) to avoid diversion of some of the acetoacetyl-CoA formed *in vivo* to the PHA pathway. Mutants of *Paracoccus* sp. strain R114 lacking activity of *phaB* could be obtained by gene replacement techniques (specifically replacing the wild-type *phaB* gene in the chromosome with an inactive form of the gene) or by classical mutagenesis and screening.

Example 11: Model for the Industrial Production of Lycopene Using Mutants Derived from *Paracoccus* sp. strain R114

Lycopene is a red carotenoid that is an intermediate in the biosynthesis of zeaxanthin in the new *Paracoccus* species represented by strain R-1512 and its mutant derivatives R1534 and R114. As lycopene itself has significant commercial potential, it was of interest to test the potential of the new *Paracoccus* species to produce lycopene by industrial fermentation. To obtain mutants blocked in zeaxanthin biosynthesis that accumulated lycopene, *Paracoccus* sp. strain R114 was subjected to mutagenesis with ultraviolet (UV) light followed by screening for red colonies. The UV mutagenesis was performed as follows. An overnight culture of strain R114 was grown in ME medium (see Example 2). The overnight culture was subcultured into fresh ME medium (initial $OD_{610} = 0.1$) and incubated at 28°C for 3 hours. Aliquots of this culture were centrifuged and the pellet washed with 20mM potassium phosphate buffer (pH 7.2). After a second centrifugation, the pellet was resuspended to a final OD_{610} of 0.1. Ten milliliter aliquots of the cell suspension were placed in a sterile 100-ml glass beaker. The thin layer of cell suspension was irradiated with UV light at a flux of $1450\mu W/cm^2$ for a pre-determined optimal length of time. The cell suspension was mixed during the irradiation by means of a paper clip in the beaker and a magnetic stirrer. The mutagenized cell suspensions (and the unmutagenized controls) were plated on 362/F2 agar medium (Table 28). Triplicate viable plate counts (in dim room light) were done on suspensions before and after mutagenesis. Plates were incubated for 4-5 days at 28°C, and the colonies were scored. Several red colonies (putative lycopene producers) were identified and purified by re-streaking. One mutant, designated UV7-1, was further evaluated for lycopene production.

Table 29 shows the zeaxanthin production and lycopene production by the control strain R114 and its mutant derivative UV7-1. Strain R114 produced only zeaxanthin. Mutant UV7-1 produced mostly lycopene, but also produced a residual amount of zeaxanthin, suggesting that the mutational block in UV7-1 (presumably in the *crtY* gene) is not complete. These results show that it is possible to derive lycopene producing strains from *Paracoccus* sp. strain R114.

Table 28. Recipe and preparation for medium 362F/2

| Component | Amount |
|--|----------------------------------|
| Glucose monohydrate | 33 g |
| Yeast extract | 10 g |
| Tryptone | 10 g |
| NaCl | 5 g |
| MgSO ₄ ·7H ₂ O | 2.5 g |
| Agar (for solid medium) | 20 g |
| Distilled water | To 932 ml |
| -adjust pH to 7.4 | |
| -sterilize by filtration (liquid medium) or autoclaving (solid medium) | |
| -Add 2.5 ml each of microelements solution, NKP solution and CaFe solution | |
| Microelements solution | Amount per liter distilled water |
| (NH ₄) ₂ Fe(SO ₄) ₂ ·6H ₂ O | 80 g |
| ZnSO ₄ ·7H ₂ O | 6 g |
| MnSO ₄ ·H ₂ O | 2 g |
| NiSO ₄ ·6H ₂ O | 0.2 g |
| EDTA | 6 g |
| -sterilize by filtration | |
| NKP solution | Amount per liter distilled water |
| K ₂ HPO ₄ | 250 g |
| (NH ₄) ₂ HPO ₄ | 300 g |
| -sterilize by filtration | |
| CaFe solution | Amount per liter distilled water |
| CaCl ₂ ·2H ₂ O | 75 g |
| FeCl ₃ ·6H ₂ O | 5 g |
| Concentrated HCl | 3.75 ml |
| -sterilize by filtration | |

Table 29. Zeaxanthin and lycopene production by *Paracoccus* sp. strain R114 and its red mutant derivative UV7-1.

| | Zeaxanthin (mg/l) | Lycopene (mg/l) |
|----------|-------------------|-----------------|
| 24 hours | | |
| R114 | 36.65 | 0 |
| UV7-1 | 3.85 | 20.85 |
| 48 hours | | |
| R114 | 72.95 | 0 |
| UV7-1 | 5.75 | 85.95 |
| 72 hours | | |
| R114 | 83.9 | 0 |
| UV7-1 | 5.85 | 124.55 |

Example 12: Model for the Industrial Production of Astaxanthin by Fermentation Using

5

Strains Derived from *Paracoccus* sp. strain R114

Astaxanthin is a commercially important carotenoid used primarily in the aquaculture industry. EP 872,554 showed that astaxanthin production could be achieved in *E. coli* by introducing plasmids containing combinations of the cloned carotenoid (*crt*) genes from *Paracoccus* sp. strain R1534 and *Paracoccus carotinifaciens* E-396^T. Together, the cloned *crt* genes (*crtEBIYZ*) and *crtW* (β -carotene β -4 oxygenase) encoded a total biosynthetic pathway from FPP through zeaxanthin to astaxanthin. The sequences of the *P. carotinifaciens* E-396 *crtW*, *Paracoccus* sp. R1534 *crtZ*, and *Paracoccus* sp. R1534 *crtE* genes and encoded polypeptides are set forth in (SEQ ID NOs:180 and 181 (*crtW*); 182 and 184 (*crtZ*); and 184 and 185 (*crtE*)). However, it was not shown that astaxanthin production could be achieved in the *Paracoccus* sp. strain R114 host family. To demonstrate the utility of recombinant strains derived from strain R114 for astaxanthin production, the cloned *crtW* gene (SEQ ID NO:180) was introduced into strain R114 as follows.

Table 30. PCR primers-used for the work described in Example 12.

| Primer name | Sequence |
|-------------|--|
| CrtW-Nde | 5' AAGGCCTCATATGAGCGCACATGCCCTGCC 3' (SEQ ID NO:186) |
| CrtW-Bam | 5' CGGGATCCTCATGCGGTGTCCCCCTTGG 3' (SEQ ID NO:187) |
| CrtZ-Nde | 5' AAGGCCTCATATGAGCACTTGGGCCGCAAT 3' (SEQ ID NO:188) |
| CrtZ-Bam | 5' AGGATCCTCATGTATTGCGATCCGCCCTT 3' (SEQ ID NO:189) |

The *crtW* gene was amplified by PCR from the cloned *crt* cluster of *Paracoccus carotini-faciens* strain E-396^T (Tsubokura et al., supra; EP 872,554) using the primers *crtW*-Nde and *crtW*-Bam (Table 30). The primers were designed such that the ATG start codon constitutes the second half of an *NdeI* site (cleavage recognition site CATATG), and a *BamHI* site (GGATCC) was introduced immediately after the stop codon. The PCR product was
5 cloned in the pCR[®]2.1-TOPO vector, resulting in plasmid TOPO-*crtW*. The *crtW* gene was excised with *NdeI* and *BamHI* and subcloned in the *NdeI*-*BamHI* cut vector pBBR-K-*PcrtE* (described in Example 6) to create plasmid pBBR-K-*PcrtE-crtW*.

Plasmid pBBR-K-*PcrtE-crtW* was transferred to *Paracoccus* sp. strain R114 using a standard
10 bacterial conjugation procedure [*E. coli* strain S17 [Priefer et al., J. Bacteriol. 163:324-330 (1985)] was the donor organism]. Transconjugants were selected on medium 362F/2 agar (Table 28) containing 50 mg/l kanamycin and purified by restreaking on the same medium. The presence of plasmid pBBR-K-*PcrtE-crtW* in the strain was confirmed by
15 PCR. Carotenoid production by strains R114 (host control), R114/pBBR-K (empty vector control) and R114/ pBBR-K-*PcrtE-crtW* was measured in shake flask cultures as described in Examples 1 and 2, except that liquid 362F/2 medium was used instead of ME medium. These results are shown in Table 31. The control strains R114 and R114/pBBR-K produced only zeaxanthin. In strain R114/ pBBR-K-*PcrtE-crtW*, the zeaxanthin was completely
20 consumed by the plasmid-encoded β -carotene β -4 oxygenase. However, although astaxanthin was produced, two other ketocarotenoids, adonixanthin and canthaxanthin, accumulated at higher levels. This indicated an imbalance *in vivo* of the β -carotene hydroxylase (encoded by the chromosomal *crtZ* gene in strain R114) and the cloned β carotene β -4 oxygenase (*CrtW*).

To test this hypothesis, two new plasmids were created that contained the *crtZ* and *crtW*
25 genes together in mini-operons. The order of the genes was made different in the two constructs (i.e., *crtZ-crtW* and *crtW-crtZ*) to try and create different ratios of expression of the *crtZ* and *crtW* genes. The construction of the new plasmids required the assembly of a special set of cloning vectors as follows. A series of operon construction vectors (based on the vector pCR[®]2.1-TOPO) was designed to facilitate the assembly of genes (in this case,
30 *crtZ* and *crtW*) into operons. The genes of interest must have an ATG start codon, embedded in an *NdeI* site (CATATG), and a TGA stop codon immediately followed by a *BamHI* site.

Table 31. Astaxanthin production in *Paracoccus* sp. strain R114 containing plasmids expressing the *crtW* gene alone and in combination with the *crtZ* gene.

| Strain | 24 hours | | | | | |
|--------------------------|----------|------|------|------|-------|------------------------|
| | ZXN | ADN | CXN | AXN | Total | Sp. Form. ^a |
| R114 | 46.5 | 0 | 0 | 0 | 46.5 | 2.1 |
| R114/pBBR-K | 38.8 | 0 | 0 | 0 | 41.4 | 2.2 |
| R114/pBBR-K-PcrtE -crtW | 0 | 13.0 | 21.8 | 2.3 | 37.5 | 2.1 |
| R114/pBBR-K-PcrtE -crtWZ | 0 | 14.9 | 29.5 | 1.3 | 45.6 | 2.1 |
| R114/pBBR-K-PcrtE -crtZW | 0 | 18.0 | 20.4 | 7.3 | 45.65 | 2.1 |
| | | | | | | |
| Strain | 48 hours | | | | | |
| | ZXN | ADN | CXN | AXN | Total | Sp. Form. ^a |
| R114 | 72.6 | 0 | 0 | 0 | 74.4 | 2.8 |
| R114/pBBR-K | 70.1 | 0 | 0 | 0 | 70.1 | 3.1 |
| R114/pBBR-K-PcrtE -crtW | 0 | 26.7 | 22.0 | 26.9 | 75.5 | 3.9 |
| R114/pBBR-K-PcrtE -crtWZ | 0 | 30.9 | 27.2 | 34.8 | 92.9 | 4.0 |
| R114/pBBR-K-PcrtE -crtZW | 0 | 15.7 | 11.2 | 58.3 | 85.1 | 4.1 |
| | | | | | | |
| Strain | 72 hours | | | | | |
| | ZXN | ADN | CXN | AXN | Total | Sp. Form. ^a |
| R114 | 82.5 | 0 | 0 | 0 | 82.5 | 5.3 |
| R114/pBBR-K | 82.9 | 0 | 0 | 0 | 82.9 | 5.1 |
| R114/pBBR-K-PcrtE -crtW | 0 | 19.7 | 17.0 | 46.8 | 83.5 | 5.2 |
| R114/pBBR-K-PcrtE -crtWZ | 0 | 28.7 | 26.4 | 43.8 | 98.8 | 6.1 |
| R114/pBBR-K-PcrtE -crtZW | 0 | 18.3 | 14.4 | 66.3 | 98.9 | 5.9 |

^aZXN, zeaxanthin; ADN, adonixanthin; CXN, canthaxanthin; AXN, astaxanthin.

^bSpecific Formation, expressed as mg/l total carotenoid/OD₆₆₀.

- 5 Furthermore, the first nucleotide after the start codon and the last nucleotide before the stop codon must be adenine and the gene must lack sites for at least one of the enzymes *BsgI*, *BseMII*, *BseRI* and *GsuI*. Four operon construction vectors were constructed, differing in the arrangements of their polylinker sequences (SEQ ID NOs: 190-197). The cleavage sites of the first two enzymes are within the *NdeI* site. The cleavage sites of the
- 10 last two enzymes are before the *BamHI* site. The *BseRI* site in pOCV-1 and pOCV-4 is not unique and cannot be used for operon construction.

The genes to be assembled in operons are first inserted individually between the *NdeI* and the *BamHI* sites of the appropriate operon construction vectors. The resulting plasmid with the upstream gene of the envisioned operon is then cut with one of the two enzymes

at the end of the polylinker and with an enzyme, which has a unique site within the vector backbone. The plasmid containing the downstream gene of the envisioned operon is cut with one of the first two enzymes of the polylinker and with the same enzyme (with a unique site in the vector backbone) used for the first plasmid (containing the desired upstream gene). The fragments carrying the genes are isolated and ligated, resulting in a pOCV plasmid with both genes between the *NdeI* and the *BamHI* sites. More genes can be added in an analogous fashion. The assembled genes overlap such that the first two nucleotides, TG, of the TGA stop codon of the upstream gene coincide the last two nucleotides of the ATG start codon of the downstream gene. The same overlap is found between all genes in the carotenoid (*crt*) operon (*crtZYB*) in *Paracoccus* sp. strain R1534 (Pasamontes et al., supra).

The pOCV backbone is derived from pCR[®]2.1-TOPO. The *BseMII* site in the region necessary for replication, upstream of the *ColE1* origin, was eliminated by site directed mutagenesis changing the site from CTCAG into CACAG. The remaining three *BseMII* sites and one *GsuI* site were eliminated by removing a 0.8 kb *DdeI*-*Asp700* fragment. The remaining vector was blunt-end ligated after fill-in of the *DdeI* recessed end. The polylinkers were inserted between the *BamHI* and *XbaI* sites by means of annealed oligonucleotides with the appropriate 5' overhangs.

Plasmid pBBR-K-*PcrtE-crtZW*, was constructed using the operon construction vector pOCV-2 as follows. The *crtZ* gene was amplified by PCR from *Paracoccus* sp. strain R114 using the primers *crtZ*-*Nde* and *crtZ*-*Bam* (Table 30). The primers were designed such that the ATG start codon constitutes the second half of a *NdeI* site (cleavage recognition site CATATG) and a *BamHI* site (GGATCC) was introduced immediately after the stop codon. The PCR product was cloned in the pCR[®]2.1-TOPO vector, resulting in plasmid TOPO-*crtZ*. To assemble the two genes in a mini-operon, both genes, *crtZ* and *crtW* were excised with *NdeI* and *BamHI* from the plasmids TOPO-*crtZ* and TOPO-*crtW* and subcloned in the *NdeI*-*BamHI* cut vector pOCV-2, creating plasmids pOCV-2-*crtZ* and pOCV-2-*crtW*. Plasmid pOCV-2-*crtZ* was cut with *BseMII* and *PstI* (there is a unique *PstI* site in the kanamycin resistance gene) and the 2.4 kb fragment (containing *crtZ*) was ligated with the *crtW*-containing 1876 bp *BseRI*-*PstI* fragment from pOCV-2-*crtW*. The resulting plasmid, pOCV-2-*crtZW*, was cut with *NdeI* and *BamHI* and the *crtZW* fragment was ligated with the *NdeI*-*BamHI* backbone of pBBR-K-*PcrtE* to yield pBBR-K-*PcrtE-crtZW*. Plasmid pBBR-K-*PcrtE-crtWZ*, was constructed in an analogous fashion.

The data in Table 31 show that the ratio of adonixanthin, canthaxanthin and astaxanthin did not change appreciably in strain R114/ pBBR-K-*PcrtE-crtWZ* compared to strain

pBBR-K-*PcrtE-crtW*. However, in strain pBBR-K-*PcrtE-crtZW*, the production of the ketocarotenoids was shifted in favor of astaxanthin. This result indicates that the level of expression is dependent on the position of the gene within the mini-operon, and suggests that increasing the *in vivo* level of β -carotene hydroxylase activity creates a balance
5 between the activities of this enzyme and β -carotene β -4 oxygenase that is more favorable for full conversion of zeaxanthin to astaxanthin.

The results described in this Example also show that it is possible, through appropriate genetic engineering, to produce not only astaxanthin, but also other ketocarotenoids of commercial interest in *Paracoccus* sp. strain R114 or its relatives. For example, expression
10 of a gene coding for β -carotene β -4 oxygenase in a *crtZ* mutant of strain R114 (lacking β -carotene hydroxylase activity) would provide for production of exclusively ketocarotenoids, e.g., echinenone or canthaxanthin, without co-production of hydroxylated carotenoids. Taken together, the results presented in this Example and Example 11 show the broad utility of *Paracoccus* sp. strain R114 and its relatives to produce industrially im-
15 portant carotenoids.

Example 13: Accumulation of mevalonate in cultures of *Paracoccus* sp. strain R114 overexpressing genes of the mevalonate pathway

Overexpression of the genes of the mevalonate pathway in *Paracoccus* sp. strain R114 leads to increased carbon flow to through the mevalonate pathway. The construction of plasmid
20 pBBR-K-mev-op16-2 was described in Example 5. Plasmid pBBR-K-mev-op-up-4 was constructed as follows. A DNA fragment containing containing most of the *mvaA* gene and the entire *idi* and *hcs* genes was obtained on a 3.1 kb *SmaI-SalI* fragment following partial digestion of a λ -clone containing the *Paracoccus* sp. strain R114 mevalonate operon (see Example 4). This fragment was subcloned in pUC19, yielding the plasmid
25 pUC19mev-op-up'. To facilitate subcloning, the *KpnI-HindIII* fragment of pUC19mev-op-up' containing the mevalonate genes was recloned in the vector pBluescriptKS⁺, resulting in plasmid pBluKSp-mev-op-up'. A 1.7 kb *SalI* fragment from pUC19mev-op-up' was then cloned in the *SalI* site of plasmid 2ES2-1, which is a pUC19-derived plasmid containing the cloned *SalI-EcoRI* fragment M from *Paracoccus* sp. strain R114 (refer to
30 Example 4). This resulted in plasmid pUC19mev-op-up-2. Plasmid pUCmev-op-up-3 was then obtained by combining the *BbsI-BsaI* fragment from pUC19mev-op-up-2 carrying the beginning of the mevalonate operon with the *BbsI-BsaI* fragment from pBluKSp-mev-op-up' containing *idi* and *hcs*. Separately, a unique *MluI* site was introduced between the *NsiI* and *KpnI* sites of the vector pBBR1MCS-2 (refer to Example
35 5) by inserting an annealed primer containing an *MluI* restriction site. The resulting new

cloning vector pBBR-K-Mlu was cut with *Mlu*I and *Kpn*I and the *Mlu*I-*Kpn*I fragment from pUCmev-op-up-3, containing the first three genes of the mevalonate operon, was inserted, yielding plasmid pBBR-K-mev-op-up-3. Plasmid pBBR-K-mev-op-up-4 was then constructed by insertion of the *Sma*I fragment from plasmid 16SB3, which contains
5 most of the *mvk* gene and the 5' end of *pmk* (plasmid 16SB3 is a pUC19-derived plasmid containing the *Paracoccus* sp. strain R114 *Sa*II-*Bam*HI fragment A; refer to Example 4). The insert of plasmid pBBR-K-mev-op-up-4 contains the putative mevalonate operon promoter region, the first four genes of the mevalonate operon and the 5' end of *pmk*.

Plasmids pBBR-K-mev-op16-2 and pBBR-K-mev-op-up-4 were each introduced into
10 *Paracoccus* sp. strain R114 by electroporation. Production of zeaxanthin and mevalonate by the new strains were compared to the control strain R114. The strains were grown in baffled shake flasks in liquid medium 362F/2 (see Example 11) for 72 hours. For strains R114/pBBR-K-mev-op16-2 and R114/pBBR-K-mev-op-up-4, kanamycin (50 mg/l) was also added to the cultures. The cultivation temperature was 28°C and shaking was at 200
15 rpm. Zeaxanthin was measured by the method set forth in Example 1, while mevalonate in the culture supernatants was measured as follows: A 0.6 ml sample of the culture was centrifuged for 4 minutes at 13,000 x g. Four hundred microliters of the supernatant were added to 400 microliters of methanol and mixed by vortexing for 1 min. The mixture was centrifuged again for 4 minutes at 13,000 x g. The resulting supernatant was then analyzed
20 directly by gas chromatography (GC) using the method of Lindemann et al. [J. Pharm. Biomed. Anal. 9:311-316 (1991)] with minor modification as follows. The GC was a Hewlett-Packard 6890plus instrument (Hewlett-Packard, Avondale, PA, USA) equipped with a cool-on-column injector and a flame ionization detector. One microliter of sample prepared as described above was injected onto a fused silica capillary column (15m length
25 x 0.32mm ID) coated with a 0.52 micron film of crosslinked modified polyethylene glycol (HP-FFAP, Agilent Technologies, USA). Helium was used as the carrier gas at an inlet pressure of 0.6 bar. The temperature of the programmable injector was ramped from 82°C to 250°C at a rate of 30°C/minute. The column temperature profile was 80°C for 0.5 minutes, followed by a linear temperature gradient at 15°C/min to 250°C and finally held
30 at 250°C for 5 minutes. The detector temperature was maintained at 320°C.

In the first experiment, zeaxanthin and mevalonate production were measured in strains R114 and R114/pBBR-K-mev-op16-2 (Table 32). Both strains produced similar amounts of zeaxanthin, but strain R114/pBBR-K-mev-op16-2 produced a four-fold higher level of mevalonate. These results show that overexpression of the genes of the mevalonate path-
35 way in *Paracoccus* sp. strain R114 results in increased carbon flow through the mevalonate

pathway. The accumulation of mevalonate was expected because strain R114/pBBR-K-mev-op16-2 does not have an overexpressed *crtE* gene, and the *crtE* gene product (GGPP synthase) is known to be a limiting step in zeaxanthin production in *Paracoccus* sp. strain R114 (see Examples 6 and 8). Cells having a limiting amount of GGPP synthase, upon overproduction of the enzymes of the mevalonate pathway, would be expected to accumulate FPP, and it is well known that FPP is a potent inhibitor of mevalonate kinase [Dorsey and Porter, J. Biol. Chem. 243:4667-4670 (1968); Gray and Kekwick, BBA 279:290-296 (1972); Hinson et al. J. Lipids Res. 38:2216-2223 (1997)]. Therefore, accumulation of FPP resulting from overexpression of the genes of the mevalonate pathway would cause inhibition of mevalonate kinase, which in turn is manifested as mevalonate accumulation in the culture.

Table 32. Zeaxanthin and mevalonate production in strains R114 and R114/pBBR-K-mev-op16-2.

| Strain/plasmid | Mevalonate (mg/l) | Zeaxanthin(mg/l) |
|------------------------|-------------------|------------------|
| R114 | 50.5 | 70.0 |
| R114/pBBR-K-mev-op16-2 | 208.2 | 65.2 |

In a second experiment, zeaxanthin and mevalonate production were measured in strain R114 and two independent isolates of R114/pBBR-K-mev-op-up-4 (Table 33). These results again show that overexpression of the genes of the mevalonate pathway increased carbon flow through the mevalonate pathway.

Table 33. Zeaxanthin and mevalonate production in strains R114 and R114/pBBR-K-mev-op-up-4.

| Strain/plasmid | Mevalonate (mg/l) | Zeaxanthin(mg/l) |
|-------------------------------------|-------------------|------------------|
| R114 | 45 | 67.5 |
| R114/pBBR-K-mev-op-up-4 (Isolate 1) | 133.2 | 53.7 |
| R114/pBBR-K-mev-op-up-4 (Isolate 2) | 163.7 | 47.6 |

The following biological material was deposited under the terms of the Budapest Treaty with the American Type Culture Collection (ATCC) at 10801 University Blvd., Manassas, VA 20110-2201, USA, and were assigned the following accession numbers:

| Strain | Accession No. | Date of Deposit |
|------------------------------|---------------|-----------------|
| <i>Paracoccus</i> sp. R114 | PTA-3335 | April 24, 2001 |
| <i>Paracoccus</i> sp. R1534 | PTA-3336 | April 24, 2001 |
| <i>Paracoccus</i> sp. R-1506 | PTA-3431 | June 5, 2001 |

- 5 All patents, patent applications, and publications cited above are incorporated herein by reference in their entirety as if recited in full herein.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of

- 10 the following claims.

THIS PAGE BLANK (USPTO)

What is Claimed Is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 340 of SEQ ID NO:43;
 - 5 (b) an amino acid sequence shown as residues 1 to 349 of SEQ ID NO:45;
 - (c) an amino acid sequence shown as residues 1 to 388 of SEQ ID NO:47;
 - (d) an amino acid sequence shown as residues 1 to 378 of SEQ ID NO:49;
 - (e) an amino acid sequence shown as residues 1 to 305 of SEQ ID NO:51;
 - (f) an amino acid sequence shown as residues 1 to 332 of SEQ ID NO:53;
 - 10 (g) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, wherein said fragment has at least 30 contiguous amino acid residues;
 - (h) an amino acid sequence of a fragment of a polypeptide selected from the group consisting of SEQ ID NOs: 43, 45, 47, 49, 51, and 53, the fragment having the activity of
 - 15 hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase), mevalonate kinase, phosphomevalonate kinase, or diphosphomevalonate decarboxylase;
 - (i) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive
 - 20 nucleotides of SEQ ID NO:42 or a complement of SEQ ID NO:42, wherein the polypeptide has the activity of ^{mvaA}HMG-CoA reductase, ^{idi}isopentenyl diphosphate isomerase, ^{hcs}HMG-CoA synthase, ^{mvk}mevalonate kinase, ^{pmk}phosphomevalonate kinase, ^{mval}diphosphomevalonate decarboxylase; and
 - (j) a conservatively modified variant of SEQ ID NO:43, 45, 47, 49, 51 or 53.
- 25 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 287 of SEQ ID NO:159;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:159;
 - (c) an amino acid sequence of a fragment of SEQ ID NO: 159, the fragment having the
 - 30 activity of farnesyl diphosphate synthase (FPP synthase);
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 295-1158 of SEQ ID NO:157 or a complement thereof, wherein the polypeptide has the activity of FPP synthase; and
 - 35 (e) a conservatively modified variant of SEQ ID NO:159.

THIS PAGE BLANK (USPTO)

3. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 142 of SEQ ID NO:160;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:160;
 - 5 (c) an amino acid sequence of a fragment of SEQ ID NO: 160, the fragment having the activity of 1-deoxyxylulose-5-phosphate synthase (DXPS);
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 1185-1610 of SEQ ID NO:157 or a complement thereof,
 - 10 wherein the polypeptide has the activity of DXPS;
 - (e) a conservatively modified variant of SEQ ID NO:160.
4. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) an amino acid sequence shown as residues 1 to 390 of SEQ ID NO:178;
 - 15 (b) at least 30 contiguous amino acid residues of SEQ ID NO:178;
 - (c) an amino acid sequence of a fragment of a polypeptide of SEQ ID NO: 178, the fragment having the activity of acetyl-CoA acetyltransferase;
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a hybridization probe comprising at least 30 consecutive
 - 20 nucleotides spanning positions 1-1170 of SEQ ID NO:177 or a complement thereof, wherein the polypeptide has the activity of acetyl-CoA acetyltransferase; and
 - (e) a conservatively modified variant of SEQ ID NO:178.
5. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- 25 (a) an amino acid sequence shown as residues 1 to 240 of SEQ ID NO:179;
 - (b) at least 30 contiguous amino acid residues of SEQ ID NO:179;
 - (c) an amino acid sequence of a fragment of a polypeptide of SEQ ID NO: 179, the fragment having the activity of acetoacetyl-CoA reductase;
 - (d) an amino acid sequence of a polypeptide encoded by a polynucleotide that hybridizes
 - 30 under stringent conditions to a hybridization probe comprising at least 30 consecutive nucleotides spanning positions 1258-1980 of SEQ ID NO:177 or a complement thereof, wherein the polypeptide has the activity of acetoacetyl-CoA reductase; and
 - (e) a conservatively modified variant of SEQ ID NO:179.
6. An isolated polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:42, variants of SEQ ID NO:42 containing one or more

muralanah
option

THIS PAGE BLANK (USPTO)

substitutions according to the *Paracoccus* sp. strain R1534 codon usage table, fragments of SEQ ID NO:42 that encode a polypeptide having an activity selected from the group consisting of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), isopentenyl diphosphate isomerase, hydroxymethylglutaryl-CoA synthase (HMG-CoA synthase),
5 mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:42, or the complement of SEQ ID NO:42, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of HMG-CoA reductase,
10 isopentenyl diphosphate isomerase, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase.

7. An isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:157, variants of SEQ ID NO:157 containing one or more substitutions according to the *Paracoccus* sp. strain
15 R1534 codon usage table, fragments of SEQ ID NO:157 that encode a polypeptide having farnesyl diphosphate (FPP) synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity or a polypeptide having the activity of XseB, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30 contiguous nucleotides of SEQ ID NO:157, or the complement
20 of SEQ ID NO:157, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of FPP synthase activity, 1-deoxy-D-xylulose 5-phosphate synthase activity, and the activity of XseB.

8. An isolated polynucleotide sequence comprising a polynucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO:177, variants of SEQ
25 ID NO:177 containing one or more substitutions according to the *Paracoccus* sp. strain R1534 codon usage table, fragments of SEQ ID NO:177 that encode a polypeptide having an activity selected from the group consisting of acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase, and polynucleotide sequences that hybridize under stringent conditions to a hybridization probe the nucleotide sequence of which consists of at least 30
30 contiguous nucleotides of SEQ ID NO:177, or the complement of SEQ ID NO:177, which polynucleotide encodes a polypeptide having an activity selected from the group consisting of acetyl-CoA acetyltransferase and acetoacetyl-CoA reductase.

9. An isolated polynucleotide sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:42, SEQ ID NO:157, SEQ ID NO:177, and combinations
35 thereof.

THIS PAGE BLANK (USPTO)

10. An expression vector comprising the polynucleotide sequence according to claim 6, 7, 8 or 9.
11. An expression vector selected from the group consisting of pBBR-K-mev-op16-1, pBBR-K-mev-op16-2, pDS-*mvaA*, pDS-*idi*, pDS-*hcs*, pDS-*mvk*, pDS-*pmk*, pDS-*mvd*, pDS-*His-mvaA*, pDS-*His-idi*, pDS-*His-hcs*, pDS-*His-mvk*, pDS-*His-pmk*, pDS-*His-mvd*, pBBR-K-Zea4, pBBR-K-Zea4-up, pBBR-K-Zea4-down, pBBR-K-*PctE-crtE-3*, pBBR-tK-*PctE-mvaA*, pBBR-tK-*PctE-idi*, pBBR-tK-*PctE-hcs*, pBBR-tK-*PctE-mvk*, pBBR-tK-*PctE-pmk*, pBBR-tK-*PctE-mvd*, pBBR-K-*PctE-mvaA-crtE-3*, pDS-*His-phaA*, pBBR-K-*PctE-crtW*, pBBR-K-*PctE-crtWZ*, pBBR-K-*PctE-crtZW*, and combinations thereof.
12. A cultured cell comprising the polynucleotide sequence according to claim 6, 7, 8 or 9, or an expression vector according to claim 10 or 11, or a progeny of the cell, wherein the cell expresses a polypeptide encoded by the polynucleotide sequence.
13. A method of producing a carotenoid comprising culturing a cell according to claim 12 under conditions permitting expression of a polypeptide encoded by the polynucleotide sequence, and isolating the carotenoid from the cell or the medium of the cell.
14. A method of making a carotenoid-producing cell comprising:
- (a) introducing into a cell a polynucleotide sequence encoding an enzyme in the mevalonate pathway, which enzyme is expressed in the cell; and
 - (b) selecting a cell containing the polynucleotide sequence of step (a) that produces a carotenoid at a level that is about 1.1-1,000 times the level of the carotenoid produced by the cell before introduction of the polynucleotide sequence.
15. A method for engineering a bacterium to produce an isoprenoid compound comprising:
- (a) culturing a parent bacterium in a medium under conditions permitting expression of an isoprenoid compound, and selecting a mutant bacterium from the culture medium that produces about 1.1-1,000 times more of an isoprenoid compound than the parent bacterium;
 - (b) introducing into the mutant bacterium an expression vector comprising a polynucleotide sequence represented by SEQ ID NO:42 operably linked to an expression control sequence; and
 - (c) selecting a bacterium that contains the expression vector and produces at least about 1.1 times more of an isoprenoid compound than the mutant in step (a).
- mevalonate operon*

THIS PAGE BLANK (USPTO)

16. A microorganism of the genus *Paracoccus*, which microorganism has the following characteristics:
- (i) a sequence similarity to SEQ ID NO:12 of >97% using a similarity matrix obtained from a homology calculation using GeneCompar v. 2.0 software with a gap penalty of 0%;
 - 5 a homology to strain R-1512, R1534, R114 or R-1506 of >70% using DNA:DNA hybridization at 81.5°C;
 - a G+C content of its genomic DNA that varies less than 1% from the G+C content of the genomic DNA of R114, R-1512, R1534, and R-1506; and
 - an average DNA fingerprint that clusters at about 58% similarity to strains R-1512, R1534,
 - 10 R114 and R-1506 using the AFLP procedure of Example 2, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966);
 - (ii) 18:1w7c comprising at least about 75% of the total fatty acids of the cell membranes;
 - an inability to use adonitol, i-erythritol, gentiobiose, β -methylglucoside, D-sorbitol, xylitol and quinic acid as carbon sources for growth; and
 - 15 an ability to use L-asparagine and L-aspartic acid as carbon sources for growth, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966); or
 - (iii) an ability to grow at 40°C;
 - an ability to grow in a medium having 8% NaCl;
 - an ability to grow in a medium having a pH of 9.1; and
 - 20 a yellow-orange colony pigmentation, with the proviso that the microorganism is not *Paracoccus* sp. (MBIC3966).

THIS PAGE BLANK (USPTO)

SEQUENCE LISTING

<110> BERRY, Alan

BRETZEL, Werner

HUMBELIN, Markus

LOPEZ-ULIBARRI, Rual

MAYER, Anne

YELISEEV, Alexei

<120> IMPROVED ISOPRENOID PRODUCTION

<130> C38435/121966

<160> 197

<170> PatentIn version 3.0

<210> 1

<211> 20

<212> DNA

<213> synthetic construct

<400> 1
agagtttgat cctggctcag

20

<210> 2

<211> 20

<212> DNA

<213> synthetic construct

<220>

<221> misc_feature

<223> n i s c o r t

<400> 2
ctggctcagg angaacgctg

20

<210> 3

<211> 20

<212> DNA

<213> synthetic construct

<400> 3
aaggaggtga tccagccgca

20

<210> 4

<211> 20

<212> DNA

<213> synthetic construct

<400> 4
ctcctacggg aggcagcagt

20

<210> 5

<211> 18

<212> DNA

<213> synthetic construct

<400> 5
cagcagccgc ggtaatac

18

<210> 6

<211> 19

<212> DNA

<213> synthetic construct

<400> 6

aactcaaagg aattgacgg

19

<210> 7

<211> 20

<212> DNA

<213> synthetic construct

<400> 7

agtcccgcaa cgagcgcaac

20

<210> 8

<211> 20

<212> DNA

<213> synthetic construct

<400> 8

gctacacacg tgctacaatg

20

<210> 9

<211> 20

<212> DNA

<213> synthetic construct

<400> 9

actgctgcct cccgtaggag

20

<210> 10

<211> 18

<212> DNA

<213> synthetic construct

<400> 10

gtattaccgc ggctgctg

18

<210> 11

<211> 20

<212> DNA

<213> synthetic construct

<400> 11

gttgcgctcg ttgcgggact

20

<210> 12

<211> 1404

<212> DNA

<213> Paracoccus sp. R-1512

<400> 12

gcggcaggct taacacatgc aagtcgagcg aggtcttcgg acctagcggc ggacgggtga 60

gtaacgcgtg ggaacgtgcc ctttgctacg gaatagtccc gggaaactgg gtttaataacc 120

gtatgtgccc tacgggggaa agatttatcg gcaaaggatc ggcccgcgtt ggattagta 180

gttggtgggg taatggccta ccaagccgac gatccatagc tggtttgaga ggatgatcag 240

ccacactggg actgagacac ggcccagact cctacgggag gcagcagtgg ggaatcttag 300

acaatggggg caaccctgat ctagccatgc cgcgtgagtg atgaaggccc tagggttgta 360

aagctctttc agctgggaag ataatgacgg taccagcaga agaagccccg gctaactccg 420

tgccagcagc cgcggttaata cggagggggc tagcgttggt cggaattact gggcgtaaag 480

cgcacgtagg cggactggaa agttgggggt gaaatcccgg ggctcaacct cggaactgcc 540

tccaaaacta tcagtctgga gttcgagaga ggtgagtgga ataccgagtg tagaggtgaa 600

attcgtagat attcgggtgga acaccagtgg cgaaggcggc tcaactggctc gatactgacg 660


```

ctgagggtgcg aaagcgtggg gagcaaacag gattagatac cctggtagtc cacgccgtaa    720
acgatgaatg ccagtcgtcg ggttgcattg aattcgggtga cacacctaac ggattaagca    780
ttccgcctgg ggagtacggt cgcaagatta aaactcaaag gaattgacgg gggcccgcac    840
aagcgggtgga gcatgtgggt taattcgaag caacgcgcag aaccttacca acccttgaca    900
tccctggaca tcccagagaga tcgggctttc acttcgggtga ccaggagaca ggtgctgcat    960
ggctgtcgtc agctcgtgtc gtgagatggt cggttaagtc cggcaacgag cgcaaccac    1020
gtccctagtt gccagcattc agttgggcac tctatggaaa ctgccgatga taagtcggag    1080
gaagggtgtg atgacgtcaa gtcctcatgg cccttacggg ttgggtaca cacgtgctac    1140
aatggtggtg acagtgggtt aatccccaaa agccatctca gttcggattg tctctgcaa    1200
ctcgagggca tgaagttgga atcgctagta atcgcggaac agcatgccgc ggtgaatacg    1260
ttccccggcc ttgtacacac cgcccgtcac accatgggag ttggttctac ccgacgacgc    1320
tgcgctaacc cttcggggag gcaggcgccc acggtaggat cagcgactgg ggtgaagtcg    1380
taacaaggta gccgtagggg aacc                                           1404

```

<210> 13

<211> 20

<212> DNA

<213> synthetic construct

<400> 13

tcgtagactg cgtacaggcc

20

<210> 14

<211> 14

<212> DNA

<213> synthetic construct

<400> 14

catctgacgc atgt

14

<210> 15

<211> 16

<212> DNA

<213> synthetic construct

<400> 15

gacgatgagt cctgac

16

<210> 16

<211> 14

<212> DNA

<213> synthetic construct

<400> 16

tactcaggac tggc

14

<210> 17

<211> 17

<212> DNA

<213> synthetic construct

<400> 17

gactgcgtac aggccca

17

<210> 18

<211> 18

<212> DNA

<213> synthetic construct

<400> 18

cgatgagtcc tgaccgaa

18

<210> 19

<211> 18

<212> DNA

<213> synthetic construct

<400> 19

cgatgagtcc tgaccgac

18

<210> 20

<211> 17

<212> DNA

<213> synthetic construct

<400> 20

gactgcgtac aggcccc

17

<210> 21

<211> 17

<212> DNA

<213> synthetic construct

<400> 21

gactgcgtac aggcccg

17

<210> 22

<211> 18

<212> DNA

<213> synthetic construct

<400> 22

cgatgagtcc tgaccgag

18

<210> 23

<211> 8

<212> PRT

<213> Paracoccus sp. R1534

<220>

<221> UNSURE

<222> (2)..(2)

<223> Xaa is Leu or Ile

<400> 23

Ala Xaa Ile Lys Tyr Trp Gly Lys
1 5

<210> 24

<211> 27

<212> DNA

<213> Paracoccus sp. R1534

<400> 24

ccsctgatca artaytgggg baaratc

27

<210> 25

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 25

gcsctgatca artaytgggg

20

<210> 26

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 26
gcsatcatca artaytgggg

20

—<210> 27

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 27
atcaartayt ggggtaa

17

<210> 28

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 28
atcaartayt ggggcaa

17

<210> 29

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 29
atcaartayt gggggaa

17

<210> 30

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 30
atcaartayt ggggaaa

17

<210> 31

<211> 8

<212> PRT

<213> Paracoccus sp. R1534

<220>

<221> UNSURE

<222> (7)..(7)

<223> Xaa is Asn or Gln

<400> 31

Thr Met Asp Ala Gly Pro Xaa Val
1 5

<210> 32

<211> 24

<212> DNA

<213> Paracoccus sp. R1534

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is a or c

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is y or r

<400> 32
acsatggayg csggbccsna ngts

24

<210> 33

<211> 24

<212> DNA

<213> Paracoccus sp. R1534

<220>

<221> misc_feature

<222> (19)..(19)

<223> n is t or g

<220>

<221> misc_feature

<222> (21)..(21)

<223> n is r or y

<400> 33
tgstacctr c gscvvggsnt ncas

24

<210> 34

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 34
tggtacctac gscvvgg

17

<210> 35

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 35

tggtacctgc gscvvgg

17

<210> 36

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 36

tgctacctac gscvvgg

17

<210> 37

<211> 17

<212> DNA

<213> Paracoccus sp. R1534

<400> 37

tgctacctgc gscvvgg

17

<210> 38

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 38

tacctacgsc cvggsttrca

20

<210> 39

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 39

tacctgcgsc cvggsttrca

20

<210> 40

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 40

tacctacgsc cvggsgtyca

20

<210> 41

<211> 20

<212> DNA

<213> Paracoccus sp. R1534

<400> 41

tacctgcgsc cvggsgtyca

20

<210> 42

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (2622) .. (3644)

<223> mvaA gene

<400> 42

| | |
|--|------|
| ggatccggca gctcgacacg ccgcagaacc tgtacgaacg tcccgccagc cgcttcgctcg | 60 |
| cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgcg | 120 |
| cccgcatect gggggccgag gtggcggtga acgcccgcgc gcaatcgcg tttgtcgatc | 180 |
| acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg | 240 |
| tcgcgcgcgt cacctatctt ggcgggaaat acctgctgga aacctgctg gattgcggca | 300 |
| cccggctggt gaccgagacc cgcgcccgtc tcgatacggg cgcgcagctt ggcctgacca | 360 |
| tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca | 420 |
| tgggcgtgaa gggccctgcc tgcacaggc tggatgtcgg cgggatgcgc ctgatcctcg | 480 |
| attgcgggac cggcccgac gagggcgcg agttcgacc cgcctggctg gcggacgcgg | 540 |
| atgcggtgct gatcacccat gaccacgtgg accatatcgg cggcgcgct caccggtcg | 600 |
| cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcggggcgcg | 660 |
| atctgcgcct gctgcccga cgcggtgtca cgcggatcgc cggggtcgat ctgacgaccg | 720 |
| gtcgcaacgg gcatgccg cgcggtgtct ggatgcattt cgacatgggc gaggggctgt | 780 |
| tctattccgg cgactggtcc gaggaatccg actggttcgc cttcgatccg cccccgcctg | 840 |
| cggggacggc gattctcgac tgctcctatg gcggtttcga cgtggcgcaa tcggattgca | 900 |
| tcgcggaact ggacgacctg ctcgaggtgc tgccggggca ggtactgctg ccggtgccgc | 960 |
| catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg | 1020 |
| tgatggtcga cgacgcctgc ctgccggcca tcgcgcaact gcccgaggcg cgcggactgg | 1080 |
| cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg | 1140 |
| gcatggcggc atctgcaagc atggcgcat gcgggcaggc tggggcgga cgcgcatgtc | 1200 |
| gtcttcaccg ggcacatgaa cgtccatgcg cgcgattct gcgaccgcc cggcgggcat | 1260 |
| ttccgcgcgt ggaacgtgca tccgccgtg cgcgaccagc gacggatgct ggaacggctg | 1320 |
| gccgcgcggc gctttgcccc ggccttctgc cccgaccccg agatctatct ggcgctggac | 1380 |
| atgggcgcgc aggtcttcat gcaccaggag gtgacgcat gatccccgcc cgcagcttct | 1440 |
| gcctgatccg ccacggcgaa acgaccgcca atgcaggggc gatcatcgcg gcgcaaccg | 1500 |
| atgtgcccct gacgccaaagg ggccgcgac agggccgcgc cctggcaggg cgcgaatggc | 1560 |
| catcgggcat cgcgctgttc gccagcccga tgtcgcgtgc ccgcgatacc gcgctgctgg | 1620 |

| | |
|---|------|
| cctttccggg ggcgcaccac cagcccgaac ccgatctgcg cgaacgcgac tggggcatct | 1680 |
| tcgagggacg ccccgtcgcc gatctgcccc cgcgcgaaat cagccgcgag gggggcgagg | 1740 |
| gctgggacga cgtgatggcc cgcggtggacc ggcgatccg gcggatctgc gcgacctcgg | 1800 |
| gcgatgcgct gccggtgctg gtctgccatt cgggctgat ccgtgccgag cgcggtgctgt | 1860 |
| ggaccaccgg cgatgcgggc gatcgccgc ccaacgccac gccgatcctg ttcagcccgg | 1920 |
| acggcgaccg attaaaggaa ggaacgatat gaccgccacc accccctgcg tcgtcttcga | 1980 |
| acgtggacgg cagccttgcc gaattcgacg ccgaccgcct gggccatctt gtccacggca | 2040 |
| cgaccaagca ctgggacgcc ttccaccacg cgatggccga cggcccgccc atccccgagg | 2100 |
| tcgccccct gatgcgcaag ctgaaggagg ggggcgagac ggctgctatc tgctcggggc | 2160 |
| ggcccccgcg ctggcaggat cagacgatcg catggctgcg caagcacgac ctgcccttcg | 2220 |
| acgggatcta tctgcgcccc gaggatcagg acggcgccag cgaccccgag gtcaagcgcc | 2280 |
| gcgccttagc cgagatgcgc gccgacgggc tggcgccctg gctggtcgtg gacgaccggc | 2340 |
| ggctcgtcgt ggatgcctgg cgggcccagg ggctggctc cctgcaatgc gcgccggggg | 2400 |
| acttctaggg ccgcgcgacg ggggcgcgga caggctgggc gggaaaccgc cccgccacca | 2460 |
| tgtcctgcac gcgtcgaacc gcccgccga cgccggtttc cgcacggaaa cgcgcgga | 2520 |
| gttgacataa cttgcacgag acgtctcgat tctgcccgcg aagaatgcga tgcattcaga | 2580 |
| tgatgcagaa cgaagaagcg gaagcgcccc tgaaagacca g atg att tcc cat acc | 2636 |
| Met Ile Ser His Thr | |
| 1 5 | |
| ccg gtg ccc acg caa tgg gtc ggc ccg atc ctg ttc cgc ggc ccc gtc | 2684 |
| Pro Val Pro Thr Gln Trp Val Gly Pro Ile Leu Phe Arg Gly Pro Val | |
| 10 15 20 | |
| gtc gag ggc ccg atc agc gcg ccg ctg gcc acc tac gag acg ccg ctc | 2732 |
| Val Glu Gly Pro Ile Ser Ala Pro Leu Ala Thr Tyr Glu Thr Pro Leu | |
| 25 30 35 | |
| tgg ccc tcg acc gcg cgg ggg gca ggg gtt tcc cgg cat tcg ggc ggg | 2780 |
| Trp Pro Ser Thr Ala Arg Gly Ala Gly Val Ser Arg His Ser Gly Gly | |
| 40 45 50 | |
| atc cag gtc tcg ctg gtc gac gaa cgc atg agc cgc tcg atc gcg ctg | 2828 |
| Ile Gln Val Ser Leu Val Asp Glu Arg Met Ser Arg Ser Ile Ala Leu | |
| 55 60 65 | |
| cgg gcg cat gac ggg gcg gcg gcg acc gcc gcc tgg cag tcg atc aag | 2876 |
| Arg Ala His Asp Gly Ala Ala Ala Thr Ala Ala Trp Gln Ser Ile Lys | |
| 70 75 80 85 | |

| | |
|---|------|
| gcc cgc cag gaa gag gtc gcg gcc gtg gtc gcc acc acc agc cgc ttc Ala Arg Gln Glu Glu Val Ala Ala Val Val Ala Thr Thr Ser Arg Phe 90 95 100 | 2924 |
| gcc cgc ctt gtc gag ctg aat cgc cag atc gtg ggc aac ctg ctt tac Ala Arg Leu Val Glu Leu Asn Arg Gln Ile Val Gly Asn Leu Leu Tyr 105 110 115 | 2972 |
| atc cgc atc gaa tgc gtg acg ggc gac gcc tcg ggt cac aac atg gtc Ile Arg Ile Glu Cys Val Thr Gly Asp Ala Ser Gly His Asn Met Val 120 125 130 | 3020 |
| acc aag gcc gcc gag gcc gtg cag ggc tgg atc ctg tcg gaa tac ccg Thr Lys Ala Ala Glu Ala Val Gln Gly Trp Ile Leu Ser Glu Tyr Pro 135 140 145 | 3068 |
| atg ctg gcc tat tcc acg atc tcg ggg aac ctg tgc acc gac aag aag Met Leu Ala Tyr Ser Thr Ile Ser Gly Asn Leu Cys Thr Asp Lys Lys 150 155 160 165 | 3116 |
| gcg tcg gcg gtc aac ggc atc ctg ggc cgc ggc aaa tac gcc gtc gcc Ala Ser Ala Val Asn Gly Ile Leu Gly Arg Gly Lys Tyr Ala Val Ala 170 175 180 | 3164 |
| gag gtc gag atc ccg cgc aag atc ctg acc cgc gtg ctg cgc acc agc Glu Val Glu Ile Pro Arg Lys Ile Leu Thr Arg Val Leu Arg Thr Ser 185 190 195 | 3212 |
| gcc gag aag atg gtc cgc ctg aac tac gag aag aac tat gtc ggg ggt Ala Glu Lys Met Val Arg Leu Asn Tyr Glu Lys Asn Tyr Val Gly Gly 200 205 210 | 3260 |
| acg ctg gcg ggg tcg ctg cgc agt gcg aac gcg cat ttc gcc aac atg Thr Leu Ala Gly Ser Leu Arg Ser Ala Asn Ala His Phe Ala Asn Met 215 220 225 | 3308 |
| ctg ctg ggc ttc tac ctg gcg acg ggg cag gac gcg gcc aac atc atc Leu Leu Gly Phe Tyr Leu Ala Thr Gly Gln Asp Ala Ala Asn Ile Ile 230 235 240 245 | 3356 |
| gag gcc agc cag ggc ttc gtc cat tgc gag gcc cgc ggc gag gat ctg Glu Ala Ser Gln Gly Phe Val His Cys Glu Ala Arg Gly Glu Asp Leu 250 255 260 | 3404 |
| tat ttc tcg tgc acg ctg ccc aac ctc atc atg ggc tcg gtc ggt gcc Tyr Phe Ser Cys Thr Leu Pro Asn Leu Ile Met Gly Ser Val Gly Ala 265 270 275 | 3452 |
| ggc aag ggc atc ccc tcg atc gag gag aac ctg tcg cgg atg ggc tgc Gly Lys Gly Ile Pro Ser Ile Glu Glu Asn Leu Ser Arg Met Gly Cys 280 285 290 | 3500 |
| cgc cag ccg ggc gaa ccc ggc gac aac gcg cgc cgt ctt gcg gcg atc Arg Gln Pro Gly Glu Pro Gly Asp Asn Ala Arg Arg Leu Ala Ala Ile 295 300 305 | 3548 |
| tgc gcg ggc gtc gtg ctg tgt ggt gaa ttg tcg ctg ctt gcg gcc cag | 3596 |

| | | | | | | | | | | | | | | | | |
|---|-------------|------------|-------------|-------------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| Cys | Ala | Gly | Val | Val | Leu | Cys | Gly | Glu | Leu | Ser | Leu | Leu | Ala | Ala | Gln | |
| 310 | | | | | 315 | | | | 320 | | | | | | 325 | |
| acc aac ccc gga gag ttg gtc cgc acc cac atg gag atg gag cga tga | | | | | | | | | | | | | | | | 3644 |
| Thr Asn Pro Gly Glu Leu Val Arg Thr His Met Glu Met Glu Arg | | | | | | | | | | | | | | | | |
| | | | 330 | | | | | 335 | | | | | | | 340 | |
| | | | | | | | | | | | | | | | | |
| ccgacagcaa | ggatcaccat | gtcgcggggc | gcaagctgga | ccatctgcgt | gcattggacg | | | | | | | | | | | 3704 |
| acgatgcgga | tatcgaccgg | ggcgacagcg | gcttcgaccg | catcgcgctg | acccatcgcg | | | | | | | | | | | 3764 |
| ccctgcccga | ggtggatttc | gacgccatcg | acacggcgac | cagcttcctg | ggccgtgaac | | | | | | | | | | | 3824 |
| tgctcctccc | gctgctgata | tcgtccatga | ccggcggcac | cggcgaggag | atcgagcgca | | | | | | | | | | | 3884 |
| tcaaccgcaa | cctggcgcgt | ggtgccgagg | aggcccgcgt | cgccatggcg | gtgggctcgc | | | | | | | | | | | 3944 |
| agcgcgtgat | gttcaccgac | ccctcggcgc | gggccagctt | cgacctgcgc | gcccatgcgc | | | | | | | | | | | 4004 |
| ccaccgtgcc | gctgctggcc | aatatcggcg | cggtgcagct | gaacatgggg | ctggggctga | | | | | | | | | | | 4064 |
| aggaatgcct | ggccgcgata | gaggtgctgc | aggcggacgg | cctgtatctg | cacctgaacc | | | | | | | | | | | 4124 |
| ccctgcaaga | ggccgtccag | cccgaggggg | atcgcgactt | tgccgatctg | ggcagcaaga | | | | | | | | | | | 4184 |
| tcgcggccat | cgccccgcgc | gttcccgtgc | ccgtcctgct | gaaggagggtg | ggctgcggcc | | | | | | | | | | | 4244 |
| tgtcggcgcc | cgatatcgcc | atcgggctgc | gcgcgggat | ccggcatttc | gacgtggccg | | | | | | | | | | | 4304 |
| gtcgcggcgg | cacatcctgg | agccggatcg | agtatcgccg | ccgccagcgg | gccgatgacg | | | | | | | | | | | 4364 |
| acctgggcct | ggtcttcocag | gactggggcc | tgacagaccgt | ggacgccctg | cgcgaggcgc | | | | | | | | | | | 4424 |
| ggccccgcgt | tcgcggccat | gatggaacca | gcgtgctgat | cgccagcggc | ggcatccgca | | | | | | | | | | | 4484 |
| acggtgtcga | catggcgaaa | tgctcatcc | tgggggcca | catgtgcggg | gtcgcgcgc | | | | | | | | | | | 4544 |
| ccctgctgaa | agcggcccaa | aactcgcgcg | aggcggttgt | atccgccatc | cggaaactgc | | | | | | | | | | | 4604 |
| atctggagtt | ccggacagcc | atgttcctcc | tgggttgccg | cacgcttgcc | gacctgaagg | | | | | | | | | | | 4664 |
| acaattctct | gcttatccgt | caatgaaagt | gcctaagatg | accgtgacag | gaatcgaagc | | | | | | | | | | | 4724 |
| gatcagcttc | tacaccccc | agaactacgt | gggactggat | atccttgccg | cgcatacagg | | | | | | | | | | | 4784 |
| gatcgacccc | gagaagttct | cgaaggggat | cgggcaggag | aaaatcgcac | tgccccggcca | | | | | | | | | | | 4844 |
| tgacgaggat | atcgtgacca | tggccgccga | ggccgcgctg | ccgatcatcg | aacgcgcggg | | | | | | | | | | | 4904 |
| cacgcagggc | atcgacacgg | ttctgttcgc | caccgagagc | gggatcgacc | agtcgaaggc | | | | | | | | | | | 4964 |
| cgccgccatc | tatctgcgcc | gcctgctgga | cctgtcggcc | aactgccgtt | gcgtcgagct | | | | | | | | | | | 5024 |
| gaagcaggcc | tgctattccg | cgacggcgcc | gctgcagatg | gcctgcgcgc | atgtcgcccc | | | | | | | | | | | 5084 |
| caagccccgac | cgcaagggtg | tgggtgatcg | gtccgatgtc | gcgcgctatg | accgcgaaag | | | | | | | | | | | 5144 |

ctcggggcgag gcgacgcagg gtgcggggcgc cgtcgccatc cttgtcagcg ccgatcccaa 5204
ggtggccgag atcggcaccg tctcgggggt gttcaccgag gatatcatgg atttctggcg 5264
gccgaaccac cgccgcacgc ccctgttcga cggcaaggca tcgacgctgc gctatctgaa 5324
cgcgctggtc gaggcgtgga acgactatcg cgcaaatggc ggccacgagt tcgccgattt 5384
cgcgcatttc tgctatcacg tgccgttctc gcggatgggc gagaaggcga acagccacct 5444
ggccaaggcg aacaagacgc cgggtggacat ggggcagggt cagacgggcc tgatctacaa 5504
ccggcaggtc gggaactgct ataccgggtc gatctacctg gcattcgctt cgctgctgga 5564
gaacgctcag gaggacctga ccggcgcgct ggtcgggtctg ttcagctatg gctcgggtgc 5624
gacggggcga ttcttcgatg cgcggtatcg gcccggttac cgcgaccacc tggtcgcgga 5684
acgccatcgc gaattgctgc aggatcgac gcccgtcaca tatgacgaat acgttgccct 5744
gtgggacgag atcgacctga cgcaggggcgc gcccgacaag gcgcgcggtc gtttcaggct 5804
ggcaggatatc gaggacgaga agcgcatcta tgtcgaccgg caggcctgaa gcaggcgccc 5864
atgccccggg caagctgac ctgtccgggg aacattccgt gctctatggt gcgccccgcgc 5924
ttgccatggc catcgccgc tataccgagg tgtggttcac gccgcttggc attggcgagg 5984
ggatacgcac gacattcgcc aatctctcgg gcggggcgac ctattcgctg aagctgctgt 6044
cgggggttcaa gtgcgggctg gaccgcccgt tcgagcagtt cctgaacggc gacctaaagg 6104
tgcacaaggc cctgacctat ccgacgatc tggcggtcta tgcgctggcg tcgcttctgc 6164
acgacaagcc gccggggacc gccgcgatgc cgggcacgag cgcgatgcac cacctgccgc 6224
gaccgggtga gctgggcagc cggacggagc tgcccatcgg cgcgggcatg gggtcgtctg 6284
cggccatcgt cgcggccacc acggctcctgt tcgagacgct gctggaccgg cccaagacgc 6344
ccgaacagcg cttcgaccgc gtccgcttct gcgagcgggt gaagcacggc aaggccggtc 6404
ccatcgacgc ggccagcgtc gtgcgcggcg ggcttgtccg cgtgggcggg aacgggcccgg 6464
gttcgatcag cagcttcgat ttgcccagg atcacacct tgtcgcgga cgcggtggt 6524
actgggtact gcacggggcg cccgtcagcg ggaccggcga atgcgtcagc gcggtcgcg 6584
cgcgcatgg tcgcatgcg gcgctgtggg acgccttcgc agtctgcacc cgcggttgg 6644
aggccgcgct gctgtctggg ggcagccccg acgccccat caccgagaac cagcgctgc 6704
tggaacgcat cggcgtcgtg ccggcagcga cgcaggccct cgtggcccag atcgaggagg 6764
cgggtggcg gcgcaagatc tgcgggcgag gtcccgctgc gggcgatcac ggcgggcg 6824
tcctcgtgcg gattgacgac gcgcaggcga tggcttcggt catggcgcg catcccagc 6884

| | | | | | | |
|-------------|------------|-------------|-------------|-------------|------------|------|
| tcgactgggc | gcccctgcgc | atgtcgcgca | cgggggcggc | accggcccc | ggcgcgctg | 6944 |
| cgcaaccgct | gcccgggag | ggctgatgga | tcaggatc | cgccagcg | cgccgggttc | 7004 |
| ggatcatgatc | acggggaac | atgccgtggt | ctatggacac | cgcccatcg | tcgcccggat | 7064 |
| cgagcagcgc | gcccattgta | cgatcgctcc | gcgtgccgac | cgcatgtttc | gcacacctc | 7124 |
| gcagatcggg | gcgcgcgag | aggggtcgct | ggacgatctg | cctgcggcg | ggacctatcg | 7184 |
| cttcgtgctg | gcccgcacg | cgccgacctg | ccttgcgggt | tcgacatgga | | 7244 |
| catcacctcg | gggatcgatc | cgaggctcgg | gcttgatcc | tcggcgcg | tgacggctcg | 7304 |
| ctgcctcggc | gcgctgtcgc | ggctggcg | gcggggacc | gagggtgc | atgacgacgc | 7364 |
| gctgcgcatc | gtccgcgcca | tccaggcg | gggcagcg | gccgatctg | cgccagcct | 7424 |
| gcagggcg | ttcgtgcct | atcgcgcc | cgatggcggt | gcccgcaga | tcgaggcgct | 7484 |
| tccggtgcg | ccggggccgt | tcggcctcg | ctatgcggc | tacaagacc | cgacagccga | 7544 |
| gggtgctgcg | cttgtggcg | atcgatggc | gggcaacgag | gccgcttcg | acgcgctcta | 7604 |
| ctcccggatg | ggcgcaagcg | cagatgccg | gatccgcgcg | gcgcaaggc | tggactggg | 7664 |
| tgcattccac | gacgcgctga | acgaatacca | gcgcctgatg | gagcagctgg | gcgtgtccga | 7724 |
| cgacacgctg | gacgcgatca | tccgcgaggc | gcgcgacgcg | ggcgccgag | tcgccaagat | 7784 |
| ctccggctcg | gggctgggg | attgcgtgct | ggcactggc | gaccagcca | agggtttcgt | 7844 |
| gcccgaagc | attgccgaga | agggaactgt | tttcgatgac | tgatgccgtc | cgcgacatga | 7904 |
| tcgcccgtgc | catggcgggc | gcgaccgaca | tccgagcagc | cgaggcttat | gcgcccagca | 7964 |
| acatcgcgct | gtcgaaatac | tggggcaagc | gcgacgccgc | gcggaacctt | ccgctgaaca | 8024 |
| gctccgtctc | gatctcgttg | gcgaactggg | gctctcatac | gcgggtcgag | gggtccggca | 8084 |
| cgggccacga | cgaggtgcat | cacaacggca | cgctgctgga | tccgggcgac | gccttcgcgc | 8144 |
| gccgcgcgtt | ggcattcgct | gacctgttcc | ggggggggag | gcacctgccg | ctgcggatca | 8204 |
| cgacgcagaa | ctcgatcccg | acggcgggcg | ggcttgccctc | gtcggcctcg | gggttcgcgg | 8264 |
| cgctgaccgc | tgcgctggcg | ggggcgcttcg | ggctggatct | ggacgacacg | gatctgagcc | 8324 |
| gcacgcgccg | gatcggcagt | ggcagcgccg | cccgtcgat | ctggcacggc | ttcgtccgct | 8384 |
| ggaaccgggg | cgaggccgag | gatgggcatg | acagccacgg | cgtcccgcgtg | gacctgcgct | 8444 |
| ggccccggtt | ccgcatcgcg | atcgtggccg | tggacaagg | gccaagcct | ttcagttcgc | 8504 |
| gcgacggcat | gaaccacacg | gtcgagacca | gcccgtgtt | ccgccttg | cctgcgcagg | 8564 |

cggaagcgga ttgccgcgtc atcgaggatg cgatcgccgc ccgcgacatg gccgccttg 8624
 gtccgcgggt cgaggcgaac gcccttgca tgcacgccac gatgatggcc gcgcgcccgc 8684
 cgctctgcta cctgacgggc ggcagctggc aggtgctgga acgcctgtgg caggcccgcg 8744
 cggacgggct tgcggccttt gcgacgatgg atgccggccc gaacgtcaag ctgatcttcg 8804
 aggaaagcag cgccgccgac gtgctgtacc tgttccccga cgccagcctg atcgcgccgt 8864
 tcgaggggcg ttgaacgcgt aagacgacca ctgggtaagg ttctgccgcg cgtggtctcg 8924
 actgcctgca aagaggtgct tgagttgctg cgtgactgcg gcggccgact tcgtgggact 8984
 tgcccgccac gctgacgcgc tggaaacgcg cccgcggatt acgaccgcgt cattgccctg 9044
 aaccaatttc ccgtcggtcg ac 9066

<210> 43

<211> 340

<212> PRT

<213> Paracoccus sp. R114

<400> 43

Met Ile Ser His Thr Pro Val Pro Thr Gln Trp Val Gly Pro Ile Leu
1 5 10 15

Phe Arg Gly Pro Val Val Glu Gly Pro Ile Ser Ala Pro Leu Ala Thr
20 25 30

Tyr Glu Thr Pro Leu Trp Pro Ser Thr Ala Arg Gly Ala Gly Val Ser
35 40 45

Arg His Ser Gly Gly Ile Gln Val Ser Leu Val Asp Glu Arg Met Ser
50 55 60

Arg Ser Ile Ala Leu Arg Ala His Asp Gly Ala Ala Ala Thr Ala Ala
65 70 75 80

Trp Gln Ser Ile Lys Ala Arg Gln Glu Glu Val Ala Ala Val Val Ala
85 90 95

Thr Thr Ser Arg Phe Ala Arg Leu Val Glu Leu Asn Arg Gln Ile Val
100 105 110

Gly Asn Leu Leu Tyr Ile Arg Ile Glu Cys Val Thr Gly Asp Ala Ser
 115 120 125

Gly His Asn Met Val Thr Lys Ala Ala Glu Ala Val Gln Gly Trp Ile
 130 135 140

Leu Ser Glu Tyr Pro Met Leu Ala Tyr Ser Thr Ile Ser Gly Asn Leu
 145 150 155 160

Cys Thr Asp Lys Lys Ala Ser Ala Val Asn Gly Ile Leu Gly Arg Gly
 165 170 175

Lys Tyr Ala Val Ala Glu Val Glu Ile Pro Arg Lys Ile Leu Thr Arg
 180 185 190

Val Leu Arg Thr Ser Ala Glu Lys Met Val Arg Leu Asn Tyr Glu Lys
 195 200 205

Asn Tyr Val Gly Gly Thr Leu Ala Gly Ser Leu Arg Ser Ala Asn Ala
 210 215 220

His Phe Ala Asn Met Leu Leu Gly Phe Tyr Leu Ala Thr Gly Gln Asp
 225 230 235 240

Ala Ala Asn Ile Ile Glu Ala Ser Gln Gly Phe Val His Cys Glu Ala
 245 250 255

Arg Gly Glu Asp Leu Tyr Phe Ser Cys Thr Leu Pro Asn Leu Ile Met
 260 265 270

Gly Ser Val Gly Ala Gly Lys Gly Ile Pro Ser Ile Glu Glu Asn Leu
 275 280 285

Ser Arg Met Gly Cys Arg Gln Pro Gly Glu Pro Gly Asp Asn Ala Arg
 290 295 300

Arg Leu Ala Ala Ile Cys Ala Gly Val Val Leu Cys Gly Glu Leu Ser
 305 310 315 320

Leu Leu Ala Ala Gln Thr Asn Pro Gly Glu Leu Val Arg Thr His Met
 325 330 335

Glu Met Glu Arg
340

<210> 44

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (3641) .. (4690)

<223> idi

<400> 44

```

ggatccggca gctcgacacg ccgcagaacc tgtacgaacg tcccgccagc cgcttcgtcg      60
cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgc      120
cccgcatcct gggggccgag gtggcggtga acgccgcccc gcaatcgcgc tttgtcgatc      180
acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg      240
tcgcgcgcgt cacctatcct ggccgggaaat acctgctgga aaccgtgctg gattgcggca      300
cccggtctgt gaccgagacc cgcgcccgtc tcgatacggg cgcgcagctt ggcctgacca      360
tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca      420
tgggcgtgaa gggccctgcc tgcatacagg tggatgtcgg cgggatgcgc ctgatcctcg      480
attgcgggac cggcccggac gagggcgagg agttcgaccc cgcctggctg gcggacgcgg      540
atgcggtgct gatcacccat gaccacgtgg accatatcgg cggcgcgcggt caccggtcg      600
cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcgggggcgg      660
atctgcgcct gctgcccga aacgggtgtca cgcggatcgc cggggtcgat ctgacgaccg      720
gtcgcaacgg gcatgccgcg ggccggctct ggatgcattt cgacatgggc gaggggctgt      780
tctattccgg cgactggtcc gaggaatccg actggttcgc cttcgatccg cccccgctg      840
cggggacggc gattctcgac tgcctctatg gcggtttcga cgtggcgcaa tcggattgca      900
tcgcggacct ggacgacctg ctcgaggtgc tgccggggca ggtactgctg ccggtgccgc      960

```

catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg 1020
tgatggtcga cgacgcctgc ctgcccggca tcgcgcaact gcccgaggcg cgcggactgg 1080
cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg 1140
gcatggcggc atctgcaagc atggcgcgat gcgggcaggg tggggcgggg cgcgcatgtc 1200
gtcttcaccg ggcacatgaa cgtccatgcg cgcgcattct gcgaccgccc cggcgggcat 1260
ttccgcccgt ggaacgtgca tccgcccgtg cgcgaccagc gacggatgct ggaacggctg 1320
gccgcggcgc gctttgcccc ggcttctctg cccgaccccg agatctatct ggcgctggac 1380
atgggcgcgc aggtcttcat gcaccaggag gtgacgccat gatccccgcc cgcagcttct 1440
gcctgatccg ccacggcgaa acgaccgcca atgcaggggc gatcatcgcg ggcgcaaccg 1500
atgtgccctt gacgccaagg ggcgcgcatc aggcccgcg cctggcaggg cgcgaatggc 1560
catcgggcat cgcgctgttc gccagcccga tgcgcgtgc ccgcgatacc gcgctgctgg 1620
cctttccggg gcgcgaccac cagcccgaac ccgatctgcg cgaacgcgac tggggcatct 1680
tcgaggggacg ccccgctgcc gatctgcccc cgcgcgaaat cacgccgag gggggcgagg 1740
gctgggacga cgtgatggcc cgcgtggacc gcgcgatccg gcggatctgc gcgacctcgg 1800
gcgatgcgct gccggtgctg gtctgccatt cgggcgtgat ccgtgcccg cgcgtgctgt 1860
ggaccaccgg cgatgcgggc gatcgtccgc ccaacgccac gccgatcctg ttcagcccgg 1920
acggcgaccg attaaaggaa ggaacgatat gaccgccacc accccctgcg tcgtcttcga 1980
acgtggacgg cacgcttgcc gaattcgacg ccgaccgcct gggccatctt gtccacggca 2040
cgaccaagca ctgggacgcc ttccaccacg cgatggccga cggcccgccc atccccgagg 2100
tcgcccgcct gatgcgcaag ctgaaggagg ggggcgagac ggtcgtcatc tgctcggggc 2160
ggcccccgcg ctggcaggat cagacgatcg catggctgcg caagcacgac ctgcccttcg 2220
acgggatcta tctgcgcccc gaggatcagg acggcgccag cgaccccgag gtcaagcgcc 2280
gcgccttagc cgagatgcgc gccgacgggc tggcgccctg gctggtcgtg gacgaccggc 2340
ggtccgtcgt ggatgcctgg cgggcccagg ggctggctct cctgcaatgc gcgcccgggg 2400
acttctaggg ccgcgcgacg ggggcgcgga caggctgggc gggaaaccgc cccgccacca 2460
tgtctgcac gcgtcgaacc gccgtccga cgcgggttcc cgcacggaaa cgcgcggcaa 2520
gttgacataa cttgcacgcg acgtctcgat tctgcccgcg aagaatgcga tgcattcaga 2580
tgatgcagaa cgaagaagcg gaagcggccg tgaaagacca gatgatttcc cataccccgg 2640

| | |
|--|---------------------|
| tgcccacgca atgggtcggc cccatcctgt tccgcggccc cgtcgtcgag ggcccgatca | 2700 |
| ggcgcccgct ggccacctac gagacgccgc tctggccctc gaccgcgcgg ggggcagggg | 2760 |
| tttcccggca ttcgggcggg atccaggtct cgtcgtcgca cgaacgcatg agccgctcga | 2820 |
| tcgcgctgcg ggcgcatgac ggggcggcgg cgaccgcgcg ctggcagtcg atcaaggccc | 2880 |
| gccaggaaga ggtcgcggcc gtggtcgcca ccaccagccg cttcgccgcg cttgtcgagc | 2940 |
| tgaatcgcca gatcgtgggc aacctgcttt acatccgcat cgaatgcgtg acgggcgacg | 3000 |
| cctcgggtca caacatggtc accaaggccg ccgaggccgt gcagggtggtg atcctgtcgg | 3060 |
| aatacccgat gctggcctat tccacgatct cggggaacct gtgcaccgac aagaaggcgt | 3120 |
| cggcgggtcaa cggcatcctg ggccgcggca aatacgccgt cgccgaggtc gagatccgcg | 3180 |
| gcaagatcct gaccgcgtg ctgcgcacca gcgcgagaa gatggtccgc ctgaactacg | 3240 |
| agaagaacta tgtcgggggt acgctggcgg ggtcgtgcg cagtgcgaac gcgcatttcg | 3300 |
| ccaacatgct gctgggcttc tacctggcga cggggcagga cgccgccaac atcatcgagg | 3360 |
| ccagccaggg cttcgtccat tgcgaggccc gcggcgagga tctgtatttc tcgtgcacgc | 3420 |
| tgcccaacct catcatgggc tcggtcgggt cgggcaaggg catcccctcg atcgaggaga | 3480 |
| acctgtcgcg gatgggctgc cgccagccgg gcgaaccgg cgacaacgcg cgccgtcttg | 3540 |
| cggcgatctg cgccggcgtc gtgctgtgtg gtgaattgtc gctgcttgcg gccagacca | 3600 |
| accccgagga gttggtccgc acccacatgg agatggagcg atg acc gac agc aag | 3655 |
| | Met Thr Asp Ser Lys |
| | 1 5 |
| gat cac cat gtc gcg ggg cgc aag ctg gac cat ctg cgt gca ttg gac | 3703 |
| Asp His His Val Ala Gly Arg Lys Leu Asp His Leu Arg Ala, Leu Asp | |
| | 10 15 20 |
| gac gat gcg gat atc gac cgg ggc gac agc ggc ttc gac cgc atc gcg | 3751 |
| Asp Asp Ala Asp Ile Asp Arg Gly Asp Ser Gly Phe Asp Arg Ile Ala | |
| | 25 30 35 |
| ctg acc cat cgc gcc ctg ccc gag gtg gat ttc gac gcc atc gac acg | 3799 |
| Leu Thr His Arg Ala Leu Pro Glu Val Asp Phe Asp Ala Ile Asp Thr | |
| | 40 45 50 |
| gcg acc agc ttc ctg ggc cgt gaa ctg tcc ttc ccg ctg ctg atc tcg | 3847 |
| Ala Thr Ser Phe Leu Gly Arg Glu Leu Ser Phe Pro Leu Leu Ile Ser | |
| | 55 60 65 |
| tcc atg acc ggc ggc acc ggc gag gag atc gag cgc atc aac cgc aac | 3895 |
| Ser Met Thr Gly Gly Thr Gly Glu Glu Ile Glu Arg Ile Asn Arg Asn | |
| | 70 75 80 85 |
| ctg gcc gct ggt gcc gag gag gcc cgc gtc gcc atg gcg gtg ggc tcg | 3943 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|
| Leu | Ala | Ala | Gly | Ala | Glu | Glu | Ala | Arg | Val | Ala | Met | Ala | Val | Gly | Ser | |
| | | | | 90 | | | | | 95 | | | | | 100 | | |
| cag | cgc | gtg | atg | ttc | acc | gac | ccc | tcg | gcg | cgg | gcc | agc | ttc | gac | ctg | 3991 |
| Gln | Arg | Val | Met | Phe | Thr | Asp | Pro | Ser | Ala | Arg | Ala | Ser | Phe | Asp | Leu | |
| | | | 105 | | | | | 110 | | | | | 115 | | | |
| cgc | gcc | cat | gcg | ccc | acc | gtg | ccg | ctg | ctg | gcc | aat | atc | ggc | gcg | gtg | 4039 |
| Arg | Ala | His | Ala | Pro | Thr | Val | Pro | Leu | Leu | Ala | Asn | Ile | Gly | Ala | Val | |
| | | | 120 | | | | 125 | | | | | 130 | | | | |
| cag | ctg | aac | atg | ggg | ctg | ggg | ctg | aag | gaa | tgc | ctg | gcc | gcg | atc | gag | 4087 |
| Gln | Leu | Asn | Met | Gly | Leu | Gly | Leu | Lys | Glu | Cys | Leu | Ala | Ala | Ile | Glu | |
| | | | 135 | | | 140 | | | | | 145 | | | | | |
| gtg | ctg | cag | gcg | gac | ggc | ctg | tat | ctg | cac | ctg | aac | ccc | ctg | caa | gag | 4135 |
| Val | Leu | Gln | Ala | Asp | Gly | Leu | Tyr | Leu | His | Leu | Asn | Pro | Leu | Gln | Glu | |
| | 150 | | | | 155 | | | | | 160 | | | | | 165 | |
| gcc | gtc | cag | ccc | gag | ggg | gat | cgc | gac | ttt | gcc | gat | ctg | ggc | agc | aag | 4183 |
| Ala | Val | Gln | Pro | Glu | Gly | Asp | Arg | Asp | Phe | Ala | Asp | Leu | Gly | Ser | Lys | |
| | | | | 170 | | | | | 175 | | | | | 180 | | |
| atc | gcg | gcc | atc | gcc | cgc | gac | gtt | ccc | gtg | ccc | gtc | ctg | ctg | aag | gag | 4231 |
| Ile | Ala | Ala | Ile | Ala | Arg | Asp | Val | Pro | Val | Pro | Val | Leu | Leu | Lys | Glu | |
| | | | 185 | | | | | 190 | | | | | 195 | | | |
| gtg | ggc | tgc | ggc | ctg | tcg | gcg | gcc | gat | atc | gcc | atc | ggg | ctg | cgc | gcc | 4279 |
| Val | Gly | Cys | Gly | Leu | Ser | Ala | Ala | Asp | Ile | Ala | Ile | Gly | Leu | Arg | Ala | |
| | | 200 | | | | | 205 | | | | | 210 | | | | |
| ggg | atc | cgc | cat | ttc | gac | gtg | gcc | ggt | cgc | ggc | ggc | aca | tcc | tgg | agc | 4327 |
| Gly | Ile | Arg | His | Phe | Asp | Val | Ala | Gly | Arg | Gly | Gly | Thr | Ser | Trp | Ser | |
| | | 215 | | | | 220 | | | | | 225 | | | | | |
| cgc | atc | gag | tat | cgc | cgc | cgc | cag | cgc | gcc | gat | gac | gac | ctg | ggc | ctg | 4375 |
| Arg | Ile | Glu | Tyr | Arg | Arg | Arg | Gln | Arg | Ala | Asp | Asp | Asp | Leu | Gly | Leu | |
| | 230 | | | | 235 | | | | | 240 | | | | | 245 | |
| gtc | ttc | cag | gac | tgg | ggc | ctg | cag | acc | gtg | gac | gcc | ctg | cgc | gag | gcg | 4423 |
| Val | Phe | Gln | Asp | Trp | Gly | Leu | Gln | Thr | Val | Asp | Ala | Leu | Arg | Glu | Ala | |
| | | | | 250 | | | | | 255 | | | | | 260 | | |
| cgc | ccc | gcg | ctt | gcg | gcc | cat | gat | gga | acc | agc | gtg | ctg | atc | gcc | agc | 4471 |
| Arg | Pro | Ala | Leu | Ala | Ala | His | Asp | Gly | Thr | Ser | Val | Leu | Ile | Ala | Ser | |
| | | | 265 | | | | 270 | | | | | | 275 | | | |
| ggc | ggc | atc | cgc | aac | ggt | gtc | gac | atg | gcg | aaa | tgc | gtc | atc | ctg | ggg | 4519 |
| Gly | Gly | Ile | Arg | Asn | Gly | Val | Asp | Met | Ala | Lys | Cys | Val | Ile | Leu | Gly | |
| | | 280 | | | | | 285 | | | | | 290 | | | | |
| gcc | gac | atg | tgc | ggg | gtc | gcc | gcg | ccc | ctg | ctg | aaa | gcg | gcc | caa | aac | 4567 |
| Ala | Asp | Met | Cys | Gly | Val | Ala | Ala | Pro | Leu | Leu | Lys | Ala | Ala | Gln | Asn | |
| | | 295 | | | | 300 | | | | | 305 | | | | | |
| tcg | cgc | gag | gcg | gtt | gta | tcc | gcc | atc | cgc | aaa | ctg | cat | ctg | gag | ttc | 4615 |
| Ser | Arg | Glu | Ala | Val | Val | Ser | Ala | Ile | Arg | Lys | Leu | His | Leu | Glu | Phe | |

| 310 | 315 | 320 | 325 | |
|--|-----|-----|-----|------|
| cgg aca gcc atg ttc ctc ctg ggt tgc ggc acg ctt gcc gac ctg aag | | | | 4663 |
| Arg Thr Ala Met Phe Leu Leu Gly Cys Gly Thr Leu Ala Asp Leu Lys | | | | |
| | 330 | 335 | 340 | |
| gac aat tcc tgc ctt atc cgt caa tga aagtgcctaa gatgaccgtg | | | | 4710 |
| Asp Asn Ser Ser Leu Ile Arg Gln | | | | |
| | 345 | | | |
| acaggaatcg aagcgatcag cttctacacc cccagaaact acgtgggact ggatatacctt | | | | 4770 |
| gccgcgcac acgggatcga ccccgagaag ttctcgaagg ggatcgggca ggagaaaatc | | | | 4830 |
| gcaactgccc gccatgacga ggatatacgtg accatggccg ccgaggccgc gctgccgac | | | | 4890 |
| atcgaacgcg cgggcacgca gggcatcgac acggttctgt tcgccaccga gagcgggac | | | | 4950 |
| gaccagtcga aggcgcgcgc catctatctg cgccgcctgc tggacctgtc gcccaactgc | | | | 5010 |
| cgttgctgc agctgaagca ggcctgctat tccgcgacgg cggcgtgca gatggcctgc | | | | 5070 |
| gcgcatgtcg cccgcaagcc cgaccgcaag gtgctggtga tcgctccga tgcgcgcgc | | | | 5130 |
| tatgaccgcg aaagctcggg cgaggcgacg cagggtgcgg gcgccgtgc catccttgc | | | | 5190 |
| agcgcgcac ccaaggtggc cgagatcggc accgtctcgg ggctgttcac cgaggatatac | | | | 5250 |
| atggatttct ggcgccgaa ccaccgcgc acgcccctgt tcgacggcaa ggcacgcacg | | | | 5310 |
| ctgcgtatc tgaacgcgt ggtcgaggcg tggaaacgact atcgcgcaa tggcgccac | | | | 5370 |
| gagttcgccg atttcgcgca tttctgctat cacgtgccgt tctcgcgat gggcgaag | | | | 5430 |
| gcgaacagcc acctggccaa ggcaacaag acgccggtgg acatggggca ggtgcagacg | | | | 5490 |
| ggcctgatct acaaccggca ggtcggaac tgctataccg ggtcgatcta cctggcatc | | | | 5550 |
| gcctcgctgc tggagaacgc tcaggaggac ctgaccggcg cgctggtcgg tctgttcagc | | | | 5610 |
| tatggctcgg gtgcgacggg cgaattcttc gatgcgcgga tcgcgcccg ttaccgcgac | | | | 5670 |
| cacctgttcg cggaacgcca tcgcgaattg ctgcaggatc gcacgcccg cacatatgac | | | | 5730 |
| gaatacgttg ccctgtggga cgagatcgac ctgacgcagg gcgcgccga caaggcgcg | | | | 5790 |
| ggtcgtttca ggctggcagg tatcgaggac gagaagcgca tctatgtcga ccggcaggcc | | | | 5850 |
| tgaagcaggc gcccatgccc cgggcaagct gatcctgtcc ggggaacatt ccgtgctcta | | | | 5910 |
| tggtgcgccc gcgcttgcca tggccatcgc ccgtatacc gaggtgtggt tcacgccgt | | | | 5970 |
| tggcattggc gaggggatac gcacgacatt cgccaatctc tcgggcgggg cgacctatc | | | | 6030 |
| gctgaagctg ctgtcgggggt tcaagtgcg gctggaccgc cggttcgagc agttcctgaa | | | | 6090 |
| cggcgacctt aaggtgcaca aggtcctgac ccatcccgac gatctggcgg tctatgcgt | | | | 6150 |

ggcgtcgctt ctgcacgaca agccgccggg gaccgccgcg atgccgggca tcggcgcgat 6210
gcaccacctg ccgcgaccgg gtgagctggg cagccggacg gagctgcca tcggcgcggg 6270
catggggctg tctgcggcca tcgtcgcggc caccacggtc ctgttcgaga cgctgctgga 6330
ccggcccaag acgcccgaac agcgettcga cegcgtccgc ttctgcgagc ggttgaagca 6390
cggcaaggcc ggtcccatcg acgcgccag cgtcgtgcgc ggcgggcttg tccgcgtggg 6450
cgggaacggg ccgggttcga tcagcagctt cgatttgccc gaggatcacg accttgctgc 6510
gggacgcggc tgggtactggg tactgcacgg gcgccccgtc agcgggaccg gcgaatgct 6570
cagcgcggtc gcggcgcggc atggtcgca tgcggcgctg tgggacgct tcgcagtctg 6630
caccgcgcg ttggaggccg cgctgctgtc tgggggcagc cccgacgcc ccataccga 6690
gaaccagcgc ctgctggaac gcatcgcgct cgtgccggca gcgacgcagg cctcgtggc 6750
ccagatcgag gaggcgggtg gcgcgccaa gatctcggc gcaggttccg tgcggggcga 6810
tcacggcggg gcggtcctcg tgcggattga cgacgcgcag gcgatggctt cggtcatggc 6870
gcgccatccc gacctgact gggcgcccct gcgcatgtc gcgacggggg cggcacccgg 6930
ccccgcgcc cgtgcgcaac cgctgccggg gcagggctga tggatcaggt catccgcgcc 6990
agcgcgccgg gttcggtcac gatcacgggc gaacatgccg tggcttatgg acaccgcgcc 7050
atcgtcgccg ggatcgagca gcgccccat gtgacgatc tcccgcgtgc cgaccgcag 7110
tttcgcatca cctcgagat cggggcgccg cagcaggggt cgctggacga tctgcctgcg 7170
ggcgggacct atcgcttcgt gctggccgcc atcgcgcgac acgcgccgga cctgccttgc 7230
gggttcgaca tggacatcac ctcggggatc gatccgaggc tcgggcttgg atcctcgcg 7290
gcggtgacgg tcgctgcct cggcgcgctg tgcggctgg cggggcgggg gaccgagggg 7350
ctgcatgacg acgcgtgcg catcgtccgc gccatccagg gcaggggcag cggggccgat 7410
ctggcgcca gcctgcatg cggttcgtc gcctatcgcg cggccgatgg cggtgccgcg 7470
cagatcgagg cgcttcgggt gccgccggg ccgttcggc tgcgctatgc gggctacaag 7530
accccgacag ccgaggtgct gcgcttctg gccgatcgga tggcgggcaa cgaggccgct 7590
ttcgacgcgc tctactccg gatgggcgca agcgagatg ccgcatccg cgcggcgcaa 7650
gggctggact gggctgcatt ccacgacgcg ctgaacgaat accagcgct gatggagcag 7710
ctgggcgtgt ccgacgacac gctggacgcg atcatccgc aggcgcgcga cgcggcgcc 7770
gcagtcgcca agatctccg ctcggggctg ggggattgcg tgctggcact gggcgaccag 7830

```

cccaaggggtt tcgtgcccgc aagcattgcc gagaagggac ttgttttcga tgactgatgc 7890
cgtcgcgcac atgatcgccc gtgccatggc gggcgcgacc gacatccgag cagccgaggc 7950
ttatgcgccc agcaacatcg cgctgtcgaa atactggggc aagcgcgacg ccgcgcggaa 8010
ccttcgcgtg aacagctccg tctcgatctc gttggcgaaac tggggctctc atacgcgggt 8070
cgaggggtcc ggcacggggc acgacgaggt gcatcacaac ggcacgctgc tggatccggg 8130
cgacgccttc gcgcgcgcgc cgttggcatt cgctgacctg ttccgggggg ggaggcacct 8190
gccgctgcgg atcacgacgc agaactcgat cccgacggcg gcggggcttg cctcgtcggc 8250
ctcgggggttc gcggcgctga cccgtgcgct ggcgggggcg ttcgggctgg atctggacga 8310
cacggatctg agccgcacgc cccggatcgg cagtggcagc gccgcccgtc cgatctggca 8370
cggtctcgtc cgctggaacc gggcgagggc cgaggatggg catgacagcc acggcgctcc 8430
gctggacctg cgctggcccg gcttccgcac cgcatcgctg gccgtggaca aggggcccaa 8490
gcctttcagt tcgcgcgacg gcatgaacca cacggtcgag accagcccgc tgttcccgcc 8550
ctggcctgcg caggcggaag cggattgccg cgcatcgag gatgcgatcg ccgcccgca 8610
catggccgcc ctgggtccgc gggtcgagggc gaacgccctt gcgatgcacg ccacgatgat 8670
ggccgcgcgc ccgcgcgtct gctacctgac gggcgcgacg tggcaggtgc tggaacgcct 8730
gtggcaggcc cgcgcgagcg ggcttgcggc ctttgcgacg atggatgccg gcccgaaagt 8790
caagctgatc ttcgaggaaa gcagcgccgc cgacgtgctg tacctgttcc ccgacgccag 8850
cctgatcgcg ccgttcgagg ggcgttgaaac gcgtaagacg accactgggt aaggttctgc 8910
cgcgcggtgg ctcgactgcc tgcaaagagg tgcttgagtt gctgcgtgac tcggcgggcc 8970
gacttcgtgg gacttgcccg ccacgctgac gcgctggaaa cgcgcccgcg gattacgacc 9030
gcgtcattgc cctgaaccaa tttcccgctg gtcgac 9066

```

<210> 45

<211> 349

<212> PRT

<213> Paracoccus sp. R114

<400> 45

```

Met Thr Asp Ser Lys Asp His His Val Ala Gly Arg Lys Leu Asp His
1           5           10          15

```


Leu Arg Ala Leu Asp Asp Asp Ala Asp Ile Asp Arg Gly Asp Ser Gly
20 25 30

Phe Asp Arg Ile Ala Leu Thr His Arg Ala Leu Pro Glu Val Asp Phe
35 40 45

Asp Ala Ile Asp Thr Ala Thr Ser Phe Leu Gly Arg Glu Leu Ser Phe
50 55 60

Pro Leu Leu Ile Ser Ser Met Thr Gly Gly Thr Gly Glu Glu Ile Glu
65 70 75 80

Arg Ile Asn Arg Asn Leu Ala Ala Gly Ala Glu Glu Ala Arg Val Ala
85 90 95

Met Ala Val Gly Ser Gln Arg Val Met Phe Thr Asp Pro Ser Ala Arg
100 105 110

Ala Ser Phe Asp Leu Arg Ala His Ala Pro Thr Val Pro Leu Leu Ala
115 120 125

Asn Ile Gly Ala Val Gln Leu Asn Met Gly Leu Gly Leu Lys Glu Cys
130 135 140

Leu Ala Ala Ile Glu Val Leu Gln Ala Asp Gly Leu Tyr Leu His Leu
145 150 155 160

Asn Pro Leu Gln Glu Ala Val Gln Pro Glu Gly Asp Arg Asp Phe Ala
165 170 175

Asp Leu Gly Ser Lys Ile Ala Ala Ile Ala Arg Asp Val Pro Val Pro
180 185 190

Val Leu Leu Lys Glu Val Gly Cys Gly Leu Ser Ala Ala Asp Ile Ala
195 200 205

Ile Gly Leu Arg Ala Gly Ile Arg His Phe Asp Val Ala Gly Arg Gly
210 215 220

Gly Thr Ser Trp Ser Arg Ile Glu Tyr Arg Arg Arg Gln Arg Ala Asp
225 230 235 240

Asp Asp Leu Gly Leu Val Phe Gln Asp Trp Gly Leu Gln Thr Val Asp
245 250 255

Ala Leu Arg Glu Ala Arg Pro Ala Leu Ala Ala His Asp Gly Thr Ser
260 265 270

Val Leu Ile Ala Ser Gly Gly Ile Arg Asn Gly Val Asp Met Ala Lys
275 280 285

Cys Val Ile Leu Gly Ala Asp Met Cys Gly Val Ala Ala Pro Leu Leu
290 295 300

Lys Ala Ala Gln Asn Ser Arg Glu Ala Val Val Ser Ala Ile Arg Lys
305 310 315 320

Leu His Leu Glu Phe Arg Thr Ala Met Phe Leu Leu Gly Cys Gly Thr
325 330 335

Leu Ala Asp Leu Lys Asp Asn Ser Ser Leu Ile Arg Gln
340 345

<210> 46

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (4687) .. (5853)

<223> hcs

<400> 46

| | |
|--|-----|
| ggatccggca gctcgacacg ccgcagaacc tgtaagaacg tcccgccagc cgcttcgtcg | 60 |
| cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgcg | 120 |
| cccgcatacct gggggccgag gtggcggtga acgccgcccc gcaatcgcg tttgtcgatc | 180 |
| acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg | 240 |

tcgcgcgcgt cacctatctt ggcgggaaat acctgctgga aaccgtgctg gattgcggca 300
cccggctggt gaccgagacc cgcgcccgtt tcgatacggg cgcgcagctt ggcctgacca 360
tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca 420
tgggcgtgaa gggccctgcc tgcacagggc tggatgtcgg cgggatgcgc ctgatcctcg 480
attgcgggac cggcccggac gagggcgagg agttcgaccc cgcctggctg gcgagcgcgg 540
atgcggtgct gatcacccat gaccacgtgg accatatcgg cggcgcgctg cacgcggtcg 600
cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcggggcgcg 660
atctgcgcct gctgcccga cgcggtgtca cgcggatcgc cggggtcgat ctgacgaccg 720
gtcgcaacgg gcatgcccg ggcggcgctt gtagcattt cgacatgggc gaggggctgt 780
tctattccgg cgactggtec gaggaatccg actggttcgc cttegatccg cccccgcctg 840
cggggacggc gattctcgac tgctcctatg gcggtttcga cgtggcgcaa tcggattgca 900
tcgcggacct ggacgacctg ctcgaggtgc tgccggggca ggtactgctg ccggtgccgc 960
catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg 1020
tgatggtcga cgacgcctgc ctgccggcca tcgcgcaact gcccgaggcg cgcggactgg 1080
cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg 1140
gcatggcggc atctgcaagc atggcgcgat gcgggcaggc tggggcgagg cgcgcattgc 1200
gtcttcaccg ggcacatgaa cgtccatgcg cgcgcattct gcgaccgcc cggcgggcat 1260
ttccgcgcgt ggaacgtgca tccgcgcgtg cgcgaccagc gacggatgct ggaacggctg 1320
gccgcggggc gctttgcccc ggccttctgc cccgaccccg agatctatct ggcgctggac 1380
atgggcgcgc aggtcttcat gcaccaggag gtgacgccat gatccccgcc cgcagcttct 1440
gcctgatccg ccacggcgaa acgaccgcca atgcaggggc gatcatcgcg ggcgcaaccg 1500
atgtgcccct gacgccaagg ggccgcgatc aggccgcgc cctggcaggg cggaatggc 1560
catcgggcat cgcgctgttc gccagccgga tgtcgcgtgc ccgcgatacc gcgctgctgg 1620
cctttccggg gcgcgaccac cagcccgaac ccgatctgcg cgaacgcgac tggggcatct 1680
tcgaggggac ccccgctgcc gatctgcccc cgcgcgaaat cacgcccgag gggggcgagg 1740
gctgggacga cgtgatggcc cgcgtggacc gcgcatccg gcggatctgc gcgacctcgg 1800
gcgatgcgct gccgggtgct gtctgccatt cgggcgtgat ccgtgcccg cgcgtgctgt 1860
ggaccaccgg cgatgcgggc gatcgtccgc ccaacgccac gccgatcctg ttcagccccg 1920

acggcgaccg attaaaggaa ggaacgatat gaccgccacc accccctgcg tcgtcttcga 1980
acgtggacgg cacgcttgcc gaattcgacg ccgaccgcct gggccatctt gtccacggca 2040
cgaccaagca ctgggacgcc ttccaccacg cgatggccga cggcccgccc atccccgagg 2100
tcgcccgcct gatgcgaag ctgaaggagg ggggagagac ggtcgtcatc tgctcggggc 2160
ggccccgagg ctggcaggat cagacgatcg catggctgcg caagcacgac ctgcccttcg 2220
acgggatcta tctgcgcccc gaggatcagg acggcgccag cgaccccgag gtcaagcgcc 2280
gcgcccctagc cgagatgcgc gccgacgggc tggcgccctg gctggctcgtg gacgaccggc 2340
ggtccgctgt ggatgcctgg cgggcccagg ggctggctctg cctgcaatgc gcgcccgggg 2400
acttctaggg ccgcgcgacg ggggagcgga caggctgggc gggaaaccgc cccgccacca 2460
tgtcctgcac gcgtcgaacc gcccgctcca cggcggtttc cgcacggaaa cgcgcggcaa 2520
gttgacataa cttgcacgcg acgtctcgat tctgcccgcg aagaatgcga tgcattcaga 2580
tgatgcagaa cgaagaagcg gaagcgcccg tgaaagacca gatgatttcc cataccccgg 2640
tgcccacgca atgggtcggc ccgatcctgt tccgaggccc cgtcgtcgag ggcccgatca 2700
gcgcgcgctt ggccacctac gagacggcgc tctggccctc gaccgcgcgg ggggagggg 2760
tttcccgcca ttcggggggg atccaggtct cgctggctga cgaacgcatg agccgctcga 2820
tcgcgctgcg ggcgcatgac ggggagggcg ccgaccgcgc ctggcagtcg atcaaggccc 2880
gccaggaaga ggtcgcggcc gtggtcgcca ccaccagccg cttcgcccgcc cttgtcgagc 2940
tgaatcgcca gatcgtgggc aacctgcttt acatccgcat cgaatgcgtg acgggagcgc 3000
cctcgggtca caacatggtc accaaggccg ccgaggccgt gcagggctgg atcctgtcgg 3060
aatacccgat gctggcctat tccacgatct cggggaacct gtgcaccgac aagaaggcgt 3120
cggcgggtcaa cggcatcctg ggccgaggca aatacgccgt cggcgaggtc gagatccgc 3180
gcaagatcct gaccgcgctg ctgcgacca gcgcgagaa gatgggtccg ctgaactacg 3240
agaagaacta tgtcgggggt acgctggcgg ggtcgtcgcg cagtgcgaac gcgcatttcg 3300
ccaacatgct gctgggcttc tacctggcga cggggcagga cgggccaac atcatcgagg 3360
ccagccaggg cttcgtccat tgcgaggccc gggcgagga tctgtatttc tcgtgcacgc 3420
tgcccaacct catcatgggc tcggtcgggt cggcaaggg catccccctg atcgaggaga 3480
acctgtcgcg gatgggctgc cggcagccgg gcgaaccgg cgacaacgcg cggcgtcttg 3540
cggcgatctg cgcgggctgc gtgctgtgtg gtgaattgtc gctgcttgcg gccagacca 3600
acccgggaga gttgggtccg acccacatgg agatggagcg atgaccgaca gcaaggatca 3660

ccatgtcgcg gggcgcaagc tggaccatct gcgtgcattg gacgacgatg cggatatcga 3720
 ccggggcgac agcggcttcg accgcatcgc gctgacccat cgcgccctgc ccgaggtgga 3780
 tttcgcagcc atcgacacgg cgaccagctt cctgggccgt gaactgtcct tcccgtgct 3840
 gatctcgtcc atgaccggcg gcaccggcga-ggagatcgag cgcatacaacc gcaacctggc 3900
 cgctggtgcc gaggaggccc gcgtcgccat ggcggtgggc tcgcagcgcg tgatgttcac 3960
 cgacccctcg gcgcgggcca gcttcgacct gcgcgcccat gcgccaccg tgccgctgct 4020
 ggccaatatc ggcgcggtgc agctgaacat ggggctgggg ctgaaggaat gcctggccgc 4080
 gatcgagggtg ctgcaggcgg acggcctgta tctgcacctg aacccctgc aagaggccgt 4140
 ccagcccagag ggggatcgcg actttgccga tctgggcagc aagatcgcgg ccatcgcccg 4200
 cgacgttccc gtgcccgtcc tgctgaagga ggtgggctgc ggctgtcgg cggccgatat 4260
 cgccatcggg ctgcgcgccg ggatccggca tttcgacctg gccggtcgcg gcggcacatc 4320
 ctggagcccg atcgagtatc gccgcgccca gcgggccgat gacgacctgg gcctggtctt 4380
 ccaggactgg ggcctgcaga ccgtggacgc cctgcgcgag gcgcggcccg cgcttgccggc 4440
 ccatgatgga accagcgtgc tgatcgccag cggcggcatc cgcaacgggtg tcgacatggc 4500
 gaaatgcgtc atcctggggg ccgacatgtg cggggctgcc gcgccctgc tgaaagcggc 4560
 ccaaaactcg cgcgaggcgg ttgtatccgc catccgaaa ctgcatctgg agttccggac 4620
 agccatgttc ctctggggtt gcggcacgct tgccgacctg aaggacaatt cctcgcttat 4680
 ccgtca atg aaa gtg cct aag atg acc gtg aca gga atc gaa gcg atc 4728
 Met Lys Val Pro Lys Met Thr Val Thr Gly Ile Glu Ala Ile
 1 5 10
 agc ttc tac acc ccc cag aac tac gtg gga ctg gat atc ctt gcc gcg 4776
 Ser Phe Tyr Thr Pro Gln Asn Tyr Val Gly Leu Asp Ile Leu Ala Ala
 15 20 25 30
 cat cac ggg atc gac ccc gag aag ttc tcg aag ggg atc ggg cag gag 4824
 His His Gly Ile Asp Pro Glu Lys Phe Ser Lys Gly Ile Gly Gln Glu
 35 40 45
 aaa atc gca ctg ccc ggc cat gac gag gat atc gtg acc atg gcc gcc 4872
 Lys Ile Ala Leu Pro Gly His Asp Glu Asp Ile Val Thr Met Ala Ala
 50 55 60
 gag gcc gcg ctg ccg atc atc gaa cgc gcg ggc acg cag ggc atc gac 4920
 Glu Ala Ala Leu Pro Ile Ile Glu Arg Ala Gly Thr Gln Gly Ile Asp
 65 70 75
 acg gtt ctg ttc gcc acc gag agc ggg atc gac cag tcg aag gcc gcc 4968
 Thr Val Leu Phe Ala Thr Glu Ser Gly Ile Asp Gln Ser Lys Ala Ala

| 80 | 85 | 90 | |
|---|----|----|------|
| gcc atc tat ctg cgc cgc ctg ctg gac ctg tcg ccc aac tgc cgt tgc Ala Ile Tyr Leu Arg Arg Leu Leu Asp Leu Ser Pro Asn Cys Arg Cys 95 100 105 110 | | | 5016 |
| gtc gag ctg aag cag gcc tgc tat tcc gcg acg gcg gcg ctg cag atg Val Glu Leu Lys Gln Ala Cys Tyr Ser Ala Thr Ala Ala Leu Gln Met 115 120 125 | | | 5064 |
| gcc tgc gcg cat gtc gcc cgc aag ccc gac cgc aag gtg ctg gtg atc Ala Cys Ala His Val Ala Arg Lys Pro Asp Arg Lys Val Leu Val Ile 130 135 140 | | | 5112 |
| gcg tcc gat gtc gcg cgc tat gac cgc gaa agc tcg ggc gag gcg acg Ala Ser Asp Val Ala Arg Tyr Asp Arg Glu Ser Ser Gly Glu Ala Thr 145 150 155 | | | 5160 |
| cag ggt gcg ggc gcc gtc gcc atc ctt gtc agc gcc gat ccc aag gtg Gln Gly Ala Gly Ala Val Ala Ile Leu Val Ser Ala Asp Pro Lys Val 160 165 170 | | | 5208 |
| gcc gag atc ggc acc gtc tcg ggg ctg ttc acc gag gat atc atg gat Ala Glu Ile Gly Thr Val Ser Gly Leu Phe Thr Glu Asp Ile Met Asp 175 180 185 190 | | | 5256 |
| ttc tgg cgg ccg aac cac cgc cgc acg ccc ctg ttc gac ggc aag gca Phe Trp Arg Pro Asn His Arg Arg Thr Pro Leu Phe Asp Gly Lys Ala 195 200 205 | | | 5304 |
| tcg acg ctg cgc tat ctg aac gcg ctg gtc gag gcg tgg aac gac tat Ser Thr Leu Arg Tyr Leu Asn Ala Leu Val Glu Ala Trp Asn Asp Tyr 210 215 220 | | | 5352 |
| cgc gcg aat ggc ggc cac gag ttc gcc gat ttc gcg cat ttc tgc tat Arg Ala Asn Gly Gly His Glu Phe Ala Asp Phe Ala His Phe Cys Tyr 225 230 235 | | | 5400 |
| cac gtg ccg ttc tcg cgg atg ggc gag aag gcg aac agc cac ctg gcc His Val Pro Phe Ser Arg Met Gly Glu Lys Ala Asn Ser His Leu Ala 240 245 250 | | | 5448 |
| aag gcg aac aag acg ccg gtg gac atg ggg cag gtg cag acg ggc ctg Lys Ala Asn Lys Thr Pro Val Asp Met Gly Gln Val Gln Thr Gly Leu 255 260 265 270 | | | 5496 |
| atc tac aac cgg cag gtc ggg aac tgc tat acc ggg tcg atc tac ctg Ile Tyr Asn Arg Gln Val Gly Asn Cys Tyr Thr Gly Ser Ile Tyr Leu 275 280 285 | | | 5544 |
| gca ttc gcc tcg ctg ctg gag aac gct cag gag gac ctg acc ggc gcg Ala Phe Ala Ser Leu Leu Glu Asn Ala Gln Glu Asp Leu Thr Gly Ala 290 295 300 | | | 5592 |
| ctg gtc ggt ctg ttc agc tat ggc tcg ggt gcg acg ggc gaa ttc ttc Leu Val Gly Leu Phe Ser Tyr Gly Ser Gly Ala Thr Gly Glu Phe Phe 305 310 315 | | | 5640 |

gat gcg cgg atc gcg ccc ggt tac cgc gac cac ctg ttc gcg gaa cgc 5688
Asp Ala Arg Ile Ala Pro Gly Tyr Arg Asp His Leu Phe Ala Glu Arg
320 325 330

cat cgc gaa ttg ctg cag gat cgc acg ccc gtc aca tat gac gaa tac 5736
His Arg Glu Leu Leu Gln Asp Arg Thr Pro Val Thr Tyr Asp Glu Tyr
335 340 345 350

gtt gcc ctg tgg gac gag atc gac ctg acg cag ggc gcg ccc gac aag 5784
Val Ala Leu Trp Asp Glu Ile Asp Leu Thr Gln Gly Ala Pro Asp Lys
355 360 365

gcg cgc ggt cgt ttc agg ctg gca ggt atc gag gac gag aag cgc atc 5832
Ala Arg Gly Arg Phe Arg Leu Ala Gly Ile Glu Asp Glu Lys Arg Ile
370 375 380

tat gtc gac cgg cag gcc tga agcaggcgcc catgccccgg gcaagctgat 5883
Tyr Val Asp Arg Gln Ala
385

cctgtccggg gaacattccg tgctctatgg tgcgcccgcg cttgccatgg ccatcgcccc 5943

ctataccgag gtgtggttca cgccgcttgg cattggcgag gggatacgca cgacattcgc 6003

caatctctcg ggcggggcga cctattcgct gaagctgctg tcgggggttca agtcgcggct 6063

ggaccgcggg ttcgagcagt tcctgaacgg cgacctaaag gtgcacaagg tcctgaccca 6123

tccccgacgat ctggcggtct atgcgctggc gtcgcttctg caccgacaagc cgccgggggac 6183

cgccgcgatg cggggcatcg gcgcgatgca ccacctgccg cgaccgggtg agctgggcag 6243

cgggacggag ctgccatcg gcgcgggcat ggggtcgtct gcggccatcg tcgcggccac 6303

cacggtcctg ttcgagacgc tgctggaccg gcccaagacg cccgaacagc gcttcgaccg 6363

cgtccgcttc tgcgagcggg tgaagcacgg caaggccggt cccatcgacg cggccagcgt 6423

cgtgcgcggc gggcttgtcc gcgtggggcg gaacggggcg ggttcgatca gcagcttcga 6483

tttgcccagag gatcacgacc ttgtcgcggg acgcggctgg tactgggtac tgcacgggcg 6543

ccccgtcagc gggaccggcg aatgcgtcag cgcggtcgcg gcggcgcatg gtcgcgatgc 6603

ggcgctgtgg gacgccttcg cagtctgcac ccgcgcgttg gaggccgcgc tgctgtctgg 6663

gggcagcccc gacgccgcca tcaccgagaa ccagcgcttg ctggaacgca tcggcgctcg 6723

gccggcagcg acgcaggccc tcgtggccca gatcgaggag gcgggtggcg cggccaagat 6783

ctgcggcgca ggttccgtgc gggcgatca cggcggggcg gtccctcgtgc ggattgacga 6843

cgcgaggcg atggcttcgg tcatggcgcg ccatcccgac ctcgactggg cgccccctgcg 6903

catgtcgcgc acggggggcg caccggcccc cgcgccgct gcgcaaccgc tgccggggga 6963

gggctgatgg atcagggtcat ccgcgccagc gcgccgggtt cggtcacatgat cacggggcgaa 7023
 catgccgtgg tctatggaca ccgcgccatc gtcgccggga tcgagcagcg cgcccatgtg 7083
 acgatcgtcc cgcgtgccga ccgcattgtt cgcacacact cgcagatcgg ggccgccag 7143
 caggggtcgc tggacgatct gcctgcgggc gggacctatc gcttcgtgct ggccgccatc 7203
 gcgcgacacg cgccggacct gccttcgggg ttgcacatgg acatcacctc ggggatcgat 7263
 ccgaggctcg ggcttggatc ctccggcgcg gtgacggtcg cctgcctcgg cgcgctgtcg 7323
 cggctggcgg ggccggggac cgaggggctg catgacgacg cgctgcgcat cgtccgcgcc 7383
 atccagggca ggggcagcgg ggccgatctg gcggccagcc tgcatggcgg cttcgtcgcc 7443
 tategcgcgc ccgatggcgg tgccgcgcag atcgaggcgc ttccggtgcc gccggggccg 7503
 ttccggcctgc gctatgcggg ctacaagacc ccgacagccg aggtgctgcg cttgttgcc 7563
 gatcggatgg cgggcaacga ggccgcttcc gacgcgctct actcccggat gggcgcaagc 7623
 gcagatgccg cgatccgcgc ggccgaaggc ctggactggg ctgcattcca cgacgcgctg 7683
 aacgaatacc agcgcctgat ggagcagctg ggctgttccg acgacacgct ggacgcgac 7743
 atccgcgagg cgcgcgacgc gggcgccgca gtcgccaaga tctccggctc ggggctgggg 7803
 gattgcgtgc tggcactggg cgaccagccc aagggtttcg tgcccgaag cattgccgag 7863
 aagggaactg ttttcgatga ctgatgccgt ccgcgacatg atcgcccgtg ccatggcggg 7923
 cgcgaccgac atccgagcag ccgaggctta tgcccccagc aacatcgcg tgctgaaata 7983
 ctggggcaag cgcgacgccg ccgggaacct tccgctgaac agctccgtct cgatctcgtt 8043
 ggccaactgg ggctctcata cgcgggtcga ggggtccggc acggggccagc acgaggtgca 8103
 tcacaacggc acgctgctgg atccgggcca cgccttcgcg cgccgcgctg tggcattcgc 8163
 tgacctgttc cgggggggga ggcacctgcc gctgcggatc acgacgcaga actcgatccc 8223
 gacggcgggc gggcttgccct cgtcggcctc ggggttcgcg gcgctgaccc gtgcgctggc 8283
 gggggcgctt cggctggatc tggacgacac gcatctgagc cgcacgccc ggatcggcag 8343
 tggcagcgcc gcccgctcga tctggcacgg cttcgtccgc tggaaccggg gcgaggccga 8403
 ggatgggcat gacagccacg gcgtcccgtt ggaacctgcg tgggccggct tccgcatcgc 8463
 gatcgtggcc gtggacaagg ggcccaagcc ttccagttcg cgcgacggca tgaaccacac 8523
 ggtcgagacc agcccgtgtt tcccgccttg gcctgcgcag gcggaagcgg attgccgcgt 8583
 catcgaggat gcgacgccc cccgcgacat ggccgccttg ggtccgcggg tcgaggcgaa 8643
 cgcccttgcg atgcacgcca cgatgatggc cgcgcgccc cgcgtctgct acctgacggg 8703

cggcagctgg caggtgctgg aacgcctgtg gcaggcccg gcggacgggc ttgcggcctt 8763
 tgcgacgatg gatgccggcc cgaacgtcaa gctgatcttc gaggaagca gcgccgccga 8823
 cgtgctgtac ctgttccccg acgccagcct gatcgcgccg ttcgaggggc gttgaacgcg 8883
 taagacgacc actgggtaag gttctgccgc gcgtggtctc gactgcctgc aaagaggtgc 8943
 ttgagttgct gcgtgactgc ggcggccgac ttcgtgggac ttgcccgcca cgctgacgcg 9003
 ctggaaacgc gcccgcgat tacgaccgcg tcattgcctt gaaccaattt cccgtcggtc 9063
 gac 9066

<210> 47

<211> 388

<212> PRT

<213> Paracoccus sp. R114

<400> 47

Met Lys Val Pro Lys Met Thr Val Thr Gly Ile Glu Ala Ile Ser Phe
1 5 10 15

Tyr Thr Pro Gln Asn Tyr Val Gly Leu Asp Ile Leu Ala Ala His His
20 25 30

Gly Ile Asp Pro Glu Lys Phe Ser Lys Gly Ile Gly Gln Glu Lys Ile
35 40 45

Ala Leu Pro Gly His Asp Glu Asp Ile Val Thr Met Ala Ala Glu Ala
50 55 60

Ala Leu Pro Ile Ile Glu Arg Ala Gly Thr Gln Gly Ile Asp Thr Val
65 70 75 80

Leu Phe Ala Thr Glu Ser Gly Ile Asp Gln Ser Lys Ala Ala Ala Ile
85 90 95

Tyr Leu Arg Arg Leu Leu Asp Leu Ser Pro Asn Cys Arg Cys Val Glu
100 105 110

Leu Lys Gln Ala Cys Tyr Ser Ala Thr Ala Ala Leu Gln Met Ala Cys

| | | | |
|---|-----|-----|-----|
| 115 | 120 | 125 | |
| Ala His Val Ala Arg Lys Pro Asp Arg Lys Val Leu Val Ile Ala Ser | | | |
| 130 | 135 | 140 | |
| Asp Val Ala Arg Tyr Asp Arg Glu Ser Ser Gly Glu Ala Thr Gln Gly | | | |
| 145 | 150 | 155 | 160 |
| Ala Gly Ala Val Ala Ile Leu Val Ser Ala Asp Pro Lys Val Ala Glu | | | |
| | 165 | 170 | 175 |
| Ile Gly Thr Val Ser Gly Leu Phe Thr Glu Asp Ile Met Asp Phe Trp | | | |
| | 180 | 185 | 190 |
| Arg Pro Asn His Arg Arg Thr Pro Leu Phe Asp Gly Lys Ala Ser Thr | | | |
| | 195 | 200 | 205 |
| Leu Arg Tyr Leu Asn Ala Leu Val Glu Ala Trp Asn Asp Tyr Arg Ala | | | |
| | 210 | 215 | 220 |
| Asn Gly Gly His Glu Phe Ala Asp Phe Ala His Phe Cys Tyr His Val | | | |
| | 225 | 230 | 235 |
| Pro Phe Ser Arg Met Gly Glu Lys Ala Asn Ser His Leu Ala Lys Ala | | | |
| | 245 | 250 | 255 |
| Asn Lys Thr Pro Val Asp Met Gly Gln Val Gln Thr Gly Leu Ile Tyr | | | |
| | 260 | 265 | 270 |
| Asn Arg Gln Val Gly Asn Cys Tyr Thr Gly Ser Ile Tyr Leu Ala Phe | | | |
| | 275 | 280 | 285 |
| Ala Ser Leu Leu Glu Asn Ala Gln Glu Asp Leu Thr Gly Ala Leu Val | | | |
| | 290 | 295 | 300 |
| Gly Leu Phe Ser Tyr Gly Ser Gly Ala Thr Gly Glu Phe Phe Asp Ala | | | |
| | 305 | 310 | 315 |
| Arg Ile Ala Pro Gly Tyr Arg Asp His Leu Phe Ala Glu Arg His Arg | | | |
| | 325 | 330 | 335 |
| Glu Leu Leu Gln Asp Arg Thr Pro Val Thr Tyr Asp Glu Tyr Val Ala | | | |
| | 340 | 345 | 350 |

Leu Trp Asp Glu Ile Asp Leu Thr Gln Gly Ala Pro Asp Lys Ala Arg
 355 360 365

Gly Arg Phe Arg Leu Ala Gly Ile Glu Asp Glu Lys Arg Ile Tyr Val
 370 375 380

Asp Arg Gln Ala
 385

<210> 48

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (5834) .. (6970)

<223> mvk

<400> 48

```

ggatccggca gctcgacacg cgcgagaacc tgtacgaacg tcccgcacgc cgcttcgctg      60
cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgc      120
cccgatcctt gggggccgag gtggcggtga acgccgcccc gcaatcgcgc tttgtcgatc      180
acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg      240
tcgcgcgcgt cacctatctt ggcgggaaat acctgctgga aacctgctg gattgcggca      300
cccggtggtt gaccgagacc cgcgcccgtt tcgatacggg cgcgcagctt ggcctgacca      360
tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca      420
tgggcgtgaa gggccctgcc tgcatacaggc tggatgtcgg cgggatgcgc ctgatacctc      480
attgcgggac cggcccgagc gagggcgagg agttcgaccc cgcttggtg gcggacgcgg      540
atgcgggtgt gatcaccatc gaccacgtgg accatatcgg cggcgcgctt cagcggtctg      600
cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcgggggcgg      660

```

| | |
|--|------|
| atctgcgccct gctgcccga cgcggtgtca cgcggatcgc cggggtcgat ctgacgaccg | 720 |
| gtcgcaacgg gcatgccggc ggcggcgctc ggatgcattt cgacatgggc gaggggctgt | 780 |
| tctattccgg cgactgggtcc gaggaatccg actggttcgc cttegatccg ccccgccctg | 840 |
| cggggacggc gattctcgac tgctcctatg gcggtttcga cgtggcgcaa tcggattgca | 900 |
| tcgcgacact ggacgacctg ctcgagggtc tgccggggca ggtactgctg ccggtgccgc | 960 |
| catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg | 1020 |
| tgatggtcga cgacgcctgc ctgccggcca tcgcgcaact gcccgaggcg cgcggactgg | 1080 |
| cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg | 1140 |
| gcatggcggc atctgcaagc atggcgcat gcgggcaggc tggggcgga cgcgcatgtc | 1200 |
| gtcttcaccg ggcacatgaa cgtccatgcg cgcgcattct gcgaccgcc cggcgggcat | 1260 |
| ttccgccgct ggaacgtgca tccgccgtg cgcgaccagc gacggatgct ggaacggctg | 1320 |
| gccgcggcg cgtttgcccc ggctttctgc cccgaccccg agatctatct ggcgctggac | 1380 |
| atgggcgcgc aggtcttcat gcaccaggag gtgacgccat gatccccgcc cgcagcttct | 1440 |
| gcctgatccg ccacggcgaa acgaccgcca atgcaggggc gatcatcgcg ggcgcaaccg | 1500 |
| atgtgccccct gacgccaaag gcccgcgatc agggccgcgc cctggcaggg cgcgaatggc | 1560 |
| catcgggcat cgcgctgttc gccagcccga tgcgcgtgc ccgcgatacc gcgctgctgg | 1620 |
| cctttccggg gcgcgaccac cagcccgaac ccgatctgcg cgaacgcgac tggggcatct | 1680 |
| tcgagggacg ccccgctgcc gatctgcccc cgcgcgaaat cacgccgcag gggggcgagg | 1740 |
| gctgggacga cgtgatggcc cgcgtggacc gcgcgatccg gcggatctgc gcgacctcg | 1800 |
| gcgatgcgct gccgggtgctg gtctgccatt cgggcgtgat ccgtgccgcg cgcgtgctgt | 1860 |
| ggaccaccgg cgatgcgggc gatcgctcgc ccaacgccac gccgatcctg ttcagcccg | 1920 |
| acggcgaccg attaaaggaa ggaacgatat gaccgccacc accccctgcg tcgtcttcga | 1980 |
| acgtggacgg cacgcttgcc gaattcgac ccgaccgcct gggccatctt gtccacggca | 2040 |
| cgaccaagca ctgggacgcc ttccaccacg cgatggccga cgcgccgcc atccccgagg | 2100 |
| tcgcccgcct gatgcgcaag ctgaaggagg gggcgagac ggtcgtcatc tgctcgggc | 2160 |
| ggccccgcgg ctggcaggat cagacgatcg catggctgcg caagcacgac ctgcccttcg | 2220 |
| acgggatcta tctgcgcccc gaggatcagg acggcgccag cgaccccgag gtcaagcgcc | 2280 |
| gcgccttagc cgagatgcgc gccgacgggc tggcgccctg gctggctgtg gacgacggc | 2340 |
| ggtccgtcgt ggatgcctgg cgggcccagg ggctggtctg cctgcaatgc gcgcggggg | 2400 |

| | | | | | | |
|------------|-------------|-------------|-------------|-------------|-------------|------|
| acttctaggg | ccgcgcgacg | ggggcgcgga | caggctgggc | gggaaaccgc | cccgccacca | 2460 |
| tgtcctgcac | gcgtcgaacc | gcccgtccga | cgccggtttc | cgcacggaaa | cgcgcgggcaa | 2520 |
| gttgacataa | cttgacgcg | acgtctcgat | tctgcccgcg | aagaatgcga | tgcattccaga | 2580 |
| tgatgcagaa | cgaagaagcg | gaagcgcccc | tgaaagacca | gatgatttcc | catacccccg | 2640 |
| tggccacgca | atgggtcggc | ccgatactgt | tccgcggccc | cgtcgtcgag | ggcccgatca | 2700 |
| gcgcgcgcgt | ggccacctac | gagacgccgc | tctggccctc | gaccgcgcgg | ggggcagggg | 2760 |
| tttcccgcca | ttcggggcgg | atccaggtct | cgctggtcga | cgaacgcattg | agccgctcga | 2820 |
| tcgcgctcgc | ggcgcatgac | ggggcgggcg | cgaccgccgc | ctggcagtcg | atcaaggccc | 2880 |
| gccaggaaga | ggtcgcggcc | gtggtcgccca | ccaccagccg | cttcgcccgc | cttgtcgagc | 2940 |
| tgaatcgcca | gatcgtgggc | aacctgcttt | acatccgcat | cgaatgcgtg | acgggcgacg | 3000 |
| cctcggttca | caacatggtc | accaaggccg | ccgaggccgt | gcagggtcgg | atcctgtcgg | 3060 |
| aatacccgat | gctggcctat | tccacgatct | cggggaacct | gtgcaccgac | aagaaggcgt | 3120 |
| cggcggtcaa | cggcatcctg | ggccgcggca | aatacgccgt | cgccgaggtc | gagatcccgc | 3180 |
| gcaagatcct | gaccgcgctg | ctgcgcacca | gcgccgagaa | gatggtcgcg | ctgaactacg | 3240 |
| agaagaacta | tgctgggggt | acgctggcgg | ggctcgtcgc | cagtgcgaac | gcgcatttctg | 3300 |
| ccaacatgct | gctgggcttc | tacctggcga | cggggcagga | cgcggccaac | atcatcgagg | 3360 |
| ccagccaggg | cttcgtccat | tgcgaggccc | gcggcgagga | tctgtatttc | tcgtgcacgc | 3420 |
| tgcccaacct | catcatgggc | tcggtcggtg | ccggcaaggg | catcccctcg | atcgaggaga | 3480 |
| acctgtcgcg | gatgggctgc | cgccagcccg | gcgaaccggg | cgacaacgcg | cgccgtcttg | 3540 |
| cggcgatctg | cgcgggcgtc | gtgctgtgtg | gtgaattgtc | gctgcttgcg | gcccagacca | 3600 |
| accccggaga | gttggtcgcg | accacatgg | agatggagcg | atgaccgaca | gcaaggatca | 3660 |
| ccatgtcgcg | gggcgcaagc | tggaccatct | gcgtgcattg | gacgacgatg | cggatatcga | 3720 |
| ccggggcgac | agcggtctcg | accgcatcgc | gctgacctat | cgcgccctgc | ccgaggtgga | 3780 |
| tttcgacgcc | atcgacacgg | cgaccagctt | cctgggcccgt | gaactgtcct | tcccgtctgt | 3840 |
| gatctcgtcc | atgaccggcg | gcaccggcga | ggagatcgag | cgcattcaacc | gcaacctggc | 3900 |
| cgctgggtcc | gaggaggccc | gcgtcgccat | ggcggtgggc | tcgcagcgcg | tgatgttcac | 3960 |
| cgacccctcg | gcgcggggcca | gcttcgacct | gcgcgcccat | gcgccaccg | tgccgctgct | 4020 |
| ggccaatata | ggcgcggtgc | agctgaacat | ggggctgggg | ctgaaggaat | gcctggccgc | 4080 |

gatcgagggtg ctgcaggcgg acggcctgta tctgcacctg aacccccctgc aagaggccgt 4140
ccagcccagag ggggatcgcg actttgcca tctgggcagc aagatcgcgg ccatcggccg 4200
cgacgttccc gtgcccgtcc tgctgaagga ggtgggctgc ggctgtcgg cgccgatat 4260
cgccatcggg ctgcgcgcgg ggatccggca tttcgacgtg gccggtcgcg gcggcacatc 4320
ctggagccgg atcgagtatc gccgccgcca gcgggccgat gacgacctgg gcctggcttt 4380
ccaggactgg ggcctgcaga ccgtggacgc cctgcgcgag gcgcggcccg cgcttgccgc 4440
ccatgatgga accagcgtgc tgatcgccag cggcggcatc cgcaacggtg tcgacatggc 4500
gaaatgcgtc atcctggggg ccgacatgtg cggggctgcc gcgccctgc tgaaagcggc 4560
ccaaaactcg cgcgaggcgg ttgtatccgc catccggaaa ctgcatctgg agttccggac 4620
agccatgttc ctctggggtt gcggcacgct tgccgacctg aaggacaatt cctcgcttat 4680
ccgtcaatga aagtgcctaa gatgacctg acaggaatcg aagcgatcag cttctacacc 4740
ccccagaact acgtgggact ggatatcctt gccgcgcatc acgggatcga ccccgagaag 4800
ttctcgaagg ggatcgggca ggagaaaatc gcactgcccg gccatgacga ggatatcgtg 4860
accatggccg ccgaggccgc gctgccgatc atcgaacgcg cgggcacgca gggcatcgac 4920
acggttctgt tcgccaccga gagcgggatc gaccagtcga aggcgcgcgc catctatctg 4980
cgccgcctgc tggacctgtc gcccaactgc cgttgcgctg agctgaagca ggctgctat 5040
tccgcgacgg cggcgctgca gatggcctgc gcgcatgtcg cccgcaagcc cgaccgcaag 5100
gtgctggtga tcgcgtccga tgtcgcgcgc tatgaccgcg aaagctcggg cgaggcgacg 5160
cagggtgagg gcgccgtcgc catccttgtc agcgccgatc ccaagtggtg cgagatcggc 5220
accgtctcgg ggctgttcac cgaggatc atggatttct ggcgccgaa ccaccgccgc 5280
acgcccctgt tcgacggcaa ggcacgcagc ctgcgctatc tgaacgcgct ggtcgaggcg 5340
tggaacgact atcgcgcaa tggcgccac gagttcgccg atttcgcgca tttctgctat 5400
cacgtgccgt tctcgcggat gggcgagaag gcgaacagcc acctggccaa ggcaacaag 5460
acgccggtgg acatggggca ggtgcagacg ggcctgatct acaaccggca ggtcgggaac 5520
tgctataccg ggtcgatcta cctggcattc gcctcgtcgc tggagaacgc tcaggaggac 5580
ctgaccggcg cgctggtcgg tctgttcagc tatggctcgg gtgcgacggg cgaattcttc 5640
gatgcgcgga tcgcgcccgg ttaccgcgac cacctgttcg cggaacgcca tcgcgaattg 5700
ctgcaggatc gcacgcccgt cacatatgac gaatacgttg ccctgtggga cgagatcgac 5760
ctgacgcagg gcgcgcccga caaggcgcgc ggtcgtttca ggctggcagg tatcgaggac 5820

| | |
|---|------|
| gagaagcgca tct atg tcg acc ggc agg cct gaa gca ggc gcc cat gcc | 5869 |
| Met Ser Thr Gly Arg Pro Glu Ala Gly Ala His Ala | |
| 1 5 10 | |
| ccg ggc aag ctg atc ctg tcc ggg gaa cat tcc gtg ctc tat ggt gcg | 5917 |
| Pro Gly Lys Leu Ile Leu Ser Gly Glu His Ser Val Leu Tyr Gly Ala | |
| 15 20 25 | |
| ccc gcg ctt gcc atg gcc atc gcc cgc tat acc gag gtg tgg ttc acg | 5965 |
| Pro Ala Leu Ala Met Ala Ile Ala Arg Tyr Thr Glu Val Trp Phe Thr | |
| 30 35 40 | |
| ccg ctt ggc att ggc gag ggg ata cgc acg aca ttc gcc aat ctc tcg | 6013 |
| Pro Leu Gly Ile Gly Glu Gly Ile Arg Thr Thr Phe Ala Asn Leu Ser | |
| 45 50 55 60 | |
| ggc ggc gcg acc tat tcg ctg aag ctg ctg tcg ggg ttc aag tcg cgg | 6061 |
| Gly Gly Ala Thr Tyr Ser Leu Lys Leu Leu Ser Gly Phe Lys Ser Arg | |
| 65 70 75 | |
| ctg gac cgc cgg ttc gag cag ttc ctg aac ggc gac cta aag gtg cac | 6109 |
| Leu Asp Arg Arg Phe Glu Gln Phe Leu Asn Gly Asp Leu Lys Val His | |
| 80 85 90 | |
| aag gtc ctg acc cat ccc gac gat ctg gcg gtc tat gcg ctg gcg tcg | 6157 |
| Lys Val Leu Thr His Pro Asp Asp Leu Ala Val Tyr Ala Leu Ala Ser | |
| 95 100 105 | |
| ctt ctg cac gac aag ccg ccg ggg acc gcc gcg atg ccg ggc atc ggc | 6205 |
| Leu Leu His Asp Lys Pro Pro Gly Thr Ala Ala Met Pro Gly Ile Gly | |
| 110 115 120 | |
| gcg atg cac cac ctg ccg cga ccg ggt gag ctg ggc agc cgg acg gag | 6253 |
| Ala Met His His Leu Pro Arg Pro Gly Glu Leu Gly Ser Arg Thr Glu | |
| 125 130 135 140 | |
| ctg ccc atc ggc gcg ggc atg ggg tcg tct gcg gcc atc gtc gcg gcc | 6301 |
| Leu Pro Ile Gly Ala Gly Met Gly Ser Ser Ala Ala Ile Val Ala Ala | |
| 145 150 155 | |
| acc acg gtc ctg ttc gag acg ctg ctg gac cgg ccc aag acg ccc gaa | 6349 |
| Thr Thr Val Leu Phe Glu Thr Leu Leu Asp Arg Pro Lys Thr Pro Glu | |
| 160 165 170 | |
| cag cgc ttc gac cgc gtc cgc ttc tgc gag cgg ttg aag cac ggc aag | 6397 |
| Gln Arg Phe Asp Arg Val Arg Phe Cys Glu Arg Leu Lys His Gly Lys | |
| 175 180 185 | |
| gcc ggt ccc atc gac gcg gcc agc gtc gtg cgc ggc ggg ctt gtc cgc | 6445 |
| Ala Gly Pro Ile Asp Ala Ala Ser Val Val Arg Gly Gly Leu Val Arg | |
| 190 195 200 | |
| gtg ggc ggg aac ggg ccg ggt tcg atc agc agc ttc gat ttg ccc gag | 6493 |
| Val Gly Gly Asn Gly Pro Gly Ser Ile Ser Ser Phe Asp Leu Pro Glu | |
| 205 210 215 220 | |

| | |
|---|------|
| gat cac gac ctt gtc gcg gga cgc ggc tgg tac tgg gta ctg cac ggg Asp His Asp Leu Val Ala Gly Arg Gly Trp Tyr Trp Val Leu His Gly 225 230 235 | 6541 |
| cgc ccc gtc agc ggg acc ggc gaa tgc gtc agc gcg gtc gcg gcg gcg Arg Pro Val Ser Gly Thr Gly Glu Cys Val Ser Ala Val Ala Ala Ala 240 245 250 | 6589 |
| cat ggt cgc gat gcg gcg ctg tgg gac gcc ttc gca gtc tgc acc cgc His Gly Arg Asp Ala Ala Leu Trp Asp Ala Phe Ala Val Cys Thr Arg 255 260 265 | 6637 |
| gcg ttg gag gcc gcg ctg ctg tct ggg ggc agc ccc gac gcc gcc atc Ala Leu Glu Ala Ala Leu Leu Ser Gly Gly Ser Pro Asp Ala Ala Ile 270 275 280 | 6685 |
| acc gag aac cag cgc ctg ctg gaa cgc atc ggc gtc gtg cgc gca gcg Thr Glu Asn Gln Arg Leu Leu Glu Arg Ile Gly Val Val Pro Ala Ala 285 290 295 300 | 6733 |
| acg cag gcc ctc gtg gcc cag atc gag gag gcg ggt ggc gcg gcc aag Thr Gln Ala Leu Val Ala Gln Ile Glu Glu Ala Gly Gly Ala Ala Lys 305 310 315 | 6781 |
| atc tgc ggc gca ggt tcc gtg cgg ggc gat cac ggc ggg gcg gtc ctc Ile Cys Gly Ala Gly Ser Val Arg Gly Asp His Gly Gly Ala Val Leu 320 325 330 | 6829 |
| gtg cgg att gac gac gcg cag gcg atg gct tgc gtc atg gcg cgc cat Val Arg Ile Asp Asp Ala Gln Ala Met Ala Ser Val Met Ala Arg His 335 340 345 | 6877 |
| ccc gac ctc gac tgg gcg ccc ctg cgc atg tgc cgc acg ggg gcg gca Pro Asp Leu Asp Trp Ala Pro Leu Arg Met Ser Arg Thr Gly Ala Ala 350 355 360 | 6925 |
| ccc ggc ccc gcg ccg cgt gcg caa ccg ctg ccg ggg cag ggc tga Pro Gly Pro Ala Pro Arg Ala Gln Pro Leu Pro Gly Gln Gly 365 370 375 | 6970 |
| tggtatcaggt catccgcgcc agcgcgccgg gtccggtcat gatcacgggc gaacatgccg | 7030 |
| tggtctatgg acaccgcgcc atcgtcgccg ggatcgagca gcgcgcccat gtgacgatcg | 7090 |
| tcccgcgtgc cgaccgcatg ttctgcatca cctcgcatg cggggcgccg cagcaggggt | 7150 |
| cgctggacga tctgcctgcg ggcgggacct atcgcttcgt gctggccgcc atcgcgcgac | 7210 |
| acgcgcggga cctgccttgc gggttcgaca tggacatcac ctccggggatc gatccgaggc | 7270 |
| tcgggcttgg atcctcgccg gcgggtgacgg tcgcctgcct cggcgcgctg tcgcggctgg | 7330 |
| cggggcgggg gaccgagggg ctgcatgacg acgcgtcgcg catcgctccgc gccatccagg | 7390 |
| gcagggggcag cggggccgat ctggcgccca gcctgcatgg cggcttcgtc gcctatcgcg | 7450 |
| cgcccgatgg cgggtcccgcg cagatcgagg cgcttcgggt gccgcccggg ccgttcggcc | 7510 |

tgcgctatgc gggctacaag accccgacag ccgaggtgct ggccttctg gccgatcgga 7570
tggcgggcaa cgaggccgct ttcgacgcgc tctactcccg gatgggcgca agcgagatg 7630
ccgcgatccg cgcgggcgaa gggctggact gggctgcatt ccacgacgcg ctgaacgaat 7690
accagcgcct gatggagcag ctgggcgtgt ccgacgacac gctggacgcg atcatccgcg 7750
aggcgcgca cgcgggcgcc gcagtcgcca agatctcccg ctcggggctg ggggattgcy 7810
tgctggcact gggcgaccag cccaagggtt tcgtgcccgc aagcattgcc gagaaggagc 7870
ttgttttcga tgactgatgc cgtccgcgac atgatcgccc gtgccatggc gggcgcgacc 7930
gacatccgag cagccgaggc ttatgcgccc agcaacatcg cgctgtcgaa atactggggc 7990
aagcgcgacg ccgcgcggaa ccttccgctg aacagctccg tctcgatctc gttggcgaa 8050
tggggctctc atacgcggtt cgaggggtcc ggcacgggccc acgacgaggt gcatcacaac 8110
ggcacgctgc tggatccggg cgacgccttc gcgcgccgcg cgctggcatt cgctgacctg 8170
ttccgggggg ggaggcacct gccgctgcgg atcacgacgc agaactcgat cccgacggcg 8230
gcggggcttg cctcgtcggc ctcggggttc gcggcgctga cccgtgcgct ggcgggggcy 8290
ttcgggctgg atctggacga cacggatctg agccgcacgc cccggatcgg cagtggcagc 8350
gccgcccgt cgatctggca cggcttcgtc cgctggaacc gggcgaggc cgaggatggg 8410
catgacagcc acggcgctcc gctggacctg cgctggccc gcttccgcat cgcgatcgtg 8470
gccgtggaca aggggccc aa gcctttcagt tcgcgcgacg gcatgaacca cacggtcgag 8530
accagcccgc tgttcccgc ctggcctgcg caggcggaag cggattgccg cgatcatcgag 8590
gatgcgatcg ccgcccgcga catggccgcg ctgggtccgc gggtcgaggc gaacgcctt 8650
gcgatgcacg ccacgatgat ggccgcgcgc ccgcccgtct gctacctgac gggcggcagc 8710
tggcaggtgc tggaaacgct gtggcaggcc cgcgcgagc ggcttgcgcc ctttgcgacg 8770
atggatgccg gcccgaaagt caagctgac ttcgaggaaa gcagcgccgc cgacgtgctg 8830
tacctgttcc ccgacgccag cctgatcgcg ccgttcgagg ggcgttgaac gcgtaagacg 8890
accactgggt aaggttctgc cgcgcggtgt ctcgactgcc tgcaaagagg tgcttgagtt 8950
gctgcgtgac tgcggcgccc gacttcgtgg gacttgccc ccacgctgac gcgctggaaa 9010
cgcgcccgcg gattacgacc gcgtcattgc cctgaaccaa tttcccgctg gtcgac 9066

<210> 49

<211> 378

<212> PRT

<213> Paracoccus sp. R114

<400> 49

Met Ser Thr Gly Arg Pro Glu Ala Gly Ala His Ala Pro Gly Lys Leu
 1 5 10 15

Ile Leu Ser Gly Glu His Ser Val Leu Tyr Gly Ala Pro Ala Leu Ala
 20 25 30

Met Ala Ile Ala Arg Tyr Thr Glu Val Trp Phe Thr Pro Leu Gly Ile
 35 40 45

Gly Glu Gly Ile Arg Thr Thr Phe Ala Asn Leu Ser Gly Gly Ala Thr
 50 55 60

Tyr Ser Leu Lys Leu Leu Ser Gly Phe Lys Ser Arg Leu Asp Arg Arg
 65 70 75 80

Phe Glu Gln Phe Leu Asn Gly Asp Leu Lys Val His Lys Val Leu Thr
 85 90 95

His Pro Asp Asp Leu Ala Val Tyr Ala Leu Ala Ser Leu Leu His Asp
 100 105 110

Lys Pro Pro Gly Thr Ala Ala Met Pro Gly Ile Gly Ala Met His His
 115 120 125

Leu Pro Arg Pro Gly Glu Leu Gly Ser Arg Thr Glu Leu Pro Ile Gly
 130 135 140

Ala Gly Met Gly Ser Ser Ala Ala Ile Val Ala Ala Thr Thr Val Leu
 145 150 155 160

Phe Glu Thr Leu Leu Asp Arg Pro Lys Thr Pro Glu Gln Arg Phe Asp
 165 170 175

Arg Val Arg Phe Cys Glu Arg Leu Lys His Gly Lys Ala Gly Pro Ile
 180 185 190

Asp Ala Ala Ser Val Val Arg Gly Gly Leu Val Arg Val Gly Gly Asn
 195 200 205

Gly Pro Gly Ser Ile Ser Ser Phe Asp Leu Pro Glu Asp His Asp Leu
 210 215 220

Val Ala Gly Arg Gly Trp Tyr Trp Val Leu His Gly Arg Pro Val Ser
 225 230 235 240

Gly Thr Gly Glu Cys Val Ser Ala Val Ala Ala His Gly Arg Asp
 245 250 255

Ala Ala Leu Trp Asp Ala Phe Ala Val Cys Thr Arg Ala Leu Glu Ala
 260 265 270

Ala Leu Leu Ser Gly Gly Ser Pro Asp Ala Ala Ile Thr Glu Asn Gln
 275 280 285

Arg Leu Leu Glu Arg Ile Gly Val Val Pro Ala Ala Thr Gln Ala Leu
 290 295 300

Val Ala Gln Ile Glu Glu Ala Gly Gly Ala Ala Lys Ile Cys Gly Ala
 305 310 315 320

Gly Ser Val Arg Gly Asp His Gly Gly Ala Val Leu Val Arg Ile Asp
 325 330 335

Asp Ala Gln Ala Met Ala Ser Val Met Ala Arg His Pro Asp Leu Asp
 340 345 350

Trp Ala Pro Leu Arg Met Ser Arg Thr Gly Ala Ala Pro Gly Pro Ala
 355 360 365

Pro Arg Ala Gln Pro Leu Pro Gly Gln Gly
 370 375

<210> 50

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (6970) .. (7887)

<223> pmk

<400> 50

| | |
|--|------|
| ggatccggca gctcgacacg ccgcagaacc tgtacgaacg tcccgcacgc cgcttcgctg | 60 |
| cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgcg | 120 |
| cccgcatcct gggggccgag gtggcgggtga acgcccgcgc gcaatcgcg cttgtcgatc | 180 |
| acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg | 240 |
| tcgcgcgcgt cacctatctt ggcgggaaat acctgctgga aaccgtgctg gattgcccga | 300 |
| cccggtggt gaccgagacc cgcgcccgt tcgatacggg cgcgcagctt ggctgacca | 360 |
| tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca | 420 |
| tgggcgtgaa gggccctgcc tgcacaggc tggatgtcgg cgggatgcgc ctgacccctg | 480 |
| attgcgggac cggcccggac gagggcgcg agttcgaccc cgcctggctg gcggacgcgg | 540 |
| atgcggtgct gatcacccat gaccacgtgg accatatcgg cggcgcgct caccggtcg | 600 |
| cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcggggcgcg | 660 |
| atctgcgcct gctgcccga cgcggtgtca cgcggatcgc cggggtcgat ctgacgaccg | 720 |
| gtcgcaacgg gcatgccgcg ggcggcgctt ggatgcattt cgacatgggc gaggggctgt | 780 |
| tctattccgg cgactggtcc gaggaatccg actggttcgc cttcgatccg cccccgcctg | 840 |
| cggggacggc gattctcgac tgctcctatg gcggtttcga cgtggcgcaa tcggattgca | 900 |
| tcgcggacct ggacgacctg ctcgaggtgc tgccggggca ggtactgctg ccggtgccgc | 960 |
| catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg | 1020 |
| tgatggtcga cgacgcctgc ctgccggcca tcgcgcaact gcccgaggcg cgcggactgg | 1080 |
| cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg | 1140 |
| gcatggcggc atctgcaagc atggcgcgat gcgggcaggc tggggcggga cgcgcatgtc | 1200 |
| gtcttcaccg ggcacatgaa cgtccatgcg cgcgcattct gcgaccgcc cggcgggcat | 1260 |
| ttccgcgcgt ggaacgtgca tccgcgcgtg cgcgaccagc gacggatgct ggaacggctg | 1320 |
| gccgcggggc gctttgcccc ggcctttctgc cccgaccccg agatctatct ggcgctggac | 1380 |

| | | | | | | |
|-------------|------------|-------------|-------------|------------|-------------|------|
| atgggcgcg | aggtcttcat | gcaccaggag | gtgacgccat | gatccccgcc | cgcagcttct | 1440 |
| gcctgatccg | ccacggcgaa | acgaccgcca | atgcaggggc | gatcatcgcg | ggcgcaaccg | 1500 |
| atgtgcccct | gacgccaagg | ggccgcgatc | aggcccgcg | cctggcaggg | cgcgaatggc | 1560 |
| catcgggcat | cgcgctgttc | gccagcccga | tgtcgcgctg | ccgcgatacc | gcgctgctgg | 1620 |
| cctttccggg | gcgcgaccac | cagcccgaac | ccgatctgcg | cgaacgcgac | tggggcatct | 1680 |
| tcgagggacg | ccccgtcgcc | gatctgcccc | cgcgcgaaat | cacgccgcag | gggggcgagg | 1740 |
| gctgggacga | cgtgatggcc | cgcgtggacc | gcgcatccg | gcggatctgc | gcgacctcgg | 1800 |
| gcgatgcgct | gccggtgctg | gtctgccatt | cggggcgtgat | ccgtgcccg | cgcgtgctgt | 1860 |
| ggaccaccgg | cgatgcgggc | gacgtccgc | ccaacgccac | gccgatectg | ttcagcccgg | 1920 |
| acggcgaccg | attaaaggaa | ggaacgatat | gaccgccacc | acccctcg | tcgtcttcga | 1980 |
| acgtggacgg | cacgcttgcc | gaattcgacg | ccgaccgcct | gggccatctt | gtccacggca | 2040 |
| cgaccaagca | ctgggacgcc | ttccaccacg | cgatggccga | cggccgccc | atccccgagg | 2100 |
| tcgcccgcct | gatgcgcaag | ctgaaggagg | ggggcgagac | ggtcgtcatc | tgctcggggc | 2160 |
| ggccccgcgg | ctggcaggat | cagacgatcg | catggctgcg | caagcacgac | ctgcccttcg | 2220 |
| acgggatcta | tctgcgcccc | gaggatcagg | acggcgccag | cgaccccgag | gtcaagcgcc | 2280 |
| gcgcccctagc | cgagatgcgc | gccgacgggc | tggcgccctg | gctggctcgt | gacgaccggc | 2340 |
| ggtcgctcgt | ggatgcctgg | cgggcccagg | ggctggctct | cctgcaatgc | gcgcccgggg | 2400 |
| acttctaggg | ccgcgcgacg | ggggcgcgga | caggctgggc | gggaaaccgc | cccgccacca | 2460 |
| tgtcctgcac | gcgtcgaaac | gcccgtccga | cgcgggtttc | cgcacggaaa | cgcgcgggaa | 2520 |
| gttgacataa | cttgacacgc | acgtctcgat | tctgcccgcg | agaatgcga | tgcatccaga | 2580 |
| tgatgcagaa | cgaagaagcg | gaagcgcccc | tgaaagacca | gatgatttcc | cataccccg | 2640 |
| tgcccacgca | atgggtcggc | ccgatcctgt | tccgcgcccc | cgtcgtcgag | ggcccgatca | 2700 |
| gcgcgccgct | ggccacctac | gagacgcgc | tctggccctc | gaccgcgcgg | ggggcagggg | 2760 |
| tttcccggca | ttcgggcggg | atccaggctc | cgctggctga | cgaacgcag | agccgctcga | 2820 |
| tcgcgctcgc | ggcgcatgac | ggggcgcgcg | cgaccgcgc | ctggcagtcg | atcaaggccc | 2880 |
| gccaggaaga | ggtcgcgccc | gtggctcgcca | ccaccagccc | cttcgccccg | cttgctcgagc | 2940 |
| tgaatcgcca | gatcgtgggc | aacctgcttt | acatccgcat | cgaatgcgtg | acgggcgacg | 3000 |
| cctcggttca | caacatggtc | accaaggccc | ccgaggccgt | gcagggctgg | atcctgtcgg | 3060 |

aatacccgat gctggcctat tccacgatct cggggaacct gtgcaccgac aagaaggcgt 3120
cggcgggtcaa cggcatcctg ggccgcggca aatacgccgt cgccgaggtc gagatcccgc 3180
gcaagatcct gacccgcgtg ctgcgcacca gcgccgagaa gatgggccgc ctgaactacg 3240
agaagaacta tgtcgggggt acgctggcgg ggctcgtcgc cagtgcgaac gcgcatttcg 3300
ccaacatgct gctgggcttc tacctggcga cggggcagga cgccggccaac atcatcgagg 3360
ccagccaggg ctctgtccat tgcgaggccc gcggcgagga tctgtatttc tcgtgcacgc 3420
tgcccaacct catcatgggc tcggtcggtg ccggcaaggg catcccctcg atcgaggaga 3480
acctgtcgcg gatgggctgc cgccagccgg gcgaacccgg cgacaacgcg cgccgtcttg 3540
cggcgatctg cgccggcgtc gtgctgtgtg gtgaattgtc gctgcttgcg gccagacca 3600
accccgagga gttgggccgc acccatgag agatggagcg atgaccgaca gcaaggatca 3660
ccatgtcgcg ggccgcaagc tggaccatct gcgtgcattg gacgacgatg cggatatcga 3720
ccggggcgac agcggcttcg accgcacgcg gctgacccat cgcgccctgc ccgagggtga 3780
tttcgacgcc atcgacacgg cgaccagctt cctgggccgt gaactgtcct tcccgtgct 3840
gatctcgtcc atgaccggcg gcaccggcga ggagatcgag cgcaccaacc gcaacctggc 3900
cgctggtgcc gaggaggccc gcgtcgccat ggccgtgggc tcgcagcgcg tgatgttcac 3960
cgacccctcg gcgcgggcca gcttcgacct gcgcgccat gcgccaccg tgccgtgct 4020
ggccaatatc ggccgggtgc agctgaacat ggggctgggg ctgaaggaaat gcctggccgc 4080
gatcgagggtg ctgcaggcgg acggcctgta tctgcacctg aacccctgc aagaggccgt 4140
ccagcccgag ggggatcgcg actttgccga tctgggcagc aagatcgcg ccacgcgccg 4200
cgacgttccc gtgccgtcc tgctgaagga ggtgggctgc ggccgtcgc cggccgatat 4260
cgccatcggg ctgcgcgccg ggatccggca ttctgacgtg gccggtcgcg gcggcacatc 4320
ctggagccgg atcgagtatc gccgcccca gcggccgat gacgacctgg gcctggtctt 4380
ccaggactgg ggccctgcaga ccgtggacgc cctgcgcgag gcgcggcccg cgcttgccgc 4440
ccatgatgga accagcgtgc tgatcgccag cggcgccatc cgcaacggtg tcgacatggc 4500
gaaatgcgtc atcctggggg ccgacatgtg cggggtcgcc gcgccctgc tgaaagcggc 4560
ccaaaactcg cgcgaggcgg ttgtatccgc catccggaaa ctgcatctgg agttccggac 4620
agccatgttc ctccctgggtt gcggcacgct tgccgacctg aaggacaatt cctcgcttat 4680
ccgtcaatga aagtgcctaa gatgaccgtg acaggaatcg aagcgatcag cttctacacc 4740
ccccagaact acgtgggact ggatatcctt gccgcgcac acgggatcga ccccgagaag 4800

ttctcgaagg ggatcgggca ggagaaaatc gcactgcccc gccatgacga ggatatcgtg 4860
accatggccg ccgaggccgc gctgccgac atcgaacgcg cgggcacgca gggcatcgac 4920
acgggttctgt tcgccaccga gagcgggacg gaccagtcca aggcggccgc catctatctg 4980
cgccgcctgc tggacctgtc gcccaactgc cgttgcgctc agctgaagca ggcctgctat 5040
tccgcgacgg cggcgctgca gatggcctgc gcgcatgtcg cccgaagcc cgaccgaag 5100
gtgctggtga tcgcgtccga tgcgcgcgc tatgaccgcg aaagctcggg cgaggcgacg 5160
cagggtgccg gcgccgtcgc catccttgtc agcggcgac ccaagggtggc cgagatcggc 5220
accgtctcgg ggctgttcac cgaggatata atggatttct ggcggccgaa ccaccgccgc 5280
acgccccgt tcgacggcaa ggcacgacg ctgcgctatc tgaacgcgct ggtcgaggcg 5340
tggaacgact atcgcgcgaa tggcgccac gagttcgccg atttcgcgca tttctgctat 5400
cacgtgccgt tctcgcggat gggcgagaag gcgaacagcc acctggccaa ggcgaacaag 5460
acgccggtgg acatggggca ggtgcagacg ggcctgatct acaaccggca ggtcgggaac 5520
tgctataccg ggtcgatcta cctggcatct gcctcgctgc tggagaacgc tcaggaggac 5580
ctgaccggcg cgctggtcgg tctgttcagc tatggctcgg gtgcgacggg cgaattcttc 5640
gatgcgcgga tcgcgccccg ttaccgcgac cacctgttcg cggaacgcca tcgcgaattg 5700
ctgcaggatc gcacgccccg cacatatgac gaatacgttg ccctgtggga cgagatcgac 5760
ctgaecgagg gcgcgccccg caaggcgccg ggtcgtttca ggctggcagg tatcgaggac 5820
gagaagcgca tctatgtcga ccggcaggcc tgaagcaggc gcccatgcc cgggcaagct 5880
gatcctgtcc ggggaacatt ccgtgctcta tggtcgcccc gcgcttgcca tggccatcgc 5940
ccgctatacc gaggtgtggt tcacgcccgt tggcattggc gaggggatac gcacgacatt 6000
cgccaatctc tcggggcggg cgacctatct gctgaagctg ctgtcggggg tcaagtcgcg 6060
gctggaccgc cgttcgagc agttcctgaa cggcgacctc aaggtgcaca aggtcctgac 6120
ccatcccgac gatctggcgg tctatgcgct ggcgtcgctt ctgcacgaca agccgcccgg 6180
gaccgcccgc atgccgggca tcggcgcgat gcaccacctg ccgcgaccgg gtgagctggg 6240
cagccggacg gagctgcccc tcggcgcggg catggggctc tctgcccga tcgtcgcggc 6300
caccacggtc ctgttcgaga cgctgctgga ccggcccaag acgcccgaac agcgcttcga 6360
ccgcgtccgc ttctgcgagc ggttgaagca cggcaaggcc ggtcccatcg acgcggccag 6420
cgctcgtcgc ggcgggcttg tccgcgtggg cgggaacggg ccgggttcga tcagcagctt 6480

| | | | | | | |
|---|---|---|------------|------------|-------------|------|
| cgattttgcc | gaggatcacg | accttgctgc | gggacgcggc | tggtactggg | tactgcacgg | 6540 |
| gcgccccgtc | agcgggaccg | gcgaatgcgt | cagcgcggtc | gcggcggcgc | atggctcgca | 6600 |
| tgcggcgctg | tgggacgcct | tcgcagtctg | cacccgcgcg | ttggaggccg | cgctgctgtc | 6660 |
| tgggggcagc | cccgcgcgcg | ccatcaccga | gaaccagcgc | ctgctggaac | gcatcggcgt | 6720 |
| ctgtccggca | gcgacgcagg | ccctcgtggc | ccagatcgag | gaggcgggtg | gcgcggccaa | 6780 |
| gatctgcggc | gcaggttccg | tgcggggcga | tcacggcggg | gcggtcctcg | tgcggtattga | 6840 |
| cgacgcgcag | gcgatggctt | cggtcatggc | gcgccatccc | gacctcgact | gggcgcccct | 6900 |
| gcgcatgtcg | cgacgggggg | cggcacccgg | ccccgcgcgc | cgctgcgaac | cgctgccggg | 6960 |
| gcagggctg | atg gat cag gtc atc cgc gcc agc gcg ccg ggt tcg gtc atg | Met Asp Gln Val Ile Arg Ala Ser Ala Pro Gly Ser Val Met | 7011 | | | |
| | 1 | 5 | 10 | | | |
| atc acg ggc gaa cat gcc gtg gtc tat gga cac cgc gcc atc gtc gcc | 7059 | | | | | |
| Ile Thr Gly Glu His Ala Val Val Tyr Gly His Arg Ala Ile Val Ala | | | | | | |
| 15 | 20 | 25 | 30 | | | |
| ggg atc gag cag cgc gcc cat gtg acg atc gtc ccg cgt gcc gac cgc | 7107 | | | | | |
| Gly Ile Glu Gln Arg Ala His Val Thr Ile Val Pro Arg Ala Asp Arg | | | | | | |
| 35 | 40 | 45 | | | | |
| atg ttt cgc atc acc tcg cag atc ggg gcg ccg cag cag ggg tcg ctg | 7155 | | | | | |
| Met Phe Arg Ile Thr Ser Gln Ile Gly Ala Pro Gln Gln Gly Ser Leu | | | | | | |
| 50 | 55 | 60 | | | | |
| gac gat ctg cct gcg ggc ggg acc tat cgc ttc gtg ctg gcc gcc atc | 7203 | | | | | |
| Asp Asp Leu Pro Ala Gly Gly Thr Tyr Arg Phe Val Leu Ala Ala Ile | | | | | | |
| 65 | 70 | 75 | | | | |
| gcg cga cac gcg ccg gac ctg cct tgc ggg ttc gac atg gac atc acc | 7251 | | | | | |
| Ala Arg His Ala Pro Asp Leu Pro Cys Gly Phe Asp Met Asp Ile Thr | | | | | | |
| 80 | 85 | 90 | | | | |
| tcg ggg atc gat ccg agg ctc ggg ctt gga tcc tcg gcg gcg gtg acg | 7299 | | | | | |
| Ser Gly Ile Asp Pro Arg Leu Gly Leu Gly Ser Ser Ala Ala Val Thr | | | | | | |
| 95 | 100 | 105 | 110 | | | |
| gtc gcc tgc ctc ggc gcg ctg tcg cgg ctg gcg ggg cgg ggg acc gag | 7347 | | | | | |
| Val Ala Cys Leu Gly Ala Leu Ser Arg Leu Ala Gly Arg Gly Thr Glu | | | | | | |
| 115 | 120 | 125 | | | | |
| ggg ctg cat gac gac gcg ctg cgc atc gtc cgc gcc atc cag ggc agg | 7395 | | | | | |
| Gly Leu His Asp Asp Ala Leu Arg Ile Val Arg Ala Ile Gln Gly Arg | | | | | | |
| 130 | 135 | 140 | | | | |
| ggc agc ggg gcc gat ctg gcg gcc agc ctg cat ggc ggc ttc gtc gcc | 7443 | | | | | |
| Gly Ser Gly Ala Asp Leu Ala Ala Ser Leu His Gly Gly Phe Val Ala | | | | | | |
| 145 | 150 | 155 | | | | |
| tat cgc gcg ccc gat ggc ggt gcc gcg cag atc gag gcg ctt ccg gtg | 7491 | | | | | |

| | | | | | | | | | | | | | | | | | |
|-------------|-------------|-------------|------------|------------|------------|------------|-------------|-----|-----|-----|-----|-----|-----|-----|-----|------|--|
| Tyr | Arg | Ala | Pro | Asp | Gly | Gly | Ala | Ala | Gln | Ile | Glu | Ala | Leu | Pro | Val | | |
| 160 | | | | | | 165 | | | | | 170 | | | | | | |
| ccg | ccg | ggg | ccg | ttc | ggc | ctg | cgc | tat | gcg | ggc | tac | aag | acc | ccg | aca | 7539 | |
| Pro | Pro | Gly | Pro | Phe | Gly | Leu | Arg | Tyr | Ala | Gly | Tyr | Lys | Thr | Pro | Thr | | |
| 175 | | | | | 180 | | | | 185 | | | | | 190 | | | |
| gcc | gag | gtg | ctg | cgc | ctt | gtg | gcc | gat | cgg | atg | gcg | ggc | aac | gag | gcc | 7587 | |
| Ala | Glu | Val | Leu | Arg | Leu | Val | Ala | Asp | Arg | Met | Ala | Gly | Asn | Glu | Ala | | |
| | | | | 195 | | | | 200 | | | | | | 205 | | | |
| gct | ttc | gac | gcg | ctc | tac | tcc | cgg | atg | ggc | gca | agc | gca | gat | gcc | gcg | 7635 | |
| Ala | Phe | Asp | Ala | Leu | Tyr | Ser | Arg | Met | Gly | Ala | Ser | Ala | Asp | Ala | Ala | | |
| | | | 210 | | | | | 215 | | | | | 220 | | | | |
| atc | cgc | gcg | gcg | caa | ggg | ctg | gac | tgg | gct | gca | ttc | cac | gac | gcg | ctg | 7683 | |
| Ile | Arg | Ala | Ala | Gln | Gly | Leu | Asp | Trp | Ala | Ala | Phe | His | Asp | Ala | Leu | | |
| | | 225 | | | | 230 | | | | | 235 | | | | | | |
| aac | gaa | tac | cag | cgc | ctg | atg | gag | cag | ctg | ggc | gtg | tcc | gac | gac | acg | 7731 | |
| Asn | Glu | Tyr | Gln | Arg | Leu | Met | Glu | Gln | Leu | Gly | Val | Ser | Asp | Asp | Thr | | |
| | 240 | | | | | 245 | | | | | 250 | | | | | | |
| ctg | gac | gcg | atc | atc | cgc | gag | gcg | cgc | gac | gcg | ggc | gcc | gca | gtc | gcc | 7779 | |
| Leu | Asp | Ala | Ile | Ile | Arg | Glu | Ala | Arg | Asp | Ala | Gly | Ala | Ala | Val | Ala | | |
| 255 | | | | | 260 | | | | | 265 | | | | 270 | | | |
| aag | atc | tcc | ggc | tcg | ggg | ctg | ggg | gat | tgc | gtg | ctg | gca | ctg | ggc | gac | 7827 | |
| Lys | Ile | Ser | Gly | Ser | Gly | Leu | Gly | Asp | Cys | Val | Leu | Ala | Leu | Gly | Asp | | |
| | | | 275 | | | | | 280 | | | | | | 285 | | | |
| cag | ccc | aag | ggt | ttc | gtg | ccc | gca | agc | att | gcc | gag | aag | gga | ctt | ggt | 7875 | |
| Gln | Pro | Lys | Gly | Phe | Val | Pro | Ala | Ser | Ile | Ala | Glu | Lys | Gly | Leu | Val | | |
| | | 290 | | | | | | 295 | | | | | 300 | | | | |
| ttc | gat | gac | tga | tgccgtccgc | gacatgatcg | cccgtgccat | ggcggggcgcg | | | | | | | | | 7927 | |
| Phe | Asp | Asp | | | | | | | | | | | | | | | |
| | | 305 | | | | | | | | | | | | | | | |
| accgacatcc | gagcagccga | ggcttatgcg | cccagcaaca | tcgcgctgtc | gaaatactgg | | | | | | | | | | | 7987 | |
| ggcaagcgcg | acgcgcgcgcg | gaaccttccg | ctgaacagct | ccgtctcgat | ctcgttggcg | | | | | | | | | | | 8047 | |
| aactggggct | ctcatagcgcg | ggtcgagggg | tccggcacgg | gccacgacga | ggtgcatcac | | | | | | | | | | | 8107 | |
| aacggcacgc | tgctggatcc | gggcgacgcc | ttcgcgcgcc | gcgcgttggc | attcgctgac | | | | | | | | | | | 8167 | |
| ctgttccggg | gggggaggca | cctgccgctg | cggatcacga | cgcagaactc | gatcccgacg | | | | | | | | | | | 8227 | |
| gcggcggggg | ttgcctcgtc | ggcctcgggg | ttcgcggcgc | tgacctgtgc | gctggcgggg | | | | | | | | | | | 8287 | |
| gcgttcgggc | tggatctgga | cgacacggat | ctgagccgca | tcgcccggat | cggcagtggc | | | | | | | | | | | 8347 | |
| agcgccgccc | gctcgatctg | gcacggcttc | gtccgctgga | accggggcga | ggccgaggat | | | | | | | | | | | 8407 | |
| gggcgatgaca | gccacggcgt | cccgcctggac | ctgcgctggc | ccggcttccg | catacgcatc | | | | | | | | | | | 8467 | |

gtggccgtgg acaagggggcc caagcctttc agttcgcgcg acggcatgaa ccacacggtc 8527
gagaccagcc cgctgttccc gccctggcct gcgcaggcgg aagcggattg ccgcgtcatc 8587
gaggatgcca tcgccgcccg cgacatggcc gccctgggtc cgcgggtcga ggcgaaacgcc 8647
cttgcatgac acgccacgat gatggccgcg cgcgcgccgc tctgctacct gacgggcggc 8707
agctggcagg tgctggaacg cctgtggcag gcccgcgagg acgggcttgc ggcctttgag 8767
acgatggatg ccggcccga cgtcaagctg atcttcgagg aaagcagcgc cgcgcagctg 8827
ctgtacctgt tccccgacgc cagcctgacg gcgcggttcg aggggcgttg aacgcgtaag 8887
acgaccactg ggtaagggtc tgccgcgcgt ggtctcgact gcctgcaaag aggtgcttga 8947
gttgctgcgt gactgcggcg gccgacttcg tgggacttgc ccgccacgct gacgcgctgg 9007
aaacgcgccc gcggattacg accgcgtcat tgccctgaac caatttcccg tcggtcgac 9066

<210> 51

<211> 305

<212> PRT

<213> Paracoccus sp. R114

<400> 51

Met Asp Gln Val Ile Arg Ala Ser Ala Pro Gly Ser Val Met Ile Thr
1 5 10 15

Gly Glu His Ala Val Val Tyr Gly His Arg Ala Ile Val Ala Gly Ile
20 25 30

Glu Gln Arg Ala His Val Thr Ile Val Pro Arg Ala Asp Arg Met Phe
35 40 45

Arg Ile Thr Ser Gln Ile Gly Ala Pro Gln Gln Gly Ser Leu Asp Asp
50 55 60

Leu Pro Ala Gly Gly Thr Tyr Arg Phe Val Leu Ala Ala Ile Ala Arg
65 70 75 80

His Ala Pro Asp Leu Pro Cys Gly Phe Asp Met Asp Ile Thr Ser Gly
85 90 95

Ile Asp Pro Arg Leu Gly Leu Gly Ser Ser Ala Ala Val Thr Val Ala
 100 105 110

Cys Leu Gly Ala Leu Ser Arg Leu Ala Gly Arg Gly Thr Glu Gly Leu
 115 120 125

His Asp Asp Ala Leu Arg Ile Val Arg Ala Ile Gln Gly Arg Gly Ser
 130 135 140

Gly Ala Asp Leu Ala Ala Ser Leu His Gly Gly Phe Val Ala Tyr Arg
 145 150 155 160

Ala Pro Asp Gly Gly Ala Ala Gln Ile Glu Ala Leu Pro Val Pro Pro
 165 170 175

Gly Pro Phe Gly Leu Arg Tyr Ala Gly Tyr Lys Thr Pro Thr Ala Glu
 180 185 190

Val Leu Arg Leu Val Ala Asp Arg Met Ala Gly Asn Glu Ala Ala Phe
 195 200 205

Asp Ala Leu Tyr Ser Arg Met Gly Ala Ser Ala Asp Ala Ala Ile Arg
 210 215 220

Ala Ala Gln Gly Leu Asp Trp Ala Ala Phe His Asp Ala Leu Asn Glu
 225 230 235 240

Tyr Gln Arg Leu Met Glu Gln Leu Gly Val Ser Asp Asp Thr Leu Asp
 245 250 255

Ala Ile Ile Arg Glu Ala Arg Asp Ala Gly Ala Ala Val Ala Lys Ile
 260 265 270

Ser Gly Ser Gly Leu Gly Asp Cys Val Leu Ala Leu Gly Asp Gln Pro
 275 280 285

Lys Gly Phe Val Pro Ala Ser Ile Ala Glu Lys Gly Leu Val Phe Asp
 290 295 300

Asp
 305

<210> 52

<211> 9066

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (7880) .. (8878)

<223> mvd

<400> 52

```

ggatccggca gctcgacacg ccgcagaacc tgtacgaacg tcccgccagc cgcttcgctc 60
cggaattcgt cgggcgcggg acggtggtgc ccgtgcaggc ccatgacggc gcgggcccgc 120
cccgcatcct gggggccgag gtggcggtga acgccgccc gcaatcgcg cttgtcgatc 180
acgtctgcct gcgccccgag aaccttgcca tctccgagac gggcgacctg cgcgccaagg 240
tcgcgcgctt cacctatctt ggcgggaaat acctgctgga aaccgtgctg gattgcgcca 300
cccggttgtt gaccgagacc cgcgcccgtt tcgatacggg cgcgcagctt ggctgacca 360
tcaacgcccc ctgggccttt gccgaggatt gaatggacag cgtgaagatc ctttcgggca 420
tgggctgtaa gggccctgcc tgcatacaggc tggatgtcgg cgggatgcgc ctgatacctc 480
attgcgggac cggcccggac gagggcgcg agttcgaccc cgcctggctg gcggacgcgg 540
atgcggtgct gatcacccat gaccacgtgg accatatcgg cggcgcgctt caccggtcgc 600
cggcggggct gccgatccat gcgacgcggc agacggcggg gttgctgccc gcgggggcgg 660
atctgcgcct gctgcccgaa cgcggtgtca cgcggatcgc cggggtcgat ctgacgaccg 720
gtcgcaacgg gcatgccgcg ggcggcgctt ggatgcattt cgacatgggc gaggggctgt 780
tctattccgg cgactggctc gaggaatccg actggttcgc cttcgatccg cccccgctc 840
cggggacggc gattctcgac tgctcctatg gcggtttcga cgtggcgcaa tcggattgca 900
tcgcggaact ggacgacctg ctcgaggtgc tgccggggca ggtactgctg ccggtgccgc 960
catccggccg cgcggccgag ctggccctgc ggctgatccg ccgccacgga ccgggcagcg 1020
tgatggtcga cgacgcctgc ctgccggcca tcgcgcaact gcccaggcgg cgcggactgg 1080
cctacgccac cgaggcacgc tttcttgtct gcgacacgcc gaacgccgaa agccggcgcg 1140

```

| | |
|---|------|
| gcatggcggc atctgcaagc atggcgcgat gcgggcaggc tggggcgggg cgcgcatgtc | 1200 |
| gtcttcaccg ggcacatgaa cgtccatgcy cgcgattctt gcgaccgccc cggcgggcat | 1260 |
| ttccgcccgt ggaacgtgca tccgcccgtg cgcgaccagc gacggatgct ggaacggctg | 1320 |
| gcgcgcgggc gcttttgcccc ggccttctgc cccgaccccg agatctatct-ggcgtggac | 1380 |
| atggcgcgcg aggtcttcat gcaccaggag gtgacgccat gatccccgcc cgcagcttct | 1440 |
| gcctgatccg ccacggcgaa acgaccgcca atgcaggggc gatcatcgcy ggcgaaccg | 1500 |
| atgtgcccct gacgccaagg ggccgcyatc agggccgcy cctggcaggg cgcgaatggc | 1560 |
| catcgggcat cgcgctgttc gccagcccga tgtcgcytgc ccgcyatacc gcgctgctgg | 1620 |
| cctttccggg gcgcyaccac cagcccgaac ccgatctgcy cgaacgcgac tggggcatct | 1680 |
| tcgagggagc ccccgctgcc gatctgcccc cgcgcyaaat cagcccgcy gggggcgagg | 1740 |
| gctgggacga cgtgatggc cgcggtggac gcgcyatccg gcgcyatgcy gcgacctcg | 1800 |
| gcgatcgct gccggtgctg gtctgccatt cgggcgtgat ccgtgccgcy cgcgtgctgt | 1860 |
| ggaccaccg cyatgcggc gatcgtccgc ccaacgccac gccgatcctg ttcagcccg | 1920 |
| acggcgaccg attaaaggaa ggaacgatat gaccgccacc accccctgcy tcgtcttga | 1980 |
| acgtggacgg cagccttgcc gaattcgcy ccgaccgct gggccatctt gtccacggca | 2040 |
| cgaccaagca ctgggacgcc ttccaccacy cyatggccga cggccgccc atccccgagg | 2100 |
| tcgcccgcct gatcgcyaa ctgaaggagg ggggcgagac ggtcgtcatc tgctcgggg | 2160 |
| ggccccgcy ctggcaggat cagacgatcy catggctgcy caagcacgac ctgcccttcg | 2220 |
| acgggatcta tctcgcccc gaggatcagg acggcgccag cgaccccgag 'gtcaagcgcc | 2280 |
| gcgcccctagc cgagatgcgc gccgacggc tggcgccctg gctggtcgtg gacgaccggc | 2340 |
| ggtccgtcgt ggatgcctg cgggcccagg ggctggtctg cctgcaatgc gcgccccggg | 2400 |
| acttctaggg ccgcygcyg ggggcgcyga caggctggc gggaaaccgc cccgccacca | 2460 |
| tgtcctgcac gcgtcgaacc gcccgctcga cggcggttc cgcacggaaa cgcgcygcaa | 2520 |
| gttgacataa ctgcyacgcy acgtctcgat tctgccccg aagaatgcy tgcatccaga | 2580 |
| tgatgcagaa cgaagaagcy gaagcggccg tgaaagacca gatgatttcc cataccccg | 2640 |
| tgccacgca atgggtcgc ccgatcctgt tccgcyccc cgtcgtcgag ggcccgatca | 2700 |
| gcgcyccgct ggccacctac gagacggcy tctggccctc gaccgcyg ggggcagggg | 2760 |
| tttcccgca ttcgggcggg atccaggtct cgtggtcga cgaacgcatg agccgctcga | 2820 |

| | |
|--|------|
| tcgcgctgcg ggcgcacgac ggggcggcgg cgaccgccgc ctggcagtcg atcaaggccc | 2880 |
| gccaggaaga ggtcgcggcc gtggtcgcca ccaccagccg cttegccgcg cttgtcgagc | 2940 |
| tgaatcgcca gatcgtgggc aacctgcttt acatccgcac cgaatgcgtg acgggcgagc | 3000 |
| cctcgggtca caacatggtc accaaggccg ccgaggccgt gcagggctgg atcctgtcgg | 3060 |
| aatacccgat gctggcctat tccacgatct cggggaacct gtgcaccgac aagaaggcgt | 3120 |
| cggcgggtcaa cggcaccctg ggccgcggca aatacgccgt cgccgaggtc gagatcccgc | 3180 |
| gcaagatcct gaccgcgtg ctgcgcacca gcgccgagaa gatggtccgc ctgaactacg | 3240 |
| agaagaacta tgtcgggggt acgctggcgg ggtcgcctgc cagtgcgaac gcgcatttcg | 3300 |
| ccaacatgct gctgggcttc tacctggcga cggggcagga cgccgccaac atcatcgagg | 3360 |
| ccagccaggg cttegtccat tgcgaggccc gcggcgagga tctgtatttc tcgtgcacgc | 3420 |
| tgcccaacct catcatgggc tgggtcgggt ccggcaaggg catcccctcg atcgaggaga | 3480 |
| acctgtcgcg gatgggctgc cgccagccgg gcgaaccgg cgacaacgcg cgccgtcttg | 3540 |
| cggcgatctg cgccggcgctc gtgctgtgtg gtgaattgtc gctgcttgcg gccagacca | 3600 |
| accccgagga gttggtccgc acccacatgg agatggagcg atgaccgaca gcaaggatca | 3660 |
| ccatgtcgcg gggcgcaagc tggaccatct gcgtgcattg gacgacgat cgcatatcga | 3720 |
| cggggcgac agcggcttcg accgcacgc gctgaccat cgccccctgc ccgagggtgga | 3780 |
| tttcgacgcc atcgacacgg cgaccagctt cctgggccgt gaactgtcct tcccgtgct | 3840 |
| gatctcgtcc atgaccggcg gcaccggcga ggagatcgag cgcatcaacc gcaacctggc | 3900 |
| cgctgggtgc gaggaggccc gcgtcgccat ggcggtgggc tcgcagcgcg tgatgttcac | 3960 |
| cgacccctcg gcgcgggcca gcttcgacct gcgcgcccat gcgccaccg tgccgtgct | 4020 |
| ggccaatata ggcgcgggtgc agctgaacat ggggctgggg ctgaaggaat gcctggccgc | 4080 |
| gatcgagggt ctgcaggcgg acggcctgta tctgcacctg aacccctgc aagaggccgt | 4140 |
| ccagcccag ggggatcgcg actttgccga tctgggcagc aagatcgcg ccacgccccg | 4200 |
| cgacgttccc gtgcccgtcc tgctgaagga ggtgggctgc ggcctgtcgg cgccgatata | 4260 |
| cgccatcggg ctgcgcgccg ggatccggca ttctgacgtg gccggtcgcg gcggcacatc | 4320 |
| ctggagccgg atcgagtat gccgcgcga gcgggccgat gacgacctg gcctggtctt | 4380 |
| ccaggactgg ggcctgcaga ccgtggacgc cctgcgcgag gcgcggcccc cgcttgccggc | 4440 |
| ccatgatgga accagcgtgc tgatcgccag cggcggcac cgcaacgggt tcgacatggc | 4500 |
| gaaatgcgtc atcctggggg ccgacatgtg cggggtcgcc gcgccctgc tgaaagcggc | 4560 |

ccaaaactcg cgcgaggcgg ttgtatccgc catccggaaa ctgcatctgg agttccggac 4620
 agccatgttc ctctggggtt ggggcacgct tgccgacctg aaggacaatt cctcgcttat 4680
 ccgtcaatga aagtgcctaa gatgaccgtg acaggaatcg aagcgatcag cttctacacc 4740
 ccccagaact acgtgggact ggatatacctt gccgcgcacg acgggatcga-ccccgagaag 4800—
 ttctcgaagg ggatcgggca ggagaaaatc gcaactgccg gccatgacga ggatatacgtg 4860
 accatggcgg ccgaggccgc gctgccgacg atcgaacgcg cgggcacgca gggcatcgac 4920
 acggttctgt tcgccaccga gagcgggacg gaccagtcga aggcgcgcgc catctatctg 4980
 cgccgcctgc tggacctgtc gcccaactgc cggtgcgctg agctgaagca ggctgctat 5040
 tccgcgacgg cggcgctgca gatggcctgc gcgcatgtcg cccgcaagcc cgaccgcaag 5100
 gtgctggtga tcgcgtccga tgcgcgcgcg tatgaccgcg aaagctcggg cgaggcgacg 5160
 caggggtcgg gcgcgctgcg catccttgct agcgccgacg ccaaggtggc cgagatcggc 5220
 accgtctcgg ggctgttcac cgaggatata atggatttct ggcgccgcaa ccaccgcccgc 5280
 acgcccctgt tcgacggcaa ggcacgacg ctgcgctatc tgaacgcgct ggtcgaggcg 5340
 tggaacgact atcgcgcgaa tggcgccacg gagttcgccg atttcgcgca tttctgctat 5400
 cacgtgccgt tctcgcggat gggcgagaag gcgaacagcc acctggccaa ggcaacaag 5460
 acgccggtgg acatggggca ggtgcagacg ggctgatct acaaccggca ggtcgggaac 5520
 tgctataacc ggtcgatcta cctggcattc gcctcgctgc tggagaacgc tcaggaggac 5580
 ctgaccggcg cgctggtcgg tctgttcagc tatggctcgg gtgcgacggg cgaattcttc 5640
 gatgcgcgga tcgcgcccgg ttaccgcgac cacctgttcg cggaacgcca tcgcgaattg 5700
 ctgcaggatc gcacgcccgt cacatatgac gaatacgttg ccctgtggga cgagatcgac 5760
 ctgacgcagg gcgcgcccga caaggcgcgc ggtcgtttca ggctggcagg tatcgaggac 5820
 gagaagcgca tctatgtcga ccggcaggcc tgaagcaggc gcccatgccc cgggcaagct 5880
 gatcctgtcc ggggaacatt ccgtgctcta tggcgccccc gcgcttgcca tggccatcgc 5940
 ccgctatacc gaggtgtggt tcacgcccgt tggcattggc gaggggatàc gcacgacatt 6000
 cgccaatctc tcgggcgggg cgacctatc gctgaagctg ctgtcggggg tcaagtgcgc 6060
 gctggaccgc cggttcgagc agttcctgaa cggcgaccta aaggtgcaca aggtcctgac 6120
 ccateccgac gatctggcgg tctatgcgct ggcgtcgctt ctgcacgaca agccgcccgg 6180
 gaccgcccgc atgccgggca tcggcgcgat gcaccacctg ccgcgaccgg gtgagctggg 6240

cagccggacg gagctgcccc tcggcgcggg catgggggtcg tctgcggcca tcgtcgcggc 6300
 caccacgggtc ctgttcgaga cgctgctgga cgggcccaag acgcccgaac agcgcttcga 6360
 ccgcgtccgc ttctgcgagc ggttgaagca cggcaaggcc ggtcccatcg acgcggccag 6420
 cgctgtgcgc ggcgggcttg tccgcgtggg cgggaacggg cggggttcga tcagcagctt 6480
 cgatttgccc gaggatcacg accttgtcgc gggacgcggc tgggtactggg tactgcacgg 6540
 gcgccccgtc agcgggaccg gcgaatgcgt cagcgcggtc gcggcggcgc atggtcgcga 6600
 tgcggcgctg tgggacgcct tcgcagtctg caccgcgcgc ttggaggccg cgctgctgtc 6660
 tgggggcagc cccgacgcgc ccataccga gaaccagcgc ctgctggaac gcatcggcgt 6720
 cgtgccggca gcgacgcagg ccctcgtggc ccagatcgag gaggcgggtg gcgcggccaa 6780
 gatctgcggc gcaggttccg tgcggggcga tcacggcggg gcggtcctcg tcgcgattga 6840
 cgacgcgcag gcgatggctt cggtcatggc gcgccatccc gacctgact gggcgcccct 6900
 gcgcatgtcg cgcacggggg cggcaccggg ccccgcgccg cgtgcgcaac cgctgccggg 6960
 gcagggtga tggatcaggc catccgcgcc agcgcgccg gttcggtcac gatcacgggc 7020
 gaacatgccg tggctctatg acaccgcgcc atcgtcgccg ggatcgagca gcgcgcccat 7080
 gtgacgatcg tccccgctgc cgaccgcatg tttcgcatca cctcgcagat cggggcgccg 7140
 cagcaggggt cgctggacga tctgcctcgc ggcgggacct atcgcttcgt gctggccgcc 7200
 atcgcgcgac acgcgcggga cctgccttgc ggggttcgaca tggacatcac ctcggggatc 7260
 gatccgaggc tcgggcttgg atcctcggcg gcggtgacgg tcgcctgcct cggcgcgctg 7320
 tcgcggtgg cggggcgggg gaccgagggg ctgcatgacg acgcgctcgc catcgctccg 7380
 gccatccagg gcaggggcag cggggccgat ctggcgcca gcctgcatgg cggttcgtc 7440
 gcctatcgcg cggccgatgg cggtgccgcg cagatcgagg cgcttcgggt gccgcgggg 7500
 ccgttcggcc tcgcttatgc gggctacaag accccgacag ccgaggtgct gcgccttgtg 7560
 gccgatcgga tggcgggcaa cgaggccgct ttcgacgcgc tctactcccg gatgggcgca 7620
 agcgcagatg ccgcgatccg cgcggcgcaa gggctggact gggctgcatt ccacgacgcg 7680
 ctgaacgaat accagcgcct gatggagcag ctgggcgtgt ccgacgacac gctggacgcg 7740
 atcatccgcg aggcgcgcga cgcgggcgcc gcagtcgcca agatctccgg ctcggggctg 7800
 ggggattgcg tgctggcact gggcgaccag cccaagggtt tcgtgcccgc aagcattgcc 7860
 gagaagggac ttgttttcg atg act gat gcc gtc cgc gac atg atc gcc cgt 7912
 Met Thr Asp Ala Val Arg Asp Met Ile Ala Arg

1

5

10

| | |
|---|-------|
| gcc atg gcg ggc gcg acc gac atc cga gca gcc gag gct tat gcg ccc | 7960 |
| Ala Met Ala Gly Ala Thr Asp Ile Arg Ala Ala Glu Ala Tyr Ala Pro | |
| 15 20 25 | |
| agc aac atc gcg ctg tgc aaa tac tgg ggc aag cgc gac gcc gcg cgg | 8008 |
| Ser Asn Ile Ala Leu Ser Lys Tyr Trp Gly Lys Arg Asp Ala Ala Arg | |
| 30 35 40 | |
| aac ctt ccg ctg aac agc tcc gtc tgc atc tgc ttg gcg aac tgg ggc | 8056 |
| Asn Leu Pro Leu Asn Ser Ser Val Ser Ile Ser Leu Ala Asn Trp Gly | |
| 45 50 55 | |
| tct cat acg cgg gtc gag ggg tcc ggc acg ggc cac gac gag gtg cat | 8104 |
| Ser His Thr Arg Val Glu Gly Ser Gly Thr Gly His Asp Glu Val His | |
| 60 65 70 75 | |
| cac aac ggc acg ctg ctg gat ccg ggc gac gcc ttc gcg cgc cgc gcg | 8152 |
| His Asn Gly Thr Leu Asp Pro Gly Asp Ala Phe Ala Arg Arg Ala | |
| 80 85 90 | |
| ttg gca ttc gct gac ctg ttc cgg ggg ggg agg cac ctg ccg ctg cgg | 8200 |
| Leu Ala Phe Ala Asp Leu Phe Arg Gly Gly Arg His Leu Pro Leu Arg | |
| 95 100 105 | |
| atc acg acg cag aac tgc atc ccg acg gcg gcg ggg ctt gcc tgc tgc | 8248 |
| Ile Thr Thr Gln Asn Ser Ile Pro Thr Ala Ala Gly Leu Ala Ser Ser | |
| 110 115 120 | |
| gcc tgc ggg ttc gcg gcg ctg acc cgt gcg ctg gcg ggg gcg ttc ggg | 8296 |
| Ala Ser Gly Phe Ala Ala Leu Thr Arg Ala Leu Ala Gly Ala Phe Gly | |
| 125 130 135 | |
| ctg gat ctg gac gac acg gat ctg agc cgc atc gcc cgg atc ggc agt | 8344 |
| Leu Asp Leu Asp Asp Thr Asp Leu Ser Arg Ile Ala Arg Ile Gly Ser | |
| 140 145 150 155 | |
| ggc agc gcc gcc cgc tgc atc tgg cac ggc ttc gtc cgc tgg aac cgg | 8392 |
| Gly Ser Ala Ala Arg Ser Ile Trp His Gly Phe Val Arg Trp Asn Arg | |
| 160 165 170 | |
| ggc gag gcc gag gat ggg cat gac agc cac ggc gtc ccg ctg gac ctg | 8440 |
| Gly Glu Ala Glu Asp Gly His Asp Ser His Gly Val Pro Leu Asp Leu | |
| 175 180 185 | |
| cgc tgg ccc ggc ttc cgc atc gcg atc gtg gcc gtg gac-aag ggg-ccc | -8488 |
| Arg Trp Pro Gly Phe Arg Ile Ala Ile Val Ala Val Asp Lys Gly Pro | |
| 190 195 200 | |
| aag cct ttc agt tgc cgc gac ggc atg aac cac acg gtc gag acc agc | 8536 |
| Lys Pro Phe Ser Ser Arg Asp Gly Met Asn His Thr Val Glu Thr Ser | |
| 205 210 215 | |
| ccg ctg ttc ccg ccc tgg cct gcg cag gcg gaa gcg gat tgc cgc gtc | 8584 |
| Pro Leu Phe Pro Pro Trp Pro Ala Gln Ala Glu Ala Asp Cys Arg Val | |
| 220 225 230 235 | |

atc gag gat gcg atc gcc gcc cgc gac atg gcc gcc ctg ggt ccg cgg 8632
 Ile Glu Asp Ala Ile Ala Ala Arg Asp Met Ala Ala Leu Gly Pro Arg
 240 245 250
 gtc gag gcg aac gcc ctt gcg atg cac gcc acg atg atg gcc gcg cgc 8680
 Val Glu Ala Asn Ala Leu Ala Met His Ala Thr Met Met Ala Ala Arg
 255 260 265
 ccg ccg ctc tgc tac ctg acg ggc ggc agc tgg cag gtg ctg gaa cgc 8728
 Pro Pro Leu Cys Tyr Leu Thr Gly Ser Trp Gln Val Leu Glu Arg
 270 275 280
 ctg tgg cag gcc cgc gcg gac ggg ctt gcg gcc ttt gcg acg atg gat 8776
 Leu Trp Gln Ala Arg Ala Asp Gly Leu Ala Ala Phe Ala Thr Met Asp
 285 290 295
 gcc ggc ccg aac gtc aag ctg atc ttc gag gaa agc agc gcc gcc gac 8824
 Ala Gly Pro Asn Val Lys Leu Ile Phe Glu Glu Ser Ser Ala Ala Asp
 300 305 310 315
 gtg ctg tac ctg ttc ccc gac gcc agc ctg atc gcg ccg ttc gag ggg 8872
 Val Leu Tyr Leu Phe Pro Asp Ala Ser Leu Ile Ala Pro Phe Glu Gly
 320 325 330
 cgt tga acgcgtaaga cgaccactgg gtaagggtct gccgcgcgtg gtctcgactg 8928
 Arg
 cctgcaaaga ggtgcttgag ttgctgcgtg actgcggcgg ccgacttcgt gggacttgcc 8988
 cgccacgctg acgcgctgga aacgcgcccc cggtattacga ccgcgtcatt gccctgaacc 9048
 aatttcccggt cggtcgac 9066

<210> 53

<211> 332

<212> PRT

<213> Paracoccus sp. R114

<400> 53

Met Thr Asp Ala Val Arg Asp Met Ile Ala Arg Ala Met Ala Gly Ala
 1 5 10 15

Thr Asp Ile Arg Ala Ala Glu Ala Tyr Ala Pro Ser Asn Ile Ala Leu
 20 25 30

Ser Lys Tyr Trp Gly Lys Arg Asp Ala Ala Arg Asn Leu Pro Leu Asn
 35 40 45

Ser Ser Val Ser Ile Ser Leu Ala Asn Trp Gly Ser His Thr Arg Val
50 55 60

Glu Gly Ser Gly Thr Gly His Asp Glu Val His His Asn Gly Thr Leu
65 70 75 80

Leu Asp Pro Gly Asp Ala Phe Ala Arg Arg Ala Leu Ala Phe Ala Asp
85 90 95

Leu Phe Arg Gly Gly Arg His Leu Pro Leu Arg Ile Thr Thr Gln Asn
100 105 110

Ser Ile Pro Thr Ala Ala Gly Leu Ala Ser Ser Ala Ser Gly Phe Ala
115 120 125

Ala Leu Thr Arg Ala Leu Ala Gly Ala Phe Gly Leu Asp Leu Asp Asp
130 135 140

Thr Asp Leu Ser Arg Ile Ala Arg Ile Gly Ser Gly Ser Ala Ala Arg
145 150 155 160

Ser Ile Trp His Gly Phe Val Arg Trp Asn Arg Gly Glu Ala Glu Asp
165 170 175

Gly His Asp Ser His Gly Val Pro Leu Asp Leu Arg Trp Pro Gly Phe
180 185 190

Arg Ile Ala Ile Val Ala Val Asp Lys Gly Pro Lys Pro Phe Ser Ser
195 200 205

Arg Asp Gly Met Asn His Thr Val Glu Thr Ser Pro Leu Phe Pro Pro
210 215 220

Trp Pro Ala Gln Ala Glu Ala Asp Cys Arg Val Ile Glu Asp Ala Ile
225 230 235 240

Ala Ala Arg Asp Met Ala Ala Leu Gly Pro Arg Val Glu Ala Asn Ala
245 250 255

Leu Ala Met His Ala Thr Met Met Ala Ala Arg Pro Pro Leu Cys Tyr
260 265 270

Leu Thr Gly Gly Ser Trp Gln Val Leu Glu Arg Leu Trp Gln Ala Arg
 275 280 285

Ala Asp Gly Leu Ala Ala Phe Ala Thr Met Asp Ala Gly Pro Asn Val
 290 295 300

Lys Leu Ile Phe Glu Glu Ser Ser Ala Ala Asp Val Leu Tyr Leu Phe
 305 310 315 320

Pro Asp Ala Ser Leu Ile Ala Pro Phe Glu Gly Arg
 325 330

<210> 54

<211> 353

<212> PRT

<213> Streptomyces sp. strain CL190

<400> 54

Met Thr Glu Thr His Ala Ile Ala Gly Val Pro Met Arg Trp Val Gly
 1 5 10 15

Pro Leu Arg Ile Ser Gly Asn Val Ala Glu Thr Glu Thr Gln Val Pro
 20 25 30

Leu Ala Thr Tyr Glu Ser Pro Leu Trp Pro Ser Val Gly Arg Gly Ala
 35 40 45

Lys Val Ser Arg Leu Thr Glu Lys Gly Ile Val Ala Thr Leu Val Asp
 50 55 60

Glu Arg Met Thr Arg Ser Val Ile Val Glu Ala Thr Asp Ala Gln Thr
 65 70 75 80

Ala Tyr Met Ala Ala Gln Thr Ile His Ala Arg Ile Asp Glu Leu Arg
 85 90 95

Glu Val Val Arg Gly Cys Ser Arg Phe Ala Gln Leu Ile Asn Ile Lys
 100 105 110

His Glu Ile Asn Ala Asn Leu Leu Phe Ile Arg Phe Glu Phe Thr Thr
 115 120 125

Gly Asp Ala Ser Gly His Asn Met Ala Thr Leu Ala Ser Asp Val Leu
 130 135 140

Leu Gly His Leu Leu Glu Thr Ile Pro Gly Ile Ser Tyr Gly Ser Ile

145 150 155 160
 Ser Gly Asn Tyr Cys Thr Asp Lys Lys Ala Thr Ala Ile Asn Gly Ile
 165 170 175
 Leu Gly Arg Gly Lys Asn Val Ile Thr Glu Leu Leu Val Pro Arg Asp
 180 185 190
 Val Val Glu Asn Asn Leu His Thr Thr Ala Ala Lys Ile Val Glu Leu
 195 200 205
 Asn Ile Arg Lys Asn Leu Leu Gly Thr Leu Leu Ala Gly Gly Ile Arg
 210 215 220
 Ser Ala Asn Ala His Phe Ala Asn Met Leu Leu Gly Phe Tyr Leu Ala
 225 230 235 240
 Thr Gly Gln Asp Ala Ala Asn Ile Val Glu Gly Ser Gln Gly Val Val
 245 250 255
 Met Ala Glu Asp Arg Asp Gly Asp Leu Tyr Phe Ala Cys Thr Leu Pro
 260 265 270
 Asn Leu Ile Val Gly Thr Val Gly Asn Gly Lys Gly Leu Gly Phe Val
 275 280 285
 Glu Thr Asn Leu Ala Arg Leu Gly Cys Arg Ala Asp Arg Glu Pro Gly
 290 295 300
 Glu Asn Ala Arg Arg Leu Ala Val Ile Ala Ala Ala Thr Val Leu Cys
 305 310 315 320
 Gly Glu Leu Ser Leu Leu Ala Ala Gln Thr Asn Pro Gly Glu Leu Met
 325 330 335
 Arg Ala His Val Gln Leu Glu Arg Asp Asn Lys Thr Ala Lys Val Gly
 340 345 350
 Ala

<210> 55

<211> 353

<212> PRT

<213> Streptomyces griseolosporeus

<400> 55

Met Thr Glu Ala His Ala Thr Ala Gly Val Pro Met Arg Trp Val Gly
 1 5 10 15

Pro Val Arg Ile Ser Gly Asn Val Ala Thr Ile Glu Thr Gln Val Pro

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ala | Thr | Tyr | Glu | Ser | Pro | Leu | Trp | Pro | Ser | Val | Gly | Arg | Gly | Ala |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Lys | Val | Ser | Arg | Leu | Thr | Glu | Lys | Gly | Ile | Val | Ala | Thr | Leu | Val | Asp |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Glu | Arg | Met | Thr | Arg | Ser | Val | Leu | Val | Glu | Ala | Thr | Asp | Ala | Leu | Thr |
| | 65 | | | | | 70 | | | | | 75 | | | | 80 |
| Ala | Leu | Ser | Ala | Ala | Arg | Thr | Ile | Glu | Ala | Arg | Ile | Asp | Glu | Leu | Arg |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Glu | Leu | Val | Arg | Gly | Cys | Ser | Arg | Phe | Ala | Gln | Leu | Ile | Gly | Ile | Arg |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| His | Glu | Ile | Thr | Gly | Asn | Leu | Leu | Phe | Val | Arg | Phe | Glu | Phe | Ser | Thr |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Gly | Asp | Ala | Ser | Gly | His | Asn | Met | Ala | Thr | Leu | Ala | Ser | Asp | Val | Leu |
| | 130 | | | | | | 135 | | | | | 140 | | | |
| Leu | Gln | His | Leu | Leu | Glu | Thr | Val | Pro | Gly | Ile | Ser | Tyr | Gly | Ser | Ile |
| | 145 | | | | | 150 | | | | | 155 | | | | 160 |
| Ser | Gly | Asn | Tyr | Cys | Thr | Asp | Lys | Lys | Ala | Thr | Ala | Ile | Asn | Gly | Ile |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Leu | Gly | Arg | Gly | Lys | Asn | Val | Val | Thr | Glu | Leu | Leu | Val | Pro | Arg | Asp |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Val | Val | Ala | Asp | Val | Leu | Asn | Thr | Thr | Ala | Ala | Lys | Ile | Ala | Glu | Leu |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Asn | Leu | Arg | Lys | Asn | Leu | Leu | Gly | Thr | Leu | Leu | Ala | Gly | Gly | Ile | Arg |
| | 210 | | | | | | 215 | | | | 220 | | | | |
| Ser | Ala | Asn | Ala | His | Tyr | Ala | Asn | Met | Leu | Leu | Ala | Phe | Tyr | Leu | Ala |
| | 225 | | | | | 230 | | | | | 235 | | | | 240 |
| Thr | Gly | Gln | Asp | Ala | Ala | Asn | Ile | Val | Glu | Gly | Ser | Gln | Gly | Val | Val |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Thr | Ala | Glu | Asp | Arg | Asp | Gly | Asp | Leu | Tyr | Leu | Ala | Cys | Thr | Leu | Pro |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Asn | Leu | Ile | Val | Gly | Thr | Val | Gly | Asn | Gly | Lys | Gly | Leu | Gly | Phe | Val |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Glu | Thr | Asn | Leu | Asn | Arg | Leu | Gly | Cys | Arg | Ala | Asp | Arg | Glu | Pro | Gly |
| | | 290 | | | | | 295 | | | | 300 | | | | |
| Glu | Asn | Ala | Arg | Arg | Leu | Ala | Val | Ile | Ala | Ala | Ala | Thr | Val | Leu | Cys |
| | 305 | | | | | 310 | | | | | 315 | | | | 320 |
| Gly | Glu | Leu | Ser | Leu | Leu | Ala | Ala | Gln | Thr | Asn | Pro | Gly | Glu | Leu | Met |

325 330 335
 Arg Ala His Val Gln Leu Glu Arg Gly His Thr Thr Ala Lys Ala Gly
 340 345 350

Val

<210> 56

<211> 353

<212> PRT

<213> Streptomyces sp. strain KO-3899

<400> 56

Met Thr Asp Thr His Ala Ile Ala Met Val Pro Met Lys Trp Val Gly
 1 5 10 15

Pro Leu Arg Ile Ser Gly Asn Val Ala Thr Thr Glu Thr His Val Pro
 20 25 30

Leu Ala Thr Tyr Glu Thr Pro Leu Trp Pro Ser Val Gly Arg Gly Ala
 35 40 45

Lys Val Ser Met Leu Ser Glu Arg Gly Ile Ala Ala Thr Leu Val Asp
 50 55 60

Glu Arg Met Thr Arg Ser Val Leu Val Glu Ala Thr Asp Ala Gln Thr
 65 70 75 80

Ala Tyr Thr Ala Ala Arg Ala Ile Glu Ala Arg Ile Glu Glu Leu Arg
 85 90 95

Ala Val Val Arg Thr Cys Ser Arg Phe Ala Glu Leu Leu Gln Val Arg
 100 105 110

His Glu Ile Ala Gly Asn Leu Leu Phe Val Arg Phe Glu Phe Ser Thr
 115 120 125

Arg Arg Pro Ser Gly His Asn Met Ala Thr Leu Ala Ser Asp Ala Leu
 130 135 140

Leu Ala His Leu Leu Gln Thr Ile Pro Gly Ile Ser Tyr Gly Ser Ile
 145 150 155 160

Ser Gly Asn Tyr Cys Thr Asp Lys Lys Ala Thr Ala Ile Asn Gly Ile
 165 170 175

Leu Gly Arg Gly Lys Asn Val Val Thr Glu Leu Val Val Pro Arg Glu
 180 185 190

Val Val Glu Arg Val Leu His Thr Thr Ala Ala-Lys Ile Val Glu Leu

195 200 205
 Asn Ile Arg Lys Asn Leu Leu Gly Thr Leu Leu Ala Gly Gly Ile Arg
 210 215 220
 Ser Ala Asn Ala His Tyr Ala Asn Met Leu Leu Gly Phe Tyr Leu Ala
 225 230 235 240
 Thr Gly Gln Asp Ala Ala Asn Ile Val Glu Gly Ser Gln Gly Val Thr
 245 250 255
 Leu Ala Glu Asp Arg Asp Gly Asp Leu Tyr Phe Ser Cys Asn Leu Pro
 260 265 270
 Asn Leu Ile Val Gly Thr Val Gly Asn Gly Lys Gly Leu Glu Phe Val
 275 280 285
 Glu Thr Asn Leu Asn Arg Leu Gly Cys Arg Glu Asp Arg Ala Pro Gly
 290 295 300
 Glu Asn Ala Arg Arg Leu Ala Val Ile Ala Ala Ala Thr Val Leu Cys
 305 310 315 320
 Gly Glu Leu Ser Leu Leu Ala Ala Gln Thr Asn Pro Gly Glu Leu Met
 325 330 335
 Arg Ala His Val Glu Leu Glu Arg Asp Asn Thr Thr Ala Glu Val Gly
 340 345 350
 Val

<210> 57

<211> 347

<212> PRT

<213> Erwinia herbicola

<400> 57

Met Lys Asp Glu Arg Leu Val Gln Arg Lys Asn Asp His Leu Asp Ile
 1 5 10 15
 Val Leu Asp Pro Arg Arg Ala Val Thr Gln Ala Ser Ala Gly Phe Glu
 20 25 30
 Arg Trp Arg Phe Thr His Cys Ala Leu Pro Glu Leu Asn Phe Ser Asp
 35 40 45
 Ile Thr Leu Glu Thr Thr Phe Leu Asn Arg Gln Leu Gln Ala Pro Leu
 50 55 60
 Leu Ile Ser Ser Met Thr Gly Gly Val Glu Arg Ser Arg His Ile Asn

| | | | | | | |
|---------------------|-----------------|---------------------|-------------|----|--|-----|
| 65 | | 70 | | 75 | | 80 |
| Arg His Leu Ala Glu | Ala Ala Gln Val | Leu Lys Ile Ala Met | Gly Val | | | |
| | 85 | 90 | 95 | | | |
| Gly Ser Gln Arg Val | Ala Ile Glu Ser | Asp Ala Gly Leu | Gly Leu Asp | | | |
| | 100 | 105 | 110 | | | |
| Lys Thr Leu Arg Gln | Leu Ala Pro Asp | Val Pro Leu Leu | Ala Asn Leu | | | |
| | 115 | 120 | 125 | | | |
| Gly Ala Ala Gln Leu | Thr Gly Arg Lys | Gly Ile Asp Tyr | Ala Arg Arg | | | |
| | 130 | 135 | 140 | | | |
| Ala Val Glu Met Ile | Glu Ala Asp Ala | Leu Ile Val His | Leu Asn Pro | | | |
| | 145 | 150 | 155 | | | 160 |
| Leu Gln Glu Ala Leu | Gln Pro Gly Gly | Asp Arg Asp Trp | Arg Gly Arg | | | |
| | 165 | 170 | 175 | | | |
| Leu Ala Ala Ile Glu | Thr Leu Val Arg | Glu Leu Pro Val | Pro Leu Val | | | |
| | 180 | 185 | 190 | | | |
| Val Lys Glu Val Gly | Ala Gly Ile Ser | Arg Thr Val Ala | Gly Gln Leu | | | |
| | 195 | 200 | 205 | | | |
| Ile Asp Ala Gly Val | Thr Val Ile Asp | Val Ala Gly Ala | Gly Gly Thr | | | |
| | 210 | 215 | 220 | | | |
| Ser Trp Ala Ala Val | Glu Gly Glu Arg | Ala Ala Thr Glu | Gln Gln Arg | | | |
| | 225 | 230 | 235 | | | 240 |
| Ser Val Ala Asn Val | Phe Ala Asp Trp | Gly Ile Pro Thr | Ala Glu Ala | | | |
| | 245 | 250 | 255 | | | |
| Leu Val Asp Ile Ala | Glu Ala Trp Pro | Gln Met Pro Leu | Ile Ala Ser | | | |
| | 260 | 265 | 270 | | | |
| Gly Gly Ile Lys Asn | Gly Val Asp Ala | Ala Lys Ala Leu | Arg Leu Gly | | | |
| | 275 | 280 | 285 | | | |
| Ala Cys Met Val Gly | Gln Ala Ala Val | Leu Gly Ser Ala | Gly Val | | | |
| | 290 | 295 | 300 | | | |
| Ser Thr Glu Lys Val | Ile Asp His Phe | Asn Val Ile Ile | Glu Gln Leu | | | |
| | 305 | 310 | 315 | | | 320 |
| Arg Val Ala Cys Phe | Cys Thr Gly Ser | Arg Ser Leu Ser | Asp Leu Lys | | | |
| | 325 | 330 | 335 | | | |
| Gln Ala Asp Ile Arg | Tyr Val Arg Asp | Thr Pro | | | | |
| | 340 | 345 | | | | |

<210> .58

<211> 360

<212> PRT

<213> *Borrelia burgdorferi*

<400> 58

Met Met Asp Thr Glu Phe Met Gly Ile Glu Pro Asn Ile Leu Glu Asn
 1 5 10 15

Lys Lys Arg His Ile Glu Ile Cys Leu Asn Lys Asn Asp Val Lys Gly
 20 25 30

Gly Cys Asn Phe Leu Lys Phe Ile Lys Leu Lys His Asn Ala Leu Ser
 35 40 45

Asp Phe Asn Phe Ser Glu Ile Asn Ile Lys Glu Glu Ile Phe Gly Tyr
 50 55 60

Asn Ile Ser Met Pro Val Phe Ile Ser Ser Met Thr Gly Gly Ser Lys
 65 70 75 80

Glu Gly Asn Asp Phe Asn Lys Ser Leu Val Arg Ile Ala Asn Tyr Leu
 85 90 95

Lys Ile Pro Ile Gly Leu Gly Ser Phe Lys Leu Leu Phe Lys Tyr Pro
 100 105 110

Glu Tyr Ile Arg Asp Phe Thr Leu Lys Arg Tyr Ala His Asn Ile Pro
 115 120 125

Leu Phe Ala Asn Val Gly Ala Val Gln Ile Val Glu Phe Gly Ile Ser
 130 135 140

Lys Ile Ala Glu Met Ile Lys Arg Leu Glu Val Asp Ala Ile Ile Val
 145 150 155 160

His Leu Asn Ala Gly Gln Glu Leu Met Lys Val Asp Gly Asp Arg Asn
 165 170 175

Phe Lys Gly Ile Arg Glu Ser Ile Ala Lys Leu Ser Asp Phe Leu Ser
 180 185 190

Val Pro Leu Ile Val Lys Glu Thr Gly Phe Gly Ile Ser Pro Lys Asp
 195 200 205

Val Lys Glu Leu Phe Ser Leu Gly Ala Ser Tyr Val Asp Leu Ala Gly
 210 215 220

Ser Gly Gly Thr Asn Trp Ile Leu Val Glu Gly Met Lys Ser Asn Asn
 225 230 235 240

Leu Asn Ile Ala Ser Cys Phe Ser Asp Trp Gly Ile Pro Ser Val Phe
 245 250 255

Thr Leu Leu Ser Ile Asp Asp Ser Leu Lys Ala Asn Ile Phe Ala Ser

```
<210> 59
<211> 349
<212> PRT
<213> Synechocystis sp. PCC 6803
```

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Ser | Thr | Pro | His | Arg | Lys | Ser | Asp | His | Ile | Arg | Ile | Val | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Glu | Glu | Asp | Val | Val | Gly | Lys | Gly | Ile | Ser | Thr | Gly | Phe | Glu | Arg | Leu |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Met | Leu | Glu | His | Cys | Ala | Leu | Pro | Ala | Val | Asp | Leu | Asp | Ala | Val | Asp |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Leu | Gly | Leu | Thr | Leu | Trp | Gly | Lys | Ser | Leu | Thr | Tyr | Pro | Trp | Leu | Ile |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ser | Ser | Met | Thr | Gly | Gly | Thr | Pro | Glu | Ala | Lys | Gln | Ile | Asn | Leu | Phe |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Leu | Ala | Glu | Val | Ala | Gln | Ala | Leu | Gly | Ile | Ala | Met | Gly | Leu | Gly | Ser |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Gln | Arg | Ala | Ala | Ile | Glu | Asn | Pro | Asp | Leu | Ala | Phe | Thr | Tyr | Gln | Val |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Arg | Ser | Val | Ala | Pro | Asp | Ile | Leu | Leu | Phe | Ala | Asn | Leu | Gly | Leu | Val |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Gln | Leu | Asn | Tyr | Gly | Tyr | Gly | Leu | Glu | Gln | Ala | Gln | Arg | Ala | Val | Asp |

130 135 140
 Met Ile Glu Ala Asp Ala Leu Ile Leu His Leu Asn Pro Leu Gln Glu
 145 150 155 160
 Ala Val Gln Pro Asp Gly Asp Arg Leu Trp Ser Gly Leu Trp Ser Lys
 165 170 175
 Leu Glu Ala Leu Val Glu Ala Leu Glu Val Pro Val Ile Val Lys Glu
 180 185 190
 Val Gly Asn Gly Ile Ser Gly Pro Val Ala Lys Arg Leu Gln Glu Cys
 195 200 205
 Gly Val Gly Ala Ile Asp Val Ala Gly Ala Gly Gly Thr Ser Trp Ser
 210 215 220
 Glu Val Glu Ala His Arg Gln Thr Asp Arg Gln Ala Lys Glu Val Ala
 225 230 235 240
 His Asn Phe Ala Asp Trp Gly Leu Pro Thr Ala Trp Ser Leu Gln Gln
 245 250 255
 Val Val Gln Asn Thr Glu Gln Ile Leu Val Phe Ala Ser Gly Gly Ile
 260 265 270
 Arg Ser Gly Ile Asp Gly Ala Lys Ala Ile Ala Leu Gly Ala Thr Leu
 275 280 285
 Val Gly Ser Ala Ala Pro Val Leu Ala Glu Ala Lys Ile Asn Ala Gln
 290 295 300
 Arg Val Tyr Asp His Tyr Gln Ala Arg Leu Arg Glu Leu Gln Ile Ala
 305 310 315 320
 Ala Phe Cys Cys Asp Ala Ala Asn Leu Thr Gln Leu Ala Gln Val Pro
 325 330 335
 Leu Trp Asp Arg Gln Ser Gly Gln Arg Leu Thr Lys Pro
 340 345

<210> 60

<211> 361

<212> PRT

<213> Streptomyces sp. CL190

<400> 60

Met Thr Ser Ala Gln Arg Lys Asp Asp His Val Arg Leu Ala Ile Glu
 1 5 10 15
 Gln His Asn Ala His Ser Gly Arg Asn Gln Asp Asp Val Ser Phe Val

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| His | His | Ala | Leu | Ala | Gly | Ile | Asp | Arg | Pro | Asp | Val | Ser | Leu | Ala | Thr |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Ser | Phe | Ala | Gly | Ile | Ser | Trp | Gln | Val | Pro | Ile | Tyr | Ile | Asn | Ala | Met |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Thr | Gly | Gly | Ser | Glu | Lys | Thr | Gly | Leu | Ile | Asn | Arg | Asp | Leu | Ala | Thr |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Ala | Ala | Arg | Glu | Thr | Gly | Val | Pro | Ile | Ala | Ser | Gly | Ser | Met | Asn | Ala |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Tyr | Ile | Lys | Asp | Pro | Cys | Ala | Asp | Thr | Phe | Arg | Val | Leu | Arg | Asp | Glu |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Asn | Pro | Asn | Gly | Phe | Val | Ile | Ala | Asn | Ile | Asn | Ala | Thr | Thr | Thr | Val |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Asp | Asn | Ala | Gln | Arg | Ala | Ile | Asp | Leu | Ile | Glu | Ala | Asn | Ala | Leu | Gln |
| | 130 | | | | | 135 | | | | 140 | | | | | |
| Ile | His | Ile | Asn | Thr | Ala | Gln | Glu | Thr | Pro | Met | Pro | Glu | Gly | Asp | Arg |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Ser | Phe | Ala | Ser | Trp | Val | Pro | Gln | Ile | Glu | Lys | Ile | Ala | Ala | Ala | Val |
| | | | | 165 | | | | | 170 | | | | | | 175 |
| Asp | Ile | Pro | Val | Ile | Val | Lys | Glu | Val | Gly | Asn | Gly | Leu | Ser | Arg | Gln |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Thr | Ile | Leu | Leu | Leu | Ala | Asp | Leu | Gly | Val | Gln | Ala | Ala | Asp | Val | Ser |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Gly | Arg | Gly | Gly | Thr | Asp | Phe | Ala | Arg | Ile | Glu | Asn | Gly | Arg | Arg | Glu |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Leu | Gly | Asp | Tyr | Ala | Phe | Leu | His | Gly | Trp | Gly | Gln | Ser | Thr | Ala | Ala |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Cys | Leu | Leu | Asp | Ala | Gln | Asp | Ile | Ser | Leu | Pro | Val | Leu | Ala | Ser | Gly |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Gly | Val | Arg | His | Pro | Leu | Asp | Val | Val | Arg | Ala | Leu | Ala | Leu | Gly | Ala |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Arg | Ala | Val | Gly | Ser | Ser | Ala | Gly | Phe | Leu | Arg | Thr | Leu | Met | Asp | Asp |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Gly | Val | Asp | Ala | Leu | Ile | Thr | Lys | Leu | Thr | Thr | Trp | Leu | Asp | Gln | Leu |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Ala | Ala | Leu | Gln | Thr | Met | Leu | Gly | Ala | Arg | Thr | Pro | Ala | Asp | Leu | Thr |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Arg | Cys | Asp | Val | Leu | Leu | His | Gly | Glu | Leu | Arg | Asp | Phe | Cys | Ala | Asp |

74

195 200 205
 Val Ser Gly Arg Gly Gly Thr Asp Phe Ala Arg Ile Glu Asn Ser Arg
 210 215 220
 Arg Pro Leu Gly Asp Tyr Ala Phe Leu His Gly Trp Gly Gln Ser Thr
 225 230 235 240
 Pro Ala Cys Leu Leu Asp Ala Gln Asp Val Gly Phe Pro Leu Leu Ala
 245 250 255
 Ser Gly Gly Ile Arg Asn Pro Leu Asp Val Ala Arg Ala Leu Ala Leu
 260 265 270
 Gly Ala Gly Ala Val Gly Ser Ser Gly Val Phe Leu Arg Thr Leu Ile
 275 280 285
 Asp Gly Gly Val Ser Ala Leu Val Ala Gln Ile Ser Thr Trp Leu Asp
 290 295 300
 Gln Leu Ala Ala Leu Gln Thr Met Leu Gly Ala Arg Thr Pro Ala Asp
 305 310 315 320
 Leu Thr Arg Cys Asp Val Leu Ile His Gly Pro Leu Arg Ser Phe Cys
 325 330 335
 Thr Asp Arg Gly Ile Asp Ile Gly Arg Phe Ala Arg Arg Ser Ser Ser
 340 345 350
 Ala Asp Ile Arg Ser Glu Met Thr Gly Ser Thr Arg
 355 360

 <210> 62
 <211> 368
 <212> PRT
 <213> Sulfolobus solfataricus

 <400> 62
 Met Pro Asp Ile Val Asn Arg Lys Val Glu His Val Glu Ile Ala Ala
 1 5 10 15
 Phe Glu Asn Val Asp Gly Leu Ser Ser Ser Thr Phe Leu Asn Asp Val
 20 25 30
 Ile Leu Val His Gln Gly Phe Pro Gly Ile Ser Phe Ser Glu Ile Asn
 35 40 45
 Thr Lys Thr Lys Phe Phe Arg Lys Glu Ile Ser Ala Pro Ile Met Val
 50 55 60
 Thr Gly Met Thr Gly Gly Arg Asn Glu Leu Gly Arg Ile Asn Arg Ile

<210> 63

<211> 342

<212> PRT

<213> Rickettsia prowazekii

<400> 63

Met Pro Lys Glu Gln Asn Leu Asp Ile Glu Arg Lys Gln Glu His Ile
 1 5 10 15

Glu Ile Asn Leu Lys Gln Asn Val Asn Ser Thr Leu Lys Ser Gly Leu
 20 25 30

Glu Ser Ile Lys Phe Ile His Asn Ala Leu Pro Glu Ile Asn Tyr Asp
 35 40 45

Ser Ile Asp Thr Thr Thr Thr Phe Leu Gly Lys Asp Met Lys Ala Pro
 50 55 60

Ile Leu Ile Ser Ser Met Thr Gly Gly Thr Ala Arg Ala Arg Asp Ile
 65 70 75 80

Asn Tyr Arg Leu Ala Gln Ala Ala Gln Lys Ser Gly Ile Ala Met Gly
 85 90 95

Leu Gly Ser Met Arg Ile Leu Leu Thr Lys Pro Asp Thr Ile Lys Thr
 100 105 110

Phe Thr Val Arg His Val Ala Pro Asp Ile Pro Leu Leu Ala Asn Ile
 115 120 125

Gly Ala Val Gln Leu Asn Tyr Gly Val Thr Pro Lys Glu Cys Gln Tyr
 130 135 140

Leu Ile Asp Thr Ile Lys Ala Asp Ala Leu Ile Leu His Leu Asn Val
 145 150 155 160

Leu His Glu Leu Thr Gln Pro Glu Gly Asn Lys Asn Trp Glu Asn Leu
 165 170 175

Leu Pro Lys Ile Lys Glu Val Ile Asn Tyr Leu Ser Val Pro Val Ile
 180 185 190

Val Lys Glu Val Gly Tyr Gly Leu Ser Lys Gln Val Ala Lys Lys Leu
 195 200 205

Ile Lys Ala Gly Val Lys Val Leu Asp Ile Ala Gly Ser Gly Gly Thr
 210 215 220

Ser Trp Ser Gln Val Glu Ala Tyr Arg Ala Lys Asn Ser Met Gln Asn
 225 230 235 240

Arg Ile Ala Ser Ser Phe Ile Asn Trp Gly Ile Thr Thr Leu Asp Ser

| | |
|-------|-------------------------|
| <210> | 64 |
| <211> | 286 |
| <212> | PRT |
| <213> | Deinococcus radiodurans |

| | | | | | | | | | | | | | | | |
|-----------|-----------|------------|-----------|----------|-----------|-----------|------------|------------|-----------|-----------|-----|------------|------------|-----------|-----------|
| Met 1 | Arg | Leu | Asp | Thr 5 | Val | Phe | Leu | Gly | Arg 10 | Arg | Leu | Lys | Ala | Pro 15 | Val |
| Leu | Ile | Gly | Ala 20 | Met | Thr | Gly | Gly | Ala 25 | Glu | Lys | Ala | Gly | Val 30 | Ile | Asn |
| Arg | Asn 35 | Leu | Ala | Thr | Ala | Ala | Arg 40 | Asn | Leu | Gly | Leu | Gly 45 | Met | Met | Leu |
| Gly 50 | Ser | Gln | Arg | Val | Met | Leu 55 | Glu | His | Pro | Asp 60 | Ala | Trp | Glu | Ser | Phe |
| Asn 65 | Val | Arg | Glu | Val | Ala 70 | Pro | Glu | Ile | Leu | Leu 75 | Ile | Gly | Asn | Leu | Gly 80 |
| Ala | Ala | Gln | Phe 85 | Met | Leu | Gly | Tyr | Gly | Ala 90 | Glu | Gln | Ala | Arg | Arg 95 | Ala |
| Val | Asp | Glu 100 | Val | Met | Ala | Asp | Ala | Leu 105 | Ala | Ile | His | Leu | Asn 110 | Pro | Leu |
| Gln | Glu | Ala 115 | Leu | Gln | Arg | Gly | Gly 120 | Asp | Thr | Arg | Trp | Gln 125 | Gly | Val | Thr |
| Tyr | Arg | Leu | Lys | Gln | Val | Ala | Arg | Glu | Leu | Asp | Phe | Pro | Val | Ile | Ile |

130 135 140
 Lys Glu Val Gly His Gly Leu Asp Ala Ala Thr Leu Arg Ala Leu Ala
 145 150 155 160
 Asp Gly Pro Phe Ala Ala Tyr Asp Val Ala Gly Ala Gly Gly Thr Ser
 165 170 175
 Trp Ala Arg Val Glu Gln Leu Val Ala His Gly Gln Val His Ser Pro
 180 185 190
 Asp Leu Cys Glu Leu Gly Val Pro Thr Ala Gln Ala Leu Arg Gln Ala
 195 200 205
 Arg Lys Thr Leu Pro Gly Ala Gln Leu Ile Ala Ser Gly Gly Ile Arg
 210 215 220
 Ser Gly Leu Asp Ala Ala Arg Ala Leu Ser Leu Gly Ala Glu Val Val
 225 230 235 240
 Ala Val Ala Arg Pro Leu Leu Glu Pro Ala Leu Asp Ser Ser Glu Ala
 245 250 255
 Ala Glu Ala Trp Leu Arg Asn Phe Ile Gln Glu Leu Arg Val Ala Leu
 260 265 270
 Phe Val Gly Gly Tyr Arg Asp Val Arg Glu Val Arg Gly Gly
 275 280 285

<210> 65

<211> 361

<212> PRT

<213> Aeropyrum pernix

<400> 65

Met Ile Val Ser Ser Lys Val Glu Ser Arg Glu Ser Thr Leu Leu Glu
 1 5 10 15
 Tyr Val Arg Ile Val His Asn Pro Thr Pro Glu Val Asn Leu Gly Asp
 20 25 30
 Val Ser Leu Glu Ile Asp Phe Cys Gly Gly Arg Leu Arg Ala Pro Leu
 35 40 45
 Val Ile Thr Gly Met Thr Gly Gly His Pro Asp Val Glu Trp Ile Asn
 50 55 60
 Arg Glu Leu Ala Ser Val Ala Glu Glu Leu Gly Ile Ala Ile Gly Val
 65 70 75 80
 Gly Ser Gln Arg Ala Ala Ile Glu Asp Pro Ser Leu Ala Arg Thr Phe

| 85 | | | | | 90 | | | | | 95 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Ala | Ala | Arg | Glu | Ala | Ala | Pro | Asn | Ala | Phe | Leu | Ile | Ala | Asn | Leu |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Gly | Ala | Pro | Gln | Leu | Ser | Leu | Gly | Tyr | Ser | Val | Arg | Glu | Val | Arg | Met |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Ala | Val | Glu | Met | Ile | Asp | Ala | Asp | Ala | Ile | Ala | Ile | His | Leu | Asn | Pro |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Gly | Gln | Glu | Ala | Tyr | Gln | Pro | Glu | Gly | Asp | Pro | Phe | Tyr | Arg | Gly | Val |
| 145 | | | | 150 | | | | | 155 | | | | | 160 | |
| Val | Gly | Lys | Ile | Ala | Glu | Ala | Ala | Glu | Ala | Ala | Gly | Val | Pro | Val | Ile |
| | | | 165 | | | | | 170 | | | | | 175 | | |
| Val | Lys | Glu | Thr | Gly | Asn | Gly | Leu | Ser | Arg | Glu | Ala | Val | Ala | Gln | Leu |
| | | 180 | | | | | 185 | | | | | | 190 | | |
| Arg | Ala | Leu | Gly | Val | Arg | Cys | Phe | Asp | Val | Ala | Gly | Leu | Gly | Gly | Thr |
| | 195 | | | | | 200 | | | | | | 205 | | | |
| Asn | Trp | Ile | Lys | Ile | Glu | Val | Leu | Arg | Gly | Arg | Lys | Ala | Gly | Ser | Pro |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Leu | Glu | Ala | Gly | Pro | Leu | Gln | Asp | Phe | Trp | Gly | Asn | Pro | Thr | Ala | Ala |
| 225 | | | | 230 | | | | | 235 | | | | | 240 | |
| Ala | Leu | Met | Glu | Ala | Arg | Thr | Ala | Ala | Pro | Asp | Ala | Tyr | Ile | Ile | Ala |
| | | | 245 | | | | | 250 | | | | | 255 | | |
| Ser | Gly | Gly | Val | Arg | Asn | Gly | Leu | Asp | Ala | Ala | Arg | Ala | Ile | Ala | Leu |
| | | 260 | | | | | 265 | | | | | 270 | | | |
| Gly | Ala | Asp | Ala | Ala | Gly | Val | Ala | Leu | Pro | Ala | Ile | Arg | Ser | Leu | Leu |
| | 275 | | | | | 280 | | | | | 285 | | | | |
| Ser | Gly | Gly | Arg | Gln | Ala | Thr | Leu | Lys | Leu | Leu | Lys | Ala | Ile | Glu | Tyr |
| | 290 | | | 295 | | | | | 300 | | | | | | |
| Gln | Leu | Lys | Thr | Ala | Val | Tyr | Met | Val | Gly | Glu | Thr | Arg | Val | Arg | Gly |
| 305 | | | 310 | | | | | | 315 | | | | | 320 | |
| Leu | Trp | Arg | Ala | Pro | Ile | Val | Val | Trp | Gly | Arg | Leu | Ala | Glu | Glu | Ala |
| | | | 325 | | | | | 330 | | | | | 335 | | |
| Glu | Ala | Arg | Gly | Ile | Asp | Pro | Arg | Trp | Tyr | Thr | Asn | Thr | Leu | Arg | Leu |
| | | 340 | | | | 345 | | | | | | | 350 | | |
| Glu | Ala | Leu | Val | Tyr | Lys | Asp | Val | Lys | | | | | | | |
| | 355 | | | | | 360 | | | | | | | | | |

<210> 66

<211> 379

<212> PRT

<213> Halobacterium sp. NRC-1

<400> 66

Met Gly Glu Ser Arg Tyr Asn Ser Ile Val Phe Pro Ser Leu Val Gln
 1 5 10 15
 Thr Arg Leu Met Thr Ala Gln Asp Ser Thr Gln Thr Glu Asp Arg Lys
 20 25 30
 Asp Asp His Leu Gln Ile Val Gln Glu Arg Asp Val Glu Thr Thr Gly
 35 40 45
 Thr Gly Phe Asp Asp Val His Leu Val His Asn Ala Leu Pro Glu Leu
 50 55 60
 Asp Tyr Asp Ala Ile Asp Pro Ser Ile Asp Phe Leu Gly His Asp Leu
 65 70 75 80
 Ser Ala Pro Ile Phe Ile Glu Ser Met Thr Gly Gly His His Asn Thr
 85 90 95
 Thr Glu Ile Asn Arg Ala Leu Ala Arg Ala Ala Ser Glu Thr Gly Ile
 100 105 110
 Ala Met Gly Leu Gly Ser Gln Arg Ala Gly Leu Glu Leu Asp Asp Glu
 115 120 125
 Arg Val Leu Glu Ser Tyr Thr Val Val Arg Asp Ala Ala Pro Asp Ala
 130 135 140
 Phe Ile Tyr Gly Asn Leu Gly Ala Ala Gln Leu Arg Glu Tyr Asp Ile
 145 150 155 160
 Glu Met Val Glu Gln Ala Val Glu Met Ile Asp Ala Asp Ala Leu Ala
 165 170 175
 Val His Leu Asn Phe Leu Gln Glu Ala Thr Gln Pro Glu Gly Asp Val
 180 185 190
 Asp Gly Arg Asn Cys Val Ala Ala Ile Glu Arg Val Ser Glu Ala Leu
 195 200 205
 Ser Val Pro Ile Ile Val Lys Glu Thr Gly Asn Gly Ile Ser Gly Glu
 210 215 220
 Thr Ala Arg Glu Leu Thr Ala Ala Gly Val Asp Ala Leu Asp Val Ala
 225 230 235 240
 Gly Lys Gly Gly Thr Thr Trp Ser Gly Ile Glu Ala Tyr Arg Ala Ala
 245 250 255
 Ala Ala Asn Ala Pro Arg Gln Lys Gln Ile Gly Thr Leu Phe Arg Glu

```
<210> 67
<211> 317
<212> PRT
<213> Archaeoglobus fulgidus
```

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Met | Leu | Ile | His | Lys | Ala | Leu | Pro | Glu | Val | Asp | Tyr | Trp | Lys | Ile |
| 1 | | | 5 | | | | | | 10 | | | | | 15 | |
| Asp | Thr | Glu | Ile | Glu | Phe | Phe | Gly | Lys | Lys | Leu | Ser | Phe | Pro | Leu | Leu |
| | | 20 | | | | | | 25 | | | | | 30 | | |
| Ile | Ala | Ser | Met | Thr | Gly | Gly | His | Pro | Glu | Thr | Lys | Glu | Ile | Asn | Ala |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Arg | Leu | Gly | Glu | Ala | Val | Glu | Glu | Ala | Gly | Ile | Gly | Met | Gly | Val | Gly |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Ser | Gln | Arg | Ala | Ala | Ile | Glu | Asp | Glu | Ser | Leu | Ala | Asp | Ser | Phe | Thr |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Val | Val | Arg | Glu | Lys | Ala | Pro | Asn | Ala | Phe | Val | Tyr | Ala | Asn | Ile | Gly |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Met | Pro | Gln | Val | Ile | Glu | Arg | Gly | Val | Glu | Ile | Val | Asp | Arg | Ala | Val |
| | | 100 | | | | | | 105 | | | | | 110 | | |
| Glu | Met | Ile | Asp | Ala | Asp | Ala | Val | Ala | Ile | His | Leu | Asn | Tyr | Leu | Gln |

115 120 125
 Glu Ala Ile Gln Pro Glu Gly Asp Leu Asn Ala Glu Lys Gly Leu Glu
 130 135 140
 Val Leu Glu Glu Val Cys Arg Ser Val Lys Val Pro Val Ile Ala Lys
 145 150 155 160
 Glu Thr Gly Ala Gly Ile Ser Arg Glu Val Ala Val Met Leu Lys Arg
 165 170 175
 Ala Gly Val Ser Ala Ile Asp Val Gly Gly Lys Gly Gly Thr Thr Phe
 180 185 190
 Ser Gly Val Glu Val Tyr Arg Val Asn Asp Glu Val Ser Lys Ser Val
 195 200 205
 Gly Ile Asp Phe Trp Asp Trp Gly Leu Pro Thr Ala Phe Ser Ile Val
 210 215 220
 Asp Cys Arg Gly Ile Leu Pro Val Ile Ala Thr Gly Gly Leu Arg Ser
 225 230 235 240
 Gly Leu Asp Val Ala Lys Ser Ile Ala Ile Gly Ala Glu Leu Gly Ser
 245 250 255
 Ala Ala Leu Pro Phe Leu Arg Ala Ala Val Glu Ser Ala Glu Lys Val
 260 265 270
 Arg Glu Glu Ile Glu Tyr Phe Arg Arg Gly Leu Lys Thr Ala Met Phe
 275 280 285
 Leu Thr Gly Cys Lys Asn Val Glu Glu Leu Lys Gly Leu Lys Val Phe
 290 295 300
 Val Ser Gly Arg Leu Lys Glu Trp Ile Asp Phe Arg Gly
 305 310 315

<210> 68

<211> 370

<212> PRT

<213> *Pyrococcus abyssi*

<400> 68

Met Glu Glu Gln Thr Ile Leu Arg Lys Phe Glu His Ile Lys His Cys
 1 5 10 15
 Leu Thr Lys Asn Val Glu Ala His Val Thr Asn Gly Phe Glu Asp Val
 20 25 30
 His Leu Ile His Lys Ser Leu Pro Glu Ile Asp Lys Asp Glu Ile Asp

| 35 | | | | | 40 | | | | | 45 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ser | Val | Lys | Phe | Leu | Gly | Arg | Lys | Phe | Asp | Tyr | Pro | Ile | Met | Ile |
| 50 | | | | | 55 | | | | | 60 | | | | | |
| Thr | Gly | Met | Thr | Gly | Gly | Thr | Arg | Lys | Gly | Glu | Ile | Ala | Trp | Arg | Ile |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Asn | Arg | Thr | Leu | Ala | Gln | Ala | Ala | Gln | Glu | Leu | Asn | Ile | Pro | Leu | Gly |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Leu | Gly | Ser | Gln | Arg | Ala | Met | Ile | Glu | Lys | Pro | Glu | Thr | Trp | Glu | Ser |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Tyr | Tyr | Val | Arg | Asp | Val | Ala | Pro | Asp | Val | Phe | Leu | Val | Gly | Asn | Leu |
| | | 115 | | | | | 120 | | | | | | 125 | | |
| Gly | Ala | Pro | Gln | Phe | Gly | Arg | Asn | Ala | Lys | Lys | Arg | Tyr | Ser | Val | Asp |
| 130 | | | | | 135 | | | | | 140 | | | | | |
| Glu | Val | Leu | Tyr | Ala | Ile | Glu | Lys | Ile | Glu | Ala | Asp | Ala | Ile | Ala | Ile |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| His | Met | Asn | Pro | Leu | Gln | Glu | Ser | Ile | Gln | Pro | Glu | Gly | Asp | Thr | Thr |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Phe | Ser | Gly | Val | Leu | Glu | Ala | Leu | Ala | Glu | Ile | Thr | Ser | Thr | Ile | Asp |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Tyr | Pro | Val | Ile | Ala | Lys | Glu | Thr | Gly | Ala | Gly | Val | Ser | Lys | Glu | Val |
| | | 195 | | | | | 200 | | | | | | 205 | | |
| Ala | Val | Glu | Leu | Glu | Ala | Val | Gly | Val | Asp | Ala | Ile | Asp | Ile | Ser | Gly |
| 210 | | | | | 215 | | | | | 220 | | | | | |
| Leu | Gly | Gly | Thr | Ser | Trp | Ser | Ala | Val | Glu | Tyr | Tyr | Arg | Thr | Lys | Asp |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Gly | Glu | Lys | Arg | Asn | Leu | Ala | Leu | Lys | Phe | Trp | Asp | Trp | Gly | Ile | Lys |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Thr | Ala | Ile | Ser | Leu | Ala | Glu | Val | Arg | Trp | Ala | Thr | Asn | Leu | Pro | Ile |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Ile | Ala | Ser | Gly | Gly | Met | Arg | Asp | Gly | Ile | Thr | Met | Ala | Lys | Ala | Leu |
| | | | 275 | | | | 280 | | | | | | 285 | | |
| Ala | Met | Gly | Ala | Ser | Met | Val | Gly | Ile | Ala | Leu | Pro | Val | Leu | Arg | Pro |
| | | | 290 | | | | 295 | | | | | | 300 | | |
| Ala | Ala | Lys | Gly | Asp | Val | Glu | Gly | Val | Ile | Arg | Ile | Ile | Lys | Gly | Tyr |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Ala | Glu | Glu | Ile | Arg | Asn | Val | Met | Phe | Leu | Val | Gly | Ala | Arg | Asn | Ile |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Lys | Glu | Leu | Arg | Lys | Val | Pro | Leu | Val | Ile | Thr | Gly | Phe | Val | Arg | Glu |

85-

195 200 205
 Val Ala Ile Glu Leu Glu Ser Val Gly Ile Asp Ala Ile Asp Ile Ser
 210 215 220
 Gly Leu Gly Gly Thr Ser Trp Ser Ala Val Glu Tyr Tyr Arg Ala Lys
 225 230 235 240
 Asp Ser Glu Lys Arg Lys Ile Ala Leu Lys Phe Trp Asp Trp Gly Ile
 245 250 255
 Lys Thr Ala Ile Ser Leu Ala Glu Val Arg Trp Ala Thr Asn Leu Pro
 260 265 270
 Ile Ile Ala Ser Gly Gly Met Arg Asp Gly Val Met Met Ala Lys Ala
 275 280 285
 Leu Ala Met Gly Ala Ser Leu Val Gly Ile Ala Leu Pro Val Leu Arg
 290 295 300
 Pro Ala Ala Arg Gly Asp Val Glu Gly Val Val Arg Ile Ile Arg Gly
 305 310 315 320
 Tyr Ala Glu Glu Ile Lys Asn Val Met Phe Leu Val Gly Ala Arg Asn
 325 330 335
 Ile Arg Glu Leu Arg Arg Val Pro Leu Val Ile Thr Gly Phe Val Arg
 340 345 350
 Glu Trp Leu Leu Gln Arg Ile Asp Leu Asn Ser Tyr Leu Arg Ser Arg
 355 360 365
 Phe Lys His
 370

<210> 70

<211> 349

<212> PRT

<213> Methanobacterium thermoautotrophicum

<400> 70

Met Ile Ser Asp Arg Lys Leu Glu His Leu Ile Leu Cys Ala Ser Cys
 1 5 10 15
 Asp Val Glu Tyr Arg Lys Lys Thr Gly Phe Glu Asp Ile Glu Ile Val
 20 25 30
 His Arg Ala Ile Pro Glu Ile Asn Lys Glu Lys Ile Asp Ile Ser Leu
 35 40 45
 Asp Phe Leu Gly Arg Glu Leu Ser Ser Pro Val Met Ile Ser Ala Ile

| 50 | 55 | 60 |
|--|----|----|
| Thr Gly Gly His Pro Ala Ser Met Lys Ile Asn Arg Glu Leu Ala Arg 65 70 75 80 | | |
| Ala Ala Glu Lys Leu Gly Ile Ala Leu Gly Leu Gly Ser Gln Arg Ala 85 90 95 | | |
| Gly Val Glu His Pro Glu Leu Glu Gly Thr Tyr Thr Ile Ala Arg Glu 100 105 110 | | |
| Glu Ala Pro Ser Ala Met Leu Ile Gly Asn Ile Gly Ser Ser His Ile 115 120 125 | | |
| Glu Tyr Ala Glu Arg Ala Val Glu Met Ile Asp Ala Asp Ala Leu Ala 130 135 140 | | |
| Val His Leu Asn Pro Leu Gln Glu Ser Ile Gln Pro Gly Gly Asp Val 145 150 155 160 | | |
| Asp Ser Ser Gly Ala Leu Glu Ser Ile Ser Ala Ile Val Glu Ser Val 165 170 175 | | |
| Asp Val Pro Val Met Val Lys Glu Thr Gly Ala Gly Ile Cys Ser Glu 180 185 190 | | |
| Asp Ala Ile Glu Leu Glu Ser Cys Gly Val Ser Ala Ile Asp Val Ala 195 200 205 | | |
| Gly Ala Gly Gly Thr Ser Trp Ala Ala Val Glu Thr Tyr Arg Ala Asp 210 215 220 | | |
| Asp Arg Tyr Leu Gly Glu Leu Phe Trp Asp Trp Gly Ile Pro Thr Ala 225 230 235 240 | | |
| Ala Ser Thr Val Glu Val Val Glu Ser Val Ser Ile Pro Val Ile Ala 245 250 255 | | |
| Ser Gly Gly Ile Arg Ser Gly Ile Asp Ala Ala Lys Ala Ile Ser Leu 260 265 270 | | |
| Gly Ala Glu Met Val Gly Ile Ala Leu Pro Val Leu Glu Ala Ala Gly 275 280 285 | | |
| His Gly Tyr Arg Glu Val Ile Lys Val Ile Glu Gly Phe Asn Glu Ala 290 295 300 | | |
| Leu Arg Thr Ala Met Tyr Leu Ala Gly Ala Glu Thr Leu Asp Asp Leu 305 310 315 320 | | |
| Lys Lys Ser Pro Val Ile Ile Thr Gly His Thr Gly Glu Trp Leu Asn 325 330 335 | | |
| Gln Arg Gly Phe Glu Thr Lys Lys Tyr Ala Arg Arg Ser 340 345 | | |

<210> 71

<211> 359

<212> PRT

<213> Methanococcus jannaschii

<400> 71

Met Val Asn Asn Arg Asn Glu Ile Glu Val Arg Lys Leu Glu His Ile
 1 5 10 15
 Phe Leu Cys Ser Tyr Cys Asn Val Glu Tyr Glu Lys Thr Thr Leu Leu
 20 25 30
 Glu Asp Ile Glu Leu Ile His Lys Gly Thr Cys Gly Ile Asn Phe Asn
 35 40 45
 Asp Ile Glu Thr Glu Ile Glu Leu Phe Gly Lys Lys Leu Ser Ala Pro
 50 55 60
 Ile Ile Val Ser Gly Met Thr Gly Gly His Ser Lys Ala Lys Glu Ile
 65 70 75 80
 Asn Lys Asn Ile Ala Lys Ala Val Glu Glu Leu Gly Leu Gly Met Gly
 85 90 95
 Val Gly Ser Gln Arg Ala Ala Ile Val Asn Asp Glu Leu Ile Asp Thr
 100 105 110
 Tyr Ser Ile Val Arg Asp Tyr Thr Asn Asn Leu Val Ile Gly Asn Leu
 115 120 125
 Gly Ala Val Asn Phe Ile Val Asp Asp Trp Asp Glu Glu Ile Ile Asp
 130 135 140
 Lys Ala Ile Glu Met Ile Asp Ala Asp Ala Ile Ala Ile His Phe Asn
 145 150 155 160
 Pro Leu Gln Glu Ile Ile Gln Pro Glu Gly Asp Leu Asn Phe Lys Asn
 165 170 175
 Leu Tyr Lys Leu Lys Glu Ile Ile Ser Asn Tyr Lys Lys Ser Tyr Lys
 180 185 190
 Asn Ile Pro Phe Ile Ala Lys Gln Val Gly Glu Gly Phe Ser Lys Glu
 195 200 205
 Asp Ala Leu Ile Leu Lys Asp Ile Gly Phe Asp Ala Ile Asp Val Gln
 210 215 220
 Gly Ser Gly Gly Thr Ser Trp Ala Lys Val Glu Ile Tyr Arg Val Lys
 225 230 235 240
 Glu Glu Glu Ile Lys Arg Leu Ala Glu Lys Phe Ala Asn Trp Gly Ile

| | |
|-------|--------------------------|
| <210> | 72 |
| <211> | 348 |
| <212> | PRT |
| <213> | Thermoplasma acidophilum |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Ile | Gly | Lys | Arg | Lys | Glu | Glu | His | Ile | Arg | Ile | Ala | Glu | Asn | Glu | |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| Asp | Val | Ser | Ser | Phe | His | Asn | Phe | Trp | Asp | Asp | Ile | Ser | Leu | Met | His | |
| | | | 20 | | | | | 25 | | | | | 30 | | | |
| Glu | Ala | Asp | Pro | Glu | Val | Asn | Tyr | Asp | Glu | Ile | Asp | Thr | Ser | Val | Asp | |
| | | 35 | | | | | 40 | | | | | 45 | | | | |
| Phe | Leu | Gly | Lys | Lys | Leu | Lys | Phe | Pro | Met | Ile | Ile | Ser | Ser | Met | Thr | |
| | 50 | | | | | 55 | | | | | 60 | | | | | |
| Gly | Gly | Ala | Glu | Ile | Ala | Lys | Asn | Ile | Asn | Arg | Asn | Leu | Ala | Val | Ala | |
| 65 | | | | | 70 | | | | | 75 | | | | | -80 | |
| Ala | Glu | Arg | Phe | Gly | Ile | Gly | Met | Gly | Val | Gly | Ser | Met | Arg | Ala | Ala | |
| | | | | 85 | | | | | 90 | | | | | 95 | | |
| Ile | Val | Asp | Arg | Ser | Ile | Glu | Asp | Thr | Tyr | Ser | Val | Ile | Asn | Glu | Ser | |
| | | | 100 | | | | | 105 | | | | | 110 | | | |
| His | Val | Pro | Leu | Lys | Ile | Ala | Asn | Ile | Gly | Ala | Pro | Gln | Leu | Val | Arg | |

| | | | | |
|---|--|-----|--|-----|
| 115 | | 120 | | 125 |
| Gln Asp Lys Asp Ala Val Ser Asn Arg Asp Ile Ala Tyr Ile Tyr Asp | | | | |
| 130 | | 135 | | 140 |
| Leu Ile Lys Ala Asp Phe Leu Ala Val His Phe Asn Phe Leu Gln Glu | | | | |
| 145 | | 150 | | 155 |
| Met Val Gln Pro Glu Gly Asp Arg Asn Ser Lys Gly Val Ile Asp Arg | | | | |
| | | 165 | | 170 |
| Ile Lys Asp Leu Ser Gly Ser Phe Asn Ile Ile Ala Lys Glu Thr Gly | | | | |
| | | 180 | | 185 |
| Ser Gly Phe Ser Arg Arg Thr Ala Glu Arg Leu Ile Asp Ala Gly Val | | | | |
| | | 195 | | 200 |
| Lys Ala Ile Glu Val Ser Gly Val Ser Gly Thr Thr Phe Ala Ala Val | | | | |
| | | 210 | | 215 |
| Glu Tyr Tyr Arg Ala Arg Lys Glu Asn Asn Leu Glu Lys Met Arg Ile | | | | |
| | | 225 | | 230 |
| Gly Glu Thr Phe Trp Asn Trp Gly Ile Pro Ser Pro Ala Ser Val Tyr | | | | |
| | | 245 | | 250 |
| Tyr Cys Ser Asp Leu Ala Pro Val Ile Gly Ser Gly Gly Leu Arg Asn | | | | |
| | | 260 | | 265 |
| Gly Leu Asp Leu Ala Lys Ala Ile Ala Met Gly Ala Thr Ala Gly Gly | | | | |
| | | 275 | | 280 |
| Phe Ala Arg Ser Leu Leu Lys Asp Ala Asp Thr Asp Pro Glu Met Leu | | | | |
| | | 290 | | 295 |
| Met Lys Asn Ile Glu Leu Ile Gln Arg Glu Phe Arg Val Ala Leu Phe | | | | |
| | | 305 | | 310 |
| Leu Thr Gly Asn Lys Asn Val Tyr Glu Leu Lys Phe Thr Lys Lys Val | | | | |
| | | 325 | | 330 |
| Ile Val Asp Pro Leu Arg Ser Trp Leu Glu Ala Lys | | | | |
| | | 340 | | 345 |

<210> 73

<211> 357

<212> PRT

<213> Leishmania major

<400> 73

Met Ser Ser Arg Asp Cys Thr Val Asp Arg Glu Ala Ala Val Gln Lys

| 1 | 5 | 10 | 15 |
|---|-----|-----|-----|
| Arg Lys Lys Asp His Ile Asp Ile Cys Leu His Gln Asp Val Glu Pro | 20 | 25 | 30 |
| His Lys Arg Arg Thr Ser Ile Trp Asn Lys Tyr Thr Leu Pro Tyr Lys | 35 | 40 | 45 |
| Ala Leu Pro Glu Val Asp Leu Gln Lys Ile Asp Thr Ser Cys Glu Phe | 50 | 55 | 60 |
| Met Gly Lys Arg Ile Ser Phe Pro Phe Phe Ile Ser Ser Met Thr Gly | 65 | 70 | 75 |
| Gly Glu Ala His Gly Arg Val Ile Asn Glu Asn Leu Ala Lys Ala Cys | 85 | 90 | 95 |
| Glu Ala Glu Lys Ile Pro Phe Gly Leu Gly Ser Met Arg Ile Ile Asn | 100 | 105 | 110 |
| Arg Tyr Ala Ser Ala Val His Thr Phe Asn Val Lys Glu Phe Cys Pro | 115 | 120 | 125 |
| Ser Val Pro Met Leu Ala Asn Ile Gly Leu Val Gln Leu Asn Tyr Gly | 130 | 135 | 140 |
| Phe Gly Pro Lys Glu Val Asn Asn Leu Val Asn Ser Val Arg Ala Asp | 145 | 150 | 155 |
| Gly Leu Cys Ile His Leu Asn His Thr Gln Glu Val Cys Gln Pro Glu | 165 | 170 | 175 |
| Gly Asp Thr Asn Phe Glu Gly Leu Ile Glu Lys Leu Arg Gln Leu Leu | 180 | 185 | 190 |
| Pro His Ile Lys Val Pro Val Leu Val Lys Gly Val Gly His Gly Ile | 195 | 200 | 205 |
| Asp Tyr Glu Ser Met Val Ala Ile Lys Ala Ser Gly Val Lys Tyr Val | 210 | 215 | 220 |
| Asp Val Ser Gly Cys Gly Gly Thr Ser Trp Ala Trp Ile Glu Gly Arg | 225 | 230 | 235 |
| Arg Gln Pro Tyr Lys Ala Glu Glu Glu Asn Ile Gly Tyr Leu Leu Arg | 245 | 250 | 255 |
| Asp Ile Gly Val Pro Thr Asp Val Cys Leu Arg Glu Ser Ala Pro Leu | 260 | 265 | 270 |
| Thr Val Asn Gly Asp Leu His Leu Ile Ala Gly Gly Gly Ile Arg Asn | 275 | 280 | 285 |
| Gly Met Asp Val Ala Lys Ala Leu Met Met Gly Ala Glu Tyr Ala Thr | 290 | 295 | 300 |
| Ala Ala Met Pro Phe Leu Ala Ala Ala Leu Glu Ser Ser Glu Ala Val | | | |

305 310 315 320
 Arg Ala Val Ile Gln Arg Met Arg Gln Glu Leu Arg Val Ser Met Phe
 325 330 335
 Thr Cys Gly Ala Arg Asn Ile Glu Glu Leu Arg Arg Met Lys Val Ile
 340 345 350
 Glu Leu Gly His Leu
 355
 <210> 74
 <211> 398
 <212> PRT
 <213> Streptococcus pneumoniae

 <400> 74
 Met Asn Asp Lys Thr Glu Val Asn Met Thr Ile Gly Ile Asp Lys Ile
 1 5 10 15
 Gly Phe Ala Thr Ser Gln Tyr Val Leu Lys Leu Gln Asp Leu Ala Glu
 20 25 30
 Ala Arg Gly Ile Asp Pro Glu Lys Leu Ser Lys Gly Leu Leu Leu Lys
 35 40 45
 Glu Leu Ser Ile Ala Pro Leu Thr Glu Asp Ile Val Thr Leu Ala Ala
 50 55 60
 Ser Ala Ser Asp Ser Ile Leu Thr Glu Gln Glu Arg Gln Glu Val Asp
 65 70 75 80
 Met Val Ile Val Ala Thr Glu Ser Gly Ile Asp Gln Ser Lys Ala Ala
 85 90 95
 Ala Val Phe Val His Gly Leu Leu Gly Ile Gln Pro Phe Ala Arg Ser
 100 105 110
 Phe Glu Ile Lys Glu Ala Cys Tyr Gly Ala Thr Ala Ala Leu His Tyr
 115 120 125
 Ala Lys Leu His Val Glu Asn Ser Pro Glu Ser Lys Val Leu Val Ile
 130 135 140
 Ala Ser Asp Ile Ala Lys Tyr Gly Ile Glu Thr Pro Gly Glu Pro Thr
 145 150 155 160
 Gln Gly Ala Gly Ser Val Ala Met Leu Ile Thr Gln Asn Pro Arg Met
 165 170 175
 Met Ala Phe Asn Asn Asp Asn Val Ala Gln Thr Arg Asp Ile Met Asp

| | | |
|---|-----|-----|
| 180 | 185 | 190 |
| Phe Trp Arg Pro Asn Tyr Ser Thr Thr Pro Tyr Val Asn Gly Val Tyr | | |
| 195 | 200 | 205 |
| Ser Thr Gln Gln Tyr Leu Asp Ser Leu Lys Thr Thr Trp Leu Glu Tyr | | |
| 210 | 215 | 220 |
| Gln Lys Arg Tyr Gln Leu Thr Leu Asp Asp Phe Ala Ala Val Cys Phe | | |
| 225 | 230 | 235 |
| His Leu Pro Tyr Pro Lys Leu Ala Leu Lys Gly Leu Lys Lys Ile Met | | |
| 245 | 250 | 255 |
| Asp Lys Asn Leu Pro Gln Glu Lys Lys Asp Leu Leu Gln Lys His Phe | | |
| 260 | 265 | 270 |
| Asp Gln Ser Ile Leu Tyr Ser Gln Lys Val Gly Asn Ile Tyr Thr Gly | | |
| 275 | 280 | 285 |
| Ser Leu Phe Leu Gly Leu Leu Ser Leu Leu Glu Asn Thr Asp Ser Leu | | |
| 290 | 295 | 300 |
| Lys Ala Gly Asp Lys Ile Ala Leu Tyr Ser Tyr Gly Ser Gly Ala Val | | |
| 305 | 310 | 315 |
| Ala Glu Phe Phe Ser Gly Glu Leu Val Glu Gly Tyr Glu Ala Tyr Leu | | |
| 325 | 330 | 335 |
| Asp Lys Asp Arg Leu Asn Lys Leu Asn Gln Arg Thr Ala Leu Ser Val | | |
| 340 | 345 | 350 |
| Ala Asp Tyr Glu Lys Val Phe Phe Glu Glu Val Asn Leu Asp Glu Thr | | |
| 355 | 360 | 365 |
| Asn Ser Ala Gln Phe Ala Gly Tyr Glu Asn Gln Asp Phe Ala Leu Val | | |
| 370 | 375 | 380 |
| Glu Ile Leu Asp His Gln Arg Arg Tyr Ser Lys Val Glu Lys | | |
| 385 | 390 | 395 |

<210> 75

<211> 391

<212> PRT

<213> Streptococcus pyrogenes

<400> 75

| |
|---|
| Met Thr Ile Gly Ile Asp Lys Ile Gly Phe Ala Thr Ser Gln Tyr Val |
| 1 5 10 15 |

Leu Lys Leu Glu Asp Leu Ala Leu Ala Arg Gln Val Asp Pro Ala Lys

94

325 330 335
 Asp Gln Arg Thr Arg Leu Ser Val Ser Lys Tyr Glu Asp Leu Phe Tyr
 340 345 350
 Glu Gln Val Gln Leu Asp Asp Asn Gly Asn Ala Asn Phe Asp Ile Tyr
 355 360 365
 Leu Thr Gly Lys Phe Ala Leu Thr Ala Ile Lys Glu His Gln Arg Ile
 370 375 380
 Tyr His Thr Asn Asp Lys Asn
 385 390
 <210> 76
 <211> 383
 <212> PRT
 <213> Enterococcus faecalis

 <400> 76
 Met Thr Ile Gly Ile Asp Lys Ile Ser Phe Phe Val Pro Pro Tyr Tyr
 1 5 10 15
 Ile Asp Met Thr Ala Leu Ala Glu Ala Arg Asn Val Asp Pro Gly Lys
 20 25 30
 Phe His Ile Gly Ile Gly Gln Asp Gln Met Ala Val Asn Pro Ile Ser
 35 40 45
 Gln Asp Ile Val Thr Phe Ala Ala Asn Ala Ala Glu Ala Ile Leu Thr
 50 55 60
 Lys Glu Asp Lys Glu Ala Ile Asp Met Val Ile Val Gly Thr Glu Ser
 65 70 75 80
 Ser Ile Asp Glu Ser Lys Ala Ala Ala Val Val Leu His Arg Leu Met
 85 90 95
 Gly Ile Gln Pro Phe Ala Arg Ser Phe Glu Ile Lys Glu Ala Cys Tyr
 100 105 110
 Gly Ala Thr Ala Gly Leu Gln Leu Ala Lys Asn His Val Ala Leu His
 115 120 125
 Pro Asp Lys Lys Val Leu Val Val Ala Ala Asp Ile Ala Lys Tyr Gly
 130 135 140
 Leu Asn Ser Gly Gly Glu Pro Thr Gln Gly Ala Gly Ala Val Ala Met
 145 150 155 160
 Leu Val Ala Ser Glu Pro Arg Ile Leu Ala Leu Lys Glu Asp Asn Val

Met Lys Ile Gly Ile Asp Arg Leu Ser Phe Phe Ile Pro Asn Leu Tyr
1 5 10 15
Leu Asp Met Thr Glu Leu Ala Glu Ser Arg Gly Asp Asp Pro Ala Lys

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | His | Ile | Gly | Ile | Gly | Gln | Asp | Gln | Met | Ala | Val | Asn | Arg | Ala | Asn |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Glu | Asp | Ile | Ile | Thr | Leu | Gly | Ala | Asn | Ala | Ala | Ser | Lys | Ile | Val | Thr |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Glu | Lys | Asp | Arg | Glu | Leu | Ile | Asp | Met | Val | Ile | Val | Gly | Thr | Glu | Ser |
| 65 | | | | | 70 | | | | | 75 | | | | 80 | |
| Gly | Ile | Asp | His | Ser | Lys | Ala | Ser | Ala | Val | Ile | Ile | His | His | Leu | Leu |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Lys | Ile | Gln | Ser | Phe | Ala | Arg | Ser | Phe | Glu | Val | Lys | Glu | Ala | Cys | Tyr |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Gly | Gly | Thr | Ala | Ala | Leu | His | Met | Ala | Lys | Glu | Tyr | Val | Lys | Asn | His |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Pro | Glu | Arg | Lys | Val | Leu | Val | Ile | Ala | Ser | Asp | Ile | Ala | Arg | Tyr | Gly |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Leu | Ala | Ser | Gly | Gly | Glu | Val | Thr | Gln | Gly | Val | Gly | Ala | Val | Ala | Met |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Met | Ile | Thr | Gln | Asn | Pro | Arg | Ile | Leu | Ser | Ile | Glu | Asp | Asp | Ser | Val |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Phe | Leu | Thr | Glu | Asp | Ile | Tyr | Asp | Phe | Trp | Arg | Pro | Asp | Tyr | Ser | Glu |
| | | 180 | | | | | | 185 | | | | | 190 | | |
| Phe | Pro | Val | Val | Asp | Gly | Pro | Leu | Ser | Asn | Ser | Thr | Tyr | Ile | Glu | Ser |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Phe | Gln | Lys | Val | Trp | Asn | Arg | His | Lys | Glu | Leu | Ser | Gly | Arg | Gly | Leu |
| | 210 | | | | | 215 | | | | | | 220 | | | |
| Glu | Asp | Tyr | Gln | Ala | Ile | Ala | Phe | His | Ile | Pro | Tyr | Thr | Lys | Met | Gly |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Lys | Lys | Ala | Leu | Gln | Ser | Val | Leu | Asp | Gln | Thr | Asp | Glu | Asp | Asn | Gln |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Glu | Arg | Leu | Met | Ala | Arg | Tyr | Glu | Glu | Ser | Ile | Arg | Tyr | Ser | Arg | Arg |
| | | 260 | | | | | | 265 | | | | | 270 | | |
| Ile | Gly | Asn | Leu | Tyr | Thr | Gly | Ser | Leu | Tyr | Leu | Gly | Leu | Thr | Ser | Leu |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Leu | Glu | Asn | Ser | Lys | Ser | Leu | Gln | Pro | Gly | Asp | Arg | Ile | Gly | Leu | Phe |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Ser | Tyr | Gly | Ser | Gly | Ala | Val | Ser | Glu | Phe | Phe | Thr | Gly | Tyr | Leu | Glu |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Glu | Asn | Tyr | Gln | Glu | Tyr | Leu | Phe | Ala | Gln | Ser | His | Gln | Glu | Met | Leu |

98

| 180 | 185 | 190 |
|--|-----|-----|
| Tyr Pro Leu Val Ala Gly Ala Leu Ser Lys Asp Ala Tyr Ile Lys Ser 195 200 205 | | |
| Phe Gln Glu Ser Trp Asn Glu Tyr Ala Arg Arg Glu Asp Lys Thr Leu 210 215 220 | | |
| Ser Asp Phe Glu Ser Leu Cys Phe His Val Pro Phe Thr Lys Met Gly 225 230 235 240 | | |
| Lys Lys Ala Leu Asp Ser Ile Ile Asn Asp Ala Asp Glu Thr Thr Gln 245 250 255 | | |
| Glu Arg Leu Thr Ser Gly Tyr Glu Asp Ala Val Tyr Tyr Asn Arg Tyr 260 265 270 | | |
| Val Gly Asn Ile Tyr Thr Gly Ser Leu Tyr Leu Ser Leu Ile Ser Leu 275 280 285 | | |
| Leu Glu Asn Arg Ser Leu Lys Gly Gly Gln Thr Ile Gly Leu Phe Ser 290 295 300 | | |
| Tyr Gly Ser Gly Ser Val Gly Glu Phe Phe Ser Ala Thr Leu Val Glu 305 310 315 320 | | |
| Gly Tyr Glu Lys Gln Leu Asp Ile Glu Gly His Lys Ala Leu Leu Asn 325 330 335 | | |
| Glu Arg Gln Glu Val Ser Val Glu Asp Tyr Glu Ser Phe Phe Lys Arg 340 345 350 | | |
| Phe Asp Asp Leu Glu Phe Asp His Ala Thr Glu Gln Thr Asp Asp Asp 355 360 365 | | |
| Lys Ser Ile Tyr Tyr Leu Glu Asn Ile Gln Asp Asp Ile Arg Gln Tyr 370 375 380 | | |
| His Ile Pro Lys 385 | | |

<210> 79

<211> 388

<212> PRT

<213> Staphylococcus epidermis

<400> 79

| |
|--|
| Met Asn Ile Gly Ile Asp Lys Ile Ser Phe Tyr Val Pro Lys Tyr Tyr 1 5 10 15 |
|--|

Val Asp Met Ala Lys Leu Ala Glu Ala Arg Gln Val Asp Pro Asn Lys

20 25 30
 Phe Leu Ile Gly Ile Gly Gln Thr Glu Met Thr Val Ser Pro Val Asn
 35 40 45
 Gln Asp Ile Val Ser Met Gly Ala Asn Ala Ala Lys Asp Ile Ile Thr
 50 55 60
 Glu Glu Asp Lys Lys Asn Ile Gly Met Val Ile Val Ala Thr Glu Ser
 65 70 75 80
 Ala Ile Asp Asn Ala Lys Ala Ala Ala Val Gln Ile His His Leu Leu
 85 90 95
 Gly Ile Gln Pro Phe Ala Arg Cys Phe Glu Met Lys Glu Ala Cys Tyr
 100 105 110
 Ala Ala Thr Pro Ala Ile Gln Leu Ala Lys Asp Tyr Leu Ala Gln Arg
 115 120 125
 Pro Asn Glu Lys Val Leu Val Ile Ala Ser Asp Thr Ala Arg Tyr Gly
 130 135 140
 Ile His Ser Gly Gly Glu Pro Thr Gln Gly Ala Gly Ala Val Ala Met
 145 150 155 160
 Met Ile Ser His Asp Pro Ser Ile Leu Lys Leu Asn Asp Asp Ala Val
 165 170 175
 Ala Tyr Thr Glu Asp Val Tyr Asp Phe Trp Arg Pro Thr Gly His Gln
 180 185 190
 Tyr Pro Leu Val Ala Gly Ala Leu Ser Lys Asp Ala Tyr Ile Lys Ser
 195 200 205
 Phe Gln Glu Ser Trp Asn Glu Tyr Ala Arg Arg His Asn Lys Thr Leu
 210 215 220
 Ala Asp Phe Ala Ser Leu Cys Phe His Val Pro Phe Thr Lys Met Gly
 225 230 235 240
 Gln Lys Ala Leu Asp Ser Ile Ile Asn His Ala Asp Glu Thr Thr Gln
 245 250 255
 Asp Arg Leu Asn Ser Ser Tyr Gln Asp Ala Val Asp Tyr Asn Arg Tyr
 260 265 270
 Val Gly Asn Ile Tyr Thr Gly Ser Leu Tyr Leu Ser Leu Ile Ser Leu
 275 280 285
 Leu Glu Thr Arg Asp Leu Lys Gly Gly Gln Thr Ile Gly Leu Phe Ser
 290 295 300
 Tyr Gly Ser Gly Ser Val Gly Glu Phe Phe Ser Gly Thr Leu Val Asp
 305 310 315 320
 Gly Phe Lys Glu Gln Leu Asp Val Glu Arg His Lys Ser Leu Leu Asn

325 330 335
 Asn Arg Ile Glu Val Ser Val Asp Glu Tyr Glu His Phe Phe Lys Arg
 340 345 350
 Phe Asp Gln Leu Glu Leu Asn His Glu Leu Glu Lys Ser Asn Ala Asp
 355 360 365
 Arg Asp Ile Phe Tyr Leu Lys Ser Ile Asp Asn Asn Ile Arg Glu Tyr
 370 375 380
 His Ile Ala Glu
 385
 <210> 80
 <211> 388
 <212> PRT
 <213> Staphylococcus aureus

 <400> 80
 Met Thr Ile Gly Ile Asp Lys Ile Asn Phe Tyr Val Pro Lys Tyr Tyr
 1 5 10 15
 Val Asp Met Ala Lys Leu Ala Glu Ala Arg Gln Val Asp Pro Asn Lys
 20 25 30
 Phe Leu Ile Gly Ile Gly Gln Thr Glu Met Ala Val Ser Pro Val Asn
 35 40 45
 Gln Asp Ile Val Ser Met Gly Ala Asn Ala Ala Lys Asp Ile Ile Thr
 50 55 60
 Asp Glu Asp Lys Lys Lys Ile Gly Met Val Ile Val Ala Thr Glu Ser
 65 70 75 80
 Ala Val Asp Ala Ala Lys Ala Ala Ala Val Gln Ile His Asn Leu Leu
 85 90 95
 Gly Ile Gln Pro Phe Ala Arg Cys Phe Glu Met Lys Glu Ala Cys Tyr
 100 105 110
 Ala Ala Thr Pro Ala Ile Gln Leu Ala Lys Asp Tyr Leu Ala Thr Arg
 115 120 125
 Pro Asn Glu Lys Val Leu Val Ile Ala Thr Asp Thr Ala Arg Tyr Gly
 130 135 140
 Leu Asn Ser Gly Gly Glu Pro Thr Gln Gly Ala Gly Ala Val Ala Met
 145 150 155 160
 Val Ile Ala His Asn Pro Ser Ile Leu Ala Leu Asn Glu Asp Ala Val

165 170 175
 Ala Tyr Thr Glu Asp Val Tyr Asp Phe Trp Arg Pro Thr Gly His Lys
 180 185 190
 Tyr Pro Leu Val Asp Gly Ala Leu Ser Lys Asp Ala Tyr Ile Arg Ser
 195 200 205
 Phe Gln Gln Ser Trp Asn Glu Tyr Ala Lys Arg Gln Gly Lys Ser Leu
 210 215 220
 Ala Asp Phe Ala Ser Leu Cys Phe His Val Pro Phe Thr Lys Met Gly
 225 230 235 240
 Lys Lys Ala Leu Glu Ser Ile Ile Asp Asn Ala Asp Glu Thr Thr Gln
 245 250 255
 Glu Arg Leu Arg Ser Gly Tyr Glu Asp Ala Val Asp Tyr Asn Arg Tyr
 260 265 270
 Val Gly Asn Ile Tyr Thr Gly Ser Leu Tyr Leu Ser Leu Ile Ser Leu
 275 280 285
 Leu Glu Asn Arg Asp Leu Gln Ala Gly Glu Thr Ile Gly Leu Phe Ser
 290 295 300
 Tyr Gly Ser Gly Ser Val Val Glu Phe Tyr Ser Ala Thr Leu Val Val
 305 310 315 320
 Gly Tyr Lys Asp His Leu Asp Gln Ala Ala His Lys Ala Leu Leu Asn
 325 330 335
 Asn Arg Thr Glu Val Ser Val Asp Ala Tyr Glu Thr Phe Phe Lys Arg
 340 345 350
 Phe Asp Asp Val Glu Phe Asp Glu Glu Gln Asp Ala Val His Glu Asp
 355 360 365
 Arg His Ile Phe Tyr Leu Ser Asn Ile Glu Asn Asn Val Arg Glu Tyr
 370 375 380
 His Arg Pro Glu
 385

<210> 81

<211> 389

<212> PRT

<213> Staphylococcus carnosus

<400> 81

Met Thr Ile Gly Ile Asp Gln Leu Asn Phe Tyr Ile Pro Asn Phe Tyr

| | | | |
|-------------|-------------------------|---------------------|---------------------|
| 1 | 5 | 10 | 15 |
| Val Asp Met | Ala Glu Leu | Ala Glu Ala Arg Gly | Val Asp Pro Asn Lys |
| | 20 | 25 | 30 |
| Phe Leu Ile | Gly Ile Gly Gln Ser | Gln Met Ala Val Ser | Pro Val Ser |
| 35 | 40 | 45 | |
| Gln Asp Ile | Val Ser Met Gly Ala Asn | Ala Ala Gln Pro | Ile Leu Ser |
| 50 | 55 | 60 | |
| Glu Gln Asp | Lys Lys Asp Ile Thr Met | Val Ile Val Ala Thr | Glu Ser |
| 65 | 70 | 75 | 80 |
| Ala Ile Asp | Ser Ala Lys Ala Ser Ala | Val Gln Ile His His | Leu Leu |
| | 85 | 90 | 95 |
| Gly Ile Gln | Pro Phe Ala Arg Cys Phe | Glu Met Lys Glu Ala | Cys Tyr |
| | 100 | 105 | 110 |
| Ala Ala Thr | Pro Ala Ile Gln Leu Ala | Lys Asp Tyr Leu Val | Pro Arg |
| | 115 | 120 | 125 |
| Pro Lys Glu | Lys Val Leu Val Ile Ala | Ser Asp Thr Ala Arg | Tyr Gly |
| 130 | 135 | 140 | |
| Leu Asn Ser | Gly Gly Glu Pro Thr Gln | Gly Ala Gly Ala Val | Ala Met |
| 145 | 150 | 155 | 160 |
| Val Ile Ser | His Asn Pro Ser Ile Leu | Glu Leu His Asp Asp | Ser Val |
| | 165 | 170 | 175 |
| Ala Tyr Thr | Glu Asp Val Tyr Asp Phe | Trp Arg Pro Ser Gly | Glu Ile |
| | 180 | 185 | 190 |
| Tyr Pro Leu | Val Ala Gly Lys Leu Ser | Lys Asp Ala Tyr Ile | Lys Ser |
| | 195 | 200 | 205 |
| Phe Gln Glu | Ser Trp Asn Glu Tyr Ala | Lys Arg His His Lys | Ser Leu |
| 210 | 215 | 220 | |
| Ser Asp Phe | Ala Ala Leu Cys Phe His | Val Pro Phe Thr | Lys Met Gly |
| 225 | 230 | 235 | 240 |
| Gln Lys Ala | Leu Asp Ser Ile Leu Thr | Asp Ser Ala Ser Glu | Asp Thr |
| | 245 | 250 | 255 |
| Gln Ala Arg | Leu Asn Glu Gly Tyr Lys | Ser Ala Thr Asp Tyr | Asn Arg |
| | 260 | 265 | 270 |
| Tyr Val Gly | Asn Val Tyr Thr Gly Ser | Leu Tyr Leu Ser | Leu Ile Ser |
| | 275 | 280 | 285 |
| Leu Leu Glu | Asn His Lys Leu Asn Gly | Gly Asp Asn Ile Gly | Leu Phe |
| 290 | 295 | 300 | |
| Ser Tyr Gly | Ser Gly Ser Val Gly Glu | Phe Phe Ser Ala Thr | Leu Val |

104

145 150 155 160
 Ala Met Leu Val Gly Ala Asp Pro Ala Leu Leu Arg Ile Glu Glu Pro
 165 170 175
 Ser Gly Leu Phe Thr Ala Asp Val Met Asp Phe Trp Arg Pro Asn Tyr
 180 185 190
 Leu Thr Thr Ala Leu Val Asp Gly Gln Glu Ser Ile Asn Ala Tyr Leu
 195 200 205
 Gln Ala Val Glu Gly Ala Trp Lys Asp Tyr Ala Glu Gln Asp Gly Arg
 210 215 220
 Ser Leu Glu Glu Phe Ala Ala Phe Val Tyr His Gln Pro Phe Thr Lys
 225 230 235 240
 Met Ala Tyr Lys Ala His Arg His Leu Leu Asn Phe Asn Gly Tyr Asp
 245 250 255
 Thr Asp Lys Asp Ala Ile Glu Gly Ala Leu Gly Gln Thr Thr Ala Tyr
 260 265 270
 Asn Asn Val Ile Gly Asn Ser Tyr Thr Ala Ser Val Tyr Leu Gly Leu
 275 280 285
 Ala Ala Leu Leu Asp Gln Ala Asp Asp Leu Thr Gly Arg Ser Ile Gly
 290 295 300
 Phe Leu Ser Tyr Gly Ser Gly Ser Val Ala Glu Phe Phe Ser Gly Thr
 305 310 315 320
 Val Val Ala Gly Tyr Arg Glu Arg Leu Arg Thr Glu Ala Asn Gln Glu
 325 330 335
 Ala Ile Ala Arg Arg Lys Ser Val Asp Tyr Ala Thr Tyr Arg Glu Leu
 340 345 350
 His Glu Tyr Thr Leu Pro Ser Asp Gly Gly Asp His Ala Thr Pro Val
 355 360 365
 Gln Thr Thr Gly Pro Phe Arg Leu Ala Gly Ile Asn Asp His Lys Arg
 370 375 380

Ile Tyr Glu Ala Arg
385

<210> 83

<211> 389

<212> PRT

<213> Streptomyces griseolosporeus

<400> 83

```

Met Pro Leu Ala Ile Gly Ile His Asp Leu Ser Phe Ala Thr Gly Glu
1          5          10          15

Phe Val Leu Pro His Thr Ala Leu Ala Ala His Asn Gly Thr Glu Ile
20          25          30

Gly Lys Tyr His Ala Gly Ile Gly Gln Glu Ser Met Ser Val Pro Ala
35          40          45

Ala Asp Glu Asp Ile Val Thr Leu Ala Ala Thr Ala Ala Ala Pro Ile
50          55          60

Val Ala Arg His Gly Ser Asp Arg Ile Arg Thr Val Val Leu Ala Thr
65          70          75          80

Glu Ser Ser Ile Asp Gln Ala Lys Ser Ala Gly Val Tyr Val His Ser
85          90          95

Leu Leu Gly Leu Pro Ser Ala Thr Arg Val Val Glu Leu Lys Gln Ala
100         105         110

Cys Tyr Gly Ala Thr Ala Gly Leu Gln Phe Ala Ile Gly Leu Val Gln
115         120         125

Arg Asp Pro Ala Gln Gln Val Leu Val Ile Ala Ser Asp Val Ser Lys
130         135         140

Tyr Asp Leu Asp Ser Pro Gly Glu Ala Thr Gln Gly Ala Ala Ala Val
145         150         155         160

Ala Met Leu Val Gly Ala Asp Pro Gly Leu Val Arg Ile Glu Asp Pro
165         170         175

Ser Gly Leu Phe Thr Val Asp Val Met Asp Phe Trp Arg Pro Asn Tyr
180         185         190

Arg Thr Thr Ala Leu Val Asp Gly Gln Glu Ser Ile Gly Ala Tyr Leu
195         200         205

Gln Ala Val Glu Gly Ala Trp Lys Asp Tyr Ser Glu Arg Gly Gly His
210         215         220

Ser Leu Glu Gln Phe Ala Ala Phe Cys Tyr His Gln Pro Phe Thr Lys
225         230         235         240

Met Ala His Lys Ala His Arg His Leu Leu Asn Tyr Cys Ser His Asp
245         250         255

Ile His His Asp Asp Val Thr Arg Ala Val Gly Arg Thr Thr Ala Tyr
260         265         270

Asn Arg Val Ile Gly Asn Ser Tyr Thr Ala Ser Val Tyr Leu Gly Leu
275         280         285

Ala Ala Leu Leu Asp Gln Ala Asp Asp Leu Thr Gly Glu Arg Ile Gly

```

290 295 300
 Phe Leu Ser Tyr Gly Ser Gly Ser Val Ala Glu Phe Phe Gly Gly Ile
 305 310 315 320
 Val Val Ala Gly Tyr Arg Asp Arg Leu Arg Thr Ala Ala Asn Ile Glu
 325 330 335
 Ala Val Ser Arg Arg Arg Pro Ile Asp Tyr Ala Gly Tyr Arg Glu Leu
 340 345 350
 His Glu Trp Ala Phe Pro Ala Arg Arg Gly Ala His Ser Thr Pro Gln
 355 360 365
 Gln Thr Thr Gly Pro Phe Arg Leu Ser Gly Ile Ser Gly His Lys Arg
 370 375 380
 Leu Tyr Arg Ala Cys
 385

<210> 84

<211> 407

<212> PRT

<213> Borrelia burgdorferi

<400> 84

Met Arg Ile Gly Ile Ser Asp Ile Arg Ile Phe Leu Pro Leu Asn Tyr
 1 5 10 15
 Leu Asp Phe Ser Val Leu Leu Glu Asn Pro Leu Tyr Phe Ser Asn Glu
 20 25 30
 Val Phe Phe Lys Lys Ile Asn Arg Ala Ile Asp Ala Thr Leu Gln Lys
 35 40 45
 Gly Phe Arg Phe Thr Ser Pro Asn Glu Asp Ser Val Thr Met Ala Ser
 50 55 60
 Ser Ala Val Lys Leu Ile Phe Asp Asn Asn Asn Leu Asp Leu Ser Lys
 65 70 75 80
 Ile Arg Ile Leu Leu Gly Gly Thr Glu Thr Gly Val Asp His Ser Lys
 85 90 95
 Ala Ile Ser Ser Tyr Val Phe Gly Ala Leu Lys Gln Ser Gly Ile Cys
 100 105 110
 Leu Gly Asn Asn Phe Leu Thr Phe Gln Val Gln His Ala Cys Ala Gly
 115 120 125
 Ala Ala Met Ser Leu His Thr Val Ala Ser Val Leu Ser His Ser Asn

| 130 | 135 | 140 |
|--|-----|-----|
| Asn Ser Glu Tyr Gly Ile Val Phe Ser Ser Asp Ile Ala His Tyr Ser 145 150 155 160 | | |
| Asn Leu Thr Thr Ala Glu Ile Thr Gln Gly Ala Gly Ala Thr Ala Ile 165 170 175 | | |
| Leu Ile Glu Lys Asn Pro Lys Ile Leu Ser Ile Asn Leu Ser Glu Phe 180 185 190 | | |
| Gly Val Tyr Thr Asp Asp Val Asp Asp Phe Phe Arg Pro Phe Gly Ser 195 200 205 | | |
| Val Glu Ala Lys Val Arg Gly Gln Tyr Ser Val Glu Cys Tyr Asn Asn 210 215 220 | | |
| Ala Asn Glu Asn Ala Leu Arg Asp Phe Ala Phe Lys Lys Gln Leu Ser 225 230 235 240 | | |
| Met Lys Asp Leu Phe Ser Asn Tyr Arg Phe Val Leu His Val Pro Phe 245 250 255 | | |
| Ala Lys Met Pro Ile Asp Ser Met His Tyr Ile Leu Lys Lys Tyr Tyr 260 265 270 | | |
| Ser Asp Asp Glu Ser Val Arg Asn Ala Tyr Leu Glu Ser Ile Asp Phe 275 280 285 | | |
| Tyr Asp Gly Val Glu Ala Ala Met Glu Val Gly Asn Leu Tyr Thr Gly 290 295 300 | | |
| Ser Ile Phe Leu Ser Leu Ala Phe Tyr Leu Lys Arg Val Phe Ser Lys 305 310 315 320 | | |
| Lys Asp Ile Thr Gly Glu Lys Ile Leu Phe Cys Ser Tyr Gly Ser Gly 325 330 335 | | |
| Asn Ile Met Ile Ile Tyr Glu Leu Thr Ile Glu Lys Ser Ala Phe Asp 340 345 350 | | |
| Val Ile Lys Leu Trp Asp Leu Glu Gly Leu Ile Lys Asn Arg Asn Asn 355 360 365 | | |
| Ala Asn Phe Glu Glu Tyr Lys Asp Phe Phe Gln Asn Lys Ile Ile Pro 370 375 380 | | |
| Gly Glu Ser Arg Gly Phe Tyr Leu Lys Glu Leu Arg Asn Asp Gly Tyr 385 390 395 400 | | |
| Arg Val Tyr Gly Tyr Arg Ala 405 | | |

<210> 85

<211> 317

<212> PRT

<213> Streptococcus pneumoniae

<400> 85

Met Asp Arg Glu Pro Val Thr Val Arg Ser Tyr Ala Asn Ile Ala Ile
 1 5 10 15
 Ile Lys Tyr Trp Gly Lys Lys Lys Glu Lys Glu Met Val Pro Ala Thr
 20 25 30
 Ser Ser Ile Ser Leu Thr Leu Glu Asn Met Tyr Thr Glu Thr Thr Leu
 35 40 45
 Ser Pro Leu Pro Ala Asn Val Thr Ala Asp Glu Phe Tyr Ile Asn Gly
 50 55 60
 Gln Leu Gln Asn Glu Val Glu His Ala Lys Met Ser Lys Ile Ile Asp
 65 70 75 80
 Arg Tyr Arg Pro Ala Gly Glu Gly Phe Val Arg Ile Asp Thr Gln Asn
 85 90 95
 Asn Met Pro Thr Ala Ala Gly Leu Ser Ser Ser Ser Ser Gly Leu Ser
 100 105 110
 Ala Leu Val Lys Ala Cys Asn Ala Tyr Phe Lys Leu Gly Leu Asp Arg
 115 120 125
 Ser Gln Leu Ala Gln Glu Ala Lys Phe Ala Ser Gly Ser Ser Ser Arg
 130 135 140
 Ser Phe Tyr Gly Pro Leu Gly Ala Trp Asp Lys Asp Ser Gly Glu Ile
 145 150 155 160
 Tyr Pro Val Glu Thr Asp Leu Lys Leu Ala Met Ile Met Leu Val Leu
 165 170 175
 Glu Asp Lys Lys Lys Pro Ile Ser Ser Arg Asp Gly Met Lys Leu Cys
 180 185 190
 Val Glu Thr Ser Thr Thr Phe Asp Asp Trp Val Arg Gln Ser Glu Lys
 195 200 205
 Asp Tyr Gln Asp Met Leu Ile Tyr Leu Lys Glu Asn Asp Phe Ala Lys
 210 215 220
 Ile Gly Glu Leu Thr Glu Lys Asn Ala Leu Ala Met His Ala Thr Thr
 225 230 235 240
 Lys Thr Ala Ser Pro Ala Phe Ser Tyr Leu Thr Asp Ala Ser Tyr Glu
 245 250 255
 Ala Met Ala Phe Val Arg Gln Leu Arg Glu Lys Gly Glu Ala Cys Tyr

260 265 270
 Phe Thr Met Asp Ala Gly Pro Asn Val Lys Val Phe Cys Gln Glu Lys
 275 280 285
 Asp Leu Glu His Leu Ser Glu Ile Phe Gly Gln Arg Tyr Arg Leu Ile
 290 295 300
 Val Ser Lys Thr Lys Asp Leu Ser Gln Asp Asp Cys Cys
 305 310 315
 <210> 86
 <211> 314
 <212> PRT
 <213> Streptococcus pyrogenes

 <400> 86
 Met Asp Pro Asn Val Ile Thr Val Thr Ser Tyr Ala Asn Ile Ala Ile
 1 5 10 15
 Ile Lys Tyr Trp Gly Lys Glu Asn Gln Ala Lys Met Ile Pro Ser Thr
 20 25 30
 Ser Ser Ile Ser Leu Thr Leu Glu Asn Met Phe Thr Thr Thr Ser Val
 35 40 45
 Ser Phe Leu Pro Asp Thr Ala Thr Ser Asp Gln Phe Tyr Ile Asn Gly
 50 55 60
 Val Leu Gln Asn Asp Glu Glu His Thr Lys Ile Ser Thr Ile Ile Asp
 65 70 75 80
 Gln Phe Arg Gln Pro Gly Gln Ala Phe Val Lys Met Glu Thr Gln Asn
 85 90 95
 Asn Met Pro Thr Ala Ala Gly Leu Ser Ser Ser Ser Ser Gly Leu Ser
 100 105 110
 Ala Leu Val Lys Ala Cys Asp Gln Leu Phe Asp Thr Gln Leu Asp Gln
 115 120 125
 Lys Ala Leu Ala Gln Lys Ala Lys Phe Ala Ser Gly Ser Ser Ser Arg
 130 135 140
 Ser Phe Phe Gly Pro Val Ala Ala Trp Asp Lys Asp Ser Gly Ala Ile
 145 150 155 160
 Tyr Lys Val Glu Thr Asp Leu Lys Met Ala Met Ile Met Leu Val Leu
 165 170 175
 Asn Ala Ala Lys Lys Pro Ile Ser Ser Arg Glu Gly Met Lys Leu Cys

180 185 190
 Arg Asp Thr Ser Thr Thr Phe Asp Glu Trp Val Glu Gln Ser Ala Ile
 195 200 205
 Asp Tyr Gln His Met Leu Thr Tyr Leu Lys Thr Asn Asn Phe Glu Lys
 210 215 220
 Val Gly Gln Leu Thr Glu Ala Asn Ala Leu Ala Met His Ala Thr Thr
 225 230 235 240
 Lys Thr Ala Asn Pro Phe Ser Tyr Leu Thr Lys Glu Ser Tyr Gln
 245 250 255
 Ala Met Glu Ala Val Lys Glu Leu Arg Gln Glu Gly Phe Ala Cys Tyr
 260 265 270
 Phe Thr Met Asp Ala Gly Pro Asn Val Lys Val Leu Cys Leu Glu Lys
 275 280 285
 Asp Leu Ala Gln Leu Ala Glu Arg Leu Gly Lys Asn Tyr Arg Ile Ile
 290 295 300
 Val Ser Lys Thr Lys Asp Leu Pro Asp Val
 305 310

<210> 87

<211> 331

<212> PRT

<213> Enterococcus faecalis

<400> 87

Met Leu Ser Gly Lys Ala Arg Ala His Thr Asn Ile Ala Leu Ile Lys
 5 10 15
 Tyr Trp Gly Lys Ala Asn Glu Glu Tyr Ile Leu Pro Met Asn Ser Ser
 20 25 30
 Leu Ser Leu Thr Leu Asp Ala Phe Tyr Thr Glu Thr Thr Val Thr Phe
 35 40 45
 Asp Ala His Tyr Ser Glu Asp Val Phe Ile Leu Asn Gly Ile Leu Gln
 50 55 60
 Asn Glu Lys Gln Thr Lys Lys Val Lys Glu Phe Leu Asn Leu Val Arg
 65 70 75 80
 Gln Gln Ala Asp Cys Thr Trp Phe Ala Lys Val Glu Ser Gln Asn Phe
 85 90 95
 Val Pro Thr Ala Ala Gly Leu Ala Ser Ser Ala Ser Gly Leu Ala Ala

100 105 110
 Leu Ala Gly Ala Cys Asn Val Ala Leu Gly Leu Asn Leu Ser Ala Lys
 115 120 125
 Asp Leu Ser Arg Leu Ala Arg Arg Gly Ser Gly Ser Ala Cys Arg Ser
 130 135 140
 Ile Phe Gly Gly Phe Ala Gln Trp Asn Lys Gly His Ser Asp Glu Thr
 145 150 155 160
 Ser Phe Ala Glu Asn Ile Pro Ala Asn Asn Trp Glu Asn Glu Leu Ala
 165 170 175
 Met Leu Phe Ile Leu Ile Asn Asp Gly Glu Lys Asp Val Ser Ser Arg
 180 185 190
 Asp Gly Met Lys Arg Thr Val Glu Thr Ser Ser Phe Tyr Gln Gly Trp
 195 200 205
 Leu Asp Asn Val Glu Lys Asp Leu Ser Gln Val His Glu Ala Ile Lys
 210 215 220
 Thr Lys Asp Phe Pro Arg Leu Gly Glu Ile Ile Glu Ala Asn Gly Leu
 225 230 235 240
 Arg Met His Gly Thr Thr Leu Gly Ala Val Pro Pro Phe Thr Tyr Trp
 245 250 255
 Ser Pro Gly Ser Leu Gln Ala Met Ala Leu Val Arg Gln Ala Arg Ala
 260 265 270
 Lys Gly Ile Pro Cys Tyr Phe Thr Met Asp Ala Gly Pro Asn Val Lys
 275 280 285
 Val Leu Val Glu Lys Lys Asn Leu Glu Ala Leu Lys Thr Phe Leu Ser
 290 295 300
 Glu His Phe Ser Lys Glu Gln Leu Val Pro Ala Phe Ala Gly Pro Gly
 305 310 315 320
 Ile Glu Leu Phe Glu Thr Lys Gly Met Asp Lys
 325 330

<210> 88

<211> 325

<212> PRT

<213> Enterococcus faecium

<400> 88

Met Phe Lys Gly Lys Ala Arg Ala Tyr Thr Asn Ile Ala Leu Ile Lys

| | | | |
|---|-----|-----|-----|
| 1 | 5 | 10 | 15 |
| Tyr Trp Gly Lys Lys Asn Glu Glu Leu Ile Leu Pro Met Asn Asn Ser | 20 | 25 | 30 |
| Leu Ser Leu Thr Leu Asp Ala Phe Tyr Thr Glu Thr Glu Val Ile Phe | 35 | 40 | 45 |
| Ser Asp Ser Tyr Met Val Asp Glu Phe Tyr Leu Asp Gly Thr Leu Gln | 50 | 55 | 60 |
| Asp Glu Lys Ala Thr Lys Lys Val Ser Gln Phe Leu Asp Leu Phe Arg | 65 | 70 | 75 |
| Lys Glu Ala Gly Leu Ser Leu Lys Ala Ser Val Ile Ser Gln Asn Phe | 85 | 90 | 95 |
| Val Pro Thr Ala Ala Gly Leu Ala Ser Ser Ala Ser Gly Leu Ala Ala | 100 | 105 | 110 |
| Leu Ala Gly Ala Cys Asn Thr Ala Leu Lys Leu Gly Leu Asp Asp Leu | 115 | 120 | 125 |
| Ser Leu Ser Arg Phe Ala Arg Arg Gly Ser Gly Ser Ala Cys Arg Ser | 130 | 135 | 140 |
| Ile Phe Gly Gly Phe Val Glu Trp Glu Lys Gly His Asp Asp Leu Ser | 145 | 150 | 155 |
| Ser Tyr Ala Lys Pro Val Pro Ser Asp Ser Phe Glu Asp Asp Leu Ala | 165 | 170 | 175 |
| Met Val Phe Val Leu Ile Asn Asp Gln Lys Lys Glu Val Ser Ser Arg | 180 | 185 | 190 |
| Asn Gly Met Arg Arg Thr Val Glu Thr Ser Asn Phe Tyr Gln Gly Trp | 195 | 200 | 205 |
| Leu Asp Ser Val Glu Gly Asp Leu Tyr Gln Leu Lys Gln Ala Ile Lys | 210 | 215 | 220 |
| Thr Lys Asp Phe Gln Leu Leu Gly Glu Thr Met Glu Arg Asn Gly Leu | 225 | 230 | 235 |
| Lys Met His Gly Thr Thr Leu Ala Ala Gln Pro Pro Phe Thr Tyr Trp | 245 | 250 | 255 |
| Ser Pro Asn Ser Leu Lys Ala Met Asp Ala Val Arg Gln Leu Arg Lys | 260 | 265 | 270 |
| Gln Gly Ile Pro Cys Tyr Phe Thr Met Asp Ala Gly Pro Asn Val Lys | 275 | 280 | 285 |
| Val Leu Val Glu Asn Ser His Leu Ser Glu Val Gln Glu Thr Phe Thr | 290 | 295 | 300 |
| Lys Leu Phe Ser Lys Glu Gln Val Ile Thr Ala His Ala Gly Pro Gly | | | |

114

210 215 220
 Ala Gln Lys Asp Phe Lys Arg Met Gly Glu Val Ile Glu Ala Asn Gly
 225 230 235 240
 Leu Arg Met His Ala Thr Asn Leu Gly Ala Gln Pro Pro Phe Thr Tyr
 245 250 255
 Leu Val Pro Glu Ser Tyr Asp Ala Met Arg Ile Val His Glu Cys Arg
 260 265 270
 Glu Ala Gly Leu Pro Cys Tyr Phe Thr Met Asp Ala Gly Pro Asn Val
 275 280 285
 Lys Val Leu Ile Glu Lys Lys Asn Gln Gln Ala Ile Val Asp Lys Phe
 290 295 300
 Leu Gln Glu Phe Asp Gln Ser Gln Ile Ile Thr Ser Asp Ile Thr Gln
 305 310 315 320
 Ser Gly Val Glu Ile Ile Lys
 325

<210> 90

<211> 327

<212> PRT

<213> Staphylococcus epidermis

<400> 90

Met Val Lys Ser Gly Lys Ala Arg Ala His Thr Asn Ile Ala Leu Ile
 1 5 10 15
 Lys Tyr Trp Gly Lys Ala Asp Glu Thr Tyr Ile Ile Pro Met Asn Asn
 20 25 30
 Ser Leu Ser Val Thr Leu Asp Arg Phe Tyr Thr Glu Thr Lys Val Thr
 35 40 45
 Phe Asp Pro Asp Phe Thr Glu Asp Cys Leu Ile Leu Asn Gly Asn Glu
 50 55 60
 Val Asn Ala Lys Glu Lys Glu Lys Ile Gln Asn Tyr Met Asn Ile Val
 65 70 75 80
 Arg Asp Leu Ala Gly Asn Arg Leu His Ala Arg Ile Glu Ser Glu Asn
 85 90 95
 Tyr Val Pro Thr Ala Ala Gly Leu Ala Ser Ser Ala Ser Ala Tyr Ala
 100 105 110
 Ala Leu Ala Ala Ala Cys Asn Glu Ala Leu Ser Leu Asn Leu Ser Asp

115 120 125
 Thr Asp Leu Ser Arg Leu Ala Arg Arg Gly Ser Gly Ser Ala Ser Arg
 130 135 140
 Ser Ile Phe Gly Gly Phe Ala Glu Trp Glu Lys Gly His Asp Asp Leu
 145 150 155 160
 Thr Ser Tyr Ala His Gly Ile Asn Ser Asn Gly Trp Glu Lys Asp Leu
 165 170 175
 Ser Met Ile Phe Val Val Ile Asn Asn Gln Ser Lys Lys Val Ser Ser
 180 185 190
 Arg Ser Gly Met Ser Leu Thr Arg Asp Thr Ser Arg Phe Tyr Gln Tyr
 195 200 205
 Trp Leu Asp His Val Asp Glu Asp Leu Asn Glu Ala Lys Glu Ala Val
 210 215 220
 Lys Asn Gln Asp Phe Gln Arg Leu Gly Glu Val Ile Glu Ala Asn Gly
 225 230 235 240
 Leu Arg Met His Ala Thr Asn Leu Gly Ala Gln Pro Pro Phe Thr Tyr
 245 250 255
 Leu Val Gln Glu Ser Tyr Asp Ala Met Ala Ile Val Glu Gln Cys Arg
 260 265 270
 Lys Ala Asn Leu Pro Cys Tyr Phe Thr Met Asp Ala Gly Pro Asn Val
 275 280 285
 Lys Val Leu Val Glu Lys Lys Asn Lys Gln Ala Val Met Glu Gln Phe
 290 295 300
 Leu Lys Val Phe Asp Glu Ser Lys Ile Ile Ala Ser Asp Ile Ile Ser
 305 310 315 320
 Ser Gly Val Glu Ile Ile Lys
 325

<210> 91

<211> 327

<212> PRT

<213> Staphylococcus aureus

<400> 91

Met Ile Lys Ser Gly Lys Ala Arg Ala His Thr Asn Ile Ala Leu Ile
 1 5 10 15

Lys Tyr Trp Gly Lys Lys Asp Glu Ala Leu Ile Ile Pro Met Asn Asn

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ile | Ser | Val | Thr | Leu | Glu | Lys | Phe | Tyr | Thr | Glu | Thr | Lys | Val | Thr |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Phe | Asn | Asp | Gln | Leu | Thr | Gln | Asp | Gln | Phe | Trp | Leu | Asn | Gly | Glu | Lys |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Val | Ser | Gly | Lys | Glu | Leu | Glu | Lys | Ile | Ser | Lys | Tyr | Met | Asp | Ile | Val |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Arg | Asn | Arg | Ala | Gly | Ile | Asp | Trp | Tyr | Ala | Glu | Ile | Glu | Ser | Asp | Asn |
| | | | 85 | | | | | | 90 | | | | | 95 | |
| Phe | Val | Pro | Thr | Ala | Ala | Gly | Leu | Ala | Ser | Ser | Ala | Ser | Ala | Tyr | Ala |
| | | | 100 | | | | | 105 | | | | | | 110 | |
| Ala | Leu | Ala | Ala | Ala | Cys | Asn | Gln | Ala | Leu | Asp | Leu | Gln | Leu | Ser | Asp |
| | 115 | | | | | | 120 | | | | | 125 | | | |
| Lys | Asp | Leu | Ser | Arg | Leu | Ala | Arg | Ile | Gly | Ser | Gly | Ser | Ala | Ser | Arg |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Ser | Ile | Tyr | Gly | Gly | Phe | Ala | Glu | Trp | Glu | Lys | Gly | Tyr | Asn | Asp | Glu |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Thr | Ser | Tyr | Ala | Val | Pro | Leu | Glu | Ser | Asn | His | Phe | Glu | Asp | Asp | Leu |
| | | | 165 | | | | | | 170 | | | | | 175 | |
| Ala | Met | Ile | Phe | Val | Val | Ile | Asn | Gln | His | Ser | Lys | Lys | Val | Pro | Ser |
| | | 180 | | | | | | 185 | | | | | 190 | | |
| Arg | Tyr | Gly | Met | Ser | Leu | Thr | Arg | Asn | Thr | Ser | Arg | Phe | Tyr | Gln | Tyr |
| | 195 | | | | | | 200 | | | | | 205 | | | |
| Trp | Leu | Asp | His | Ile | Asp | Glu | Asp | Leu | Ala | Glu | Ala | Lys | Ala | Ala | Ile |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Gln | Asp | Lys | Asp | Phe | Lys | Arg | Leu | Gly | Glu | Val | Ile | Glu | Glu | Asn | Gly |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Leu | Arg | Met | His | Ala | Thr | Asn | Leu | Gly | Ser | Thr | Pro | Pro | Phe | Thr | Tyr |
| | | | 245 | | | | | | 250 | | | | | 255 | |
| Leu | Val | Gln | Glu | Ser | Tyr | Asp | Val | Met | Ala | Leu | Val | His | Glu | Cys | Arg |
| | | 260 | | | | | 265 | | | | | | 270 | | |
| Glu | Ala | Gly | Tyr | Pro | Cys | Tyr | Phe | Thr | Met | Asp | Ala | Gly | Pro | Asn | Val |
| | 275 | | | | | | 280 | | | | | 285 | | | |
| Lys | Ile | Leu | Val | Glu | Lys | Lys | Asn | Lys | Gln | Gln | Ile | Ile | Asp | Lys | Leu |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Leu | Thr | Gln | Phe | Asp | Asn | Asn | Gln | Ile | Ile | Asp | Ser | Asp | Ile | Ile | Ala |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Thr | Gly | Ile | Glu | Ile | Ile | Glu | | | | | | | | | |

325

<210> 92

<211> 350

<212> PRT

<213> Streptomyces sp. CL190

<400> 92

Met Arg Ser Glu His Pro Thr Thr Thr Val Leu Gln Ser Arg Glu Gln
1 5 10 15

Gly Ser Ala Ala Gly Ala Thr Ala Val Ala His Pro Asn Ile Ala Leu
20 25 30

Ile Lys Tyr Trp Gly Lys Arg Asp Glu Arg Leu Ile Leu Pro Cys Thr
35 40 45

Thr Ser Leu Ser Met Thr Leu Asp Val Phe Pro Thr Thr Thr Glu Val
50 55 60

Arg Leu Asp Pro Ala Ala Glu His Asp Thr Ala Ala Leu Asn Gly Glu
65 70 75 80

Val Ala Thr Gly Glu Thr Leu Arg Arg Ile Ser Ala Phe Leu Ser Leu
85 90 95

Val Arg Glu Val Ala Gly Ser Asp Gln Arg Ala Val Val Asp Thr Arg
100 105 110

Asn Thr Val Pro Thr Gly Ala Gly Leu Ala Ser Ser Ala Ser Gly Phe
115 120 125

Ala Ala Leu Ala Val Ala Ala Ala Ala Tyr Gly Leu Glu Leu Asp
130 135 140

Asp Arg Gly Leu Ser Arg Leu Ala Arg Arg Gly Ser Gly Ser Ala Ser
145 150 155 160

Arg Ser Ile Phe Gly Gly Phe Ala Val Trp His Ala Gly Pro Asp Gly
165 170 175

Thr Ala Thr Glu Ala Asp Leu Gly Ser Tyr Ala Glu Pro Val Pro Ala
180 185 190

Ala Asp Leu Asp Pro Ala Leu Val Ile Ala Val Val Asn Ala Gly Pro
195 200 205

Lys Pro Val Ser Ser Arg Glu Ala Met Arg Arg Thr Val Asp Thr Ser
210 215 220

Pro Leu Tyr Arg Pro Trp Ala Asp Ser Ser Lys Asp Asp Leu Asp Glu

225 230 235 240
 Met Arg Ser Ala Leu Leu Arg Gly Asp Leu Glu Ala Val Gly Glu Ile
 245 250 255
 Ala Glu Arg Asn Ala Leu Gly Met His Ala Thr Met Leu Ala Ala Arg
 260 265 270
 Pro Ala Val Arg Tyr Leu Ser Pro Ala Thr Val Thr Val Leu Asp Ser
 275 280 285
 Val Leu Gln Leu Arg Lys Asp Gly Val Leu Ala Tyr Ala Thr Met Asp
 290 295 300
 Ala Gly Pro Asn Val Lys Val Leu Cys Arg Arg Ala Asp Ala Glu Arg
 305 310 315 320
 Val Ala Asp Val Val Arg Ala Ala Ala Ser Gly Gly Gln Val Leu Val
 325 330 335
 Ala Gly Pro Gly Asp Gly Ala Arg Leu Leu Ser Glu Gly Ala
 340 345 350

<210> 93

<211> 331

<212> PRT

<213> *Streptomyces griseolosporeus*

<400> 93

Ala Thr Ala Val Ala Gln Pro Asn Ile Ala Leu Ile Lys Tyr Trp Gly
 1 5 10 15
 Lys Lys Asp Glu His Leu Val Leu Pro Arg Thr Asp Ser Leu Ser Met
 20 25 30
 Thr Leu Asp Ile Phe Pro Thr Thr Thr Arg Val Gln Leu Ala Pro Gly
 35 40 45
 Ala Gly Gln Asp Thr Val Ala Phe Asn Gly Glu Pro Ala Thr Gly Glu
 50 55 60
 Ala Glu Arg Arg Ile Thr Ala Phe Leu Arg Leu Val Arg Glu Arg Ser
 65 70 75 80
 Gly Arg Thr Glu Arg Ala Arg Val Glu Thr Glu Asn Thr Val Pro Thr
 85 90 95
 Gly Ala Gly Leu Ala Ser Ser Ala Ser Gly Phe Ala Ala Leu Ala Val
 100 105 110
 Ala Ala Ala Ala Ala Tyr Gly Leu Gly Leu Asp Ala Arg Gly Leu Ser

| | | |
|---|-----|-----|
| 115 | 120 | 125 |
| Arg Leu Ala Arg Arg Gly Ser Gly Ser Ala Ser Arg Ser Ile Phe Asp | | |
| 130 | 135 | 140 |
| Gly Phe Ala Val Trp His Ala Gly His Ala Gly Gly Thr Pro Glu Glu | | |
| 145 | 150 | 155 |
| Ala Asp Leu Gly Ser Tyr Ala Glu Pro Val Pro Ala Val Asp Leu Glu | | |
| 165 | 170 | 175 |
| Pro Ala Leu Val Val Ala Val Val Ser Ala Ala Pro Lys Ala Val Ser | | |
| 180 | 185 | 190 |
| Ser Arg Glu Ala Met Arg Arg Thr Val Asp Thr Ser Pro Leu Tyr Glu | | |
| 195 | 200 | 205 |
| Pro Trp Ala Val Ser Ser Arg Ala Asp Leu Ala Asp Ile Gly Ala Ala | | |
| 210 | 215 | 220 |
| Leu Ala Arg Gly Asn Leu Pro Ala Val Gly Glu Ile Ala Glu Arg Asn | | |
| 225 | 230 | 235 |
| Ala Leu Gly Met His Ala Thr Met Leu Ala Ala Arg Pro Ala Val Arg | | |
| 245 | 250 | 255 |
| Tyr Leu Ser Pro Ala Ser Leu Ala Val Leu Asp Gly Val Leu Gln Leu | | |
| 260 | 265 | 270 |
| Arg Arg Asp Gly Val Pro Ala Tyr Ala Thr Met Asp Ala Gly Pro Asn | | |
| 275 | 280 | 285 |
| Val Lys Val Leu Cys Pro Arg Ser Asp Ala Glu Arg Val Ala Glu Ala | | |
| 290 | 295 | 300 |
| Leu Arg Ala Ala Ala Pro Val Gly Ala Val His Ile Ala Gly Pro Gly | | |
| 305 | 310 | 315 |
| Arg Gly Ala Arg Leu Val Ala Glu Glu Cys Arg | | |
| 325 | 330 | |

<210> 94

<211> 312

<212> PRT

<213> Borrelia burgdorferi

<400> 94

| |
|---|
| Met Lys Ile Lys Cys Lys Val His Ala Ser Leu Ala Leu Ile Lys Tyr |
| 1 5 10 15 |

Trp Gly Lys Lys Asp Val Phe Leu Asn Ile Pro Ala Thr Ser Ser Leu

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Val | Ser | Val | Asp | Lys | Phe | Tyr | Ser | Ile | Ser | Glu | Leu | Glu | Leu | Ser |
| | 35 | | | | | | 40 | | | | | 45 | | | |
| Asn | Arg | Asp | Glu | Ile | Ile | Leu | Asn | Ser | Lys | Pro | Val | Ile | Leu | Lys | Asn |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Arg | Glu | Lys | Val | Phe | Phe | Asp | Tyr | Ala | Arg | Lys | Ile | Leu | Asn | Glu | Pro |
| | 65 | | | | 70 | | | | | 75 | | | | | 80 |
| Asn | Val | Arg | Phe | Lys | Ile | Lys | Ser | Lys | Asn | Asn | Phe | Pro | Thr | Ala | Ala |
| | | | 85 | | | | | | 90 | | | | | 95 | |
| Gly | Leu | Ala | Ser | Ser | Ser | Ser | Gly | Phe | Ala | Ser | Ile | Ala | Ala | Cys | Ile |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Leu | Lys | Tyr | Phe | Asn | Lys | Tyr | Ser | Cys | Asn | Ser | Ala | Ser | Asn | Leu | Ala |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Arg | Val | Gly | Ser | Ala | Ser | Ala | Ala | Arg | Ala | Ile | Tyr | Gly | Gly | Phe | Thr |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Ile | Leu | Lys | Glu | Gly | Ser | Lys | Glu | Ser | Phe | Gln | Leu | Arg | Asp | Gln | Ser |
| | 145 | | | | 150 | | | | | 155 | | | | | 160 |
| Tyr | Phe | Asn | Asp | Leu | Arg | Ile | Ile | Phe | Ala | Ile | Ile | Asp | Ser | Asn | Glu |
| | | | 165 | | | | | | 170 | | | | | 175 | |
| Lys | Glu | Leu | Ser | Ser | Arg | Ala | Ala | Met | Asn | Ile | Cys | Lys | Arg | His | Lys |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Phe | Tyr | Tyr | Asp | Ala | Trp | Ile | Ala | Ser | Ser | Lys | Lys | Ile | Phe | Lys | Asp |
| | | 195 | | | | | 200 | | | | | | 205 | | |
| Ala | Leu | Tyr | Phe | Phe | Leu | Lys | Lys | Asp | Phe | Ile | His | Phe | Gly | Ala | Thr |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Ile | Val | Lys | Ser | Tyr | Gln | Asn | Met | Phe | Ala | Leu | Met | Phe | Ala | Ser | Ser |
| | 225 | | | | 230 | | | | | 235 | | | | 240 | |
| Ile | Phe | Tyr | Phe | Lys | Asn | Ser | Thr | Ile | Asp | Leu | Ile | Arg | Tyr | Ala | Ala |
| | | | 245 | | | | | | 250 | | | | | 255 | |
| Asp | Leu | Arg | Asn | Glu | Gly | Ile | Phe | Val | Phe | Glu | Thr | Met | Asp | Ala | Gly |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Pro | Gln | Val | Lys | Phe | Leu | Cys | Leu | Glu | Glu | Asn | Leu | Asn | Thr | Ile | Leu |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Lys | Gly | Leu | Lys | Gln | Asn | Phe | Thr | Gly | Ile | Asp | Phe | Ile | Val | Ser | Lys |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Val | Gly | Cys | Asp | Leu | Glu | Trp | Ile | | | | | | | | |
| | 305 | | | | 310 | | | | | | | | | | |

<210> 95

<211> 292

<212> PRT

<213> Streptococcus pneumoniae

<400> 95

```

Met Thr Lys Lys Val Gly Val Gly Gln Ala His Ser Lys Ile Ile Leu
1      5      10      15
Ile Gly Glu His Ala Val Val Tyr Gly Tyr Pro Ala Ile Ser Leu Pro
20      25      30
Leu Leu Glu Val Glu Val Thr Cys Lys Val Val Ser Ala Glu Ser Pro
35      40      45
Trp Arg Leu Tyr Glu Glu Asp Thr Leu Ser Met Ala Val Tyr Ala Ser
50      55      60
Leu Glu Tyr Leu Asp Ile Thr Glu Ala Cys Val Arg Cys Glu Ile Asp
65      70      75      80
Ser Ala Ile Pro Glu Lys Arg Gly Met Gly Ser Ser Ala Ala Ile Ser
85      90      95
Ile Ala Ala Ile Arg Ala Val Phe Asp Tyr Tyr Gln Ala Asp Leu Pro
100     105     110
His Asp Val Leu Glu Ile Leu Val Asn Arg Ala Glu Met Ile Ala His
115     120     125
Met Asn Pro Ser Gly Leu Asp Ala Lys Thr Cys Leu Ser Asp Gln Pro
130     135     140
Ile Arg Phe Ile Lys Asn Val Gly Phe Thr Glu Leu Glu Met Asp Leu
145     150     155     160
Ser Ala Tyr Leu Val Ile Ala Asp Thr Gly Val Tyr Gly His Thr Arg
165     170     175
Glu Ala Ile Gln Val Val Gln Asn Lys Gly Lys Asp Ala Leu Pro Phe
180     185     190
Leu His Ala Leu Gly Glu Leu Thr Gln Gln Ala Glu Val Ala Ile Ser
195     200     205
Gln Lys Tyr Ala Glu Gly Leu Gly Leu Ile Phe Ser Gln Ala His Leu
210     215     220
His Leu Lys Glu Ile Gly Val Ser Ser Pro Glu Ala Asp Phe Leu Val
225     230     235     240
Glu Thr Ala Leu Ser Tyr Gly Ala Leu Gly Ala Lys Met Ser Gly Gly

```

123

180 185 190
 Leu Ala Lys Leu Gly Ala Leu Thr Gln Ala Leu Glu Arg Ala Ile Asn
 195 200 205
 Gln Lys Asn Lys Val Ala Ile Gly Gln Leu Met Thr Gln Ala His Ser
 210 215 220
 Ala Leu Lys Ala Ile Gly Val Ser Ile Ser Lys Ala Asp Gln Leu Val
 225 230 235 240
 Glu Ala Ala Leu Arg Ala Gly Ala Leu Gly Ala Lys Met Thr Gly Gly
 245 250 255
 Gly Leu Gly Gly Cys Met Ile Ala Leu Ala Asp Thr Lys Asp Met Ala
 260 265 270
 Glu Lys Ile Ser His Lys Leu Lys Glu Glu Gly Ala Val Asn Thr Trp
 275 280 285
 Ile Gln Met Leu
 290
 <210> 97
 <211> 314
 <212> PRT
 <213> Enterococcus faecalis

 <400> 97
 Met Asn Ile Lys Lys Gln Gly Leu Gly Gln Ala Thr Gly Lys Ile Ile
 1 5 10 15
 Leu Met Gly Glu His Ala Val Val Tyr Gly Glu Pro Ala Ile Ala Phe
 20 25 30
 Pro Phe Gln Ala Thr Glu Ile Thr Ala Val Phe Thr Pro Ala Lys Thr
 35 40 45
 Met Gln Ile Asp Cys Ala Tyr Phe Thr Gly Leu Leu Glu Asp Val Pro
 50 55 60
 Gln Glu Leu Ala Asn Ile Lys Glu Val Val Gln Gln Thr Leu His Phe
 65 70 75 80
 Leu Lys Glu Asp Thr Phe Lys Gly Thr Leu Thr Leu Thr Ser Thr Ile
 85 90 95
 Pro Ala Glu Arg Gly Met Gly Ser Ser Ala Ala Thr Ala Val Ala Ile
 100 105 110
 Val Arg Ser Leu Phe Asp Tyr Phe Asp Tyr Ala Tyr Thr Tyr Gln Glu

115 120 125
 Leu Phe Glu Leu Val Ser Leu Ser Glu Lys Ile Ala His Gly Asn Pro
 130 135 140
 Ser Gly Ile Asp Ala Ala Ala Thr Ser Gly Ala Asp Pro Leu Phe Phe
 145 150 155 160
 Thr Arg Gly Phe Pro Pro Thr His Phe Ser Met Asn Leu Ser Asn Ala
 165 170 175
 Tyr Leu Val Val Ala Asp Thr Gly Ile Lys Gly Gln Thr Arg Glu Ala
 180 185 190
 Val Lys Asp Ile Ala Gln Leu Ala Gln Asn Asn Pro Thr Ala Ile Ala
 195 200 205
 Glu Thr Met Lys Gln Leu Gly Ser Phe Thr Lys Glu Ala Lys Gln Ala
 210 215 220
 Ile Leu Gln Asp Asp Lys Gln Lys Leu Gly Gln Leu Met Thr Leu Ala
 225 230 235 240
 Gln Glu Gln Leu Gln Gln Leu Thr Val Ser Asn Asp Met Leu Asp Arg
 245 250 255
 Leu Val Ala Leu Ser Leu Glu His Gly Ala Leu Gly Ala Lys Leu Thr
 260 265 270
 Gly Gly Gly Arg Gly Gly Cys Met Ile Ala Leu Thr Asp Asn Lys Lys
 275 280 285
 Thr Ala Gln Thr Ile Ala Gln Thr Leu Glu Glu Asn Gly Ala Val Ala
 290 295 300
 Thr Trp Ile Gln Ser Leu Glu Val Lys Lys
 305 310

<210> 98

<211> 314

<212> PRT

<213> Enterococcus faecium

<400> 98

Met Ala Asn Tyr Gly Gln Gly Glu Ser Ser Gly Lys Ile Ile Leu Met
 1 5 10 15
 Gly Glu His Ala Val Val Tyr Gly Glu Pro Ala Ile Ala Phe Pro Phe
 20 25 30
 Tyr Ala Thr Lys Val Thr Ala Phe Leu Glu Glu Leu Asp Ala-Met Asp

| 35 | 40 | 45 |
|---|-----|-------------|
| Asp Gln Leu Val Ser Ser Tyr Tyr Ser Gly Asn Leu Ala Glu Ala Pro | 50 | 55 60 |
| His Ala Leu Lys Asn Ile Lys Lys Leu Phe Ile His Leu Lys Lys Gln | 65 | 70 75 80 |
| His Asp Ile Gln Lys Asn Leu Gln Leu Thr Ile Glu Ser Thr Ile Pro | 85 | 90 95 |
| Ala Glu Arg Gly Met Gly Ser Ser Ala Ala Val Ala Thr Ala Val Thr | 100 | 105 110 |
| Arg Ala Phe Tyr Asp Tyr Leu Ala Phe Pro Leu Ser Arg Glu Ile Leu | 115 | 120 125 |
| Leu Glu Asn Val Gln Leu Ser Glu Lys Ile Ala His Gly Asn Pro Ser | 130 | 135 140 |
| Gly Ile Asp Ala Ala Ala Thr Ser Ser Leu Gln Pro Ile Tyr Phe Thr | 145 | 150 155 160 |
| Lys Gly His Pro Phe Asp Tyr Phe Ser Leu Asn Ile Asp Ala Phe Leu | 165 | 170 175 |
| Ile Val Ala Asp Thr Gly Ile Lys Gly Gln Thr Arg Glu Ala Val Lys | 180 | 185 190 |
| Asp Val Ala His Leu Phe Glu Thr Gln Pro His Glu Thr Gly Gln Met | 195 | 200 205 |
| Ile Gln Lys Leu Gly Tyr Leu Thr Lys Gln Ala Lys Gln Ala Ile Ile | 210 | 215 220 |
| Glu Asn Ser Pro Glu Thr Leu Ala Gln Thr Met Asp Glu Ser Gln Ser | 225 | 230 235 240 |
| Leu Leu Glu Lys Leu Thr Ile Ser Asn Asp Phe Leu Asn Leu Leu Ile | 245 | 250 255 |
| Gln Thr Ala Lys Asp Thr Gly Ala Leu Gly Ala Lys Leu Thr Gly Gly | 260 | 265 270 |
| Gly Arg Gly Gly Cys Met Ile Ala Leu Ala Gln Thr Lys Thr Lys Ala | 275 | 280 285 |
| Gln Glu Ile Ser Gln Ala Leu Glu Asp Ala Gly Ala Ala Glu Thr Trp | 290 | 295 300 |
| Ile Gln Gly Leu Gly Val His Thr Tyr Val | 305 | 310 |
| <210> | 99 | |
| <211> | 307 | |

<212> PRT

<213> Staphylococcus haemolyticus

<400> 99

Met Val Gln Arg Gly Tyr Gly Glu Ser Asn Gly Lys Ile Ile Leu Ile
 1 5 10 15
 Gly Glu His Ala Val Thr Phe Gly Glu Pro Ala Ile Ala Ile Pro Phe
 20 25 30
 Thr Ser Gly Lys Val Lys Val Leu Ile Glu Ser Leu Glu Lys Gly Asn
 35 40 45
 Tyr Ser Ala Ile Gln Ser Asp Val Tyr Asp Gly Pro Leu Tyr Asp Ala
 50 55 60
 Pro Glu His Leu Lys Ser Leu Ile Gly His Phe Val Glu Asn Lys Lys
 65 70 75 80
 Val Glu Glu Pro Leu Leu Ile Lys Ile Gln Ala Asn Leu Pro Pro Ser
 85 90 95
 Arg Gly Leu Gly Ser Ser Ala Ala Val Ala Val Ala Phe Ile Arg Ala
 100 105 110
 Ser Tyr Asp Tyr Leu Gly Leu Pro Leu Thr Asp Lys Glu Leu Leu Glu
 115 120 125
 Asn Ala Asp Trp Ala Glu Arg Ile Ala His Gly Lys Pro Ser Gly Ile
 130 135 140
 Asp Thr Lys Thr Ile Val Thr Asn Gln Pro Val Trp Tyr Gln Lys Gly
 145 150 155 160
 Glu Val Glu Ile Leu Lys Thr Leu Asp Leu Asp Gly Tyr Met Val Val
 165 170 175
 Ile Asp Thr Gly Val Lys Gly Ser Thr Lys Gln Ala Val Glu Asp Val
 180 185 190
 His Gln Leu Cys Asp Asn Asp Lys Asn Tyr Met Gln Val Val Lys His
 195- 200 205
 Ile Gly Ser Leu Val Tyr Ser Ala Ser Glu Ala Ile Glu His His Ser
 210 215 220
 Phe Asp Gln Leu Ala Thr Ile Phe Asn Gln Cys Gln Asp Asp Leu Arg
 225 230 235 240
 Thr Leu Thr Val Ser His Asp Lys Ile Glu Met Phe Leu Arg Leu Gly
 245 250 255
 Glu Glu Asn Gly Ser Val Ala Gly Lys Leu Thr Gly Gly Gly Arg Gly

128

| | | |
|---|---------------------------------|-----------------|
| 180 | 185 | 190 |
| His Val Leu Cys Glu Ser Asp | Glu Tyr Met Lys Tyr | Ile Glu His Ile |
| 195 | 200 | 205 |
| Gly Thr Leu Val His Ser Ala Ser | Glu Ser Ile Glu Gln His Asp Phe | |
| 210 | 215 | 220 |
| His His Leu Ala Asp Ile Phe Asn Ala Cys Gln Glu Asp Leu Arg His | | |
| 225 | 230 | 235 240 |
| Leu Thr Val Ser His Asp Lys Ile Glu Lys Leu Leu Gln Ile Gly Lys | | |
| 245 | 250 | 255 |
| Glu His Gly Ala Ile Ala Gly Lys Leu Thr Gly Gly Gly Arg Gly Gly | | |
| 260 | 265 | 270 |
| Ser Met Leu Leu Leu Ala Glu Asn Leu Lys Thr Ala Lys Thr Ile Val | | |
| 275 | 280 | 285 |
| Ala Ala Val Glu Lys Ala Gly Ala Ala His Thr Trp Ile Glu His Leu | | |
| 290 | 295 | 300 |

Gly Gly
305

<210> 101

<211> 306

<212> PRT

<213> Staphylococcus aureus

<400> 101

| | |
|---|--|
| Met Thr Arg Lys Gly Tyr Gly Glu Ser Thr Gly Lys Ile Ile Leu Ile | |
| 1 5 10 15 | |
| Gly Glu His Ala Val Thr Phe Gly Glu Pro Ala Ile Ala Val Pro Phe | |
| 20 25 30 | |
| Asn Ala Gly Lys Ile Lys Val Leu Ile Glu Ala Leu Glu Ser Gly Asn | |
| 35 40 45 | |
| Tyr Ser Ser Ile Lys Ser Asp Val Tyr Asp Gly Met Leu Tyr Asp Ala | |
| 50 55 60 | |
| Pro Asp His Leu Lys Ser Leu Val Asn Arg Phe Val Glu Leu Asn Asn | |
| 65 70 75 80 | |
| Ile Thr Glu Pro Leu Ala Val Thr Ile Gln Thr Asn Leu Pro Pro Ser | |
| 85 90 95 | |
| Arg Gly Leu Gly Ser Ser Ala Ala Val Ala Val Ala Phe Val Arg Ala | |

100 105 110
 Ser Tyr Asp Phe Leu Gly Lys Ser Leu Thr Lys Glu Glu Leu Ile Glu
 115 120 125
 Lys Ala Asn Trp Ala Glu Gln Ile Ala His Gly Lys Pro Ser Gly Ile
 130 135 140
 Asp Thr Gln Thr Ile Val Ser Gly Lys Pro Val Trp Phe Gln Lys Gly
 145 150 155 160
 Gln Ala Glu Thr Leu Lys Thr Leu Ser Leu Asp Gly Tyr Met Val Val
 165 170 175
 Ile Asp Thr Gly Val Lys Gly Ser Thr Arg Gln Ala Val Glu Asp Val
 180 185 190
 His Lys Leu Cys Glu Asp Pro Gln Tyr Met Ser His Val Lys His Ile
 195 200 205
 Gly Lys Leu Val Leu Arg Ala Ser Asp Val Ile Glu His His Asn Phe
 210 215 220
 Glu Ala Leu Ala Asp Ile Phe Asn Glu Cys His Ala Asp Leu Lys Ala
 225 230 235 240
 Leu Thr Val Ser His Asp Lys Ile Glu Gln Leu Met Lys Ile Gly Lys
 245 250 255
 Glu Asn Gly Ala Ile Ala Gly Lys Leu Thr Gly Ala Gly Arg Gly Gly
 260 265 270
 Ser Met Leu Leu Leu Ala Lys Asp Leu Pro Thr Ala Lys Asn Ile Val
 275 280 285
 Lys Ala Val Glu Lys Ala Gly Ala Ala His Thr Trp Ile Glu Asn Leu
 290 295 300
 Gly Gly
 305

<210> 102

<211> 345

<212> PRT

<213> Streptomyces sp. CL190

<400> 102

Met Gln Lys Arg Gln Arg Glu Leu Ser Ala Leu Thr Leu Pro Thr Ser
 1 5 10 15
 Ala Glu Gly Val Ser Glu Ser His Arg Ala Arg Ser Val Gly Ile Gly

131

132

210 215 220
 Glu Glu Arg Phe Met His Arg Ala Ala His Leu Val Asp Asp Ala Arg
 225 230 235 240
 Ala Ser Leu Ala Glu Gly Glu Pro Glu Ala Phe Gly Ser Cys Leu Thr
 245 250 255
 Glu Tyr His Gly Leu Leu Arg Gly Ala Gly Leu Ser Thr Asp Arg Ile
 260 265 270
 Asp Ala Leu Val Asp Ala Ala Leu Gln Ala Asp Ser Leu Gly Ala Lys
 275 280 285
 Ile Thr Gly Gly Gly Leu Gly Gly Cys Val Leu Ala Met Ser Arg Pro
 290 295 300
 Glu Arg Ala Glu Glu Val Ala Arg Gln Leu His Ala Ala Gly Ala Val
 305 310 315 320
 Arg Thr Trp Ala Val Gln Leu Arg Arg Ser Thr His Glu Arg
 325 330

<210> 104

<211> 296

<212> PRT

<213> Borrelia burgdorferi

<400> 104

Met Leu Arg Ile Arg Lys Pro Ala Lys Ile Leu Phe Leu Gly Glu His
 1 5 10 15
 Ser Ala Val Tyr Gly Phe Pro Val Ile Gly Ala Thr Val Pro Ile Tyr
 20 25 30
 Met Asp Leu Ile Tyr Ser Val Ser Lys Asn Trp Lys Tyr Leu Gly Lys
 35 40 45
 Pro Ser Thr Arg Leu Asn Ser Leu Ile Ser Phe Ile Val Ser Asn Tyr
 50 55 60
 Ser Lys Val Asn Pro Ile Glu Phe Asp Ile Ile Ser Glu Ile Pro Ile
 65 70 75 80
 Gly Val Gly Leu Gly Ser Ser Ala Ser Leu Ser Leu Cys Phe Ala Glu
 85 90 95
 Tyr Ile Thr Ser His Phe Glu Tyr Lys Asp Cys Asn Lys Ile Leu Leu
 100 105 110
 Ala Asn Gln Ile Glu Asn Ile Phe His Gly Lys Ser Ser Gly Met Asp

| 115 | | | | | 120 | | | | | 125 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Arg | Leu | Ile | Asp | Leu | Asn | Gly | Thr | Phe | Tyr | Leu | Glu | Lys | Lys | Glu |
| 130 | | | | | | 135 | | | | | 140 | | | | |
| Asn | Val | Leu | His | Ser | Lys | Lys | Ile | Lys | Asp | Ser | Gly | Phe | Tyr | Phe | Leu |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Ile | Gly | Ala | Ile | Lys | Arg | Asp | Leu | Thr | Thr | Lys | Glu | Ile | Val | Val | Asn |
| | | | | 165 | | | | | 170 | | | | | | 175 |
| Leu | Lys | Lys | Asp | Leu | Leu | Ser | Asn | Ala | Tyr | Leu | Phe | Val | Phe | Ile | Glu |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Lys | Leu | Gly | Leu | Ala | Val | Ser | Asn | Ser | Tyr | Ala | Ser | Phe | Gln | Asn | Lys |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Asp | Val | Tyr | Ser | Leu | Ala | Asn | Glu | Met | Asn | Ile | Ala | Gln | Cys | Cys | Leu |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Lys | Arg | Leu | Gly | Leu | Ser | Asn | Asp | Thr | Leu | Asp | Trp | Leu | Ile | Ser | Glu |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Gly | Ile | Lys | Leu | Gly | Ala | Leu | Ser | Gly | Lys | Leu | Ser | Gly | Ala | Gly | Lys |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Gly | Gly | Ala | Phe | Ile | Phe | Leu | Phe | Glu | Ser | Leu | Ile | Lys | Ala | Asn | Ile |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Val | Gln | Lys | Glu | Leu | Asn | Asn | Met | Leu | Asp | Ser | Lys | Ile | Asp | Leu | Leu |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Leu | Lys | Leu | Lys | Val | Ile | Glu | Thr | | | | | | | | |
| | 290 | | | | | 295 | | | | | | | | | |

<210> 105

<211> 336

<212> PRT

<213> Streptococcus pneumoniae

<400> 105

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ile | Ala | Val | Lys | Thr | Cys | Gly | Lys | Leu | Tyr | Trp | Ala | Gly | Glu | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ala | Ile | Leu | Glu | Pro | Gly | Gln | Leu | Ala | Leu | Ile | Lys | Asp | Ile | Pro | Ile |
| | | 20 | | | | | | 25 | | | | | 30 | | |
| Tyr | Met | Arg | Ala | Glu | Ile | Ala | Phe | Ser | Asp | Ser | Tyr | Arg | Ile | Tyr | Ser |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Asp | Met | Phe | Asp | Phe | Ala | Val | Asp | Leu | Arg | Pro | Asn | Pro | Asp | Tyr | Ser |

| 50 | 55 | 60 |
|---|---|-------------|
| Leu Ile Gln Glu Thr | Ile Ala Leu Met Gly Asp Phe Leu Ala Val Arg | |
| 65 | 70 | 75 80 |
| Gly Gln Asn Leu Arg Pro Phe Ser Leu Lys Ile Cys Gly Lys Met Glu | | |
| | 85 | 90 95 |
| Arg Glu Gly Lys Lys Phe Gly Leu Gly Ser Ser Gly Ser Val Val Val | | |
| | 100 | 105 110 |
| Leu Val Val Lys Ala Leu Leu Ala Leu Tyr Asn Leu Ser Val Asp Gln | | |
| | 115 | 120 125 |
| Asn Leu Leu Phe Lys Leu Thr Ser Ala Val Leu Leu Lys Arg Gly Asp | | |
| | 130 | 135 140 |
| Asn Gly Ser Met Gly Asp Leu Ala Cys Ile Val Ala Glu Asp Leu Val | | |
| | 145 | 150 155 160 |
| Leu Tyr Gln Ser Phe Asp Arg Gln Lys Ala Ala Ala Trp Leu Glu Glu | | |
| | 165 | 170 175 |
| Glu Asn Leu Ala Thr Val Leu Glu Arg Asp Trp Gly Phe Phe Ile Ser | | |
| | 180 | 185 190 |
| Gln Val Lys Pro Thr Leu Glu Cys Asp Phe Leu Val Gly Trp Thr Lys | | |
| | 195 | 200 205 |
| Glu Val Ala Val Ser Ser His Met Val Gln Gln Ile Lys Gln Asn Ile | | |
| | 210 | 215 220 |
| Asn Gln Asn Phe Leu Ser Ser Ser Lys Glu Thr Val Val Ser Leu Val | | |
| | 225 | 230 235 240 |
| Glu Ala Leu Glu Gln Gly Lys Ala Glu Lys Val Ile Glu Gln Val Glu | | |
| | 245 | 250 255 |
| Val Ala Ser Lys Leu Leu Glu Gly Leu Ser Thr Asp Ile Tyr Thr Pro | | |
| | 260 | 265 270 |
| Leu Leu Arg Gln Leu Lys Glu Ala Ser Gln Asp Leu Gln Ala Val Ala | | |
| | 275 | 280 285 |
| Lys Ser Ser Gly Ala Gly Gly Gly Asp Cys Gly Ile Ala Leu Ser Phe | | |
| | 290 | 295 300 |
| Asp Ala Gln Ser Ser Arg Asn Thr Leu Lys Asn Arg Trp Ala Asp Leu | | |
| | 305 | 310 315 320 |
| Gly Ile Glu Leu Leu Tyr Gln Glu Arg Ile Gly His Asp Asp Lys Ser | | |
| | 325 | 330 335 |
| <210> 106 | | |
| <211> 335 | | |

<212> PRT

<213> Streptococcus pyrogenes

<400> 106

```

Met Ser Asn Tyr Cys Val Gln Thr Gly Gly Lys Leu Tyr Leu Thr Gly
 1          5          10          15

Glu Tyr Ala Ile Leu Ile Pro Gly Gln Lys Ala Leu Ile His Phe Ile
 20          25          30

Pro Leu Met Met Thr Ala Glu Ile Ser Pro Ala Ala His Ile Gln Leu
 35          40          45

Ala Ser Asp Met Phe Ser His Lys Ala Gly Met Thr Pro Asp Ala Ser
 50          55          60

Tyr Ala Leu Ile Gln Ala Thr Val Lys Thr Phe Ala Asp Tyr Leu Gly
 65          70          75          80

Gln Ser Ile Asp Gln Leu Glu Pro Phe Ser Leu Ile Ile Thr Gly Lys
 85          90          95

Met Glu Arg Asp Gly Lys Lys Phe Gly Ile Gly Ser Ser Gly Ser Val
100          105          110

Thr Leu Leu Thr Leu Lys Ala Leu Ser Ala Tyr Tyr Gln Ile Thr Leu
115          120          125

Thr Pro Glu Leu Leu Phe Lys Leu Ala Ala Tyr Thr Leu Leu Lys Gln
130          135          140

Gly Asp Asn Gly Ser Met Gly Asp Ile Ala Cys Ile Ala Tyr Gln Thr
145          150          155          160

Leu Val Ala Tyr Thr Ser Phe Asp Arg Glu Gln Val Ser Asn Trp Leu
165          170          175

Gln Thr Met Pro Leu Lys Lys Leu Leu Val Lys Asp Trp Gly Tyr His
180          185          190

Ile Gln Val Ile Gln Pro Ala Leu Pro Cys Asp Phe Leu Val Gly Trp
195          200          205

Thr Lys Ile Pro Ala Ile Ser Arg Gln Met Ile Gln Gln Val Thr Ala
210          215          220

Ser Ile Thr Pro Ala Phe Leu Arg Thr Ser Tyr Gln Leu Thr Gln Ser
225          230          235          240

Ala Met Val Ala Leu Gln Glu Gly His Lys Glu Glu Leu Lys Lys Ser
245          250          255

Leu Ala Gly Ala Ser His Leu Leu Lys Glu Leu His Pro Ala Ile Tyr

```

260 265 270
 His Pro Lys Leu Val Thr Leu Val Ala Ala Cys Gln Lys Gln Asp Ala
 275 280 285
 Val Ala Lys Ser Ser Gly Ala Gly Gly Gly Asp Cys Gly Ile Ala Leu
 290 295 300
 Ala Phe Asn Gln Asp Ala Arg Asp Thr Leu Ile Ser Lys Trp Gln Glu
 305 310 315 320
 Ala Asp Ile Ala Leu Leu Tyr Gln Glu Arg Trp Gly Glu Asn Asp
 325 330 335

<210> 107

<211> 368

<212> PRT

<213> Enterococcus faecalis

<400> 107

Met Ile Glu Val Thr Thr Pro Gly Lys Leu Phe Ile Ala Gly Glu Tyr
 1 5 10 15
 Ala Val Val Glu Pro Gly His Pro Ala Ile Ile Val Ala Val Asp Gln
 20 25 30
 Phe Val Thr Val Thr Val Glu Glu Thr Thr Asp Glu Gly Ser Ile Gln
 35 40 45
 Ser Ala Gln Tyr Ser Ser Leu Pro Ile Arg Trp Thr Arg Arg Asn Gly
 50 55 60
 Glu Leu Val Leu Asp Ile Arg Glu Asn Pro Phe His Tyr Val Leu Ala
 65 70 75 80
 Ala Ile His Leu Thr Glu Lys Tyr Ala Gln Glu Gln Asn Lys Glu Leu
 85 90 95
 Ser Phe Tyr His Leu Lys Val Thr Ser Glu Leu Asp Ser Ser Asn Gly
 100 105 110
 Arg Lys Tyr Gly Leu Gly Ser Ser Gly Ala Val Thr Val Gly Thr Val
 115 120 125
 Lys Ala Leu Asn Ile Phe Tyr Asp Leu Gly Leu Glu Asn Glu Glu Ile
 130 135 140
 Phe Lys Leu Ser Ala Leu Ala His Leu Ala Val Gln Gly Asn Gly Ser
 145 150 155 160
 Cys Gly Asp Ile Ala Ala Ser Cys Tyr Gly Gly Trp Ile Ala Phe Ser

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|---------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ile | Glu | Val | Ser | Ala | Pro | Gly | Lys | Leu | Tyr | Ile | Ala | Gly | Glu | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Ala | Val | Val | Glu | Thr | Gly | His | Pro | Ala | Val | Ile | Ala | Ala | Val | Asp | Gln |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Phe | Val | Thr | Val | Thr | Val | Glu-Ser | Ala | Arg | Lys | Val | Gly | Ser | | Ile | Gln |

| 35 | 40 | 45 |
|---|-----|-----|
| Ser Ala Gln Tyr Ser Gly Met Pro Val Arg Trp Thr Arg Arg Asn Gly | | |
| 50 | 55 | 60 |
| Glu Leu Val Leu Asp Ile Arg Glu Asn Pro Phe His Tyr Ile Leu Ala | | |
| 65 | 70 | 75 |
| Ala Ile Arg Leu Thr Glu Lys Tyr Ala Gln Glu Lys Asn Ile Leu Leu | | |
| | 85 | 90 |
| Ser Phe Tyr Asp Leu Lys Val Thr Ser Glu Leu Asp Ser Ser Asn Gly | | |
| | 100 | 105 |
| Arg Lys Tyr Gly Leu Gly Ser Ser Gly Ala Val Thr Val Ala Thr Val | | |
| | 115 | 120 |
| Lys Ala Leu Asn Val Phe Tyr Ala Leu Asn Leu Ser Gln Leu Glu Ile | | |
| | 130 | 135 |
| Phe Lys Ile Ala Ala Leu Ala Asn Leu Ala Val Gln Asp Asn Gly Ser | | |
| | 145 | 150 |
| Cys Gly Asp Ile Ala Ala Ser Cys Tyr Gly Gly Trp Ile Ala Phe Ser | | |
| | 165 | 170 |
| Thr Phe Asp His Pro Trp Leu Gln Glu Gln Glu Thr Gln His Ser Ile | | |
| | 180 | 185 |
| Ser Glu Leu Leu Ala Leu Asp Trp Pro Gly Leu Ser Ile Glu Pro Leu | | |
| | 195 | 200 |
| Ile Ala Pro Glu Asp Leu Arg Leu Leu Ile Gly Trp Thr Gly Ser Pro | | |
| | 210 | 215 |
| Ala Ser Thr Ser Asp Leu Val Asp Gln Val His Arg Ser Arg Glu Asp | | |
| | 225 | 230 |
| Lys Met Val Ala Tyr Gln Leu Phe Leu Lys Asn Ser Thr Glu Cys Val | | |
| | 245 | 250 |
| Asn Glu Met Ile Lys Gly Phe Lys Glu Asn Asn Val Thr Leu Ile Gln | | |
| | 260 | 265 |
| Gln Met Ile Arg Lys Asn Arg Gln Leu Leu His Asp Leu Ser Ala Ile | | |
| | 275 | 280 |
| Thr Gly Val Val Ile Glu Thr Pro Ala Leu Asn Lys Leu Cys Asn Leu | | |
| | 290 | 295 |
| Ala Glu Gln Tyr Glu Gly Ala Ala Lys Ser Ser Gly Ala Gly Gly Gly | | |
| | 305 | 310 |
| Asp Cys Gly Ile Val Ile Val Asp Gln Lys Ser Gly Ile Leu Pro Leu | | |
| | 325 | 330 |
| Met Ser Ala Trp Glu Lys Ala Glu Ile Thr Pro Leu Pro Leu His Val | | |

340 345 350
 Tyr Ser Asp Gln Arg Lys Glu Asn Arg
 355 360
 <210> 109
 <211> 358
 <212> PRT
 <213> Staphylococcus haemolyticus

 <400> 109
 Met Ile Gln Val Lys Ala Pro Gly Lys Leu Tyr Val Ala Gly Glu Tyr
 1 5 10 15
 Ala Val Thr Glu Pro Gly Tyr Lys Ser Val Leu Ile Ala Val Asp Arg
 20 25 30
 Phe Val Thr Ala Ser Ile Glu Ala Ser Asn Ala Val Thr Ser Thr Ile
 35 40 45
 His Ser Lys Thr Leu His Tyr Glu Pro Val Thr Phe Asn Arg Asn Glu
 50 55 60
 Asp Lys Ile Asp Ile Ser Asp Ala Asn Ala Ala Ser Gln Leu Lys Tyr
 65 70 75 80
 Val Val Thr Ala Ile Glu Val Phe Glu Gln Tyr Ala Arg Ser Cys Asn
 85 90 95
 Val Lys Leu Lys His Phe His Leu Glu Ile Asp Ser Asn Leu Asp Asp
 100 105 110
 Ala Ser Gly Asn Lys Tyr Gly Leu Gly Ser Ser Ala Ala Val Leu Val
 115 120 125
 Ser Val Val Lys Ala Leu Asn Glu Phe Tyr Asp Met Gln Leu Ser Asn
 130 135 140
 Leu Tyr Ile Tyr Lys Leu Ala Val Ile Ser Asn Met Arg Leu Gln Ser
 145 150 155 160
 Leu Ser Ser Cys Gly Asp Ile Ala Val Ser Val Tyr Ser Gly Trp Leu
 165 170 175
 Ala Tyr Ser Thr Phe Asp His Asp Trp Val Lys Gln Gln Met Glu Glu
 180 185 190
 Thr Ser Val Asn Glu Val Leu Glu Lys Asn Trp Pro Gly Leu His Ile
 195 200 205
 Glu Pro Leu Gln Ala Pro Glu Asn Met Glu Val Leu Ile Gly Trp Thr

210 215 220
 Gly Ser Pro Ala Ser Ser Pro His Leu Val Ser Glu Val Lys Arg Leu
 225 230 235 240
 Lys Ser Asp Pro Ser Phe Tyr Gly Arg Phe Leu Asp Gln Ser His Thr
 245 250 255
 Cys Val Glu Asn Leu Ile Tyr Ala Phe Lys Thr Asp Asn Ile Lys Gly
 260 265 270
 Val Gln Lys Met Ile Arg Gln Asn Arg Met Ile Ile Gln Gln Met Asp
 275 280 285
 Asn Glu Ala Thr Val Asp Ile Glu Thr Glu Asn Leu Lys Met Leu Cys
 290 295 300
 Asp Ile Gly Glu Arg Tyr Gly Ala Ala Ala Lys Thr Ser Gly Ala Gly
 305 310 315 320
 Gly Gly Asp Cys Gly Ile Ala Ile Ile Asp Asn Arg Ile Asp Lys Asn
 325 330 335
 Arg Ile Tyr Asn Glu Trp Ala Ser His Gly Ile Lys Pro Leu Lys Phe
 340 345 350
 Lys Ile Tyr His Gly Gln
 355

<210> 110

<211> 358

<212> PRT

<213> Staphylococcus epidermis

<400> 110

Met Ile Gln Val Lys Ala Pro Gly Lys Leu Tyr Ile Ala Gly Glu Tyr
 1 5 10 15
 Ala Val Thr Glu Pro Gly Tyr Lys Ser Ile Leu Ile Ala Val Asn Arg
 20 25 30
 Phe Val Thr Ala Thr Ile Glu Ala Ser Asn Lys Val Glu Gly Ser Ile
 35 40 45
 His Ser Lys Thr Leu His Tyr Glu Pro Val Lys Phe Asp Arg Asn Glu
 50 55 60
 Asp Arg Ile Glu Ile Ser Asp Val Gln Ala Ala Lys Gln Leu Lys Tyr
 65 70 75 80
 Val Val Thr Ala Ile Glu Val Phe Glu Gln Tyr Val Arg Ser Cys Asn

| 85 | | | | | | | | | | 90 | | | | | 95 | | | | | | |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|--|--|--|--|--|
| Met | Asn | Leu | Lys | His | Phe | His | Leu | Thr | Ile | Asp | Ser | Asn | Leu | Ala | Asp | | | | | | |
| | | | 100 | | | | | 105 | | | | | 110 | | | | | | | | |
| Asn | Ser | Gly | Gln | Lys | Tyr | Gly | Leu | Gly | Ser | Ser | Ala | Ala | Val | Leu | Val | | | | | | |
| | | 115 | | | | | 120 | | | | | 125 | | | | | | | | | |
| Ser | Val | Val | Lys | Ala | Leu | Asn | Glu | Phe | Tyr | Gly | Leu | Glu | Leu | Ser | Asn | | | | | | |
| | | 130 | | | | 135 | | | | | 140 | | | | | | | | | | |
| Leu | Tyr | Ile | Tyr | Lys | Leu | Ala | Val | Ile | Ala | Asn | Met | Lys | Leu | Gln | Ser | | | | | | |
| 145 | | | | | 150 | | | | | 155 | | | | 160 | | | | | | | |
| Leu | Ser | Ser | Cys | Gly | Asp | Ile | Ala | Val | Ser | Val | Tyr | Ser | Gly | Trp | Leu | | | | | | |
| | | | 165 | | | | | | 170 | | | | | 175 | | | | | | | |
| Ala | Tyr | Ser | Thr | Phe | Asp | His | Asp | Trp | Val | Lys | Gln | Gln | Met | Glu | Glu | | | | | | |
| | | | 180 | | | | | 185 | | | | | 190 | | | | | | | | |
| Thr | Ser | Val | Asn | Asp | Val | Leu | Glu | Lys | Asn | Trp | Pro | Gly | Leu | His | Ile | | | | | | |
| | | 195 | | | | | 200 | | | | | 205 | | | | | | | | | |
| Glu | Pro | Leu | Gln | Ala | Pro | Glu | Asn | Met | Glu | Val | Leu | Ile | Gly | Trp | Thr | | | | | | |
| 210 | | | | | | 215 | | | | | 220 | | | | | | | | | | |
| Gly | Ser | Pro | Ala | Ser | Ser | Pro | His | Leu | Val | Ser | Glu | Val | Lys | Arg | Leu | | | | | | |
| 225 | | | | | 230 | | | | | 235 | | | | 240 | | | | | | | |
| Lys | Ser | Asp | Pro | Ser | Phe | Tyr | Gly | Asp | Phe | Leu | Asp | Gln | Ser | His | Ala | | | | | | |
| | | | | 245 | | | | | 250 | | | | | 255 | | | | | | | |
| Cys | Val | Glu | Ser | Leu | Ile | Gln | Ala | Phe | Lys | Thr | Asn | Asn | Ile | Lys | Gly | | | | | | |
| | | 260 | | | | | | 265 | | | | | 270 | | | | | | | | |
| Val | Gln | Lys | Met | Ile | Arg | Ile | Asn | Arg | Arg | Ile | Ile | Gln | Ser | Met | Asp | | | | | | |
| | | 275 | | | | | 280 | | | | | 285 | | | | | | | | | |
| Asn | Glu | Ala | Ser | Val | Glu | Ile | Glu | Thr | Asp | Lys | Leu | Lys | Lys | Leu | Cys | | | | | | |
| | | 290 | | | | 295 | | | | | 300 | | | | | | | | | | |
| Asp | Val | Gly | Glu | Lys | His | Gly | Gly | Ala | Ser | Lys | Thr | Ser | Gly | Ala | Gly | | | | | | |
| 305 | | | | | 310 | | | | | 315 | | | | 320 | | | | | | | |
| Gly | Gly | Asp | Cys | Gly | Ile | Thr | Ile | Ile | Asn | Lys | Val | Ile | Asp | Lys | Asn | | | | | | |
| | | | 325 | | | | | | 330 | | | | | 335 | | | | | | | |
| Ile | Ile | Tyr | Asn | Glu | Trp | Gln | Met | Asn | Asp | Ile | Lys | Pro | Leu | Lys | Phe | | | | | | |
| | | | 340 | | | | | 345 | | | | | 350 | | | | | | | | |
| Lys | Ile | Tyr | His | Gly | Gln | | | | | | | | | | | | | | | | |
| | | | 355 | | | | | | | | | | | | | | | | | | |
| <210> 111 | | | | | | | | | | | | | | | | | | | | | |
| <211> 358 | | | | | | | | | | | | | | | | | | | | | |

<212> PRT

<213> Staphylococcus aureus

<400> 111

Met Ile Gln Val Lys Ala Pro Gly Lys Leu Tyr Ile Ala Gly Glu Tyr
 1 5 10 15
 Ala Val Thr Glu Pro Gly Tyr Lys Ser Val Leu Ile Ala Leu Asp Arg
 20 25 30
 Phe Val Thr Ala Thr Ile Glu Glu Ala Thr Gln Tyr Lys Gly Thr Ile
 35 40 45
 His Ser Lys Ala Leu His His Asn Pro Val Thr Phe Ser Arg Asp Glu
 50 55 60
 Asp Ser Ile Val Ile Ser Asp Pro His Ala Ala Lys Gln Leu Asn Tyr
 65 70 75 80
 Val Val Thr Ala Ile Glu Ile Phe Glu Gln Tyr Ala Lys Ser Cys Asp
 85 90 95
 Ile Ala Met Lys His Phe His Leu Thr Ile Asp Ser Asn Leu Asp Asp
 100 105 110
 Ser Asn Gly His Lys Tyr Gly Leu Gly Ser Ser Ala Ala Val Leu Val
 115 120 125
 Ser Val Ile Lys Val Leu Asn Glu Phe Tyr Asp Met Lys Leu Ser Asn
 130 135 140
 Leu Tyr Ile Tyr Lys Leu Ala Val Ile Ala Asn Met Lys Leu Gln Ser
 145 150 155 160
 Leu Ser Ser Cys Gly Asp Ile Ala Val Ser Val Tyr Ser Gly Trp Leu
 165 170 175
 Ala Tyr Ser Thr Phe Asp His Glu Trp Val Lys His Gln Ile Glu Asp
 180 185 190
 Thr Thr Val Glu Glu Val Leu Ile Lys Asn Trp Pro Gly Leu His Ile
 195 200 205
 Glu Pro Leu Gln Ala Pro Glu Asn Met Glu Val Leu Ile Gly Trp Thr
 210 215 220
 Gly Ser Pro Ala Ser Ser Pro His Phe Val Ser Glu Val Lys Arg Leu
 225 230 235 240
 Lys Ser Asp Pro Ser Phe Tyr Gly Asp Phe Leu Glu Asp Ser His Arg
 245 250 255
 Cys Val Glu Lys Leu Ile His Ala Phe Lys Thr Asn Asn Ile Lys Gly

144

130 135 140
 Ala Val Ala Ala Phe Cys Gly Leu Glu Leu Ser Thr Asp Glu Arg Phe
 145 150 155 160
 Arg Leu Ala Met Leu Ala Thr Ala Glu Leu Asp Pro Lys Gly Ser Gly
 165 170 175
 Gly Asp Leu Ala Ala Ser Thr Trp Gly Gly Trp Ile Ala Tyr Gln Ala
 180 185 190
 Pro Asp Arg Ala Phe Val Leu Asp Leu Ala Arg Arg Val Gly Val Asp
 195 200 205
 Arg Thr Leu Lys Ala Pro Trp Pro Gly His Ser Val Arg Arg Leu Pro
 210 215 220
 Ala Pro Lys Gly Leu Thr Leu Glu Val Gly Trp Thr Gly Glu Pro Ala
 225 230 235 240
 Ser Thr Ala Ser Leu Val Ser Asp Leu His Arg Arg Thr Trp Arg Gly
 245 250 255
 Ser Ala Ser His Gln Arg Phe Val Glu Thr Thr Thr Asp Cys Val Arg
 260 265 270
 Ser Ala Val Thr Ala Leu Glu Ser Gly Asp Asp Thr Ser Leu Leu His
 275 280 285
 Glu Ile Arg Arg Ala Arg Gln Glu Leu Ala Arg Leu Asp Asp Glu Val
 290 295 300
 Gly Leu Gly Ile Phe Thr Pro Lys Leu Thr Ala Leu Cys Asp Ala Ala
 305 310 315 320
 Glu Ala Val Gly Gly Ala Ala Lys Pro Ser Gly Ala Gly Gly Gly Asp
 325 330 335
 Cys Gly Ile Ala Leu Leu Asp Ala Glu Ala Ser Arg Asp Ile Thr His
 340 345 350
 Val Arg Gln Arg Trp Glu Thr Ala Gly Val Leu Pro Leu Pro Leu Thr
 355 360 365
 Pro Ala Leu Glu Gly Ile
 370

<210> 113

<211> 360

<212> PRT

<213> Streptomyces griseolosporeus

<400> 113

```

Met Thr Gly Pro Arg Ala Val Thr Arg Arg Ala Pro Gly Lys Leu Phe
 1           5           10           15

Val Ala Gly Glu Tyr Ala Val Val Glu Pro Gly Asn Arg Ala Ile Leu
 20           25           30

Val Ala Val Asp Arg Tyr Val Thr Val Thr Val Ser Asp Gly Ala Ala
 35           40           45

Pro Gly Val Val Val Ser Ser Asp Ile Gly Ala Gly Pro Val His His
 50           55           60

Pro Trp Gln Asp Gly Arg Leu Thr Gly Gly Thr Gly Thr Pro His Val
 65           70           75           80

Val Ala Ala Val Glu Thr Val Ala Arg Leu Leu Ala Glu Arg Gly Arg
 85           90           95

Ser Val Pro Pro Leu Gly Trp Ser Ile Ser Ser Thr Leu His Glu Asp
 100          105          110

Gly Arg Lys Phe Gly Leu Gly Ser Ser Gly Ala Val Thr Val Ala Thr
 115          120          125

Val Ser Ala Val Ala Ala His Cys Gly Leu Glu Leu Thr Ala Glu Glu
 130          135          140

Arg Phe Arg Thr Ala Leu Ile Ala Ser Ala Arg Ile Asp Pro Arg Gly
 145          150          155          160

Ser Gly Gly Asp Ile Ala Thr Ser Thr Trp Gly Gly Trp Ile Ala Tyr
 165          170          175

Arg Ala Pro Asp Arg Asp Ala Val Leu Asp Leu Thr Arg Arg Gln Gly
 180          185          190

Val Asp Glu Ala Leu Arg Ala Pro Trp Pro Gly Phe Ser Val Arg Leu
 195          200          205

Ser Pro Pro Arg Asn Leu Cys Leu Glu Val Gly Trp Thr Gly Asn Pro
 210          215          220

Val Ser Thr Thr Ser Leu Leu Thr Asp Leu His Arg Arg Thr Trp Arg
 225          230          235          240

Gly Ser Pro Ala Tyr Arg Arg Tyr Val Gly Ala Thr Gly Glu Leu Val
 245          250          255

Asp Ala Ala Val Ile Ala Leu Glu Asp Gly Asp Thr Glu Gly Leu Leu
 260          265          270

Arg Gln Val Arg Arg Ala Arg His Glu Met Val Arg Leu Asp Asp Glu
 275          280          285

Val Gly Leu Gly Ile Phe Thr Pro Glu Leu Thr Ala Leu Cys Ala Ile

```

290 295 300

Ala Glu Arg Ala Gly Ala Ala Lys Pro Ser Gly Ala Gly Gly Gly Asp
305 310 315 320

Cys Gly Ile Ala Leu Leu Asp Ala Glu Ala Arg Tyr Asp Arg Ser Pro
325 330 335

Leu His Arg Gln Trp Ala Ala Ala Gly Val Leu Pro Leu Leu Val Ser
340 345 350

Pro Ala Thr Glu Gly Val Glu Glu
355 360

<210> 114

<211> 317

<212> PRT

<213> *Borrelia burgdorferi*

<400> 114

Met Asp Leu Ile Ser Phe Ser Val Pro Gly Asn Leu Leu Leu Met Gly
1 5 10 15

Glu Tyr Thr Ile Leu Glu Glu Lys Gly Leu Gly Leu Ala Ile Ala Ile
20 25 30

Asn Lys Arg Ala Phe Phe Ser Phe Lys Lys Ser Asp Ser Trp Arg Phe
35 40 45

Phe Ser Lys Lys Lys Lys Ile Asp Asp Phe Ser Leu Ile Glu Asn Arg
50 55 60

Ser Asp Phe Val Phe Lys Met Phe Ala Tyr Leu Ser Gln Asn Cys Phe
65 70 75 80

Phe Asn Leu Glu Asn Phe Ala Tyr Asp Val Tyr Ile Asp Thr Ser Asn
85 90 95

Phe Phe Phe Asn Asp Gly Thr Lys Lys Gly Phe Gly Ser Ser Ala Val
100 105 110

Val Ala Ile Gly Ile Val Cys Gly Leu Phe Leu Ile His Asn Ala Thr
115 120 125

Asn Val Val Glu Lys Gly Glu Ile Phe Lys Tyr Cys Leu Glu Ala Tyr
130 135 140

Arg Tyr Ser Gln Gly Gly Ile Gly Ser Gly Tyr Asp Ile Ala Thr Ser
145 150 155 160

Ile Phe Gly Gly Val Ile Glu Phe Glu Gly Gly Phe Asn Pro Lys Cys

165 170 175
 Arg Gln Leu Gly Ala Val Glu Phe Asn Asp Phe Tyr Leu Met Gln Gly
 180 185 190
 Leu Gln Ala Ile Lys Thr Thr Thr Ser Ile Cys Glu Tyr Asn Lys His
 195 200 205
 Arg Asn Ser Ile Leu Asp Phe Ile Leu Lys Cys Asn Leu Glu Met Lys
 210 215 220
 Lys Leu Val Leu Asn Ala Ser Asn Ser Lys Ser Ala Leu Ile Ser Ser
 225 230 235 240
 Leu Arg Arg Ala Lys Glu Leu Gly Leu Ala Ile Gly Glu Ala Ile Gly
 245 250 255
 Val Ser Ala Ala Leu Pro Ser Ser Phe Asp His Leu Leu Gly Gln Cys
 260 265 270
 Asp Leu Ile Lys Ala Leu Gly Ala Gly Asn Glu Thr Phe Leu Val Tyr
 275 280 285
 Arg Pro Asn Ile Glu Ala Phe Asn Leu Ser Lys Ile Ile Ser Ile Val
 290 295 300
 Leu Glu Asn Glu Gly Ile Lys Phe Glu Ser Asp Lys Cys
 305 310 315

<210> 115

<211> 30

<212> DNA

<213> synthetic construct

<400> 115

gggcaagctt gtccacggca cgaccaagca

30

<210> 116

<211> 30

<212> DNA

<213> synthetic construct

<400> 116

cgtaatccgc ggccgcgttt ccagcgcgtc

30

<210> 117

<211> 28

<212> DNA

<213> synthetic construct

<400> 117

aattaaagga gggtttcata tgaattcg

28

<210> 118

<211> 28

<212> DNA

<213> synthetic construct

<400> 118

gatccgaatt catatgaaac cctccttt

28

<210> 119

<211> 30

<212> DNA

<213> synthetic construct

<400> 119

aaggcctcat atgatttccc ataccccgg

30

<210> 120

<211> 28

<212> DNA

<213> synthetic construct

<400> 120

cgggatcctc atcgctccat ctccatgt

28

<210> 121

<211> 30

<212> DNA

<213> synthetic construct

<400> 121

aaggcctcat atgaccgaca gcaaggatca

30

<210> 122

<211> 28

<212> DNA

<213> synthetic construct

<400> 122

cgggatcctc attgacggat aagcgagg

28

<210> 123

<211> 29

<212> DNA

<213> synthetic construct

<400> 123

aaggcctcat atgaaagtgc ctaagatga

29

<210> 124

<211> 28

<212> DNA

<213> synthetic construct

<400> 124

cgggatcctc aggcctgccg gtcgacat

28

<210> 125

<211> 34

<212> DNA

<213> synthetic construct

<400> 125

aaggcctcat atgagcaccg gcaggcctga agca

34

<210> 126

<211> 31

<212> DNA

<213> synthetic construct

<400> 126

cgggatactc atccctgccc cggcagcggt t

31

<210> 127

<211> 30

<212> DNA

<213> synthetic construct

<400> 127

aaggcctcat atggatcagg tcattccgagc

30

<210> 128

<211> 28

<212> DNA

<213> synthetic construct

<400> 128

cgggatactc agtcattcgaa aacaagtc

28

<210> 129

<211> 30

<212> DNA

<213> synthetic construct

<400> 129

aaggcctcat atgactgatg ccgtccgcga

30

<210> 130

<211> 28

<212> DNA

<213> synthetic construct

<400> 130

cgggatcctc aacgcccctc gaacggcg

28

<210> 131

<211> 31

<212> DNA

<213> synthetic construct

<400> 131

ccggcattcg ggcggcatcc aggtctcgct g

31

<210> 132

<211> 31

<212> DNA

<213> synthetic construct

<400> 132

cagcgagacc tggatgccgc ccgaatgccg g

31

<210> 133

<211> 31

<212> DNA

<213> synthetic construct

<400> 133

cgtagcagggc tggattctgt cggaataccc g

31

<210> 134

<211> 31

<212> DNA

<213> synthetic construct

<400> 134

cgggtattcc gacagaatcc agccctgcac g

31

<210> 135

<211> 31

<212> DNA

<213> synthetic construct

<400> 135

gggctgcgcg ccggcatccg gcatttcgac g

31

<210> 136

<211> 31

<212> DNA

<213> synthetic construct

<400> 136

cgtcgaaatg ccggatgccg gcgcgcagcc c

31

<210> 137

<211> 31

<212> DNA

<213> synthetic construct

<400> 137
gggtgcgacg ggcgagttct tcgatgcgcg g

31

<210> 138

<211> 31

<212> DNA

<213> synthetic construct

<400> 138
ccgcgcacgc aagaactcgc ccgtcgcacc c

31

<210> 139

<211> 31

<212> DNA

<213> synthetic construct

<400> 139
cacgcccgtc acatacgacg aatacgttgc c

31

<210> 140

<211> 31

<212> DNA

<213> synthetic construct

<400> 140
ggcaacgtat tcgtcgatg tgacgggcgt g

31

<210> 141

<211> 31

<212> DNA

<213> synthetic construct

<400> 141

gaggctcggg cttggctcct cggcggcggt g

31

<210> 142

<211> 31

<212> DNA

<213> synthetic construct

<400> 142

caccgccgcc gaggagccaa gcccgagcct c

31

<210> 143

<211> 31

<212> DNA

<213> synthetic construct

<400> 143

cggcacgctg ctggacccgg gcgacgcctt c

31

<210> 144

<211> 31

<212> DNA

<213> synthetic construct

<400> 144

gaaggcgtcg cccgggtcca gcagcgtgcc g

31

<210> 145

<211> 36

<212> DNA

<213> synthetic construct

<400> 145
tcagaattcg gtaccatatg aagcttggat ccgggg

36

<210> 146

<211> 29

<212> DNA

<213> synthetic construct

<400> 146
ggatccaagc ttcatatggt accgaattc

29

<210> 147

<211> 26

<212> DNA

<213> synthetic construct

<400> 147
ggaattcgct gctgaacgcg atggcg

26

<210> 148

<211> 32

<212> DNA

<213> synthetic construct

<400> 148
ggggtaccat atgtgccttc gttgcgtcag tc

32

<210> 149

<211> 50

<212> DNA

<213> synthetic construct

<400> 149
gatccggcgt gtgcgcaatt taattgcgca cacgccccct gcgtttaaac

50

<210> 150

<211> 50

<212> DNA

<213> synthetic construct

<400> 150
gatcggtttaa acgcaggggg cgtgtgcgca attaaattgc gcacacgccg

50

<210> 151

<211> 30

<212> DNA

<213> synthetic construct

<400> 151
aaggcctcat atgacgccca agcagcaatt

30

<210> 152

<211> 26

<212> DNA

<213> synthetic construct

<400> 152
cgggataccta ggcgctgcgg cggatg

26

<210> 153

<211> 30

<212> DNA

<213> synthetic construct

<400> 153
ccggatcctc atgcctgccg gtcgacatag

30

<210> 154

<211> 30

<212> DNA

<213> synthetic construct

<400> 154
gaaggcacat atgaatcagg tcatccgcgc

30

<210> 155

<211> 30

<212> DNA

<213> synthetic construct

<400> 155
gccggatcct cattcatcga aaacaagtcc

30

<210> 156

<211> 30

<212> DNA

<213> synthetic construct

<400> 156
acgccggatc ctcacgcgcc ctcgaacggc

30

<210> 157

<211> 1612

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (59) .. (292)

<223> XseB

<220>

<221> CDS

<222> (1185) .. (1610)

<223> IspA

<220>

<221> CDS

<222> (295) .. (1158)

<223> Dxs

<400> 157

```

ccatggcatc cgggtcggat gccgtctatg ttggcccgaa caggcagcag gaggcccc      58
atg agc gat atc cag acc ctc tcg ttc gag gaa gcc atg cgc gag ctg      106
Met Ser Asp Ile Gln Thr Leu Ser Phe Glu Glu Ala Met Arg Glu Leu
1          5          10          15

gag gcg acc gtc ggc aag ctg gaa acc ggc gag gcg acg ctg gag gac      154
Glu Ala Thr Val Gly Lys Leu Glu Thr Gly Glu Ala Thr Leu Glu Asp
          20          25          30

tcc atc gcg ctc tat gaa cgc ggg gcg gcg ctg cgc gcc cat tgc gaa      202
Ser Ile Ala Leu Tyr Glu Arg Gly Ala Ala Leu Arg Ala His Cys Glu
          35          40          45

acc cgc ctg cgc gag gcc gag gag cgg gtc gag aag atc acc ctg gcc      250
Thr Arg Leu Arg Glu Ala Glu Glu Arg Val Glu Lys Ile Thr Leu Ala
          50          55          60

gcg aac ggg cag ccg tcc gga acc gag ccc gcc gag ggc ctg tg atg      297
Ala Asn Gly Gln Pro Ser Gly Thr Glu Pro Ala Glu Gly Leu Met
65          70          75          80

cag gcc cgc ctg gcc gag atc cgg ccc ctg gtc gag gcc gag ctg aac      345
Gln Ala Arg Leu Ala Glu Ile Arg Pro Leu Val Glu Ala Glu Leu Asn
80          85          90          95

```

| | |
|---|------|
| gcc gcc atc gac gcg ctg ccc gcg ggc gat ctg tcg gat gcg atg cgc Ala Ala Ile Asp Ala Leu Pro Ala Gly Asp Leu Ser Asp Ala Met Arg 100 105 110 | 393 |
| tat gcc gtg cag ggc ggc aag cgg ctg cgc gcg ttc ctg gtg atg gag Tyr Ala Val Gln Gly Gly Lys Arg Leu Arg Ala Phe Leu Val Met Glu 115 120 125 | 441 |
| tcg gcg cgc ctg cac ggg ctg gac gac gac gca tcg ctg ccc gtc gcc Ser Ala Arg Leu His Gly Leu Asp Asp Ala Ser Leu Pro Val Ala 130 135 140 | 489 |
| gcc gcg gtc gag gcg ctg cac gcc tac agc ttg gtc cat gac gac ctg Ala Ala Val Glu Ala Leu His Ala Tyr Ser Leu Val His Asp Asp Leu 145 150 155 | 537 |
| ccc gcg atg gat gac gac gac ctg cgg cgc ggt cag ccc acc gtc cac Pro Ala Met Asp Asp Asp Asp Leu Arg Arg Gly Gln Pro Thr Val His 160 165 170 175 | 585 |
| gtc aaa tgg acc gag gcg acc gcg atc ctt gcg ggc gat gcg ctg cag Val Lys Trp Thr Glu Ala Thr Ala Ile Leu Ala Gly Asp Ala Leu Gln 180 185 190 | 633 |
| acg ctg gcc ttc cag ctg ctg gcc gat ccg cgc gtg ggc gac gat gcg Thr Leu Ala Phe Gln Leu Leu Ala Asp Pro Arg Val Gly Asp Asp Ala 195 200 205 | 681 |
| gcg cgg atg cgg ctg gtc ggt tcg ctg gcg cag gca tcg ggg gct gcg Ala Arg Met Arg Leu Val Gly Ser Leu Ala Gln Ala Ser Gly Ala Ala 210 215 220 | 729 |
| ggc atg gtc tgg ggc cag gcg ctg gac atc gcg gcc gag acc tcg ggc Gly Met Val Trp Gly Gln Ala Leu Asp Ile Ala Ala Glu Thr Ser Gly 225 230 235 | 777 |
| gtg ccg ctg gat ctg gac gcg atc atc cgc ctg cag ggt ggc aag acc Val Pro Leu Asp Leu Asp Ala Ile Ile Arg Leu Gln Gly Gly Lys Thr 240 245 250 255 | 825 |
| ggc gcg ctg atc cgc ttt gcc gcg acc gcc ggg ccg ctg atg gcg ggg Gly Ala Leu Ile Arg Phe Ala Ala Thr Ala Gly Pro Leu Met Ala Gly 260 265 270 | 873 |
| gcg gac cct gcc gcg ctg gac gat tat gcg cag gcc gtc ggg ctg gcc Ala Asp Pro Ala Ala Leu Asp Asp Tyr Ala Gln Ala Val Gly Leu Ala 275 280 285 | 921 |
| ttc cag atc gcg gac gac atc ctg gac gtc gag ggc tgc gag gcc gcg Phe Gln Ile Ala Asp Asp Ile Leu Asp Val Glu Gly Cys Glu Ala Ala 290 295 300 | 969 |
| acc ggc aag cgc gtc ggc aag gat gcg gat gcc aac aag gcg acc ttc Thr Gly Lys Arg Val Gly Lys Asp Ala Asp Ala Asn Lys Ala Thr Phe 305 310 315 | 1017 |
| gtc tcg ctg ctg ggc ctc gag ggg gcg cgg tcc gag gcg cgt cgc ctg | 1065 |

| | |
|---|------|
| Val Ser Leu Leu Gly Leu Glu Gly Ala Arg Ser Glu Ala Arg Arg Leu | |
| 320 325 330 335 | |
| gcc gat gcg ggg cag gac gcg ctg gcg ggt tac ggc gat gct gcg ggg | 1113 |
| Ala Asp Ala Gly Gln Asp Ala Leu Ala Gly Tyr Gly Asp Ala Ala Gly | |
| 340 345 350 | |
| aac ctt cgg gac ctg gcg cgc ttc gtg atc gaa cgc gac agc tga | 1158 |
| Asn Leu Arg Asp Leu Ala Arg Phe Val Ile Glu Arg Asp Ser | |
| 355 360 365 | |
| tcgccgcctt cccgcccaagg ggcaag atg atg acc gac gga ccc gca acc ccg | 1211 |
| Met Met Thr Asp Gly Pro Ala Thr Pro | |
| 370 | |
| atc ctg gac cgc gtc cag cag cca tcc gac ctg gca tcg ctg gac gat | 1259 |
| Ile Leu Asp Arg Val Gln Gln Pro Ser Asp Leu Ala Ser Leu Asp Asp | |
| 375 380 385 390 | |
| gcg cag ctg cgc ctg ctg gcg gac gag ctg cgg gcc gag acc atc gac | 1307 |
| Ala Gln Leu Arg Leu Leu Ala Asp Glu Leu Arg Ala Glu Thr Ile Asp | |
| 395 400 405 | |
| atc gtc agc cgc acg ggc ggt cac ctg ggc gcg ggg ctg ggc gtg gtc | 1355 |
| Ile Val Ser Arg Thr Gly Gly His Leu Gly Ala Gly Leu Gly Val Val | |
| 410 415 420 | |
| gaa ctg acg gtc gcc ctg cac gcc gtc ttt cgg gcg ccg cgc gac aag | 1403 |
| Glu Leu Thr Val Ala Leu His Ala Val Phe Arg Ala Pro Arg Asp Lys | |
| 425 430 435 | |
| atc gtc tgg gac gtg ggg cat caa tgc tat ccc cac aag atc ctg acg | 1451 |
| Ile Val Trp Asp Val Gly His Gln Cys Tyr Pro His Lys Ile Leu Thr | |
| 440 445 450 | |
| ggc agg cgg gac cgg atg cgc acg ctg cgc atg ggc ggc ggg ctg tcg | 1499 |
| Gly Arg Arg Asp Arg Met Arg Thr Leu Arg Met Gly Gly Gly Leu Ser | |
| 455 460 465 470 | |
| ggg ttc acc aag cgg cag gaa agc gcg ttc gat ccg ttc ggt gcg ggg | 1547 |
| Gly Phe Thr Lys Arg Gln Glu Ser Ala Phe Asp Pro Phe Gly Ala Gly | |
| 475 480 485 | |
| cac agc tcg acc tcg atc tcg gcg gcg ctg ggc ttc gcg atg gcg cgt | 1595 |
| His Ser Ser Thr Ser Ile Ser Ala Ala Leu Gly Phe Ala Met Ala Arg | |
| 490 495 500 | |
| gaa ctt ggc ggg gat cc | 1612 |
| Glu Leu Gly Gly Asp | |
| 505 | |

<210> 158

<211> 78

<212> .PRT

<213> Paracoccus sp. R114

<400> 158

Met Ser Asp Ile Gln Thr Leu Ser Phe Glu Glu Ala Met Arg Glu Leu
1 5 10 15

Glu Ala Thr Val Gly Lys Leu Glu Thr Gly Glu Ala Thr Leu Glu Asp
20 25 30

Ser Ile Ala Leu Tyr Glu Arg Gly Ala Ala Leu Arg Ala His Cys Glu
35 40 45

Thr Arg Leu Arg Glu Ala Glu Glu Arg Val Glu Lys Ile Thr Leu Ala
50 55 60

Ala Asn Gly Gln Pro Ser Gly Thr Glu Pro Ala Glu Gly Leu
65 70 75

<210> 159

<211> 287

<212> PRT

<213> Paracoccus sp. R114

<400> 159

Met Gln Ala Arg Leu Ala Glu Ile Arg Pro Leu Val Glu Ala Glu Leu
1 5 10 15

Asn Ala Ala Ile Asp Ala Leu Pro Ala Gly Asp Leu Ser Asp Ala Met
20 25 30

Arg Tyr Ala Val Gln Gly Gly Lys Arg Leu Arg Ala Phe Leu Val Met
35 40 45

Glu Ser Ala Arg Leu His Gly Leu Asp Asp Ala Ser Leu Pro Val
50 55 60

Ala Ala Ala Val Glu Ala Leu His Ala Tyr Ser Leu Val His Asp Asp
65 70 75 80

Leu Pro Ala Met Asp Asp Asp Asp Leu Arg Arg Gly Gln Pro Thr Val
85 90 95

His Val Lys Trp Thr Glu Ala Thr Ala Ile Leu Ala Gly Asp Ala Leu
100 105 110

Gln Thr Leu Ala Phe Gln Leu Leu Ala Asp Pro Arg Val Gly Asp Asp
115 120 125

Ala Ala Arg Met Arg Leu Val Gly Ser Leu Ala Gln Ala Ser Gly Ala
130 135 140

Ala Gly Met Val Trp Gly Gln Ala Leu Asp Ile Ala Ala Glu Thr Ser
145 150 155 160

Gly Val Pro Leu Asp Leu Asp Ala Ile Ile Arg Leu Gln Gly Gly Lys
165 170 175

Thr Gly Ala Leu Ile Arg Phe Ala Ala Thr Ala Gly Pro Leu Met Ala
180 185 190

Gly Ala Asp Pro Ala Ala Leu Asp Asp Tyr Ala Gln Ala Val Gly Leu
195 200 205

Ala Phe Gln Ile Ala Asp Asp Ile Leu Asp Val Glu Gly Cys Glu Ala
210 215 220

Ala Thr Gly Lys Arg Val Gly Lys Asp Ala Asp Ala Asn Lys Ala Thr
225 230 235 240

Phe Val Ser Leu Leu Gly Leu Glu Gly Ala Arg Ser Glu Ala Arg Arg
245 250 255

Leu Ala Asp Ala Gly Gln Asp Ala Leu Ala Gly Tyr Gly Asp Ala Ala
260 265 270

Gly Asn Leu Arg Asp Leu Ala Arg Phe Val Ile Glu Arg Asp Ser
275 280 285

<210> 160

<211> 142

<212> PRT

<213> Paracoccus sp. R114

<400> 160

Met Met Thr Asp Gly Pro Ala Thr Pro Ile Leu Asp Arg Val Gln Gln
 1 5 10 15

Pro Ser Asp Leu Ala Ser Leu Asp Asp Ala Gln Leu Arg Leu Leu Ala
 20 25 30

Asp Glu Leu Arg Ala Glu Thr Ile Asp Ile Val Ser Arg Thr Gly Gly
 35 40 45

His Leu Gly Ala Gly Leu Gly Val Val Glu Leu Thr Val Ala Leu His
 50 55 60

Ala Val Phe Arg Ala Pro Arg Asp Lys Ile Val Trp Asp Val Gly His
 65 70 75 80

Gln Cys Tyr Pro His Lys Ile Leu Thr Gly Arg Arg Asp Arg Met Arg
 85 90 95

Thr Leu Arg Met Gly Gly Gly Leu Ser Gly Phe Thr Lys Arg Gln Glu
 100 105 110

Ser Ala Phe Asp Pro Phe Gly Ala Gly His Ser Ser Thr Ser Ile Ser
 115 120 125

Ala Ala Leu Gly Phe Ala Met Ala Arg Glu Leu Gly Gly Asp
 130 135 140

<210> 161

<211> 6

<212> PRT

<213> Bradyrhizobium japonicum

<400> 161

Val His Asp Asp Leu Pro
1 5

<210> 162

<211> 6

<212> PRT

<213> Rhizobium sp. strain NGR234

<400> 162

Val His Asp Asp Leu Pro
1 5

<210> 163

<211> 6

<212> PRT

<213> Bacillus stearothermophilus

<400> 163

Ile His Asp Asp Leu Pro
1 5

<210> 164

<211> 6

<212> PRT

<213> Bacillus subtilis

<400> 164

Ile His Asp Asp Leu Pro
1 5

<210> 165

<211> 6

<212> PRT

<213> Escherichia coli

<400> 165

Ile His Asp Asp Leu Pro
1 5

<210> 166

<211> 6

<212> PRT

<213> Haemophilus influenzae

<400> 166

Ile His Asp Asp Leu Pro
1 5

<210> 167

<211> 16

<212> DNA

<213> synthetic construct

<400> 167

tccaygayga yctgcc

16

<210> 168

<211> 5

<212> PRT

<213> Bradyrhizobium japonicum

<400> 168

Asp Asp Ile Leu Asp
1 5

<210> 169

<211> 5

<212> PRT

<213> Rhizobium sp. strain NGR234

<400> 169

Asp Asp Ile Leu Asp
1 5

<210> 170

<211> 5

<212> PRT

<213> *Bacillus stearothermophilus*

<400> 170

Asp Asp Ile Leu Asp
1 5

<210> 171

<211> 5

<212> PRT

<213> *Bacillus subtilis*

<400> 171

Asp Asp Ile Leu Asp
1 5

<210> 172

<211> 5

<212> PRT

<213> *Escherichia coli*

<400> 172

Asp Asp Ile Leu Asp
—1 5

<210> 173

<211> 5

<212> PRT

<213> Haemophilus influenzae

<400> 173

Asp Asp Ile Leu Asp
 1 5

<210> 174

<211> 15

<212> DNA

<213> synthetic construct

<400> 174

gaygayatcc tggay

15

<210> 175

<211> 1176

<212> DNA

<213> Paracoccus sp. R1534

<220>

<221> CDS

<222> (1)..(1173)

<223> acety-CoA acetyltransferase

<400> 175

atg gac ccc atc gtc atc acc ggc gcg atg cgc acc ccg atg ggg gca 48
 Met Asp Pro Ile Val Ile Thr Gly Ala Met Arg Thr Pro Met Gly Ala
 1 5 10 15

ttc cag ggc gat ctt gcc gcg atg gat gcc ccg acc ctt ggc gcg gcc 96
 Phe Gln Gly Asp Leu Ala Ala Met Asp Ala Pro Thr Leu Gly Ala Ala
 20 25 30

gcg atc cgc gcc gcg ctg aac ggc ctg tcg ccc gac atg gtg gac gag 144
 Ala Ile Arg Ala Ala Leu Asn Gly Leu Ser Pro Asp Met Val Asp Glu
 35 40 45

| | |
|---|-----|
| gtg ctg atg ggc tgc gtc ctg ccc gcg ggc cag ggt cag gca ccg gca Val Leu Met Gly Cys Val Leu Pro Ala Gly Gln Gly Gln Ala Pro Ala 50 55 60 | 192 |
| cgt cag gcg gcg ctt gac gcc gga ctg ccg ctg tcg gcg ggc gcg acc Arg Gln Ala Ala Leu Asp Ala Gly Leu Pro Leu Ser Ala Gly Ala Thr 65 70 75 80 | 240 |
| acc atc aac aag atg tgc gga tcg ggc atg aag gcc gcg atg ctg ggc Thr Ile Asn Lys Met Cys Gly Ser Gly Met Lys Ala Ala Met Leu Gly 85 90 95 | 288 |
| cat gac ctg atc gcc gcg gga tcg gcg ggc atc gtc gtc gcc ggc ggg His Asp Leu Ile Ala Ala Gly Ser Ala Gly Ile Val Val Ala Gly Gly 100 105 110 | 336 |
| atg gag agc atg tcg aac gcc ccc tac ctg ctg ccc aag gcg ccg tcg Met Glu Ser Met Ser Asn Ala Pro Tyr Leu Leu Pro Lys Ala Arg Ser 115 120 125 | 384 |
| ggg atg cgc atg ggc cat gac cgt gtg ctg gat cac atg ttc ctc gac Gly Met Arg Met Gly His Asp Arg Val Leu Asp His Met Phe Leu Asp 130 135 140 | 432 |
| ggg ttg gag gac gcc tat gac aag ggc cgc ctg atg ggc acc ttc gcc Gly Leu Glu Asp Ala Tyr Asp Lys Gly Arg Leu Met Gly Thr Phe Ala 145 150 155 160 | 480 |
| gag gat tgc gcc ggc gat cac ggt ttc acc cgc gag gcg cag gac gac Glu Asp Cys Ala Gly Asp His Gly Phe Thr Arg Glu Ala Gln Asp Asp 165 170 175 | 528 |
| tat gcg ctg acc agc ctg gcc cgc gcg cag gac gcc atc gcc agc ggt Tyr Ala Leu Thr Ser Leu Ala Arg Ala Gln Asp Ala Ile Ala Ser Gly 180 185 190 | 576 |
| gcc ttc gcc gcc gag atc gcg ccc gtg acc gtc acg gca cgc aag gtg Ala Phe Ala Ala Glu Ile Ala Pro Val Thr Val Thr Ala Arg Lys Val 195 200 205 | 624 |
| cag acc acc gtc gat acc gac gag atg ccc ggc aag gcc cgc ccc gag Gln Thr Thr Val Asp Thr Asp Glu Met Pro Gly Lys Ala Arg Pro Glu 210 215 220 | 672 |
| aag atc ccc cat ctg aag ccc gcc ttc cgt gac ggt ggc acg gtc acg Lys Ile Pro His Leu Lys Pro Ala Phe Arg Asp Gly Gly Thr Val Thr 225 230 235 240 | 720 |
| gcg gcg aac agc tcg tcg atc tcg gac ggc gcg gcg gcg ctg gtg atg Ala Ala Asn Ser Ser Ser Ile Ser Asp Gly Ala Ala Ala Leu Val Met 245 250 255 | 768 |
| atg cgc cag tcg cag gcc gag aag ctg ggc ctg acg ccg atc gcg ccg Met Arg Gln Ser Gln Ala Glu Lys Leu Gly Leu Thr Pro Ile Ala Arg 260 265 270 | 816 |

atc atc ggt cat gcg acc cat gcc gac cgt ccc ggc ctg ttc ccg acg 864
 Ile Ile Gly His Ala Thr His Ala Asp Arg Pro Gly Leu Phe Pro Thr
 275 280 285
 gcc ccc atc ggc gcg atg cgc aag ctg ctg gac cgc acg gac acc cgc 912
 Ala Pro Ile Gly Ala Met Arg Lys Leu Leu Asp Arg Thr Asp Thr Arg
 290 295 300
 ctt ggc gat tac gac ctg ttc gag gtg aac gag gca ttc gcc gtc gtc 960
 Leu Gly Asp Tyr Asp Leu Phe Glu Val Asn Glu Ala Phe Ala Val Val
 305 310 315 320
 gcc atg atc gcg atg aag gag ctt ggc ctg cca cac gat gcc acg aac 1008
 Ala Met Ile Ala Met Lys Glu Leu Gly Leu Pro His Asp Ala Thr Asn
 325 330 335
 atc aac ggc ggg gcc tgc gcg ctt ggg cat ccc atc ggc gcg tcg ggg 1056
 Ile Asn Gly Gly Ala Cys Ala Leu Gly His Pro Ile Gly Ala Ser Gly
 340 345 350
 gcg cgg atc atg gtc acg ctg ctg aac gcg atg gcg gcg cgg ggc gcg 1104
 Ala Arg Ile Met Val Thr Leu Leu Asn Ala Met Ala Ala Arg Gly Ala
 355 360 365
 acg cgc ggg gcc gca tcc gtc tgc atc ggc ggg ggc gag gcg acg gcc 1152
 Thr Arg Gly Ala Ala Ser Val Cys Ile Gly Gly Gly Glu Ala Thr Ala
 370 375 380
 atc gcg ctg gaa cgg ctg agc taa 1176
 Ile Ala Leu Glu Arg Leu Ser
 385 390

<210> 176

<211> 391

<212> PRT

<213> Paracoccus sp. R1534

<400> 176

Met Asp Pro Ile Val Ile Thr Gly Ala Met Arg Thr Pro Met Gly Ala
 1 5 10 15
 Phe Gln Gly Asp Leu Ala Ala Met Asp Ala Pro Thr Leu Gly Ala Ala
 20 25 30
 Ala Ile Arg Ala Ala Leu Asn Gly Leu Ser Pro Asp Met Val Asp Glu
 35 40 45

Val Leu Met Gly Cys Val Leu Pro Ala Gly Gln Gly Gln Ala Pro Ala
 50 55 60

Arg Gln Ala Ala Leu Asp Ala Gly Leu Pro Leu Ser Ala Gly Ala Thr
 65 70 75 80

Thr Ile Asn Lys Met Cys Gly Ser Gly Met Lys Ala Ala Met Leu Gly
 85 90 95

His Asp Leu Ile Ala Ala Gly Ser Ala Gly Ile Val Val Ala Gly Gly
 100 105 110

Met Glu Ser Met Ser Asn Ala Pro Tyr Leu Leu Pro Lys Ala Arg Ser
 115 120 125

Gly Met Arg Met Gly His Asp Arg Val Leu Asp His Met Phe Leu Asp
 130 135 140

Gly Leu Glu Asp Ala Tyr Asp Lys Gly Arg Leu Met Gly Thr Phe Ala
 145 150 155 160

Glu Asp Cys Ala Gly Asp His Gly Phe Thr Arg Glu Ala Gln Asp Asp
 165 170 175

Tyr Ala Leu Thr Ser Leu Ala Arg Ala Gln Asp Ala Ile Ala Ser Gly
 180 185 190

Ala Phe Ala Ala Glu Ile Ala Pro Val Thr Val Thr Ala Arg Lys Val
 195 200 205

Gln Thr Thr Val Asp Thr Asp Glu Met Pro Gly Lys Ala Arg Pro Glu
 210 215 220

Lys Ile Pro His Leu Lys Pro Ala Phe Arg Asp Gly Gly Thr Val Thr
 225 230 235 240

Ala Ala Asn Ser Ser Ser Ile Ser Asp Gly Ala Ala Ala Leu Val Met
 245 250 255

Met Arg Gln Ser Gln Ala Glu Lys Leu Gly Leu Thr Pro Ile Ala Arg
 260 265 270

Ile Ile Gly His Ala Thr His Ala Asp Arg Pro Gly Leu Phe Pro Thr

275 280 285

Ala Pro Ile Gly Ala Met Arg Lys Leu Leu Asp Arg Thr Asp Thr Arg
290 295 300

Leu Gly Asp Tyr Asp Leu Phe Glu Val Asn Glu Ala Phe Ala Val Val
305 310 315 320

Ala Met Ile Ala Met Lys Glu Leu Gly Leu Pro His Asp Ala Thr Asn
325 330 335

Ile Asn Gly Gly Ala Cys Ala Leu Gly His Pro Ile Gly Ala Ser Gly
340 345 350

Ala Arg Ile Met Val Thr Leu Leu Asn Ala Met Ala Ala Arg Gly Ala
355 360 365

Thr Arg Gly Ala Ala Ser Val Cys Ile Gly Gly Gly Glu Ala Thr Ala
370 375 380

Ile Ala Leu Glu Arg Leu Ser
385 390

<210> 177

<211> 1980

<212> DNA

<213> Paracoccus sp. R114

<220>

<221> CDS

<222> (1)..(1170)

<223> phaA

<220>

<221> misc_feature

<222> (1179)..(1194)

<223> inverted repeat between genes constituting a putative transcripti
onal sto

<220>

<221> misc_feature

<222> (1196)..(1210)

<223> inverted repeat between genes constituting a putative transcripti
onal sto

<220>

<221> CDS

<222> (1258)..(1980)

<223> phaB

<400> 177

| | |
|---|-----|
| atg acc aaa gcc gta atc gta tct gcc gca cgt acc ccc gtc ggc agc | 48 |
| Met Thr Lys Ala Val Ile Val Ser Ala Ala Arg Thr Pro Val Gly Ser | |
| 1 5 10 15 | |
| ttc atg ggc gca ttc gcc aat gtc ccc gca cat gat ctg ggc gcc gcc | 96 |
| Phe Met Gly Ala Phe Ala Asn Val Pro Ala His Asp Leu Gly Ala Ala | |
| 20 25 30 | |
| gtc ctg cgc gag gtc gtg gcc cgc gcc ggt gtc gac ccc gcc gag gtc | 144 |
| Val Leu Arg Glu Val Val Ala Arg Ala Gly Val Asp Pro Ala Glu Val | |
| 35 40 45 | |
| agc gag acg atc ctg ggc cag gtg ctg acc gcc gcg cag ggc cag aac | 192 |
| Ser Glu Thr Ile Leu Gly Gln Val Leu Thr Ala Ala Gln Gly Gln Asn | |
| 50 55 60 | |
| ccc gcg cgc cag gcg cat atc aat gcg ggc ctg ccc aag gaa tcg gcg | 240 |
| Pro Ala Arg Gln Ala His Ile Asn Ala Gly Leu Pro Lys Glu Ser Ala | |
| 65 70 75 80 | |
| gcg tgg ctc atc aac cag gtc tgc gcc tcg ggg ctg cgc gcc gtc gcg | 288 |
| Ala Trp Leu Ile Asn Gln Val Cys Gly Ser Gly Leu Arg Ala Val Ala | |
| 85 90 95 | |
| ctg gcg gcg cag cag gtc atg ctg ggc gat gcg cag atc gtt ctg gcg | 336 |
| Leu Ala Ala Gln Gln Val Met Leu Gly Asp Ala Gln Ile Val Leu Ala | |
| 100 105 110 | |
| ggg ggc cag gag agc atg tcg ctg tcg acc cat gcc gcc tat ctg cgc | 384 |
| Gly Gly Gln Glu Ser Met Ser Leu Ser Thr His Ala Ala Tyr Leu Arg | |

| 115 | 120 | 125 | |
|---|-----|-----|------|
| gcg ggc cag aag atg ggc gac atg aag atg atc gac acc atg atc cgc Ala Gly Gln Lys Met Gly Asp Met Lys Met Ile Asp Thr Met Ile Arg 130 135 140 | | | 432 |
| gac ggg ctg tgg gat gcc ttc aac ggc tat cac atg ggt cag acc gcc Asp Gly Leu Trp Asp Ala Phe Asn Gly Tyr His Met Gly Gln Thr Ala 145 150 155 160 | | | 480 |
| gag aac gtg gcc gac cag tgg tcg atc agc cgc gac cag cag gac gaa Glu Asn Val Ala Asp Gln Trp Ser Ile Ser Arg Asp Gln Gln Asp Glu 165 170 175 | | | 528 |
| ttc gcc ctg gct tcg cag aac aag gcc gag gcc gcg cag aat gcg ggc Phe Ala Leu Ala Ser Gln Asn Lys Ala Glu Ala Ala Gln Asn Ala Gly 180 185 190 | | | 576 |
| cgc ttc gat gac gaa atc gtc gcc tat acc gtc aag ggc cgc aag ggc Arg Phe Asp Asp Glu Ile Val Ala Tyr Thr Val Lys Gly Arg Lys Gly 195 200 205 | | | 624 |
| gac acg gtc gtc gac aag gac gaa tac atc cgc cac ggc gcc acg atc Asp Thr Val Val Asp Lys Asp Glu Tyr Ile Arg His Gly Ala Thr Ile 210 215 220 | | | 672 |
| gag ggc atg cag aag ctg cgc ccc gcc ttc acc aag gaa ggc tcg gtc Glu Gly Met Gln Lys Leu Arg Pro Ala Phe Thr Lys Glu Gly Ser Val 225 230 235 240 | | | 720 |
| acg gcg ggc aac gcg tcg ggc ctg aac gac ggc gcg gcg gcc gtc atg Thr Ala Gly Asn Ala Ser Gly Leu Asn Asp Gly Ala Ala Ala Val Met 245 250 255 | | | 768 |
| gtc atg tcc gag gac gag gcc gca cgc cgc ggc ctg acg ccg ctg gcg Val Met Ser Glu Asp Glu Ala Ala Arg Arg Gly Leu Thr Pro Leu Ala 260 265 270 | | | 816 |
| cgc atc gcc tcc tat gcg acg gcg ggc ctc gac ccg gcg atc atg ggc Arg Ile Ala Ser Tyr Ala Thr Ala Gly Leu Asp Pro Ala Ile Met Gly 275 280 285 | | | 864 |
| acc ggg ccg atc ccc tcc agc cgc aag gcg ctg gaa aag gcg ggc tgg Thr Gly Pro Ile Pro Ser Ser Arg Lys Ala Leu Glu Lys Ala Gly Trp 290 295 300 | | | 912 |
| tcg gtc ggc gac ctg gac ctg gtc gag gcg aac gag gcc ttt gcc gcg Ser Val Gly Asp Leu Asp Leu Val Glu Ala Asn Glu Ala Phe Ala Ala 305 310 315 320 | | | 960 |
| cag gcc tgc gcc gtg aac aag gac atg ggc tgg gat ccg tcc atc gtg Gln Ala Cys Ala Val Asn Lys Asp Met Gly Trp Asp Pro Ser Ile Val 325 330 335 | | | 1008 |
| aac gtc aac ggc ggc gcg atc gcc atc ggc cac ccg atc ggc gcc tcg Asn Val Asn Gly Gly Ala Ile Ala Ile Gly His Pro Ile Gly Ala Ser 340 345 350 | | | 1056 |

| | |
|---|------|
| ggg gcg cgg atc ctg aac acc ctg ctg ttc gag atg cag cgc cgc gac Gly Ala Arg Ile Leu Asn Thr Leu Leu Phe Glu Met Gln Arg Arg Asp 355 360 365 | 1104 |
| gcc aag aag ggc ctt gcg acg ctg tgc atc ggc ggc ggc atg ggc gtc Ala Lys Lys Gly Leu Ala Thr Leu Cys Ile Gly Gly Gly Met Gly Val 370 375 380 | 1152 |
| gcc atg tgc ctc gaa cgc tgaacgaccg gcgtgtgcgc aatttaattg Ala Met Cys Leu Glu Arg 385 390 | 1200 |
| cgcacacgcc ccctgcaaag tagcaatgtt ttacgataac gaatgaaggg gggaatc | 1257 |
| atg tcc aag gta gca ctg gtc acc ggc gga tcg cgc ggc atc ggc gcc Met Ser Lys Val Ala Leu Val Thr Gly Gly Ser Arg Gly Ile Gly Ala 395 400 405 | 1305 |
| gag atc tgc aag gcg ctt cag gcc gca ggc tat acc gtc gcc gcg aac Glu Ile Cys Lys Ala Leu Gln Ala Ala Gly Tyr Thr Val Ala Ala Asn 410 415 420 | 1353 |
| tat gcc ggc aat gac gac gcg gcc aag gcc ttc acc gag gaa acc ggc Tyr Ala Gly Asn Asp Asp Ala Ala Lys Ala Phe Thr Glu Glu Thr Gly 425 430 435 | 1401 |
| atc aag acc tac aag tgg tcg gtc gcc gat tac gat gcc tgc aag gcc Ile Lys Thr Tyr Lys Trp Ser Val Ala Asp Tyr Asp Ala Cys Lys Ala 440 445 450 | 1449 |
| ggc atc gcc cag gtc gaa gag gat ctg ggc ccg atc gcc gtg ctg atc Gly Ile Ala Gln Val Glu Glu Asp Leu Gly Pro Ile Ala Val Leu Ile 455 460 465 470 | 1497 |
| aac aat gcc ggg atc acc cgc gac gcg ccc ttc cac aag atg acg ccc Asn Asn Ala Gly Ile Thr Arg Asp Ala Pro Phe His Lys Met Thr Pro 475 480 485 | 1545 |
| gag aag tgg aag gag gtc atc gac acc aac ctg acc ggc acc ttc aac Glu Lys Trp Lys Glu Val Ile Asp Thr Asn Leu Thr Gly Thr Phe Asn 490 495 500 | 1593 |
| atg acc cat ccg gtc tgg ccg ggc atg cgc gaa cgc aag ttc gga cgc Met Thr His Pro Val Trp Pro Gly Met Arg Glu Arg Lys Phe Gly Arg 505 510 515 | 1641 |
| gtc atc aac atc agc tcg atc aac ggg cag aag ggc cag ttc ggg cag Val Ile Asn Ile Ser Ser Ile Asn Gly Gln Lys Gly Gln Phe Gly Gln 520 525 530 | 1689 |
| gcg aac tat gcc gcg gcc aag gcg ggc gac ctg ggc ttc acc aag tcg Ala Asn Tyr Ala Ala Ala Lys Ala Gly Asp Leu Gly Phe Thr Lys Ser 535 540 545 550 | 1737 |
| ctg gcg cag gaa ggc gcg cgc aac aac atc acc gtc aac gcg atc tgc Leu Ala Gln Glu Gly Ala Arg Asn Asn Ile Thr Val Asn Ala Ile Cys | 1785 |

Phe Met Gly Ala Phe Ala Asn Val Pro Ala His Asp Leu Gly Ala Ala
20 25 30

Val Leu Arg Glu Val Val Ala Arg Ala Gly Val Asp Pro Ala Glu Val
 35 40 45

Ser Glu Thr Ile Leu Gly Gln Val Leu Thr Ala Ala Gln Gly Gln Asn
 50 55 60

Pro Ala Arg Gln Ala His Ile Asn Ala Gly Leu Pro Lys Glu Ser Ala
 65 70 75 80

Ala Trp Leu Ile Asn Gln Val Cys Gly Ser Gly Leu Arg Ala Val Ala
 85 90 95

Leu Ala Ala Gln Gln Val Met Leu Gly Asp Ala Gln Ile Val Leu Ala
 100 105 110

Gly Gly Gln Glu Ser Met Ser Leu Ser Thr His Ala Ala Tyr Leu Arg
 115 120 125

Ala Gly Gln Lys Met Gly Asp Met Lys Met Ile Asp Thr Met Ile Arg
 130 135 140

Asp Gly Leu Trp Asp Ala Phe Asn Gly Tyr His Met Gly Gln Thr Ala
 145 150 155 160

Glu Asn Val Ala Asp Gln Trp Ser Ile Ser Arg Asp Gln Gln Asp Glu
 165 170 175

Phe Ala Leu Ala Ser Gln Asn Lys Ala Glu Ala Ala Gln Asn Ala Gly
 180 185 190

Arg Phe Asp Asp Glu Ile Val Ala Tyr Thr Val Lys Gly Arg Lys Gly
 195 200 205

Asp Thr Val Val Asp Lys Asp Glu Tyr Ile Arg His Gly Ala Thr Ile
 210 215 220

Glu Gly Met Gln Lys Leu Arg Pro Ala Phe Thr Lys Glu Gly Ser Val
 225 230 235 240

Thr Ala Gly Asn Ala Ser Gly Leu Asn Asp Gly Ala Ala-Ala Val Met—
 245 250 255

Val Met Ser Glu Asp Glu Ala Ala Arg Arg Gly Leu Thr Pro Leu Ala
260 265 270

Arg Ile Ala Ser Tyr Ala Thr Ala Gly Leu Asp Pro Ala Ile Met Gly
275 280 285

Thr Gly Pro Ile Pro Ser Ser Arg Lys Ala Leu Glu Lys Ala Gly Trp
290 295 300

Ser Val Gly Asp Leu Asp Leu Val Glu Ala Asn Glu Ala Phe Ala Ala
305 310 315 320

Gln Ala Cys Ala Val Asn Lys Asp Met Gly Trp Asp Pro Ser Ile Val
325 330 335

Asn Val Asn Gly Gly Ala Ile Ala Ile Gly His Pro Ile Gly Ala Ser
340 345 350

Gly Ala Arg Ile Leu Asn Thr Leu Leu Phe Glu Met Gln Arg Arg Asp
355 360 365

Ala Lys Lys Gly Leu Ala Thr Leu Cys Ile Gly Gly Gly Met Gly Val
370 375 380

Ala Met Cys Leu Glu Arg
385 390

<210> 179

<211> 240

<212> PRT

<213> Paracoccus sp. R114

<220>

<221> misc_feature

<222> (1179)..(1194)

<223> inverted repeat between genes constituting a putative transcripti
onal sto

<220>

<221> misc_feature

<222> (1196)..(1210)

<223> inverted repeat between genes constituting a putative transcript.
onal sto

<400> 179

Met Ser Lys Val Ala Leu Val Thr Gly Gly Ser Arg Gly Ile Gly Ala
1 5 10 15

Glu Ile Cys Lys Ala Leu Gln Ala Ala Gly Tyr Thr Val Ala Ala Asn
20 25 30

Tyr Ala Gly Asn Asp Asp Ala Ala Lys Ala Phe Thr Glu Glu Thr Gly
35 40 45

Ile Lys Thr Tyr Lys Trp Ser Val Ala Asp Tyr Asp Ala Cys Lys Ala
50 55 60

Gly Ile Ala Gln Val Glu Glu Asp Leu Gly Pro Ile Ala Val Leu Ile
65 70 75 80

Asn Asn Ala Gly Ile Thr Arg Asp Ala Pro Phe His Lys Met Thr Pro
85 90 95

Glu Lys Trp Lys Glu Val Ile Asp Thr Asn Leu Thr Gly Thr Phe Asn
100 105 110

Met Thr His Pro Val Trp Pro Gly Met Arg Glu Arg Lys Phe Gly Arg
115 120 125

Val Ile Asn Ile Ser Ser Ile Asn Gly Gln Lys Gly Gln Phe Gly Gln
130 135 140

Ala Asn Tyr Ala Ala Ala Lys Ala Gly Asp Leu Gly Phe Thr Lys Ser
145 150 155 160

Leu Ala Gln Glu Gly Ala Arg Asn Asn Ile Thr Val Asn Ala Ile Cys
165 170 175

Pro Gly Tyr Ile Ala Thr Asp Met Val Met Ala Val Pro Glu Gln Val
180 185 190

Arg Glu Gly Ile Ile Ala Gln Ile Pro Val Gly Arg Leu Gly Glu Pro
195 200 205

Ser Glu Ile Ala Arg Cys Val Val Phe Leu Ala Ser Asp Asp Ala Gly
210 215 220

Phe Val Thr Gly Ser Thr Ile Thr Ala Asn Gly Gly Gln Tyr Tyr Ile
225 230 235 240

<210> 180

<211> 729

<212> DNA

<213> Paracoccus carotinifaciens E-396

<220>

<221> CDS

<222> (1)..(726)

<223> Beta-carotene Beta-4 oxygenase

<400> 180

atg agc gca cat gcc ctg ccc aag gca gat ctg acc gcc acc agt ttg 48
Met Ser Ala His Ala Leu Pro Lys Ala Asp Leu Thr Ala Thr Ser Leu
1 5 10 15

atc gtc tcg ggc ggc atc atc gcc gcg tgg ctg gcc ctg cat 'gtg cat 96
Ile Val Ser Gly Gly Ile Ile Ala Ala Trp Leu Ala Leu His Val His
20 25 30

gcg ctg tgg ttt ctg gac gcg gcg gcg cat ccc atc ctg gcg gtc gcg 144
Ala Leu Trp Phe Leu Asp Ala Ala Ala His Pro Ile Leu Ala Val Ala
35 40 45

aat ttc ctg ggg ctg acc tgg ctg tcg gtc ggt ctg ttc atc atc gcg 192
Asn Phe Leu Gly Leu Thr Trp Leu Ser Val Gly Leu Phe Ile Ile Ala
50 55 60

cat gac gcg atg cat ggg tcg gtc gtg ccg ggg cgc ccg cgc gcc aat 240
His Asp Ala Met His Gly Ser Val Val Pro Gly Arg Pro Arg Ala Asn
65 70 75 80

gcg gcg atg ggc cag ctt gtc ctg tgg ctg tat gcc gga ttt tcc tgg 288
Ala Ala Met Gly Gln Leu Val Leu Trp Leu Tyr Ala Gly Phe Ser Trp
85 90 -95

cgc aag atg atc gtc aag cac atg gcc cat cat cgc cat gcc gga acc 336
 Arg Lys Met Ile Val Lys His Met Ala His His Arg His Ala Gly Thr
 100 105 110
 gac gac gac cca gat ttc gac cat ggc ggc ccg gtc cgc tgg tac gcc 384
 Asp Asp Asp Pro Asp Phe Asp His Gly Gly Pro Val Arg Trp Tyr Ala
 115 120 125
 cgc ttc atc ggc acc tat ttc ggc tgg cgc gag ggg ctg ctg ctg ccc 432
 Arg Phe Ile Gly Thr Tyr Phe Gly Trp Arg Glu Gly Leu Leu Leu Pro
 130 135 140
 gtc atc gtg acg gtc tat gcg ctg atg ttg ggg gat cgc tgg atg tac 480
 Val Ile Val Thr Val Tyr Ala Leu Met Leu Gly Asp Arg Trp Met Tyr
 145 150 155 160
 gtg gtc ttc tgg ccg ttg ccg tcg atc ctg gcg tcg atc cag ctg ttc 528
 Val Val Phe Trp Pro Leu Pro Ser Ile Leu Ala Ser Ile Gln Leu Phe
 165 170 175
 gtg ttc ggc atc tgg ctg ccg cac cgc ccc ggc cac gac gcg ttc ccg 576
 Val Phe Gly Ile Trp Leu Pro His Arg Pro Gly His Asp Ala Phe Pro
 180 185 190
 gac cgc cac aat gcg cgg tcg tcg cgg atc agc gac ccc gtg tcg ctg 624
 Asp Arg His Asn Ala Arg Ser Ser Arg Ile Ser Asp Pro Val Ser Leu
 195 200 205
 ctg acc tgc ttt cac ttt ggc ggt tat cat cac gaa cac cac ctg cac 672
 Leu Thr Cys Phe His Phe Gly Gly Tyr His His Glu His His Leu His
 210 215 220
 ccg acg gtg cct tgg tgg cgc ctg ccc agc acc cgc acc aag ggg gac 720
 Pro Thr Val Pro Trp Trp Arg Leu Pro Ser Thr Arg Thr Lys Gly Asp
 225 230 235 240
 acc gca tga 729
 Thr Ala

<210> 181

<211> 242

<212> PRT

<213> Paracoccus carotinifaciens E-396

<400> 181

Met Ser Ala His Ala Leu Pro Lys Ala Asp Leu Thr Ala Thr Ser Leu
 1 5 10 15

Ile Val Ser Gly Gly Ile Ile Ala Ala Trp Leu Ala Leu His Val His
 20 25 30
 Ala Leu Trp Phe Leu Asp Ala Ala Ala His Pro Ile Leu Ala Val Ala
 35 40 45
 Asn Phe Leu Gly Leu Thr Trp Leu Ser Val Gly Leu Phe Ile Ile Ala
 50 55 60
 His Asp Ala Met His Gly Ser Val Val Pro Gly Arg Pro Arg Ala Asn
 65 70 75 80
 Ala Ala Met Gly Gln Leu Val Leu Trp Leu Tyr Ala Gly Phe Ser Trp
 85 90 95
 Arg Lys Met Ile Val Lys His Met Ala His His Arg His Ala Gly Thr
 100 105 110
 Asp Asp Asp Pro Asp Phe Asp His Gly Gly Pro Val Arg Trp Tyr Ala
 115 120 125
 Arg Phe Ile Gly Thr Tyr Phe Gly Trp Arg Glu Gly Leu Leu Leu Pro
 130 135 140
 Val Ile Val Thr Val Tyr Ala Leu Met Leu Gly Asp Arg Trp Met Tyr
 145 150 155 160
 Val Val Phe Trp Pro Leu Pro Ser Ile Leu Ala Ser Ile Gln Leu Phe
 165 170 175
 Val Phe Gly Ile Trp Leu Pro His Arg Pro Gly His Asp Ala Phe Pro
 180 185 190
 Asp Arg His Asn Ala Arg Ser Ser Arg Ile Ser Asp Pro Val Ser Leu
 195 200 205
 Leu Thr Cys Phe His Phe Gly Gly Tyr His His Glu His His Leu His
 210 215 220
 Pro Thr Val Pro Trp Trp Arg Leu Pro Ser Thr Arg Thr Lys Gly Asp
 225 230 235 240

Thr Ala

<210> 182

<211> 510

<212> DNA

<213> Paracoccus sp. R1534

<220>

<221> CDS

<222> (1)..(507)

<223> Beta-Carotene hydroxylase

<400> 182

| | |
|---|-----|
| atg agc act tgg gcc gca atc ctg acc gtc atc ctg acc gtc gcc gcg | 48 |
| Met Ser Thr Trp Ala Ala Ile Leu Thr Val Ile Leu Thr Val Ala Ala | |
| 1 5 10 15 | |
| atg gag ctg acg gcc tac tcc gtc cat cgg tgg atc atg cat ggc ccc | 96 |
| Met Glu Leu Thr Ala Tyr Ser Val His Arg Trp Ile Met His Gly Pro | |
| 20 25 30 | |
| ctg ggc tgg ggc tgg cat aaa tcg cac cac gac gag gat cac gac cac | 144 |
| Leu Gly Trp Gly Trp His Lys Ser His His Asp Glu Asp His Asp His | |
| 35 40 45 | |
| gcg ctc gag aag aac gac ctc tat ggc gtc atc ttc gcg gta atc tcg | 192 |
| Ala Leu Glu Lys Asn Asp Leu Tyr Gly Val Ile Phe Ala Val Ile Ser | |
| 50 55 60 | |
| atc gtg ctg ttc gcg atc ggc gcg atg ggg tcg gat ctg gcc tgg tgg | 240 |
| Ile Val Leu Phe Ala Ile Gly Ala Met Gly Ser Asp Leu Ala Trp Trp | |
| 65 70 75 80 | |
| ctg gcg gtg ggg gtc acc tgc tac ggg ctg atc tac tat ttc-ctg cat | 288 |
| Leu Ala Val Gly Val Thr Cys Tyr Gly Leu Ile Tyr Tyr Phe Leu His | |
| 85 90 95 | |
| gac ggc ttg gtg cat ggg cgc tgg ccg ttc cgc tat gtc ccc aag cgc | 336 |
| Asp Gly Leu Val His Gly Arg Trp Pro Phe Arg Tyr Val Pro Lys Arg | |
| 100 105 110 | |
| ggc tat ctt cgt cgc gtc tac cag gca cac agg atg cat cac gcg gtc | 384 |
| Gly Tyr Leu Arg Arg Val Tyr Gln Ala His Arg Met His His Ala Val | |
| 115 120 125 | |

cat ggc cgc gag aac tgc gtc agc ttc ggt ttc atc tgg gcg ccc tcg 432
 His Gly Arg Glu Asn Cys Val Ser Phe Gly Phe Ile Trp Ala Pro Ser
 130 135 140

gtc gac agc ctc aag gca gag ctg aaa cgc tcg ggc gcg ctg ctg aag 480
 Val Asp Ser Leu Lys Ala Glu Leu Lys Arg Ser Gly Ala Leu Leu Lys
 145 150 155 160

gac cgc gaa ggg gcg gat cgc aat aca tga 510
 Asp Arg Glu Gly Ala Asp Arg Asn Thr
 165

<210> 183

<211> 169

<212> PRT

<213> Paracoccus sp. R1534

<400> 183

Met Ser Thr Trp Ala Ala Ile Leu Thr Val Ile Leu Thr Val Ala Ala
 1 5 10 15

Met Glu Leu Thr Ala Tyr Ser Val His Arg Trp Ile Met His Gly Pro
 20 25 30

Leu Gly Trp Gly Trp His Lys Ser His His Asp Glu Asp His Asp His
 35 40 45

Ala Leu Glu Lys Asn Asp Leu Tyr Gly Val Ile Phe Ala Val Ile Ser
 50 55 60

Ile Val Leu Phe Ala Ile Gly Ala Met Gly Ser Asp Leu Ala Trp Trp
 65 70 75 80

Leu Ala Val Gly Val Thr Cys Tyr Gly Leu Ile Tyr Tyr Phe Leu His
 85 90 95

Asp Gly Leu Val His Gly Arg Trp Pro Phe Arg Tyr Val Pro Lys Arg
 100 105 110

Gly Tyr Leu Arg Arg Val Tyr Gln Ala His Arg Met His His Ala Val
 115 120 125

His Gly Arg Glu Asn Cys Val Ser Phe Gly Phe Ile Trp Ala Pro Ser
 130 135 140

Val Asp Ser Leu Lys Ala Glu Leu Lys Arg Ser Gly Ala Leu Leu Lys
 145 150 155 160

Asp Arg Glu Gly Ala Asp Arg Asn Thr
 165

<210> 184

<211> 888

<212> DNA

<213> Paracoccus sp. R1534

<220>

<221> CDS

<222> (1)..(885)

<223> farnesyltransferase or geranylgeranyl diphosphate synthase

<400> 184

atg acg ccc aag cag caa ttc ccc cta cgc gat ctg gtc gag atc agg 48
 Met Thr Pro Lys Gln Phe Pro Leu Arg Asp Leu Val Glu Ile Arg
 1 5 10 15

ctg gcg cag atc tcg ggc cag ttc ggc gtg gtc tcg gcc ccg ctc ggc 96
 Leu Ala Gln Ile Ser Gly Gln Phe Gly Val Val Ser Ala Pro Leu Gly
 20 25 30

gcg gcc atg agc gat gcc gcc ctg tcc ccc gcc aaa cgc ttt cgc gcc 144
 Ala Ala Met Ser Asp Ala Ala Leu Ser Pro Gly Lys Arg Phe Arg Ala
 35 40 45

gtg ctg atg ctg atg gtc gcc gaa agc tcg gcc ggg_gtc_tgc gat gcg 192
 Val Leu Met Leu Met Val Ala Glu Ser Ser Gly Gly Val Cys Asp Ala
 50 55 60

atg gtc gat gcc gcc tgc gcg gtc gag atg gtc cat gcc gca tcg ctg 240
 Met Val Asp Ala Ala Cys Ala Val Glu Met Val His Ala Ala Ser Leu
 65 70 75 80

atc ttc gac gac atg ccc tgc atg gac gat gcc agg acc cgt cgc ggt 288
 Ile Phe Asp Asp Met Pro Cys Met Asp Asp Ala Arg Thr Arg Arg Gly
 85 90 95

cag ccc gcc acc cat gtc gcc cat ggc gag ggg cgc gcg gtg ctt gcg 336
 Gln Pro Ala Thr His Val Ala His Gly Glu Gly Arg Ala Val Leu Ala
 100 105 110

ggc atc gcc ctg atc acc gag gcc atg cgg att ttg ggc gag gcg cgc 384
 Gly Ile Ala Leu Ile Thr Glu Ala Met Arg Ile Leu Gly Glu Ala Arg
 115 120 125

ggc gcg acg ccg gat cag cgc gca agg ctg gtc gca tcc atg tcg cgc 432
 Gly Ala Thr Pro Asp Gln Arg Ala Arg Leu Val Ala Ser Met Ser Arg
 130 135 140

gcg atg gga ccg gtg ggg ctg tgc gca ggg cag gat ctg gac ctg cac 480
 Ala Met Gly Pro Val Gly Leu Cys Ala Gly Gln Asp Leu Asp Leu His
 145 150 155 160

gcc ccc aag gac gcc gcc ggg atc gaa cgt gaa cag gac ctc aag acc 528
 Ala Pro Lys Asp Ala Ala Gly Ile Glu Arg Glu Gln Asp Leu Lys Thr
 165 170 175

ggc gtg ctg ttc gtc gcg ggc ctc gag atg ctg tcc att att aag ggt 576
 Gly Val Leu Phe Val Ala Gly Leu Glu Met Leu Ser Ile Ile Lys Gly
 180 185 190

ctg gac aag gcc gag acc gag cag ctc atg gcc ttc ggg cgt cag ctt 624
 Leu Asp Lys Ala Glu Thr Glu Gln Leu Met Ala Phe Gly Arg Gln Leu
 195 200 205

ggt cgg gtc ttc cag tcc tat gac gac ctg ctg gac gtg atc ggc gac 672
 Gly Arg Val Phe Gln Ser Tyr Asp Asp Leu Leu Asp Val Ile Gly Asp
 210 215 220

aag gcc agc acc ggc aag gat acg ggg cgc gac acc gcc gcc ccc ggc 720
 Lys Ala Ser Thr Gly Lys Asp Thr Gly Arg Asp Thr Ala Ala Pro Gly
 225 230 235 240

cca aag cgc ggc ctg atg gcg gtc gga cag atg ggc gac gtg gcg cag 768
 Pro Lys Arg Gly Leu Met Ala Val Gly Gln Met Gly Asp Val Ala Gln
 245 250 255

cat tac cgc gcc agc cgc gcg caa ctg gac gag ctg atg cgc acc cgg 816
 His Tyr Arg Ala Ser Arg Ala Gln Leu Asp Glu Leu Met Arg Thr Arg
 260 265 270

ctg ttc cgc ggg ggg cag atc gcg gac ctg ctg gcc cgc gtg ctg ccg 864
 Leu Phe Arg Gly Gly Gln Ile Ala Asp Leu Leu Ala Arg Val Leu Pro
 275 280 285

cat gac atc cgc cgc agc gcc tag 888
 His Asp Ile Arg Arg Ser Ala
 290 295

<210> 185

<211> 295

<212> PRT

<213> Paracoccus sp. R1534

<400> 185

Met Thr Pro Lys Gln Gln Phe Pro Leu Arg Asp Leu Val Glu Ile Arg
 1 5 10 15

Leu Ala Gln Ile Ser Gly Gln Phe Gly Val Val Ser Ala Pro Leu Gly
 20 25 30

Ala Ala Met Ser Asp Ala Ala Leu Ser Pro Gly Lys Arg Phe Arg Ala
 35 40 45

Val Leu Met Leu Met Val Ala Glu Ser Ser Gly Gly Val Cys Asp Ala
 50 55 60

Met Val Asp Ala Ala Cys Ala Val Glu Met Val His Ala Ala Ser Leu
 65 70 75 80

Ile Phe Asp Asp Met Pro Cys Met Asp Asp Ala Arg Thr Arg Arg Gly
 85 90 95

Gln Pro Ala Thr His Val Ala His Gly Glu Gly Arg Ala Val Leu Ala
 100 105 110

Gly Ile Ala Leu Ile Thr Glu Ala Met Arg Ile Leu Gly Glu Ala Arg
 115 120 125

Gly Ala Thr Pro Asp Gln Arg Ala Arg Leu Val Ala Ser Met Ser Arg
 130 135 140

Ala Met Gly Pro Val Gly Leu Cys Ala Gly Gln Asp Leu Asp Leu His
 145 150 155 160

Ala Pro Lys Asp Ala Ala Gly Ile Glu Arg Glu Gln Asp Leu Lys Thr
 165 170 175

Gly Val Leu Phe Val Ala Gly Leu Glu Met Leu Ser Ile Ile Lys Gly
 180 185 190

Leu Asp Lys Ala Glu Thr Glu Gln Leu Met Ala Phe Gly Arg Gln Leu

195 200 205
 Gly Arg Val Phe Gln Ser Tyr Asp Asp Leu Leu Asp Val Ile Gly Asp
 210 215 220
 Lys Ala Ser Thr Gly Lys Asp Thr Gly Arg Asp Thr Ala Ala Pro Gly
 225 230 235 240
 Pro Lys Arg Gly Leu Met Ala Val Gly Gln Met Gly Asp Val Ala Gln
 245 250 255
 His Tyr Arg Ala Ser Arg Ala Gln Leu Asp Glu Leu Met Arg Thr Arg
 260 265 270
 Leu Phe Arg Gly Gly Gln Ile Ala Asp Leu Leu Ala Arg Val Leu Pro
 275 280 285
 His Asp Ile Arg Arg Ser Ala
 290 295

<210> 186

<211> 30

<212> DNA

<213> synthetic construct

<400> 186

aaggcctcat atgagcgcac atgccctgcc

30

<210> 187

<211> 28

<212> DNA

<213> synthetic construct

<400> 187

cgggatcctc atgcggtgtc ccccttgg

28

<210> 188

<211> 30

<212> DNA

<213> synthetic construct

<400> 188

aaggcctcat atgagcactt gggccgcaat

30

<210> 189

<211> 30

<212> DNA

<213> synthetic construct

<400> 189

aggatcctca tgtattgcga tccgccctt

30

<210> 190

<211> 52

<212> DNA

<213> synthetic construct

<400> 190

gtgcagcctc aggtcgacat atgcggccgc atccggatcc ctctcctcc ag

52

<210> 191

<211> 52

<212> DNA

<213> synthetic construct

<400> 191

cacgtcggag tccagctgta tacgccggcg taggcctagg gaggaggagg tc

52

<210> 192

<211> 52

<212> DNA

<213> synthetic construct

<400> 192

gtgcaggagg aggtcgacat atgcggccgc atccggatcc ctgaggctcc ag

52

<210> 193

<211> 52

<212> DNA

<213> synthetic construct

<400> 193

cacgtcctcc tccagctgta tacgccggcg taggcctagg gactccgagg tc

52

<210> 194

<211> 52

<212> DNA

<213> synthetic construct

<400> 194

ctggagcctc aggtcgacat atgcggccgc atccggatcc ctctcctgc ac

52

<210> 195

<211> 52

<212> DNA

<213> synthetic construct

<400> 195

gacctcggag tccagctgta tacgccggcg taggcctagg gaggaggacg tg

52

<210> 196

<211> 52

<212> DNA

<213> synthetic construct

<400> 196

ctggaggagg aggtcgacat atgcggccgc atccggatcc ctgaggctgc ac

52

<210> 197

<211> 52

<212> DNA

<213> synthetic construct

<400> 197

gacctctcc tccagctgta tacgccggcg taggcctagg gactccgacg tg

52

THIS PAGE BLANK (USPTO)

ATCC

10901 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-365-2745

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Roche Vitamins Inc.
Attn: Markus Huembelin
340 Kingsland Street
Nutley, NJ 007110-1199

Deposited on Behalf of: Roche Vitamins Inc.

Identification Reference by Depositor:

Patent Deposit Designation

Paracoccus sp.: R-1506

PTA-3431

The deposit was accompanied by: a scientific description a proposed taxonomic description indicated above.

The deposit was received June 5, 2001 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: ☒ We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested June 27, 2001. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:


Tanya Nunnally, Patent Specialist, Patent Depository

Date: June 28, 2001

cc: Kevin C. Hooper
(Ref: Docket or Case No.: C38435/121966)

THIS PAGE BLANK (USPTO)

ATCC

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-363-2700 • FAX: 703-363-2745

**BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

**RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2**

To: (Name and Address of Depositor or Attorney)

Roche Vitamins Inc.
Attn: Marlene Huenbelle
340 Kingsland Street
Nutley, NJ 07110-1199

Deposited on Behalf of: Roche Vitamins Inc.

Identification Reference by Depositor:

Paracoccus sp.: R114
Paracoccus sp.: R1534

Patent Deposit Designation

PTA-3335
PTA-3336

The deposits were accompanied by: a scientific description, a proposed taxonomic description indicated above. The deposits were received April 24, 2001 by this International Depository Authority and have been accepted.

AT YOUR REQUEST: ☒ We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested May 7, 2001. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:


Tanya Neumann, Patent Specialist, Patent Depository

Date: May 23, 2001

cc: Kevin C. Hooper
(Ref: Docket or Case No.: C38435/121966)

THIS PAGE BLANK (USPTO)

Ihre Frage

WO P 200127286

Familienmitglieder

CC PUBDAT KD DOC.NO.

AU 20010423 A5 200076860

CA 20010419 AA 2385132

EP 20020731 A1 1227155

WO 20010419 A1 200127286

ABS CHEMABS134(22)306150

ABS DERABS C2001-282036

+AU 20010423 A5 200076860 WO 20001013 PW 2000JP 200007121

+CA 20010419 AA 2385132

+EP 20020731 A1 1227155

7 MITGL. 4 LAENDER

Rechtsstandsinformation

CC TP DOC.NO. PRSDAT

WO P 200127286 20010419 + DESIGNATED STATES CITED IN A PUBLISHED

APPLICATION WITH SEARCH REPORT AE AG AL AM AT
AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK
DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK
MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW A1

... + DESIGNATED COUNTRIES FOR REGIONAL PATENTS CITED
IN A PUBLISHED APPLICATION WITH SEARCH REPORT
GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG
KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW
ML MR NE SN TD TG A1

... + PUBLICATION OF THE INTERNATIONAL APPLICATION
WITH THE INTERNATIONAL SEARCH REPORT

20010613 EP: THE EPO HAS BEEN INFORMED BY WIPO THAT EP WAS
DESIGNATED IN THIS APPLICATION

20010830 REQUEST FOR PRELIMINARY EXAMINATION FILED PRIOR
TO EXPIRATION OF 19TH MONTH FROM PRIORITY DATE

20020412 ENTRY INTO THE NATIONAL PHASE IN: JP A 2001
530489

20020514 NON-ENTRY INTO THE NATIONAL PHASE IN: RU

20020926 - DE: IMPACT ABOLISHED FOR DE

EP P 1227155 20020731 + DESIGNATED CONTRACTING STATES IN AN APPLICATION
WITH SEARCH REPORT: AT BE CH CY DE DK ES FI FR
GB GR IE IT LI LU MC NL PT SE A1

... + EXTENSION OF THE EUROPEAN PATENT TO AL PAYMENT
20020513;LT PAYMENT 20020513;LV PAYMENT
20020513;MK PAYMENT 20020513;RO PAYMENT
20020513;SI PAYMENT 20020513

... + PUBLICATION OF APPLICATION WITH SEARCH REPORT

... + REQUEST FOR EXAMINATION FILED 20020513

20021009 INVENTOR (CORRECTION) MIYAKE, KOICHIRO, C/O KYOWA
HAKKO KOGYO CO.,LTD. * HASHIMOTO, SHIN-ICHI,
KYOWA HAKKO KOGYO CO.,LTD. * OZAKI, AKIO, C/O
KYOWA HAKKO KOGYO CO.,LTD.

13 PRS-INFO
Bitte Eingabe

Kyowa Hakko
Process for prod. of CoQ10

THIS PAGE BLANK (USPTO)

 **This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)